00018723712024Q29/30FALSEhttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesUnrealizedGainLosshttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesRealizedGainLosshttp://fasb.org/us-gaap/2023#RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTaxhttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesUnrealizedGainLosshttp://fasb.org/us-gaap/2023#RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTaxhttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesUnrealizedGainLosshttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesRealizedGainLosshttp://fasb.org/us-gaap/2023#RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTaxhttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesUnrealizedGainLosshttp://fasb.org/us-gaap/2023#RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTax0.50.50.50.5.50.5xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:EURiso4217:GBPoscf:investmentoscf:borrower00018723712023-10-012024-03-310001872371oscf:CommonClassIMember2024-05-100001872371oscf:CommonClassSMember2024-05-100001872371oscf:CommonClassDMember2024-05-100001872371oscf:CommonClassTMember2024-05-1000018723712024-03-3100018723712023-09-300001872371oscf:CommonClassIMember2024-03-310001872371oscf:CommonClassIMember2023-09-300001872371oscf:CommonClassSMember2024-03-310001872371oscf:CommonClassSMember2023-09-300001872371oscf:CommonClassDMember2024-03-310001872371oscf:CommonClassDMember2023-09-3000018723712024-01-012024-03-3100018723712023-01-012023-03-3100018723712022-10-012023-03-310001872371oscf:CommonClassIMember2024-01-012024-03-310001872371oscf:CommonClassIMember2023-01-012023-03-310001872371oscf:CommonClassIMember2023-10-012024-03-310001872371oscf:CommonClassIMember2022-10-012023-03-310001872371oscf:CommonClassSMember2024-01-012024-03-310001872371oscf:CommonClassSMember2023-01-012023-03-310001872371oscf:CommonClassSMember2023-10-012024-03-310001872371oscf:CommonClassSMember2022-10-012023-03-310001872371oscf:CommonClassDMember2024-01-012024-03-310001872371oscf:CommonClassDMember2023-01-012023-03-310001872371oscf:CommonClassDMember2023-10-012024-03-310001872371oscf:CommonClassDMember2022-10-012023-03-3100018723712023-12-3100018723712022-12-3100018723712022-09-3000018723712023-03-31000187237137 Capital CLO 4, CLO Notes2024-03-310001872371107-109 Beech OAK22 LLC, First Lien Revolver2024-03-310001872371107 Fair Street LLC, First Lien Term Loan2024-03-310001872371112-126 Van Houten Real22 LLC, First Lien Term Loan2024-03-310001872371AB BSL CLO 4, CLO Notes2024-03-310001872371Access CIG, LLC, First Lien Term Loan2024-03-310001872371ACP Falcon Buyer Inc, First Lien Term Loan2024-03-310001872371ACP Falcon Buyer Inc, First Lien Revolver2024-03-310001872371Acquia Inc., First Lien Term Loan2024-03-310001872371ADC Therapeutics SA, First Lien Term Loan2024-03-310001872371ADC Therapeutics SA, Warrants2024-03-310001872371AIP RD Buyer Corp., Second Lien Term Loan2024-03-310001872371AIP RD Buyer Corp., Common Stock2024-03-310001872371Alto Pharmacy Holdings, Inc., First Lien Term Loan2024-03-310001872371Alto Pharmacy Holdings, Inc., Warrants2024-03-310001872371American Airlines Group Inc., Fixed Rate Bond2024-03-310001872371American Auto Auction Group, LLC, First Lien Term Loan2024-03-310001872371American Auto Auction Group, LLC, Second Lien Term Loan2024-03-310001872371American Rock Salt Company LLC, First Lien Term Loan2024-03-310001872371American Tire Distributors, Inc., First Lien Term Loan2024-03-310001872371AmSpec Parent LLC, First Lien Term Loan 12024-03-310001872371AmSpec Parent LLC, First Lien Term Loan 22024-03-310001872371AmSpec Parent LLC, First Lien Revolver2024-03-310001872371Amynta Agency Borrower Inc., First Lien Term Loan2024-03-310001872371Anastasia Parent, LLC, First Lien Term Loan2024-03-310001872371Anchorage Capital CLO 20, CLO Notes2024-03-310001872371Arches Buyer Inc., First Lien Term Loan2024-03-310001872371Ardonagh Midco 3 PLC, First Lien Term Loan 12024-03-310001872371Ardonagh Midco 3 PLC, First Lien Term Loan 22024-03-310001872371ARES LXIV CLO, CLO Notes2024-03-310001872371ARES LXVIII CLO, CLO Notes2024-03-310001872371Ares XLIV CLO, CLO Notes2024-03-310001872371Artera Services, LLC, First Lien Term Loan2024-03-310001872371Artera Services, LLC, Fixed Rate Bond2024-03-310001872371ASP-R-PAC Acquisition Co LLC, First Lien Term Loan2024-03-310001872371ASP-R-PAC Acquisition Co LLC, First Lien Revolver2024-03-310001872371Astra Acquisition Corp., First Lien Term Loan2024-03-310001872371Asurion, LLC, First Lien Term Loan 12024-03-310001872371Asurion, LLC, First Lien Term Loan 22024-03-310001872371athenahealth Group Inc., First Lien Term Loan2024-03-310001872371athenahealth Group Inc., Fixed Rate Bond2024-03-310001872371athenahealth Group Inc., Preferred Equity2024-03-310001872371Avalara, Inc., First Lien Term Loan2024-03-310001872371Avalara, Inc., First Lien Revolver2024-03-310001872371Bain Capital Credit CLO, Limited, CLO Notes2024-03-310001872371Bain Capital Credit CLO 2022-3, CLO Notes2024-03-310001872371Bain Capital Euro CLO 2021-2, CLO Notes2024-03-310001872371Bamboo US Bidco LLC, First Lien Term Loan 12024-03-310001872371Bamboo US Bidco LLC, First Lien Term Loan 22024-03-310001872371Bamboo US Bidco LLC, First Lien Term Loan 32024-03-310001872371Bamboo US Bidco LLC, First Lien Revolver2024-03-310001872371Bausch + Lomb Corp, First Lien Term Loan2024-03-310001872371BioXcel Therapeutics, Inc., First Lien Term Loan 12024-03-310001872371BioXcel Therapeutics, Inc., First Lien Term Loan 22024-03-310001872371BioXcel Therapeutics, Inc., First Lien Term Loan 32024-03-310001872371BioXcel Therapeutics, Inc., First Lien Term Loan 42024-03-310001872371BioXcel Therapeutics, Inc., First Lien Term Loan 52024-03-310001872371BioXcel Therapeutics, Inc., Warrants 12024-03-310001872371BioXcel Therapeutics, Inc., Warrants 22024-03-310001872371Birch Grove CLO 2 LTD, CLO Notes2024-03-310001872371Biscuit Parent, LLC, First Lien Term Loan2024-03-310001872371Biscuit Parent, LLC, First Lien Revolver2024-03-310001872371Blackhawk Network Holdings, Inc., First Lien Term Loan2024-03-310001872371Carlyle Euro CLO 2021-2, CLO Notes2024-03-310001872371CBAM 2017-2, LTD., CLO Notes2024-03-310001872371CCO Holdings LLC, Fixed Rate Bond2024-03-310001872371CD&R Firefly Bidco Limited, First Lien Term Loan 12024-03-310001872371CD&R Firefly Bidco Limited, First Lien Term Loan 22024-03-310001872371Clear Channel Outdoor Holdings, Inc., First Lien Term Loan2024-03-310001872371Clear Channel Outdoor Holdings, Inc., Fixed Rate Bond2024-03-310001872371Cloud Software Group, Inc., First Lien Term Loan 12024-03-310001872371Cloud Software Group, Inc., First Lien Term Loan 22024-03-310001872371Cloud Software Group, Inc., Fixed Rate Bond2024-03-310001872371Colony Holding Corporation, First Lien Term Loan 12024-03-310001872371Colony Holding Corporation, First Lien Term Loan 22024-03-310001872371Condor Merger Sub Inc., Fixed Rate Bond2024-03-310001872371Connect U.S. Finco LLC, Fixed Rate Bond2024-03-310001872371Coupa Holdings, LLC, First Lien Term Loan 12024-03-310001872371Coupa Holdings, LLC, First Lien Term Loan 22024-03-310001872371Coupa Holdings, LLC, First Lien Revolver2024-03-310001872371Covetrus, Inc., First Lien Term Loan2024-03-310001872371Crewline Buyer, Inc., First Lien Term Loan2024-03-310001872371Crewline Buyer, Inc., First Lien Revolver2024-03-310001872371Crown Subsea Communications Holding, Inc., First Lien Term Loan2024-03-310001872371Curium Bidco S.à.r.l., First Lien Term Loan2024-03-310001872371CVAUSA Management, LLC, First Lien Term Loan 12024-03-310001872371CVAUSA Management, LLC, First Lien Term Loan 22024-03-310001872371CVAUSA Management, LLC, First Lien Term Loan 32024-03-310001872371CVAUSA Management, LLC, First Lien Revolver2024-03-310001872371Dealer Tire Financial, LLC, Fixed Rate Bond2024-03-310001872371Delta Leasing SPV II LLC, Subordinated Debt Term Loan 12024-03-310001872371Delta Leasing SPV II LLC, Subordinated Debt Term Loan 22024-03-310001872371Delta Leasing SPV II LLC, Preferred Equity2024-03-310001872371Delta Leasing SPV II LLC, Common Stock2024-03-310001872371Delta Leasing SPV II LLC, Warrants2024-03-310001872371DirecTV Financing, LLC, First Lien Term Loan2024-03-310001872371DTI Holdco, Inc., First Lien Term Loan2024-03-310001872371Dukes Root Control Inc., First Lien Term Loan 12024-03-310001872371Dukes Root Control Inc., First Lien Term Loan 22024-03-310001872371Dukes Root Control Inc., First Lien Revolver2024-03-310001872371Eagle Parent Corp., First Lien Term Loan2024-03-310001872371Ecco Holdings Corp. First Lien Term Loan 12024-03-310001872371Ecco Holdings Corp. First Lien Term Loan 22024-03-310001872371Ecco Holdings Corp. First Lien Revolver2024-03-310001872371Entrata, Inc., First Lien Term Loan2024-03-310001872371Entrata, Inc., First Lien Revolver2024-03-310001872371Enverus Holdings, Inc., First Lien Term Loan 12024-03-310001872371Enverus Holdings, Inc., First Lien Term Loan 22024-03-310001872371Enverus Holdings, Inc., First Lien Revolver2024-03-310001872371Establishment Labs Holdings Inc., First Lien Term Loan 12024-03-310001872371Establishment Labs Holdings Inc., First Lien Term Loan 22024-03-310001872371Establishment Labs Holdings Inc., First Lien Term Loan 32024-03-310001872371Establishment Labs Holdings Inc., First Lien Term Loan 42024-03-310001872371Evergreen IX Borrower 2023, LLC, First Lien Term Loan2024-03-310001872371Evergreen IX Borrower 2023, LLC, First Lien Revolver2024-03-310001872371Fiesta Purchaser, Inc., First Lien Term Loan2024-03-310001872371Fiesta Purchaser, Inc., Fixed Rate Bond2024-03-310001872371Finastra USA, Inc., First Lien Term Loan2024-03-310001872371Finastra USA, Inc., First Lien Revolver2024-03-310001872371Fortress Credit BSL XIV, CLO Notes2024-03-310001872371Frontier Communications Holdings, LLC, First Lien Term Loan2024-03-310001872371Frontier Communications Holdings, LLC, Fixed Rate Bond2024-03-310001872371Galileo Parent, Inc., First Lien Term Loan2024-03-310001872371Galileo Parent, Inc., First Lien Revolver2024-03-310001872371Gallatin CLO X 2023-1, CLO Notes2024-03-310001872371GoldenTree Loan Management EUR CLO 2 DAC, CLO Notes2024-03-310001872371Greenway Health, LLC, First Lien Term Loan2024-03-310001872371Grove Hotel Parcel Owner, LLC, First Lien Term Loan 12024-03-310001872371Grove Hotel Parcel Owner, LLC, First Lien Term Loan 22024-03-310001872371Grove Hotel Parcel Owner, LLC, First Lien Revolver2024-03-310001872371Harbor Purchaser Inc., First Lien Term Loan2024-03-310001872371Harrow, Inc., First Lien Term Loan 12024-03-310001872371Harrow, Inc., First Lien Term Loan 22024-03-310001872371Harrow, Inc., First Lien Term Loan 32024-03-310001872371Hertz Vehicle Financing III, CLO Notes 12024-03-310001872371Hertz Vehicle Financing III, CLO Notes 22024-03-310001872371Horizon Aircraft Finance I Ltd., CLO Notes2024-03-310001872371Horizon Aircraft Finance II Ltd., CLO Notes2024-03-310001872371HPS Loan Management 10-2016, CLO Notes2024-03-310001872371HUB Pen Company, LLC, First Lien Term Loan2024-03-310001872371HUB Pen Company, LLC, First Lien Revolver2024-03-310001872371Husky Injection Molding Systems Ltd., First Lien Term Loan2024-03-310001872371Husky Injection Molding Systems Ltd., Fixed Rate Bond2024-03-310001872371IAMGOLD Corporation, Second Lien Term Loan2024-03-310001872371Icefall Parent, Inc., First Lien Term Loan2024-03-310001872371Icefall Parent, Inc., First Lien Revolver2024-03-310001872371iCIMs, Inc., First Lien Term Loan 12024-03-310001872371iCIMs, Inc., First Lien Term Loan 22024-03-310001872371iCIMs, Inc., First Lien Term Loan 32024-03-310001872371iCIMs, Inc., First Lien Revolver2024-03-310001872371Impel Pharmaceuticals Inc., First Lien Term Loan 12024-03-310001872371Impel Pharmaceuticals Inc., First Lien Term Loan 22024-03-310001872371Impel Pharmaceuticals Inc., First Lien Term Loan 32024-03-310001872371Impel Pharmaceuticals Inc., First Lien Term Loan 42024-03-310001872371Impel Pharmaceuticals Inc., Warrants2024-03-310001872371Innocoll Pharmaceuticals Limited, Warrants2024-03-310001872371Inventus Power, Inc., First Lien Term Loan2024-03-310001872371Inventus Power, Inc., First Lien Revolver2024-03-310001872371IW Buyer LLC, First Lien Term Loan2024-03-310001872371IW Buyer LLC, First Lien Revolver2024-03-310001872371KDC/ONE Development Corp Inc, First Lien Term Loan2024-03-310001872371Kings Buyer, LLC, First Lien Term Loan 12024-03-310001872371Kings Buyer, LLC, First Lien Term Loan 22024-03-310001872371Kings Buyer, LLC, First Lien Revolver 12024-03-310001872371Kings Buyer, LLC, First Lien Revolver 22024-03-310001872371LABL, Inc., First Lien Term Loan2024-03-310001872371Latam Airlines Group S.A., First Lien Term Loan2024-03-310001872371Learfield Communications, LLC, First Lien Term Loan2024-03-310001872371LSL Holdco, LLC, First Lien Term Loan 12024-03-310001872371LSL Holdco, LLC, First Lien Term Loan 22024-03-310001872371LSL Holdco, LLC, First Lien Revolver2024-03-310001872371Madison Park Euro Funding XIV, CLO Notes2024-03-310001872371Madison Park Funding LXIII, CLO Notes2024-03-310001872371Mauser Packaging Solutions Holding Company, First Lien Term Loan2024-03-310001872371Mauser Packaging Solutions Holding Company, Fixed Rate Bond2024-03-310001872371McAfee Corp., First Lien Term Loan2024-03-310001872371Mesoblast, Inc., First Lien Term Loan 12024-03-310001872371Mesoblast, Inc., Warrants 12024-03-310001872371Mesoblast, Inc., Warrants 22024-03-310001872371MHE Intermediate Holdings, LLC, First Lien Term Loan 12024-03-310001872371MHE Intermediate Holdings, LLC, First Lien Term Loan 22024-03-310001872371Mitchell International, Inc., First Lien Term Loan2024-03-310001872371Mitchell International, Inc., Second Lien Term Loan2024-03-310001872371Monotype Imaging Holdings Inc., First Lien Term Loan 12024-03-310001872371Monotype Imaging Holdings Inc., First Lien Term Loan 22024-03-310001872371Monotype Imaging Holdings Inc., First Lien Revolver2024-03-310001872371MRI Software LLC, First Lien Term Loan 12024-03-310001872371MRI Software LLC, First Lien Term Loan 22024-03-310001872371MRI Software LLC, First Lien Term Loan 32024-03-310001872371MRI Software LLC, First Lien Revolver2024-03-310001872371Neptune Platform Buyer, LLC, First Lien Term Loan 12024-03-310001872371Neptune Platform Buyer, LLC, First Lien Term Loan 22024-03-310001872371Next Holdco, LLC, First Lien Term Loan 12024-03-310001872371Next Holdco, LLC, First Lien Term Loan 22024-03-310001872371Next Holdco, LLC, First Lien Revolver2024-03-310001872371NFM & J, L.P., First Lien Term Loan 12024-03-310001872371NFM & J, L.P., First Lien Term Loan 22024-03-310001872371NFM & J, L.P., First Lien Revolver2024-03-310001872371NFP Corp., Fixed Rate Bond 12024-03-310001872371NFP Corp., Fixed Rate Bond 22024-03-310001872371North Star Acquisitionco, LLC, First Lien Term Loan 12024-03-310001872371North Star Acquisitionco, LLC, First Lien Term Loan 22024-03-310001872371North Star Acquisitionco, LLC, First Lien Revolver2024-03-310001872371Northwoods Capital 25 Ltd, CLO Notes2024-03-310001872371Northwoods Capital XV, CLO Notes2024-03-310001872371Ocean Trails CLO VIII, CLO Notes2024-03-310001872371Ocean Trails CLO XIV, CLO Notes2024-03-310001872371Octagon 66, CLO Notes2024-03-310001872371OEConnection LLC, Second Lien Term Loan2024-03-310001872371OFSI Fund Ltd, CLO Notes2024-03-310001872371OneOncology, LLC, First Lien Term Loan 12024-03-310001872371OneOncology, LLC, First Lien Term Loan 22024-03-310001872371OneOncology, LLC, First Lien Revolver2024-03-310001872371Oranje Holdco, Inc., First Lien Term Loan2024-03-310001872371Oranje Holdco, Inc., First Lien Revolver2024-03-310001872371OZLM XXIII Ltd, CLO Notes2024-03-310001872371Peraton Corp., First Lien Term Loan2024-03-310001872371PetSmart LLC, First Lien Term Loan2024-03-310001872371PetVet Care Centers, LLC, First Lien Term Loan 12024-03-310001872371PetVet Care Centers, LLC, First Lien Term Loan 22024-03-310001872371PetVet Care Centers, LLC, First Lien Revolver2024-03-310001872371PetVet Care Centers, LLC, Preferred Equity2024-03-310001872371Pluralsight, LLC, First Lien Term Loan2024-03-310001872371Pluralsight, LLC, First Lien Revolver2024-03-310001872371PPW Aero Buyer, Inc., First Lien Term Loan2024-03-310001872371PPW Aero Buyer, Inc., First Lien Revolver2024-03-310001872371Profrac Holdings II, LLC, First Lien Floating Rate Bond2024-03-310001872371Project Accelerate Parent, LLC, First Lien Term Loan2024-03-310001872371Project Accelerate Parent, LLC, First Lien Revolver2024-03-310001872371Protein for Pets Opco, LLC, First Lien Term Loan2024-03-310001872371Protein for Pets Opco, LLC, First Lien Revolver2024-03-310001872371Quantum Bidco Limited, First Lien Term Loan2024-03-310001872371Radar Bidco Sarl, First Lien Term Loan2024-03-310001872371Renaissance Holding Corp., First Lien Term Loan2024-03-310001872371Resistance Acquisition, Inc., First Lien Term Loan2024-03-310001872371Rockford Tower CLO 2024-1, CLO Notes2024-03-310001872371RR 24, CLO Notes2024-03-310001872371Salus Workers' Compensation, LLC, First Lien Term Loan2024-03-310001872371Salus Workers' Compensation, LLC, First Lien Revolver2024-03-310001872371Salus Workers' Compensation, LLC, Warrants2024-03-310001872371SCIH Salt Holdings Inc., First Lien Term Loan2024-03-310001872371SCIH Salt Holdings Inc., Fixed Rate Bond2024-03-310001872371SCP Eye Care Services, LLC, Second Lien Term Loan 12024-03-310001872371SCP Eye Care Services, LLC, Second Lien Term Loan 22024-03-310001872371SCP Eye Care Services, LLC, Common Stock2024-03-310001872371scPharmaceuticals Inc., First Lien Term Loan 12024-03-310001872371scPharmaceuticals Inc., First Lien Term Loan 22024-03-310001872371scPharmaceuticals Inc., First Lien Term Loan 32024-03-310001872371scPharmaceuticals Inc., Warrants2024-03-310001872371Secure Acquisition Inc., First Lien Term Loan2024-03-310001872371SEI Holding I Corporation, First Lien Term Loan 12024-03-310001872371SEI Holding I Corporation, First Lien Term Loan 22024-03-310001872371SEI Holding I Corporation, First Lien Term Loan 32024-03-310001872371SEI Holding I Corporation, First Lien Revolver2024-03-310001872371Seres Therapeutics, Inc., First Lien Term Loan 12024-03-310001872371Seres Therapeutics, Inc., First Lien Term Loan 22024-03-310001872371Seres Therapeutics, Inc., First Lien Term Loan 32024-03-310001872371Seres Therapeutics, Inc., First Lien Term Loan 42024-03-310001872371Seres Therapeutics, Inc., Warrants2024-03-310001872371SM Wellness Holdings, Inc., First Lien Term Loan2024-03-310001872371Southern Veterinary Partners, LLC, First Lien Term Loan2024-03-310001872371SPX Flow, Inc., First Lien Term Loan2024-03-310001872371SPX Flow, Inc., Fixed Rate Bond2024-03-310001872371Staples, Inc., First Lien Term Loan2024-03-310001872371Staples, Inc., Fixed Rate Bond2024-03-310001872371Star Parent, Inc., First Lien Term Loan2024-03-310001872371Superior Industries International, Inc., First Lien Term Loan2024-03-310001872371SupplyOne Inc., First Lien Term Loan2024-03-310001872371Supreme Fitness Group NY Holdings, LLC, First Lien Term Loan 12024-03-310001872371Supreme Fitness Group NY Holdings, LLC, First Lien Term Loan 22024-03-310001872371Supreme Fitness Group NY Holdings, LLC, First Lien Term Loan 32024-03-310001872371Supreme Fitness Group NY Holdings, LLC, First Lien Revolver2024-03-310001872371Tacala, LLC, First Lien Term Loan2024-03-310001872371Ten-X LLC, First Lien Term Loan2024-03-310001872371THL Zinc Ventures Ltd, First Lien Term Loan2024-03-310001872371Touchstone Acquisition, Inc., First Lien Term Loan2024-03-310001872371Transit Buyer LLC, First Lien Term Loan 12024-03-310001872371Transit Buyer LLC, First Lien Term Loan 22024-03-310001872371Trident TPI Holdings, Inc., First Lien Term Loan 12024-03-310001872371Trident TPI Holdings, Inc., First Lien Term Loan 22024-03-310001872371Trinitas CLO VI Ltd., CLO Notes2024-03-310001872371Trinitas CLO XII, CLO Notes2024-03-310001872371Trinitas CLO XV DAC, CLO Notes2024-03-310001872371Uniti Group LP, Fixed Rate Bond 12024-03-310001872371Uniti Group LP, Fixed Rate Bond 22024-03-310001872371Venture 41 CLO, CLO Notes2024-03-310001872371WAVE 2019-1, CLO Notes2024-03-310001872371Wellfleet CLO 2022-2, Ltd., CLO Notes2024-03-310001872371WP CPP Holdings, LLC, First Lien Term Loan2024-03-310001872371WP CPP Holdings, LLC, First Lien Revolver2024-03-310001872371Bank of New York Mellon, Settlement Date 2/8/2024 - 12024-03-310001872371Bank of New York Mellon, Settlement Date 2/8/2024 - 22024-03-310001872371us-gaap:ForeignExchangeForwardMember2024-03-310001872371oscf:InterestRateSwapMaturing2028Member2024-03-310001872371us-gaap:InterestRateSwapMember2024-03-310001872371srt:MinimumMember2024-03-310001872371srt:MaximumMember2024-03-310001872371107-109 Beech OAK22 LLC, First Lien Revolver2023-09-300001872371107 Fair Street LLC, First Lien Term Loan2023-09-300001872371112-126 Van Houten Real22 LLC, First Lien Term Loan2023-09-300001872371AB BSL CLO 4, CLO Notes2023-09-300001872371Access CIG, LLC, First Lien Term Loan2023-09-300001872371ACP Falcon Buyer Inc, First Lien Term Loan2023-09-300001872371ACP Falcon Buyer Inc, First Lien Revolver2023-09-300001872371ADC Therapeutics SA, First Lien Term Loan 12023-09-300001872371ADC Therapeutics SA, First Lien Term Loan 22023-09-300001872371ADC Therapeutics SA, Warrants2023-09-300001872371AI Sirona (Luxembourg) Acquisition S.a.r.l., First Lien Term Loan2023-09-300001872371AIP RD Buyer Corp., Second Lien Term Loan2023-09-300001872371AIP RD Buyer Corp., Common Stock2023-09-300001872371Altice France S.A., First Lien Term Loan2023-09-300001872371Altice France S.A., Fixed Rate Bond2023-09-300001872371Alto Pharmacy Holdings, Inc., First Lien Term Loan2023-09-300001872371Alto Pharmacy Holdings, Inc., Warrants2023-09-300001872371American Auto Auction Group, LLC, Second Lien Term Loan2023-09-300001872371American Rock Salt Company LLC, First Lien Term Loan2023-09-300001872371American Tire Distributors, Inc., First Lien Term Loan2023-09-300001872371Amynta Agency Borrower Inc., First Lien Term Loan2023-09-300001872371Anastasia Parent, LLC, First Lien Term Loan2023-09-300001872371Ardonagh Midco 3 PLC, First Lien Term Loan 12023-09-300001872371Ardonagh Midco 3 PLC, First Lien Term Loan 22023-09-300001872371ARES LXIV CLO, CLO Notes2023-09-300001872371ARES LXVIII CLO, CLO Notes2023-09-300001872371Arsenal AIC Parent LLC, First Lien Term Loan2023-09-300001872371ASP-R-PAC Acquisition Co LLC, First Lien Term Loan2023-09-300001872371ASP-R-PAC Acquisition Co LLC, First Lien Revolver2023-09-300001872371Astra Acquisition Corp., First Lien Term Loan2023-09-300001872371Asurion, LLC, First Lien Term Loan 12023-09-300001872371Asurion, LLC, First Lien Term Loan 22023-09-300001872371Asurion, LLC, Second Lien Term Loan2023-09-300001872371athenahealth Group Inc., First Lien Term Loan2023-09-300001872371athenahealth Group Inc., Fixed Rate Bond2023-09-300001872371athenahealth Group Inc., Preferred Equity2023-09-300001872371Avalara, Inc., First Lien Term Loan2023-09-300001872371Avalara, Inc., First Lien Revolver2023-09-300001872371Bamboo US Bidco LLC, First Lien Term Loan 12023-09-300001872371Bamboo US Bidco LLC, First Lien Term Loan 22023-09-300001872371Bamboo US Bidco LLC, First Lien Term Loan 32023-09-300001872371Bamboo US Bidco LLC, First Lien Revolver2023-09-300001872371Bausch + Lomb Corp, Fixed Rate Bond2023-09-300001872371BioXcel Therapeutics, Inc., First Lien Term Loan 12023-09-300001872371BioXcel Therapeutics, Inc., First Lien Term Loan 22023-09-300001872371BioXcel Therapeutics, Inc., First Lien Term Loan 32023-09-300001872371BioXcel Therapeutics, Inc., First Lien Term Loan 42023-09-300001872371BioXcel Therapeutics, Inc., First Lien Term Loan 52023-09-300001872371BioXcel Therapeutics, Inc., First Lien Term Loan 62023-09-300001872371BioXcel Therapeutics, Inc., Warrants2023-09-300001872371CCO Holdings LLC, Fixed Rate Bond2023-09-300001872371CD&R Firefly Bidco Limited, First Lien Term Loan2023-09-300001872371Clear Channel Outdoor Holdings, Inc., First Lien Term Loan2023-09-300001872371Clear Channel Outdoor Holdings, Inc., Fixed Rate Bond 12023-09-300001872371Clear Channel Outdoor Holdings, Inc., Fixed Rate Bond 22023-09-300001872371Colony Holding Corporation, First Lien Term Loan 12023-09-300001872371Colony Holding Corporation, First Lien Term Loan 22023-09-300001872371Condor Merger Sub Inc., Fixed Rate Bond2023-09-300001872371Coupa Holdings, LLC, First Lien Term Loan 12023-09-300001872371Coupa Holdings, LLC, First Lien Term Loan 22023-09-300001872371Coupa Holdings, LLC, First Lien Revolver2023-09-300001872371Covetrus, Inc., First Lien Term Loan2023-09-300001872371Cuppa Bidco BV, First Lien Term Loan2023-09-300001872371Curium Bidco S.à.r.l., First Lien Term Loan2023-09-300001872371CVAUSA Management, LLC, First Lien Term Loan 12023-09-300001872371CVAUSA Management, LLC, First Lien Term Loan 22023-09-300001872371CVAUSA Management, LLC, First Lien Term Loan 32023-09-300001872371CVAUSA Management, LLC, First Lien Revolver2023-09-300001872371Dealer Tire Financial, LLC, First Lien Term Loan2023-09-300001872371Delta Leasing SPV II LLC, Subordinated Debt Term Loan2023-09-300001872371Delta Leasing SPV II LLC, Preferred Equity2023-09-300001872371Delta Leasing SPV II LLC, Common Stock2023-09-300001872371Delta Leasing SPV II LLC, Warrants2023-09-300001872371DirecTV Financing, LLC, First Lien Term Loan2023-09-300001872371DirecTV Financing, LLC, Fixed Rate Bond2023-09-300001872371DTI Holdco, Inc., First Lien Term Loan2023-09-300001872371Dukes Root Control Inc., First Lien Term Loan 12023-09-300001872371Dukes Root Control Inc., First Lien Term Loan 22023-09-300001872371Dukes Root Control Inc., First Lien Revolver2023-09-300001872371Entrata, Inc., First Lien Term Loan2023-09-300001872371Entrata, Inc., First Lien Revolver2023-09-300001872371Establishment Labs Holdings Inc., First Lien Term Loan 12023-09-300001872371Establishment Labs Holdings Inc., First Lien Term Loan 22023-09-300001872371Establishment Labs Holdings Inc., First Lien Term Loan 32023-09-300001872371Establishment Labs Holdings Inc., First Lien Term Loan 42023-09-300001872371Evergreen IX Borrower 2023, LLC, First Lien Term Loan2023-09-300001872371Evergreen IX Borrower 2023, LLC, First Lien Revolver2023-09-300001872371Finastra USA, Inc., First Lien Term Loan2023-09-300001872371Finastra USA, Inc., First Lien Revolver2023-09-300001872371Frontier Communications Holdings, LLC, First Lien Term Loan2023-09-300001872371Frontier Communications Holdings, LLC, Fixed Rate Bond2023-09-300001872371Galileo Parent, Inc., First Lien Term Loan2023-09-300001872371Galileo Parent, Inc., First Lien Revolver2023-09-300001872371Gallatin CLO X 2023-1, CLO Notes2023-09-300001872371Gibson Brands, Inc., First Lien Term Loan2023-09-300001872371Global Aircraft Leasing Co Ltd, Fixed Rate Bond2023-09-300001872371GoldenTree Loan Management EUR CLO 2 DAC, CLO Notes2023-09-300001872371Grove Hotel Parcel Owner, LLC, First Lien Term Loan 12023-09-300001872371Grove Hotel Parcel Owner, LLC, First Lien Term Loan 22023-09-300001872371Grove Hotel Parcel Owner, LLC, First Lien Revolver2023-09-300001872371Harbor Purchaser Inc., First Lien Term Loan2023-09-300001872371Harrow, Inc., First Lien Term Loan 12023-09-300001872371Harrow, Inc., First Lien Term Loan 22023-09-300001872371Harrow, Inc., First Lien Term Loan 32023-09-300001872371Hertz Vehicle Financing III, CLO Notes 12023-09-300001872371Hertz Vehicle Financing III, CLO Notes 22023-09-300001872371Horizon Aircraft Finance I Ltd., CLO Notes2023-09-300001872371Horizon Aircraft Finance II Ltd., CLO Notes2023-09-300001872371HUB Pen Company, LLC, First Lien Term Loan2023-09-300001872371HUB Pen Company, LLC, First Lien Revolver2023-09-300001872371IAMGOLD Corporation, Second Lien Term Loan2023-09-300001872371iCIMs, Inc., First Lien Term Loan 12023-09-300001872371iCIMs, Inc., First Lien Term Loan 22023-09-300001872371iCIMs, Inc., First Lien Term Loan 32023-09-300001872371iCIMs, Inc., First Lien Revolver2023-09-300001872371Impel Pharmaceuticals Inc., First Lien Term Loan 12023-09-300001872371Impel Pharmaceuticals Inc., First Lien Term Loan 22023-09-300001872371Impel Pharmaceuticals Inc., First Lien Term Loan 32023-09-300001872371Impel Pharmaceuticals Inc., Warrants2023-09-300001872371Innocoll Pharmaceuticals Limited, First Lien Term Loan 12023-09-300001872371Innocoll Pharmaceuticals Limited, First Lien Term Loan 22023-09-300001872371Innocoll Pharmaceuticals Limited, First Lien Term Loan 32023-09-300001872371Innocoll Pharmaceuticals Limited, Warrants2023-09-300001872371Inventus Power, Inc., First Lien Term Loan2023-09-300001872371Inventus Power, Inc., First Lien Revolver2023-09-300001872371IW Buyer LLC, First Lien Term Loan2023-09-300001872371IW Buyer LLC, First Lien Revolver2023-09-300001872371KDC/ONE Development Corp Inc, First Lien Term Loan2023-09-300001872371Kindercare Learning Centers Kindercare Portfolio, CLO Notes2023-09-300001872371Kings Buyer, LLC, First Lien Term Loan 12023-09-300001872371Kings Buyer, LLC, First Lien Term Loan 22023-09-300001872371Kings Buyer, LLC, First Lien Revolver 12023-09-300001872371Kings Buyer, LLC, First Lien Revolver 22023-09-300001872371LABL, Inc., First Lien Term Loan2023-09-300001872371Latam Airlines Group S.A., First Lien Term Loan2023-09-300001872371LSL Holdco, LLC, First Lien Term Loan 12023-09-300001872371LSL Holdco, LLC, First Lien Term Loan 22023-09-300001872371LSL Holdco, LLC, First Lien Revolver2023-09-300001872371Madison Park Funding LXIII, CLO Notes2023-09-300001872371Mauser Packaging Solutions Holding Company, First Lien Term Loan2023-09-300001872371Mauser Packaging Solutions Holding Company, Fixed Rate Bond2023-09-300001872371McAfee Corp., First Lien Term Loan2023-09-300001872371Medline Borrower, LP, First Lien Term Loan2023-09-300001872371Mesoblast, Inc., First Lien Term Loan2023-09-300001872371Mesoblast, Inc., Warrants 12023-09-300001872371Mesoblast, Inc., Warrants 22023-09-300001872371MHE Intermediate Holdings, LLC, First Lien Term Loan 12023-09-300001872371MHE Intermediate Holdings, LLC, First Lien Term Loan 22023-09-300001872371Mitchell International, Inc., First Lien Term Loan2023-09-300001872371Mitchell International, Inc., Second Lien Term Loan2023-09-300001872371MND Holdings III Corp, First Lien Term Loan2023-09-300001872371MND Holdings III Corp, First Lien Revolver2023-09-300001872371MRI Software LLC, First Lien Term Loan 12023-09-300001872371MRI Software LLC, First Lien Term Loan 22023-09-300001872371New Enterprise Stone & Lime Co Inc, Fixed Rate Bond2023-09-300001872371NFP Corp., Fixed Rate Bond 12023-09-300001872371NFP Corp., Fixed Rate Bond 22023-09-300001872371NFP Corp., Fixed Rate Bond 32023-09-300001872371North Star Acquisitionco, LLC, First Lien Term Loan 12023-09-300001872371North Star Acquisitionco, LLC, First Lien Term Loan 22023-09-300001872371North Star Acquisitionco, LLC, First Lien Revolver2023-09-300001872371OEConnection LLC, Second Lien Term Loan2023-09-300001872371OneOncology, LLC, First Lien Term Loan 12023-09-300001872371OneOncology, LLC, First Lien Term Loan 22023-09-300001872371OneOncology, LLC, First Lien Revolver2023-09-300001872371Oranje Holdco, Inc., First Lien Term Loan2023-09-300001872371Oranje Holdco, Inc., First Lien Revolver2023-09-300001872371Park Place Technologies, LLC, First Lien Term Loan2023-09-300001872371Peraton Corp., First Lien Term Loan2023-09-300001872371PetSmart LLC, First Lien Term Loan2023-09-300001872371Pluralsight, LLC, First Lien Term Loan2023-09-300001872371Pluralsight, LLC, First Lien Revolver2023-09-300001872371PPW Aero Buyer, Inc., First Lien Term Loan2023-09-300001872371PPW Aero Buyer, Inc., First Lien Revolver2023-09-300001872371Profrac Holdings II, LLC, First Lien Term Loan 12023-09-300001872371Profrac Holdings II, LLC, First Lien Term Loan 22023-09-300001872371Quantum Bidco Limited, First Lien Term Loan2023-09-300001872371Renaissance Holding Corp., First Lien Term Loan2023-09-300001872371Resistance Acquisition, Inc., First Lien Term Loan 12023-09-300001872371Resistance Acquisition, Inc., First Lien Term Loan 22023-09-300001872371Salus Workers' Compensation, LLC, First Lien Term Loan2023-09-300001872371Salus Workers' Compensation, LLC, First Lien Revolver2023-09-300001872371Salus Workers' Compensation, LLC, Warrants2023-09-300001872371SCIH Salt Holdings Inc., First Lien Term Loan2023-09-300001872371SCIH Salt Holdings Inc., Fixed Rate Bond2023-09-300001872371SCP Eye Care Services, LLC, Second Lien Term Loan 12023-09-300001872371SCP Eye Care Services, LLC, Second Lien Term Loan 22023-09-300001872371SCP Eye Care Services, LLC, Common Stock2023-09-300001872371scPharmaceuticals Inc., First Lien Term Loan 12023-09-300001872371scPharmaceuticals Inc., First Lien Term Loan 22023-09-300001872371scPharmaceuticals Inc., First Lien Term Loan 32023-09-300001872371scPharmaceuticals Inc., Warrants2023-09-300001872371SEI Holding I Corporation, First Lien Term Loan 12023-09-300001872371SEI Holding I Corporation, First Lien Term Loan 22023-09-300001872371SEI Holding I Corporation, First Lien Revolver2023-09-300001872371Seres Therapeutics, Inc., First Lien Term Loan 12023-09-300001872371Seres Therapeutics, Inc., First Lien Term Loan 22023-09-300001872371Seres Therapeutics, Inc., First Lien Term Loan 32023-09-300001872371Seres Therapeutics, Inc., First Lien Term Loan 42023-09-300001872371Seres Therapeutics, Inc., Warrants2023-09-300001872371SM Wellness Holdings, Inc., First Lien Term Loan2023-09-300001872371Southern Veterinary Partners, LLC, First Lien Term Loan2023-09-300001872371SPX Flow, Inc., First Lien Term Loan2023-09-300001872371Star Parent, Inc., First Lien Term Loan2023-09-300001872371Sunshine Luxembourg VII Sarl, First Lien Term Loan2023-09-300001872371Superior Industries International, Inc., First Lien Term Loan2023-09-300001872371Supreme Fitness Group NY Holdings, LLC, First Lien Term Loan 12023-09-300001872371Supreme Fitness Group NY Holdings, LLC, First Lien Term Loan 22023-09-300001872371Supreme Fitness Group NY Holdings, LLC, First Lien Term Loan 32023-09-300001872371Supreme Fitness Group NY Holdings, LLC, First Lien Revolver2023-09-300001872371Tacala, LLC, First Lien Term Loan2023-09-300001872371Tacala, LLC, Second Lien Term Loan2023-09-300001872371Ten-X LLC, First Lien Term Loan2023-09-300001872371THL Zinc Ventures Ltd, First Lien Term Loan2023-09-300001872371TIBCO Software Inc., First Lien Term Loan2023-09-300001872371Touchstone Acquisition, Inc., First Lien Term Loan2023-09-300001872371Transit Buyer LLC, First Lien Term Loan 12023-09-300001872371Transit Buyer LLC, First Lien Term Loan 22023-09-300001872371Trident TPI Holdings, Inc., First Lien Term Loan2023-09-300001872371Trinitas CLO XII, CLO Notes2023-09-300001872371Trinitas CLO XV DAC, CLO Notes2023-09-300001872371Uniti Group LP, Fixed Rate Bond 12023-09-300001872371Uniti Group LP, Fixed Rate Bond 22023-09-300001872371WAVE 2019-1, CLO Notes2023-09-300001872371Wellfleet CLO 2022-2, Ltd., CLO Notes2023-09-300001872371WP CPP Holdings, LLC, First Lien Term Loan2023-09-300001872371WWEX Uni Topco Holdings, LLC, First Lien Term Loan2023-09-300001872371Bank of New York Mellon, Settlement Date 11/9/2023 - 12023-09-300001872371Bank of New York Mellon, Settlement Date 11/9/2023 - 22023-09-300001872371us-gaap:ForeignExchangeForwardMember2023-09-300001872371srt:MinimumMember2023-09-300001872371srt:MaximumMember2023-09-3000018723712022-02-0300018723712022-02-032022-02-030001872371oscf:CommonClassIMember2022-02-032024-03-310001872371oscf:CommonClassIMembersrt:AffiliatedEntityMember2022-02-032024-03-310001872371oscf:CommonClassSMember2022-02-032024-03-310001872371oscf:CommonClassDMember2022-02-032024-03-310001872371oscf:InvestmentOwnedFairValueMemberoscf:InvestmentTypeConcentrationRiskMemberoscf:NonAccrualStatusDebtSecuritiesMember2024-03-310001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedCostMemberoscf:NonAccrualStatusDebtSecuritiesMember2023-10-012024-03-310001872371oscf:InvestmentOwnedFairValueMemberoscf:InvestmentTypeConcentrationRiskMemberoscf:NonAccrualStatusDebtSecuritiesMember2023-10-012024-03-310001872371oscf:InvestmentOwnedFairValueMemberoscf:InvestmentTypeConcentrationRiskMemberoscf:NonAccrualStatusDebtSecuritiesMember2023-09-300001872371oscf:JPMSPVFacilityMemberus-gaap:LineOfCreditMember2024-03-310001872371oscf:SMBCSPVFacilityMemberus-gaap:LineOfCreditMember2024-03-310001872371oscf:CIBCLoanAndServicingAgreementMemberus-gaap:LineOfCreditMember2024-03-310001872371oscf:DebtSecuritiesSeniorSecuredMember2024-03-310001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:DebtSecuritiesSeniorSecuredMember2023-10-012024-03-310001872371oscf:DebtSecuritiesSeniorSecuredMember2023-09-300001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:DebtSecuritiesSeniorSecuredMember2022-10-012023-09-300001872371oscf:DebtSecuritiesSubordinatedMember2024-03-310001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:DebtSecuritiesSubordinatedMember2023-10-012024-03-310001872371oscf:DebtSecuritiesSubordinatedMember2023-09-300001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:DebtSecuritiesSubordinatedMember2022-10-012023-09-300001872371oscf:EquitySecuritiesPreferredMember2024-03-310001872371oscf:EquitySecuritiesPreferredMemberoscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:EquitySecuritiesPreferredMember2023-09-300001872371oscf:EquitySecuritiesPreferredMemberoscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:EquitySecuritiesCommonAndWarrantsMember2024-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMemberoscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMember2023-09-300001872371oscf:EquitySecuritiesCommonAndWarrantsMemberoscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:DebtSecuritiesSeniorSecuredMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:DebtSecuritiesSeniorSecuredMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:DebtSecuritiesSubordinatedMember2023-10-012024-03-310001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:DebtSecuritiesSubordinatedMember2022-10-012023-09-300001872371oscf:EquitySecuritiesPreferredMemberoscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:EquitySecuritiesPreferredMemberoscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:EquitySecuritiesCommonAndWarrantsMemberoscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMemberoscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InvestmentTypeConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:DebtSecuritiesFloatingRateMember2024-03-310001872371oscf:DebtSecuritiesFloatingRateMember2023-09-300001872371oscf:DebtSecuritiesFixedRateMember2024-03-310001872371oscf:DebtSecuritiesFixedRateMember2023-09-300001872371country:US2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:USoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371country:US2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:USoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371country:GB2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:GBoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371country:GB2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:GBoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371country:CA2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:CAoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371country:CA2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:CAoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371country:IN2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:INoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371country:IN2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:INoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371country:CR2024-03-310001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMembercountry:CR2023-10-012024-03-310001872371country:CR2023-09-300001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMembercountry:CR2022-10-012023-09-300001872371country:CL2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:CLoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371country:CL2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:CLoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371country:CH2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:CHoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371country:CH2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:CHoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371country:FR2024-03-310001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMembercountry:FR2023-10-012024-03-310001872371country:FR2023-09-300001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMembercountry:FR2022-10-012023-09-300001872371country:KY2024-03-310001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMembercountry:KY2023-10-012024-03-310001872371country:KY2023-09-300001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMembercountry:KY2022-10-012023-09-300001872371country:LU2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:LUoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371country:LU2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:LUoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371country:AU2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:AUoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371country:AU2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:AUoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371country:NL2024-03-310001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMembercountry:NL2023-10-012024-03-310001872371country:NL2023-09-300001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMembercountry:NL2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:USoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:USoscf:InvestmentOwnedAtFairValueMember2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:USoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:USoscf:InvestmentOwnedAtFairValueMember2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:GBoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:GBoscf:InvestmentOwnedAtFairValueMember2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:GBoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:GBoscf:InvestmentOwnedAtFairValueMember2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:CAoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:CAoscf:InvestmentOwnedAtFairValueMember2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:CAoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:CAoscf:InvestmentOwnedAtFairValueMember2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:INoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:INoscf:InvestmentOwnedAtFairValueMember2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:INoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:INoscf:InvestmentOwnedAtFairValueMember2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:CRoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:CRoscf:InvestmentOwnedAtFairValueMember2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:CRoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:CRoscf:InvestmentOwnedAtFairValueMember2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:CLoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:CLoscf:InvestmentOwnedAtFairValueMember2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:CLoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:CLoscf:InvestmentOwnedAtFairValueMember2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:CHoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:CHoscf:InvestmentOwnedAtFairValueMember2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:CHoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:CHoscf:InvestmentOwnedAtFairValueMember2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:KYoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:KYoscf:InvestmentOwnedAtFairValueMember2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:KYoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:KYoscf:InvestmentOwnedAtFairValueMember2023-09-300001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMembercountry:FR2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMembercountry:FR2024-03-310001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMembercountry:FR2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMembercountry:FR2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:LUoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:LUoscf:InvestmentOwnedAtFairValueMember2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:LUoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:LUoscf:InvestmentOwnedAtFairValueMember2023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:AUoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:AUoscf:InvestmentOwnedAtFairValueMember2024-03-310001872371us-gaap:GeographicConcentrationRiskMembercountry:AUoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMembercountry:AUoscf:InvestmentOwnedAtFairValueMember2023-09-300001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMembercountry:NL2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMembercountry:NL2024-03-310001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMembercountry:NL2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMembercountry:NL2023-09-300001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2024-03-310001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:GeographicConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-09-300001872371oscf:ApplicationSoftwareMember2024-03-310001872371oscf:ApplicationSoftwareMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:ApplicationSoftwareMember2023-09-300001872371oscf:ApplicationSoftwareMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:DiversifiedSupportServicesMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:DiversifiedSupportServicesMember2023-10-012024-03-310001872371oscf:DiversifiedSupportServicesMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:DiversifiedSupportServicesMember2022-10-012023-09-300001872371oscf:HealthCareTechnologyMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HealthCareTechnologyMember2023-10-012024-03-310001872371oscf:HealthCareTechnologyMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HealthCareTechnologyMember2022-10-012023-09-300001872371oscf:SystemsSoftwareMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:SystemsSoftwareMember2023-10-012024-03-310001872371oscf:SystemsSoftwareMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:SystemsSoftwareMember2022-10-012023-09-300001872371oscf:AerospaceDefenseMember2024-03-310001872371oscf:AerospaceDefenseMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:AerospaceDefenseMember2023-09-300001872371oscf:AerospaceDefenseMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:IndustrialMachinerySuppliesComponentsMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:IndustrialMachinerySuppliesComponentsMember2023-10-012024-03-310001872371oscf:IndustrialMachinerySuppliesComponentsMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:IndustrialMachinerySuppliesComponentsMember2022-10-012023-09-300001872371oscf:HealthCareServicesMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HealthCareServicesMember2023-10-012024-03-310001872371oscf:HealthCareServicesMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HealthCareServicesMember2022-10-012023-09-300001872371oscf:InteractiveMediaServicesMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:InteractiveMediaServicesMember2023-10-012024-03-310001872371oscf:InteractiveMediaServicesMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:InteractiveMediaServicesMember2022-10-012023-09-300001872371oscf:OtherSpecialtyRetailMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:OtherSpecialtyRetailMember2023-10-012024-03-310001872371oscf:OtherSpecialtyRetailMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:OtherSpecialtyRetailMember2022-10-012023-09-300001872371oscf:MultiSectorHoldingsMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:MultiSectorHoldingsMember2023-10-012024-03-310001872371oscf:MultiSectorHoldingsMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:MultiSectorHoldingsMember2022-10-012023-09-300001872371oscf:InsuranceBrokersMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:InsuranceBrokersMember2023-10-012024-03-310001872371oscf:InsuranceBrokersMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:InsuranceBrokersMember2022-10-012023-09-300001872371oscf:PropertyCasualtyInsuranceMember2024-03-310001872371oscf:PropertyCasualtyInsuranceMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:PropertyCasualtyInsuranceMember2023-09-300001872371oscf:PropertyCasualtyInsuranceMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:PackagedFoodsMeatsMember2024-03-310001872371oscf:PackagedFoodsMeatsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:PackagedFoodsMeatsMember2023-09-300001872371oscf:PackagedFoodsMeatsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:EducationServicesMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:EducationServicesMember2023-10-012024-03-310001872371oscf:EducationServicesMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:EducationServicesMember2022-10-012023-09-300001872371oscf:EnvironmentalFacilitiesServicesMember2024-03-310001872371oscf:EnvironmentalFacilitiesServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:EnvironmentalFacilitiesServicesMember2023-09-300001872371oscf:EnvironmentalFacilitiesServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:ElectricalComponentsEquipmentMember2024-03-310001872371oscf:ElectricalComponentsEquipmentMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:ElectricalComponentsEquipmentMember2023-09-300001872371oscf:ElectricalComponentsEquipmentMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:DiversifiedMetalsMiningMember2024-03-310001872371oscf:DiversifiedMetalsMiningMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:DiversifiedMetalsMiningMember2023-09-300001872371oscf:DiversifiedMetalsMiningMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:SpecializedFinanceMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:SpecializedFinanceMember2023-10-012024-03-310001872371oscf:SpecializedFinanceMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:SpecializedFinanceMember2022-10-012023-09-300001872371oscf:OfficeServicesSuppliesMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:OfficeServicesSuppliesMember2023-10-012024-03-310001872371oscf:OfficeServicesSuppliesMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:OfficeServicesSuppliesMember2022-10-012023-09-300001872371oscf:ConstructionMachineryHeavyTransportationEquipmentMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:ConstructionMachineryHeavyTransportationEquipmentMember2023-10-012024-03-310001872371oscf:ConstructionMachineryHeavyTransportationEquipmentMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:ConstructionMachineryHeavyTransportationEquipmentMember2022-10-012023-09-300001872371oscf:DataProcessingOutsourcedServicesMember2024-03-310001872371oscf:DataProcessingOutsourcedServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:DataProcessingOutsourcedServicesMember2023-09-300001872371oscf:DataProcessingOutsourcedServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:HealthCareSuppliesMember2024-03-310001872371oscf:HealthCareSuppliesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:HealthCareSuppliesMember2023-09-300001872371oscf:HealthCareSuppliesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:LifeSciencesToolsServicesMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:LifeSciencesToolsServicesMember2023-10-012024-03-310001872371oscf:LifeSciencesToolsServicesMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:LifeSciencesToolsServicesMember2022-10-012023-09-300001872371oscf:PharmaceuticalsMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:PharmaceuticalsMember2023-10-012024-03-310001872371oscf:PharmaceuticalsMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:PharmaceuticalsMember2022-10-012023-09-300001872371oscf:MetalGlassPlasticContainersMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:MetalGlassPlasticContainersMember2023-10-012024-03-310001872371oscf:MetalGlassPlasticContainersMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:MetalGlassPlasticContainersMember2022-10-012023-09-300001872371oscf:HealthCareEquipmentMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HealthCareEquipmentMember2023-10-012024-03-310001872371oscf:HealthCareEquipmentMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HealthCareEquipmentMember2022-10-012023-09-300001872371oscf:MoviesEntertainmentMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:MoviesEntertainmentMember2023-10-012024-03-310001872371oscf:MoviesEntertainmentMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:MoviesEntertainmentMember2022-10-012023-09-300001872371oscf:ConstructionEngineeringMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:ConstructionEngineeringMember2023-10-012024-03-310001872371oscf:ConstructionEngineeringMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:ConstructionEngineeringMember2022-10-012023-09-300001872371oscf:HealthCareDistributorsMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HealthCareDistributorsMember2023-10-012024-03-310001872371oscf:HealthCareDistributorsMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HealthCareDistributorsMember2022-10-012023-09-300001872371oscf:DiversifiedChemicalsMember2024-03-310001872371oscf:DiversifiedChemicalsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:DiversifiedChemicalsMember2023-09-300001872371oscf:DiversifiedChemicalsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:AlternativeCarriersMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:AlternativeCarriersMember2023-10-012024-03-310001872371oscf:AlternativeCarriersMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:AlternativeCarriersMember2022-10-012023-09-300001872371oscf:IntegratedTelecommunicationServicesMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:IntegratedTelecommunicationServicesMember2023-10-012024-03-310001872371oscf:IntegratedTelecommunicationServicesMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:IntegratedTelecommunicationServicesMember2022-10-012023-09-300001872371oscf:RestaurantsMember2024-03-310001872371oscf:RestaurantsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:RestaurantsMember2023-09-300001872371oscf:RestaurantsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:CableSatelliteMember2024-03-310001872371oscf:CableSatelliteMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:CableSatelliteMember2023-09-300001872371oscf:CableSatelliteMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:DistributorsMember2024-03-310001872371oscf:DistributorsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:DistributorsMember2023-09-300001872371oscf:DistributorsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:AutoPartsEquipmentMember2024-03-310001872371oscf:AutoPartsEquipmentMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:AutoPartsEquipmentMember2023-09-300001872371oscf:AutoPartsEquipmentMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:ResearchConsultingServicesMember2024-03-310001872371oscf:ResearchConsultingServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:ResearchConsultingServicesMember2023-09-300001872371oscf:ResearchConsultingServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:HealthCareFacilitiesMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HealthCareFacilitiesMember2023-10-012024-03-310001872371oscf:HealthCareFacilitiesMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HealthCareFacilitiesMember2022-10-012023-09-300001872371oscf:PersonalCareProductsMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:PersonalCareProductsMember2023-10-012024-03-310001872371oscf:PersonalCareProductsMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:PersonalCareProductsMember2022-10-012023-09-300001872371oscf:BiotechnologyMember2024-03-310001872371oscf:BiotechnologyMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:BiotechnologyMember2023-09-300001872371oscf:BiotechnologyMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:GoldIndustryMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:GoldIndustryMember2023-10-012024-03-310001872371oscf:GoldIndustryMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:GoldIndustryMember2022-10-012023-09-300001872371oscf:AirFreightLogisticsMember2024-03-310001872371oscf:AirFreightLogisticsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:AirFreightLogisticsMember2023-09-300001872371oscf:AirFreightLogisticsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:TradingCompaniesDistributorsMember2024-03-310001872371oscf:TradingCompaniesDistributorsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:TradingCompaniesDistributorsMember2023-09-300001872371oscf:TradingCompaniesDistributorsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:DiversifiedFinancialServicesMember2024-03-310001872371oscf:DiversifiedFinancialServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:DiversifiedFinancialServicesMember2023-09-300001872371oscf:DiversifiedFinancialServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:PaperPlasticPackagingProductsMaterialsMember2024-03-310001872371oscf:PaperPlasticPackagingProductsMaterialsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:PaperPlasticPackagingProductsMaterialsMember2023-09-300001872371oscf:PaperPlasticPackagingProductsMaterialsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:AdvertisingIndustryMember2024-03-310001872371oscf:AdvertisingIndustryMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:AdvertisingIndustryMember2023-09-300001872371oscf:AdvertisingIndustryMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:PassengerAirlinesMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:PassengerAirlinesMember2023-10-012024-03-310001872371oscf:PassengerAirlinesMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:PassengerAirlinesMember2022-10-012023-09-300001872371oscf:HotelsResortsCruiseLinesMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HotelsResortsCruiseLinesMember2023-10-012024-03-310001872371oscf:HotelsResortsCruiseLinesMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:HotelsResortsCruiseLinesMember2022-10-012023-09-300001872371oscf:RealEstateDevelopmentMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:RealEstateDevelopmentMember2023-10-012024-03-310001872371oscf:RealEstateDevelopmentMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:RealEstateDevelopmentMember2022-10-012023-09-300001872371oscf:FoodDistributorsMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:FoodDistributorsMember2023-10-012024-03-310001872371oscf:FoodDistributorsMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:FoodDistributorsMember2022-10-012023-09-300001872371oscf:LeisureFacilitiesMember2024-03-310001872371oscf:LeisureFacilitiesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:LeisureFacilitiesMember2023-09-300001872371oscf:LeisureFacilitiesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:InternetServicesInfrastructureMember2024-03-310001872371oscf:InternetServicesInfrastructureMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:InternetServicesInfrastructureMember2023-09-300001872371oscf:InternetServicesInfrastructureMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:ConsumerFinanceMember2024-03-310001872371oscf:ConsumerFinanceMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:ConsumerFinanceMember2023-09-300001872371oscf:ConsumerFinanceMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:SoftDrinksNonAlcoholicBeveragesMember2024-03-310001872371oscf:SoftDrinksNonAlcoholicBeveragesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:SoftDrinksNonAlcoholicBeveragesMember2023-09-300001872371oscf:SoftDrinksNonAlcoholicBeveragesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:LeisureProductsMember2024-03-310001872371oscf:LeisureProductsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:LeisureProductsMember2023-09-300001872371oscf:LeisureProductsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:DiversifiedRealEstateActivitiesMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:DiversifiedRealEstateActivitiesMember2023-10-012024-03-310001872371oscf:DiversifiedRealEstateActivitiesMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:DiversifiedRealEstateActivitiesMember2022-10-012023-09-300001872371oscf:OtherSpecializedREITsMember2024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:OtherSpecializedREITsMember2023-10-012024-03-310001872371oscf:OtherSpecializedREITsMember2023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMemberoscf:OtherSpecializedREITsMember2022-10-012023-09-300001872371oscf:ConstructionMaterialsMember2024-03-310001872371oscf:ConstructionMaterialsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2023-10-012024-03-310001872371oscf:ConstructionMaterialsMember2023-09-300001872371oscf:ConstructionMaterialsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtCostNettingMember2022-10-012023-09-300001872371oscf:InvestmentOwnedAtCostNettingMemberoscf:InvestmentSectorConcentrationRiskMember2023-10-012024-03-310001872371oscf:InvestmentOwnedAtCostNettingMemberoscf:InvestmentSectorConcentrationRiskMember2022-10-012023-09-300001872371oscf:ApplicationSoftwareMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:ApplicationSoftwareMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:DiversifiedSupportServicesMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:DiversifiedSupportServicesMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:SystemsSoftwareMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:SystemsSoftwareMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HealthCareTechnologyMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HealthCareTechnologyMember2022-10-012023-09-300001872371oscf:AerospaceDefenseMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:AerospaceDefenseMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:IndustrialMachinerySuppliesComponentsMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:IndustrialMachinerySuppliesComponentsMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HealthCareServicesMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HealthCareServicesMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:InteractiveMediaServicesMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:InteractiveMediaServicesMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:OtherSpecialtyRetailMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:OtherSpecialtyRetailMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:MultiSectorHoldingsMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:MultiSectorHoldingsMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:InsuranceBrokersMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:InsuranceBrokersMember2022-10-012023-09-300001872371oscf:PropertyCasualtyInsuranceMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:PropertyCasualtyInsuranceMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:PackagedFoodsMeatsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:PackagedFoodsMeatsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:EducationServicesMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:EducationServicesMember2022-10-012023-09-300001872371oscf:EnvironmentalFacilitiesServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:EnvironmentalFacilitiesServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:ElectricalComponentsEquipmentMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:ElectricalComponentsEquipmentMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:SpecializedFinanceMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:SpecializedFinanceMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:OfficeServicesSuppliesMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:OfficeServicesSuppliesMember2022-10-012023-09-300001872371oscf:DiversifiedMetalsMiningMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:DiversifiedMetalsMiningMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:ConstructionMachineryHeavyTransportationEquipmentMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:ConstructionMachineryHeavyTransportationEquipmentMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:DataProcessingOutsourcedServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:DataProcessingOutsourcedServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:HealthCareSuppliesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:HealthCareSuppliesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:LifeSciencesToolsServicesMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:LifeSciencesToolsServicesMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:PharmaceuticalsMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:PharmaceuticalsMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:MetalGlassPlasticContainersMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:MetalGlassPlasticContainersMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HealthCareEquipmentMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HealthCareEquipmentMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:ConstructionEngineeringMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:ConstructionEngineeringMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HealthCareDistributorsMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HealthCareDistributorsMember2022-10-012023-09-300001872371oscf:DiversifiedChemicalsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:DiversifiedChemicalsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:MoviesEntertainmentMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:MoviesEntertainmentMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:AlternativeCarriersMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:AlternativeCarriersMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:IntegratedTelecommunicationServicesMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:IntegratedTelecommunicationServicesMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:RestaurantsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:RestaurantsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:CableSatelliteMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:CableSatelliteMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:ResearchConsultingServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:ResearchConsultingServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:AutoPartsEquipmentMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:AutoPartsEquipmentMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:DistributorsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:DistributorsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HealthCareFacilitiesMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HealthCareFacilitiesMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:PersonalCareProductsMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:PersonalCareProductsMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:GoldIndustryMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:GoldIndustryMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:BiotechnologyMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:BiotechnologyMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:AirFreightLogisticsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:AirFreightLogisticsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:DiversifiedFinancialServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:DiversifiedFinancialServicesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:TradingCompaniesDistributorsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:TradingCompaniesDistributorsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:PaperPlasticPackagingProductsMaterialsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:PaperPlasticPackagingProductsMaterialsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:PassengerAirlinesMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:PassengerAirlinesMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:AdvertisingIndustryMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:AdvertisingIndustryMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HotelsResortsCruiseLinesMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:HotelsResortsCruiseLinesMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:RealEstateDevelopmentMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:RealEstateDevelopmentMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:FoodDistributorsMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:FoodDistributorsMember2022-10-012023-09-300001872371oscf:LeisureFacilitiesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:LeisureFacilitiesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InternetServicesInfrastructureMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InternetServicesInfrastructureMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:ConsumerFinanceMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:ConsumerFinanceMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:SoftDrinksNonAlcoholicBeveragesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:SoftDrinksNonAlcoholicBeveragesMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:DiversifiedRealEstateActivitiesMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMemberoscf:DiversifiedRealEstateActivitiesMember2022-10-012023-09-300001872371oscf:LeisureProductsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:LeisureProductsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:OtherSpecializedREITsMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:OtherSpecializedREITsMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:ConstructionMaterialsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:ConstructionMaterialsMemberoscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2023-10-012024-03-310001872371oscf:InvestmentSectorConcentrationRiskMemberoscf:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001872371us-gaap:FairValueInputsLevel1Memberoscf:DebtSecuritiesSeniorSecuredMember2024-03-310001872371us-gaap:FairValueInputsLevel2Memberoscf:DebtSecuritiesSeniorSecuredMember2024-03-310001872371oscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Member2024-03-310001872371us-gaap:FairValueInputsLevel1Memberoscf:DebtSecuritiesSubordinatedMember2024-03-310001872371us-gaap:FairValueInputsLevel2Memberoscf:DebtSecuritiesSubordinatedMember2024-03-310001872371us-gaap:FairValueInputsLevel3Memberoscf:DebtSecuritiesSubordinatedMember2024-03-310001872371us-gaap:FairValueInputsLevel1Memberoscf:EquitySecuritiesCommonAndWarrantsMember2024-03-310001872371us-gaap:FairValueInputsLevel2Memberoscf:EquitySecuritiesCommonAndWarrantsMember2024-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMemberus-gaap:FairValueInputsLevel3Member2024-03-310001872371us-gaap:FairValueInputsLevel1Memberoscf:EquitySecuritiesPreferredMember2024-03-310001872371oscf:EquitySecuritiesPreferredMemberus-gaap:FairValueInputsLevel2Member2024-03-310001872371oscf:EquitySecuritiesPreferredMemberus-gaap:FairValueInputsLevel3Member2024-03-310001872371us-gaap:FairValueInputsLevel1Member2024-03-310001872371us-gaap:FairValueInputsLevel2Member2024-03-310001872371us-gaap:FairValueInputsLevel3Member2024-03-310001872371us-gaap:FairValueInputsLevel1Memberoscf:DebtSecuritiesSeniorSecuredMember2023-09-300001872371us-gaap:FairValueInputsLevel2Memberoscf:DebtSecuritiesSeniorSecuredMember2023-09-300001872371oscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Member2023-09-300001872371us-gaap:FairValueInputsLevel1Memberoscf:DebtSecuritiesSubordinatedMember2023-09-300001872371us-gaap:FairValueInputsLevel2Memberoscf:DebtSecuritiesSubordinatedMember2023-09-300001872371us-gaap:FairValueInputsLevel3Memberoscf:DebtSecuritiesSubordinatedMember2023-09-300001872371us-gaap:FairValueInputsLevel1Memberoscf:EquitySecuritiesCommonAndWarrantsMember2023-09-300001872371us-gaap:FairValueInputsLevel2Memberoscf:EquitySecuritiesCommonAndWarrantsMember2023-09-300001872371oscf:EquitySecuritiesCommonAndWarrantsMemberus-gaap:FairValueInputsLevel3Member2023-09-300001872371us-gaap:FairValueInputsLevel1Memberoscf:EquitySecuritiesPreferredMember2023-09-300001872371oscf:EquitySecuritiesPreferredMemberus-gaap:FairValueInputsLevel2Member2023-09-300001872371oscf:EquitySecuritiesPreferredMemberus-gaap:FairValueInputsLevel3Member2023-09-300001872371us-gaap:FairValueInputsLevel1Member2023-09-300001872371us-gaap:FairValueInputsLevel2Member2023-09-300001872371us-gaap:FairValueInputsLevel3Member2023-09-300001872371oscf:DebtSecuritiesSeniorSecuredMember2023-12-310001872371oscf:DebtSecuritiesSubordinatedMember2023-12-310001872371oscf:EquitySecuritiesPreferredMember2023-12-310001872371oscf:EquitySecuritiesCommonAndWarrantsMember2023-12-310001872371oscf:DebtSecuritiesSeniorSecuredMember2024-01-012024-03-310001872371oscf:DebtSecuritiesSubordinatedMember2024-01-012024-03-310001872371oscf:EquitySecuritiesPreferredMember2024-01-012024-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMember2024-01-012024-03-310001872371oscf:DebtAndEquitySecuritiesUnrealizedGainLossMember2024-01-012024-03-310001872371oscf:DebtAndEquitySecuritiesUnrealizedGainLossMemberoscf:DebtSecuritiesSeniorSecuredMember2024-01-012024-03-310001872371oscf:DebtSecuritiesSubordinatedMemberoscf:DebtAndEquitySecuritiesUnrealizedGainLossMember2024-01-012024-03-310001872371oscf:EquitySecuritiesPreferredMemberoscf:DebtAndEquitySecuritiesUnrealizedGainLossMember2024-01-012024-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMemberoscf:DebtAndEquitySecuritiesUnrealizedGainLossMember2024-01-012024-03-310001872371oscf:DebtAndEquitySecuritiesRealizedGainLossMember2024-01-012024-03-310001872371oscf:DebtAndEquitySecuritiesRealizedGainLossMemberoscf:DebtSecuritiesSeniorSecuredMember2024-01-012024-03-310001872371oscf:DebtAndEquitySecuritiesRealizedGainLossMemberoscf:DebtSecuritiesSubordinatedMember2024-01-012024-03-310001872371oscf:DebtAndEquitySecuritiesRealizedGainLossMemberoscf:EquitySecuritiesPreferredMember2024-01-012024-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMemberoscf:DebtAndEquitySecuritiesRealizedGainLossMember2024-01-012024-03-310001872371oscf:DebtSecuritiesSeniorSecuredMember2024-03-310001872371oscf:DebtSecuritiesSubordinatedMember2024-03-310001872371oscf:EquitySecuritiesPreferredMember2024-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMember2024-03-310001872371oscf:DebtSecuritiesSeniorSecuredMember2022-12-310001872371oscf:DebtSecuritiesSubordinatedMember2022-12-310001872371oscf:EquitySecuritiesPreferredMember2022-12-310001872371oscf:EquitySecuritiesCommonAndWarrantsMember2022-12-310001872371oscf:DebtSecuritiesSeniorSecuredMember2023-01-012023-03-310001872371oscf:DebtSecuritiesSubordinatedMember2023-01-012023-03-310001872371oscf:EquitySecuritiesPreferredMember2023-01-012023-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMember2023-01-012023-03-310001872371oscf:DebtAndEquitySecuritiesUnrealizedGainLossMember2023-01-012023-03-310001872371oscf:DebtSecuritiesSeniorSecuredMember2023-03-310001872371oscf:DebtSecuritiesSubordinatedMember2023-03-310001872371oscf:EquitySecuritiesPreferredMember2023-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMember2023-03-310001872371oscf:DebtSecuritiesSeniorSecuredMember2023-09-300001872371oscf:DebtSecuritiesSubordinatedMember2023-09-300001872371oscf:EquitySecuritiesPreferredMember2023-09-300001872371oscf:EquitySecuritiesCommonAndWarrantsMember2023-09-300001872371oscf:DebtSecuritiesSeniorSecuredMember2023-10-012024-03-310001872371oscf:DebtSecuritiesSubordinatedMember2023-10-012024-03-310001872371oscf:EquitySecuritiesPreferredMember2023-10-012024-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMember2023-10-012024-03-310001872371oscf:DebtAndEquitySecuritiesUnrealizedGainLossMember2023-10-012024-03-310001872371oscf:DebtAndEquitySecuritiesUnrealizedGainLossMemberoscf:DebtSecuritiesSeniorSecuredMember2023-10-012024-03-310001872371oscf:DebtSecuritiesSubordinatedMemberoscf:DebtAndEquitySecuritiesUnrealizedGainLossMember2023-10-012024-03-310001872371oscf:EquitySecuritiesPreferredMemberoscf:DebtAndEquitySecuritiesUnrealizedGainLossMember2023-10-012024-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMemberoscf:DebtAndEquitySecuritiesUnrealizedGainLossMember2023-10-012024-03-310001872371oscf:DebtAndEquitySecuritiesRealizedGainLossMember2023-10-012024-03-310001872371oscf:DebtAndEquitySecuritiesRealizedGainLossMemberoscf:DebtSecuritiesSeniorSecuredMember2023-10-012024-03-310001872371oscf:DebtAndEquitySecuritiesRealizedGainLossMemberoscf:DebtSecuritiesSubordinatedMember2023-10-012024-03-310001872371oscf:DebtAndEquitySecuritiesRealizedGainLossMemberoscf:EquitySecuritiesPreferredMember2023-10-012024-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMemberoscf:DebtAndEquitySecuritiesRealizedGainLossMember2023-10-012024-03-310001872371oscf:DebtSecuritiesSeniorSecuredMember2022-09-300001872371oscf:DebtSecuritiesSubordinatedMember2022-09-300001872371oscf:EquitySecuritiesPreferredMember2022-09-300001872371oscf:EquitySecuritiesCommonAndWarrantsMember2022-09-300001872371oscf:DebtSecuritiesSeniorSecuredMember2022-10-012023-03-310001872371oscf:DebtSecuritiesSubordinatedMember2022-10-012023-03-310001872371oscf:EquitySecuritiesPreferredMember2022-10-012023-03-310001872371oscf:EquitySecuritiesCommonAndWarrantsMember2022-10-012023-03-310001872371oscf:DebtAndEquitySecuritiesUnrealizedGainLossMember2022-10-012023-03-310001872371us-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberoscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Member2024-03-310001872371us-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberoscf:DebtSecuritiesSeniorSecuredMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Member2024-03-310001872371us-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberoscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMember2024-03-310001872371srt:WeightedAverageMemberus-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberoscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Member2024-03-310001872371oscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Memberoscf:ValuationEnterpriseValueMemberus-gaap:MeasurementInputEbitdaMultipleMember2024-03-310001872371oscf:DebtSecuritiesSeniorSecuredMemberoscf:ValuationEnterpriseValueMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputEbitdaMultipleMember2024-03-310001872371oscf:DebtSecuritiesSeniorSecuredMemberoscf:ValuationEnterpriseValueMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMemberus-gaap:MeasurementInputEbitdaMultipleMember2024-03-310001872371srt:WeightedAverageMemberoscf:DebtSecuritiesSeniorSecuredMemberoscf:ValuationEnterpriseValueMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputEbitdaMultipleMember2024-03-310001872371oscf:ValuationTransactionPrecedentMemberoscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Memberoscf:MeasurementInputTransactionPriceMember2024-03-310001872371oscf:MeasurementInputBrokerQuotedPriceMemberoscf:ValuationBrokerQuotationsMemberoscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Member2024-03-310001872371us-gaap:SubordinatedDebtMemberus-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberus-gaap:FairValueInputsLevel3Member2024-03-310001872371us-gaap:SubordinatedDebtMemberus-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Member2024-03-310001872371us-gaap:SubordinatedDebtMemberus-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMember2024-03-310001872371srt:WeightedAverageMemberus-gaap:SubordinatedDebtMemberus-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberus-gaap:FairValueInputsLevel3Member2024-03-310001872371us-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberoscf:ValuationEnterpriseValueMemberoscf:EquitySecuritiesPreferredCommonMember2024-03-310001872371us-gaap:MeasurementInputRevenueMultipleMemberoscf:ValuationEnterpriseValueMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberoscf:EquitySecuritiesPreferredCommonMember2024-03-310001872371us-gaap:MeasurementInputRevenueMultipleMemberoscf:ValuationEnterpriseValueMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMemberoscf:EquitySecuritiesPreferredCommonMember2024-03-310001872371srt:WeightedAverageMemberus-gaap:MeasurementInputRevenueMultipleMemberoscf:ValuationEnterpriseValueMemberus-gaap:FairValueInputsLevel3Memberoscf:EquitySecuritiesPreferredCommonMember2024-03-310001872371us-gaap:FairValueInputsLevel3Memberoscf:ValuationEnterpriseValueMemberoscf:EquitySecuritiesPreferredCommonMemberus-gaap:MeasurementInputEbitdaMultipleMember2024-03-310001872371oscf:ValuationEnterpriseValueMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberoscf:EquitySecuritiesPreferredCommonMemberus-gaap:MeasurementInputEbitdaMultipleMember2024-03-310001872371oscf:ValuationEnterpriseValueMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMemberoscf:EquitySecuritiesPreferredCommonMemberus-gaap:MeasurementInputEbitdaMultipleMember2024-03-310001872371srt:WeightedAverageMemberoscf:ValuationEnterpriseValueMemberus-gaap:FairValueInputsLevel3Memberoscf:EquitySecuritiesPreferredCommonMemberus-gaap:MeasurementInputEbitdaMultipleMember2024-03-310001872371oscf:ValuationTransactionPrecedentMemberus-gaap:FairValueInputsLevel3Memberoscf:MeasurementInputTransactionPriceMemberoscf:EquitySecuritiesPreferredCommonMember2024-03-310001872371us-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberoscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Member2023-09-300001872371us-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberoscf:DebtSecuritiesSeniorSecuredMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Member2023-09-300001872371us-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberoscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMember2023-09-300001872371srt:WeightedAverageMemberus-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberoscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Member2023-09-300001872371oscf:ValuationTransactionPrecedentMemberoscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Memberoscf:MeasurementInputTransactionPriceMember2023-09-300001872371oscf:MeasurementInputBrokerQuotedPriceMemberoscf:ValuationBrokerQuotationsMemberoscf:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Member2023-09-300001872371us-gaap:SubordinatedDebtMemberus-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberus-gaap:FairValueInputsLevel3Member2023-09-300001872371us-gaap:SubordinatedDebtMemberus-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Member2023-09-300001872371us-gaap:SubordinatedDebtMemberus-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMember2023-09-300001872371srt:WeightedAverageMemberus-gaap:SubordinatedDebtMemberus-gaap:MarketApproachValuationTechniqueMemberoscf:MeasurementInputMarketYieldMemberus-gaap:FairValueInputsLevel3Member2023-09-300001872371us-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberoscf:ValuationEnterpriseValueMemberoscf:EquitySecuritiesPreferredCommonMember2023-09-300001872371us-gaap:MeasurementInputRevenueMultipleMemberoscf:ValuationEnterpriseValueMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberoscf:EquitySecuritiesPreferredCommonMember2023-09-300001872371us-gaap:MeasurementInputRevenueMultipleMemberoscf:ValuationEnterpriseValueMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMemberoscf:EquitySecuritiesPreferredCommonMember2023-09-300001872371srt:WeightedAverageMemberus-gaap:MeasurementInputRevenueMultipleMemberoscf:ValuationEnterpriseValueMemberus-gaap:FairValueInputsLevel3Memberoscf:EquitySecuritiesPreferredCommonMember2023-09-300001872371us-gaap:FairValueInputsLevel3Memberoscf:ValuationEnterpriseValueMemberoscf:EquitySecuritiesPreferredCommonMemberus-gaap:MeasurementInputEbitdaMultipleMember2023-09-300001872371oscf:ValuationEnterpriseValueMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberoscf:EquitySecuritiesPreferredCommonMemberus-gaap:MeasurementInputEbitdaMultipleMember2023-09-300001872371oscf:ValuationEnterpriseValueMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMemberoscf:EquitySecuritiesPreferredCommonMemberus-gaap:MeasurementInputEbitdaMultipleMember2023-09-300001872371srt:WeightedAverageMemberoscf:ValuationEnterpriseValueMemberus-gaap:FairValueInputsLevel3Memberoscf:EquitySecuritiesPreferredCommonMemberus-gaap:MeasurementInputEbitdaMultipleMember2023-09-300001872371oscf:ValuationTransactionPrecedentMemberus-gaap:FairValueInputsLevel3Memberoscf:MeasurementInputTransactionPriceMemberoscf:EquitySecuritiesPreferredCommonMember2023-09-300001872371us-gaap:CommonStockMember2023-09-300001872371us-gaap:AdditionalPaidInCapitalMember2023-09-300001872371oscf:InvestmentCompanyAccumulatedOverdistributedEarningsMember2023-09-300001872371us-gaap:CommonStockMember2023-10-012023-12-310001872371us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-3100018723712023-10-012023-12-310001872371oscf:InvestmentCompanyAccumulatedOverdistributedEarningsMember2023-10-012023-12-310001872371us-gaap:CommonStockMember2023-12-310001872371us-gaap:AdditionalPaidInCapitalMember2023-12-310001872371oscf:InvestmentCompanyAccumulatedOverdistributedEarningsMember2023-12-310001872371us-gaap:CommonStockMember2024-01-012024-03-310001872371us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001872371oscf:InvestmentCompanyAccumulatedOverdistributedEarningsMember2024-01-012024-03-310001872371us-gaap:CommonStockMember2024-03-310001872371us-gaap:AdditionalPaidInCapitalMember2024-03-310001872371oscf:InvestmentCompanyAccumulatedOverdistributedEarningsMember2024-03-310001872371us-gaap:CommonStockMember2022-09-300001872371us-gaap:AdditionalPaidInCapitalMember2022-09-300001872371oscf:InvestmentCompanyAccumulatedOverdistributedEarningsMember2022-09-300001872371us-gaap:CommonStockMember2022-10-012022-12-310001872371us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-3100018723712022-10-012022-12-310001872371oscf:InvestmentCompanyAccumulatedOverdistributedEarningsMember2022-10-012022-12-310001872371us-gaap:CommonStockMember2022-12-310001872371us-gaap:AdditionalPaidInCapitalMember2022-12-310001872371oscf:InvestmentCompanyAccumulatedOverdistributedEarningsMember2022-12-310001872371us-gaap:CommonStockMember2023-01-012023-03-310001872371us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001872371oscf:InvestmentCompanyAccumulatedOverdistributedEarningsMember2023-01-012023-03-310001872371us-gaap:CommonStockMember2023-03-310001872371us-gaap:AdditionalPaidInCapitalMember2023-03-310001872371oscf:InvestmentCompanyAccumulatedOverdistributedEarningsMember2023-03-310001872371oscf:CommonClassIMember2023-10-310001872371oscf:CommonClassSMember2023-10-310001872371oscf:CommonClassDMember2023-10-310001872371oscf:CommonClassIMember2023-11-300001872371oscf:CommonClassSMember2023-11-300001872371oscf:CommonClassDMember2023-11-300001872371oscf:CommonClassIMember2023-12-310001872371oscf:CommonClassSMember2023-12-310001872371oscf:CommonClassDMember2023-12-310001872371oscf:CommonClassIMember2024-01-310001872371oscf:CommonClassSMember2024-01-310001872371oscf:CommonClassDMember2024-01-310001872371oscf:CommonClassIMember2024-02-290001872371oscf:CommonClassSMember2024-02-290001872371oscf:CommonClassDMember2024-02-290001872371oscf:CommonClassIMember2022-10-310001872371oscf:CommonClassSMember2022-10-310001872371oscf:CommonClassDMember2022-10-310001872371oscf:CommonClassIMember2022-11-300001872371oscf:CommonClassSMember2022-11-300001872371oscf:CommonClassDMember2022-11-300001872371oscf:CommonClassIMember2022-12-310001872371oscf:CommonClassSMember2022-12-310001872371oscf:CommonClassDMember2022-12-310001872371oscf:CommonClassIMember2023-01-310001872371oscf:CommonClassSMember2023-01-310001872371oscf:CommonClassDMember2023-01-310001872371oscf:CommonClassIMember2023-02-280001872371oscf:CommonClassSMember2023-02-280001872371oscf:CommonClassDMember2023-02-280001872371oscf:CommonClassIMember2023-03-310001872371oscf:CommonClassSMember2023-03-310001872371oscf:CommonClassDMember2023-03-310001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassIMember2023-11-282023-11-280001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassIMember2023-12-272023-12-270001872371oscf:CommonClassIMemberoscf:DistributionTypeSpecialMember2023-12-272023-12-270001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassIMember2024-02-012024-02-010001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassIMember2024-02-272024-02-270001872371oscf:CommonClassIMemberoscf:DistributionTypeSpecialMember2024-03-272024-03-270001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassIMemberus-gaap:SubsequentEventMember2024-04-292024-04-290001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMember2023-11-282023-11-280001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMember2023-12-272023-12-270001872371oscf:CommonClassSMemberoscf:DistributionTypeSpecialMember2023-12-272023-12-270001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMember2024-02-012024-02-010001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMember2024-02-272024-02-270001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMember2024-03-272024-03-270001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMemberus-gaap:SubsequentEventMember2024-04-292024-04-290001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassDMember2023-11-282023-11-280001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassDMember2023-12-272023-12-270001872371oscf:CommonClassDMemberoscf:DistributionTypeSpecialMember2023-12-272023-12-270001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassDMember2024-02-012024-02-010001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassDMember2024-02-272024-02-270001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassDMember2024-03-272024-03-270001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassDMemberus-gaap:SubsequentEventMember2024-04-292024-04-290001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassIMember2022-11-282022-11-280001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassIMember2022-12-282022-12-280001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassIMember2023-01-302023-01-300001872371oscf:CommonClassIMemberoscf:DistributionTypeSpecialMember2023-01-302023-01-300001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassIMember2023-02-242023-02-240001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassIMember2023-03-292023-03-290001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassIMember2023-04-272023-04-270001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMember2022-11-282022-11-280001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMember2022-12-282022-12-280001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMember2023-01-302023-01-300001872371oscf:CommonClassSMemberoscf:DistributionTypeSpecialMember2023-01-302023-01-300001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMember2023-02-242023-02-240001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMember2023-03-292023-03-290001872371oscf:DistributionTypeMonthlyMemberoscf:CommonClassSMember2023-04-272023-04-270001872371srt:AffiliatedEntityMemberoscf:ExpenseSupportAndConditionalReimbursementAgreementMember2023-10-012024-03-310001872371oscf:December312023Member2023-10-012024-03-310001872371oscf:March312024Member2023-10-012024-03-310001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2022-05-240001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2022-05-250001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2022-05-252022-05-250001872371oscf:INGCreditAgreementMemberus-gaap:LetterOfCreditMember2022-05-250001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2022-10-060001872371oscf:INGCreditAgreementAmendmentMemberus-gaap:LineOfCreditMember2023-06-280001872371oscf:INGCreditAgreementAmendmentMemberus-gaap:LineOfCreditMember2023-06-282023-06-280001872371oscf:INGCreditAgreementAmendmentMemberus-gaap:LetterOfCreditMember2023-06-280001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2023-08-150001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2023-06-280001872371oscf:INGCreditAgreementMemberoscf:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2022-05-252022-05-250001872371oscf:INGCreditAgreementMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMember2022-05-252022-05-250001872371oscf:INGCreditAgreementMemberoscf:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2023-06-282023-06-280001872371oscf:INGCreditAgreementMemberus-gaap:ExternalCreditRatingInvestmentGradeMemberoscf:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2023-06-282023-06-280001872371oscf:INGCreditAgreementMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMember2023-06-282023-06-280001872371oscf:INGCreditAgreementMemberus-gaap:BaseRateMemberus-gaap:ExternalCreditRatingInvestmentGradeMemberus-gaap:LineOfCreditMember2023-06-282023-06-280001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2023-06-282023-06-280001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2024-03-310001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2023-09-300001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2023-03-310001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2024-01-012024-03-310001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2023-10-012024-03-310001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2023-01-012023-03-310001872371oscf:INGCreditAgreementMemberus-gaap:LineOfCreditMember2022-10-012023-03-310001872371oscf:JPMSPVFacilityMemberus-gaap:LineOfCreditMember2023-02-240001872371oscf:JPMSPVFacilityMemberus-gaap:LineOfCreditMember2023-07-050001872371oscf:JPMSPVFacilityMemberus-gaap:LineOfCreditMember2023-02-242023-02-240001872371oscf:JPMSPVFacilityMemberoscf:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2023-02-242023-02-240001872371oscf:JPMSPVFacilityMemberus-gaap:LineOfCreditMember2023-03-310001872371oscf:JPMSPVFacilityMemberus-gaap:LineOfCreditMember2024-01-012024-03-310001872371oscf:JPMSPVFacilityMemberus-gaap:LineOfCreditMember2023-10-012024-03-310001872371oscf:JPMSPVFacilityMemberus-gaap:LineOfCreditMember2023-01-012023-03-310001872371oscf:JPMSPVFacilityMemberus-gaap:LineOfCreditMember2022-10-012023-03-310001872371oscf:SMBCSPVFacilityMemberus-gaap:LineOfCreditMember2023-09-290001872371oscf:SMBCSPVFacilityMemberus-gaap:LineOfCreditMember2023-09-292023-09-290001872371oscf:SMBCSPVFacilityMembersrt:MinimumMemberoscf:InterestRateScenarioOneMemberus-gaap:LineOfCreditMemberoscf:SecuredOvernightFinancingRateSOFRMember2023-09-292023-09-290001872371oscf:SMBCSPVFacilityMembersrt:MaximumMemberoscf:InterestRateScenarioOneMemberus-gaap:LineOfCreditMemberoscf:CollateralCreditFacilityMemberoscf:SecuredOvernightFinancingRateSOFRMember2023-09-292023-09-290001872371oscf:SMBCSPVFacilityMemberus-gaap:BaseRateMemberoscf:InterestRateScenarioTwoMemberus-gaap:LineOfCreditMember2023-09-292023-09-290001872371oscf:SMBCSPVFacilityMemberoscf:InterestRateScenarioTwoMemberoscf:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2023-09-292023-09-290001872371oscf:SMBCSPVFacilityMembersrt:MinimumMemberoscf:InterestRateScenarioTwoMemberus-gaap:LineOfCreditMemberoscf:SecuredOvernightFinancingRateSOFRMember2023-09-292023-09-290001872371oscf:SMBCSPVFacilityMemberoscf:InterestRateScenarioTwoMembersrt:MaximumMemberus-gaap:LineOfCreditMemberoscf:CollateralCreditFacilityMemberoscf:SecuredOvernightFinancingRateSOFRMember2023-09-292023-09-290001872371oscf:SMBCSPVFacilityMemberus-gaap:LineOfCreditMember2024-01-012024-03-310001872371oscf:SMBCSPVFacilityMemberus-gaap:LineOfCreditMember2023-10-012024-03-310001872371oscf:CIBCLoanAndServicingAgreementMemberus-gaap:LineOfCreditMember2023-11-210001872371oscf:CIBCLoanAndServicingAgreementMemberus-gaap:LineOfCreditMember2023-11-212023-11-210001872371oscf:CIBCLoanAndServicingAgreementMemberoscf:InterestRateScenarioOneMemberoscf:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2023-11-212023-11-210001872371oscf:CIBCLoanAndServicingAgreementMemberus-gaap:BaseRateMemberoscf:InterestRateScenarioTwoMemberus-gaap:LineOfCreditMember2023-09-292023-09-290001872371oscf:CIBCLoanAndServicingAgreementMemberoscf:InterestRateScenarioTwoMemberoscf:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2023-11-212023-11-210001872371oscf:CIBCLoanAndServicingAgreementMemberoscf:InterestRateScenarioTwoMemberus-gaap:LineOfCreditMember2023-11-212023-11-210001872371oscf:CIBCLoanAndServicingAgreementMemberoscf:InterestRateScenarioThreeMemberoscf:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2023-11-212023-11-210001872371oscf:CIBCLoanAndServicingAgreementMemberus-gaap:LineOfCreditMember2024-01-012024-03-310001872371oscf:CIBCLoanAndServicingAgreementMemberus-gaap:LineOfCreditMember2023-10-012024-03-310001872371oscf:DBNYSPVFacilityMemberus-gaap:LineOfCreditMember2024-02-150001872371oscf:DBNYSPVFacilityMemberus-gaap:LineOfCreditMember2024-02-152024-02-150001872371oscf:DBNYSPVFacilityMemberoscf:InterestRateScenarioOneMemberoscf:CostOfFundsRateMemberus-gaap:LineOfCreditMember2024-02-152024-02-150001872371oscf:DBNYSPVFacilityMemberoscf:InterestRateScenarioTwoMemberoscf:CostOfFundsRateMemberus-gaap:LineOfCreditMember2024-02-152024-02-150001872371oscf:DBNYSPVFacilityMemberoscf:InterestRateScenarioThreeMemberoscf:CostOfFundsRateMemberus-gaap:LineOfCreditMember2024-02-152024-02-150001872371oscf:DBNYSPVFacilityMemberus-gaap:LineOfCreditMember2024-03-310001872371oscf:DBNYSPVFacilityMemberus-gaap:LineOfCreditMember2023-10-012024-03-310001872371oscf:MSSPVFacilityMemberus-gaap:LineOfCreditMember2024-02-230001872371oscf:MSSPVFacilityMemberus-gaap:LineOfCreditMember2024-02-232024-02-230001872371oscf:MSSPVFacilityMemberoscf:InterestRateScenarioOneMemberoscf:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2024-02-232024-02-230001872371oscf:InterestRateScenarioTwoMemberoscf:MSSPVFacilityMemberoscf:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2024-02-232024-02-230001872371oscf:InterestRateScenarioThreeMemberoscf:MSSPVFacilityMemberoscf:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2024-02-232024-02-230001872371oscf:MSSPVFacilityMemberus-gaap:LineOfCreditMember2024-03-310001872371oscf:MSSPVFacilityMemberus-gaap:LineOfCreditMember2023-10-012024-03-310001872371oscf:NotesDue2028Memberus-gaap:NotesPayableToBanksMember2023-11-1400018723712023-11-140001872371oscf:SecuredOvernightFinancingRateSOFRMember2023-11-140001872371oscf:A2028NotesMember2024-03-310001872371oscf:A2028NotesMember2024-01-012024-03-310001872371oscf:A2028NotesMember2023-10-012024-03-310001872371oscf:INGCreditAgreementMemberoscf:FederalFundsEffectiveRateMemberus-gaap:LineOfCreditMember2022-05-252022-05-250001872371oscf:INGCreditAgreementMemberoscf:OvernightBankFundingRateMemberus-gaap:LineOfCreditMember2022-05-252022-05-250001872371oscf:INGCreditAgreementMemberoscf:FederalFundsEffectiveRateMemberus-gaap:LineOfCreditMember2023-06-282023-06-280001872371oscf:INGCreditAgreementMemberoscf:OvernightBankFundingRateMemberus-gaap:LineOfCreditMember2023-06-282023-06-280001872371oscf:SMBCSPVFacilityMemberoscf:FederalFundsEffectiveRateMemberus-gaap:LineOfCreditMember2023-09-292023-09-290001872371oscf:CIBCLoanAndServicingAgreementMemberoscf:FederalFundsEffectiveRateMemberus-gaap:LineOfCreditMember2023-11-212023-11-210001872371srt:AffiliatedEntityMember2023-10-012024-03-310001872371srt:AffiliatedEntityMemberoscf:ManagementFeeMember2023-10-012024-03-310001872371srt:AffiliatedEntityMemberoscf:ManagementFeeMember2023-01-012023-03-310001872371srt:AffiliatedEntityMemberoscf:ManagementFeeMember2022-10-012023-03-310001872371oscf:InvestmentIncomeIncentiveFeeHurdleRateQuarterlyMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:InvestmentIncomeIncentiveFeeHurdleRateAnnualizedMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:InvestmentIncomeIncentiveFeeIncentiveRatePreIncentiveFeeNetInvestmentIncomeBelowCatchUpThresholdMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:InvestmentIncomeIncentiveFeeIncentiveRateQuarterlyCatchUpThresholdMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371srt:AffiliatedEntityMemberoscf:InvestmentIncomeIncentiveFeeIncentiveRateAnnualizedCatchUpThresholdMember2023-10-012024-03-310001872371oscf:InvestmentIncomeIncentiveFeeIncentiveRatePreIncentiveFeeNetInvestmentIncomeMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:IncentiveFeeMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:IncentiveFeeMembersrt:AffiliatedEntityMember2023-01-012023-03-310001872371oscf:IncentiveFeeMembersrt:AffiliatedEntityMember2022-10-012023-03-310001872371srt:AffiliatedEntityMemberoscf:CapitalGainsIncentiveFeeIncentiveRateMember2023-10-012024-03-310001872371oscf:InvestmentAdvisoryAgreementMembersrt:AffiliatedEntityMember2024-01-012024-03-310001872371oscf:InvestmentAdvisoryAgreementMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:InvestmentAdvisoryAgreementMembersrt:AffiliatedEntityMember2023-01-012023-03-310001872371oscf:InvestmentAdvisoryAgreementMembersrt:AffiliatedEntityMember2022-10-012023-03-310001872371oscf:InvestmentAdvisoryAgreementMembersrt:AffiliatedEntityMember2022-02-032024-03-310001872371oscf:AdministrationAgreementMembersrt:AffiliatedEntityMember2024-01-012024-03-310001872371oscf:AdministrationAgreementMemberoscf:AdministratorExpenseMembersrt:AffiliatedEntityMember2024-01-012024-03-310001872371oscf:AdministrationAgreementMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:AdministrationAgreementMemberoscf:AdministratorExpenseMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:AdministrationAgreementMembersrt:AffiliatedEntityMember2023-01-012023-03-310001872371oscf:AdministrationAgreementMemberoscf:AdministratorExpenseMembersrt:AffiliatedEntityMember2023-01-012023-03-310001872371oscf:AdministrationAgreementMemberus-gaap:GeneralAndAdministrativeExpenseMembersrt:AffiliatedEntityMember2023-01-012023-03-310001872371oscf:AdministrationAgreementMembersrt:AffiliatedEntityMember2022-10-012023-03-310001872371oscf:AdministrationAgreementMemberoscf:AdministratorExpenseMembersrt:AffiliatedEntityMember2022-10-012023-03-310001872371oscf:AdministrationAgreementMemberus-gaap:GeneralAndAdministrativeExpenseMembersrt:AffiliatedEntityMember2022-10-012023-03-310001872371oscf:AdministrationAgreementMemberoscf:OrganizationExpenseAndAmortizationOfOfferingCostsMembersrt:AffiliatedEntityMember2022-10-012023-03-310001872371oscf:InvestmentAdvisoryAgreementAndAdministrationAgreementMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:AdviserMembersrt:AffiliatedEntityMemberoscf:InvestmentAdvisoryAgreementMember2023-10-012024-03-310001872371oscf:AdministrationAgreementMemberoscf:AdmnistratorMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:CommonClassSMemberoscf:DistributionManagerAgreementMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:DistributionManagerAgreementMemberoscf:CommonClassDMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:DistributionManagerAgreementMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371oscf:CommonClassIMemberoscf:DistributionManagerAgreementMembersrt:AffiliatedEntityMember2023-10-012024-03-310001872371srt:AffiliatedEntityMember2022-10-012023-03-310001872371oscf:CommonClassIMember2022-09-300001872371oscf:CommonClassSMember2022-09-300001872371EUR Foreign Currency Forward Contract, Maturing May 9, 20242024-03-310001872371GBP Foreign Currency Forward Contract, Maturing May 9, 20242024-03-310001872371EUR Foreign Currency Forward Contract, Maturing November 9, 20232023-09-300001872371GBP Foreign Currency Forward Contract, Maturing November 9, 20232023-09-300001872371oscf:InterestRateSwapMaturingNovember2028Member2024-03-310001872371MRI Software LLC2024-03-310001872371MRI Software LLC2023-09-300001872371AmSpec Parent LLC2024-03-310001872371AmSpec Parent LLC2023-09-300001872371PetVet Care Centers, LLC2024-03-310001872371PetVet Care Centers, LLC2023-09-300001872371107-109 Beech OAK22 LLC2024-03-310001872371107-109 Beech OAK22 LLC2023-09-300001872371NFM & J, L.P.2024-03-310001872371NFM & J, L.P.2023-09-300001872371Next Holdco, LLC2024-03-310001872371Next Holdco, LLC2023-09-300001872371Monotype Imaging Holdings Inc.2024-03-310001872371Monotype Imaging Holdings Inc.2023-09-300001872371Biscuit Parent, LLC2024-03-310001872371Biscuit Parent, LLC2023-09-300001872371CVAUSA Management, LLC2024-03-310001872371CVAUSA Management, LLC2023-09-300001872371Ecco Holdings Corp.2024-03-310001872371Ecco Holdings Corp.2023-09-300001872371Seres Therapeutics, Inc.2024-03-310001872371Seres Therapeutics, Inc.2023-09-300001872371OneOncology, LLC2024-03-310001872371OneOncology, LLC2023-09-300001872371Neptune Platform Buyer, LLC2024-03-310001872371Neptune Platform Buyer, LLC2023-09-300001872371Bamboo US Bidco LLC2024-03-310001872371Bamboo US Bidco LLC2023-09-300001872371Ardonagh Midco 3 PLC2024-03-310001872371Ardonagh Midco 3 PLC2023-09-300001872371North Star Acquisitionco, LLC2024-03-310001872371North Star Acquisitionco, LLC2023-09-300001872371scPharmaceuticals Inc.2024-03-310001872371scPharmaceuticals Inc.2023-09-300001872371Enverus Holdings, Inc.2024-03-310001872371Enverus Holdings, Inc.2023-09-300001872371Protein for Pets Opco, LLC2024-03-310001872371Protein for Pets Opco, LLC2023-09-300001872371IW Buyer LLC2024-03-310001872371IW Buyer LLC2023-09-300001872371Project Accelerate Parent, LLC2024-03-310001872371Project Accelerate Parent, LLC2023-09-300001872371WP CPP Holdings, LLC2024-03-310001872371WP CPP Holdings, LLC2023-09-300001872371ACP Falcon Buyer Inc2024-03-310001872371ACP Falcon Buyer Inc2023-09-300001872371Grove Hotel Parcel Owner, LLC2024-03-310001872371Grove Hotel Parcel Owner, LLC2023-09-300001872371Entrata, Inc.2024-03-310001872371Entrata, Inc.2023-09-300001872371Harrow, Inc.2024-03-310001872371Harrow, Inc.2023-09-300001872371Kings Buyer, LLC2024-03-310001872371Kings Buyer, LLC2023-09-300001872371Inventus Power, Inc.2024-03-310001872371Inventus Power, Inc.2023-09-300001872371SEI Holding I Corporation2024-03-310001872371SEI Holding I Corporation2023-09-300001872371Crewline Buyer, Inc.2024-03-310001872371Crewline Buyer, Inc.2023-09-300001872371BioXcel Therapeutics, Inc.2024-03-310001872371BioXcel Therapeutics, Inc.2023-09-300001872371iCIMs, Inc.2024-03-310001872371iCIMs, Inc.2023-09-300001872371Evergreen IX Borrower 2023, LLC2024-03-310001872371Evergreen IX Borrower 2023, LLC2023-09-300001872371Finastra USA, Inc.2024-03-310001872371Finastra USA, Inc.2023-09-300001872371107 Fair Street LLC2024-03-310001872371107 Fair Street LLC2023-09-300001872371Establishment Labs Holdings Inc.2024-03-310001872371Establishment Labs Holdings Inc.2023-09-300001872371HUB Pen Company, LLC2024-03-310001872371HUB Pen Company, LLC2023-09-300001872371Icefall Parent, Inc.2024-03-310001872371Icefall Parent, Inc.2023-09-300001872371Transit Buyer LLC2024-03-310001872371Transit Buyer LLC2023-09-300001872371Dukes Root Control Inc.2024-03-310001872371Dukes Root Control Inc.2023-09-300001872371Coupa Holdings, LLC2024-03-310001872371Coupa Holdings, LLC2023-09-300001872371Oranje Holdco, Inc.2024-03-310001872371Oranje Holdco, Inc.2023-09-300001872371Avalara, Inc.2024-03-310001872371Avalara, Inc.2023-09-300001872371Salus Workers' Compensation, LLC2024-03-310001872371Salus Workers' Compensation, LLC2023-09-300001872371PPW Aero Buyer, Inc.2024-03-310001872371PPW Aero Buyer, Inc.2023-09-300001872371Galileo Parent, Inc.2024-03-310001872371Galileo Parent, Inc.2023-09-300001872371112-126 Van Houten Real22 LLC2024-03-310001872371112-126 Van Houten Real22 LLC2023-09-300001872371SCP Eye Care Services, LLC2024-03-310001872371SCP Eye Care Services, LLC2023-09-300001872371LSL Holdco, LLC2024-03-310001872371LSL Holdco, LLC2023-09-300001872371ASP-R-PAC Acquisition Co LLC2024-03-310001872371ASP-R-PAC Acquisition Co LLC2023-09-300001872371Supreme Fitness Group NY Holdings, LLC2024-03-310001872371Supreme Fitness Group NY Holdings, LLC2023-09-300001872371Delta Leasing SPV II LLC2024-03-310001872371Delta Leasing SPV II LLC2023-09-300001872371Resistance Acquisition, Inc.2024-03-310001872371Resistance Acquisition, Inc.2023-09-300001872371MND Holdings III Corp2024-03-310001872371MND Holdings III Corp2023-09-300001872371ADC Therapeutics SA2024-03-310001872371ADC Therapeutics SA2023-09-300001872371Innocoll Pharmaceuticals Limited2024-03-310001872371Innocoll Pharmaceuticals Limited2023-09-300001872371Impel Pharmaceuticals Inc.2024-03-310001872371Impel Pharmaceuticals Inc.2023-09-300001872371Pluralsight, LLC2024-03-310001872371Pluralsight, LLC2023-09-300001872371oscf:CommonClassIMemberus-gaap:SubsequentEventMember2024-04-012024-04-010001872371oscf:CommonClassSMemberus-gaap:SubsequentEventMember2024-04-012024-04-010001872371oscf:CommonClassDMemberus-gaap:SubsequentEventMember2024-04-012024-04-010001872371oscf:CommonClassIMemberus-gaap:SubsequentEventMember2024-04-182024-04-180001872371oscf:CommonClassSMemberus-gaap:SubsequentEventMember2024-04-182024-04-180001872371oscf:CommonClassDMemberus-gaap:SubsequentEventMember2024-04-182024-04-18
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 10-Q
(Mark One)
| | | | | | | | | | | |
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) |
| | OF THE SECURITIES EXCHANGE ACT OF 1934 | |
For the quarterly period ended March 31, 2024
OR
| | | | | | | | | | | |
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) |
| | OF THE SECURITIES EXCHANGE ACT OF 1934 | |
COMMISSION FILE NUMBER: 814-01471
Oaktree Strategic Credit Fund
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
| | | | | | | | |
Delaware (State or jurisdiction of incorporation or organization) | | 87-6827742 (I.R.S. Employer Identification No.) |
| | |
333 South Grand Avenue, 28th Floor Los Angeles, CA (Address of principal executive office) | | 90071 (Zip Code) |
REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE:
(213) 830-6300
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
| | | | | | | | | | | | | | | | | | | | |
Large accelerated filer o | | Accelerated filer o | | Non-accelerated filer x | | Smaller reporting company o |
| | | | | | |
Emerging growth company x | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) Yes ¨ No x
Securities registered pursuant to Section 12(b) of the Act
| | | | | | | | |
Title of Each Class | Trading Symbol(s) | Name of Exchange on Which Registered |
N/A | N/A | N/A |
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
| | | | | | | | |
Class | | Outstanding at May 10, 2024* |
Class I shares of beneficial interest, $0.01 par value | | 74,680,237 |
Class S shares of beneficial interest, $0.01 par value | | 36,717,923 |
Class D shares of beneficial interest, $0.01 par value | | 53,792 |
Class T shares of beneficial interest, $0.01 par value | | — |
* Common shares outstanding exclude May 1, 2024 subscriptions because the issuance price is not yet finalized as of the date hereof.
OAKTREE STRATEGIC CREDIT FUND
FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2024
TABLE OF CONTENTS
| | | | | | | | |
| | |
| PART I | |
Item 1. | | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
Item 2. | | |
Item 3. | | |
Item 4. | | |
| PART II | |
Item 1. | | |
Item 1A. | | |
Item 2. | | |
Item 3. | | |
Item 4. | | |
Item 5. | | |
Item 6. | | |
| |
PART I
Item 1. Financial Statements and Supplementary Data
Oaktree Strategic Credit Fund
Consolidated Statements of Assets and Liabilities
(in thousands, except per share amounts)
| | | | | | | | | | | | | | |
| | March 31, 2024 (unaudited) | | September 30, 2023 |
ASSETS | | |
Assets: | | | | |
Investments – Non-control/Non-affiliate, at fair value (cost March 31, 2024: $3,496,473; cost September 30, 2023: $1,922,218) | | $ | 3,519,936 | | | $ | 1,927,237 | |
Cash and cash equivalents | | 329,908 | | | 145,499 | |
Restricted cash | | 16,453 | | | 5,637 | |
Due from affiliates | | — | | | 861 | |
Interest receivable | | 23,197 | | | 12,591 | |
Receivables from unsettled transactions | | 17,634 | | | 11,579 | |
Deferred financing costs | | 19,392 | | | 13,887 | |
Deferred offering costs | | 594 | | | 270 | |
Derivative asset at fair value | | 2,944 | | | 2,041 | |
Other assets | | 1,644 | | | 533 | |
Total assets | | $ | 3,931,702 | | | $ | 2,120,135 | |
LIABILITIES AND NET ASSETS | | |
Liabilities: | | | | |
Accounts payable, accrued expenses and other liabilities | | $ | 2,874 | | | $ | 2,291 | |
Dividends payable | | 20,413 | | | 12,026 | |
Base management fee and incentive fee payable | | 15,709 | | | 7,543 | |
Payable for share repurchases | | 7,901 | | | 5,336 | |
Due to affiliates | | 2,964 | | | 8,175 | |
Interest payable | | 12,038 | | | 4,676 | |
Payables from unsettled transactions | | 206,510 | | | 105,883 | |
Derivative liabilities at fair value | | 252 | | | — | |
Credit facilities payable | | 845,000 | | | 445,000 | |
Unsecured notes payable (net of $4,018 of unamortized financing costs as of March 31, 2024) | | 347,295 | | | — | |
Total liabilities | | 1,460,956 | | | 590,930 | |
Commitments and contingencies (Note 12) | | | | |
Net assets: | | | | |
Common shares, $0.01 par value per share; unlimited shares authorized, 104,627 and 64,896 shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively | | 1,046 | | | 649 | |
Additional paid-in-capital | | 2,471,486 | | | 1,536,305 | |
Accumulated distributable earnings (loss) | | (1,786) | | | (7,749) | |
Total net assets (equivalent to $23.61 and $23.56 per common share as of March 31, 2024 and September 30, 2023, respectively) (Note 10) | | 2,470,746 | | | 1,529,205 | |
Total liabilities and net assets | | $ | 3,931,702 | | | $ | 2,120,135 | |
See notes to Consolidated Financial Statements.
Oaktree Strategic Credit Fund
Consolidated Statements of Assets and Liabilities
(in thousands, except per share amounts)
| | | | | | | | | | | | | | |
NET ASSET VALUE PER SHARE | | March 31, 2024 (unaudited) | | September 30, 2023 |
Class I Shares: | | | | |
Net assets | | $ | 1,652,401 | | | $ | 1,039,238 | |
Common shares outstanding ($0.01 par value, unlimited shares authorized) | | 69,973 | | | 44,103 | |
Net asset value per share | | $ | 23.61 | | | $ | 23.56 | |
Class S Shares: | | | | |
Net assets | | $ | 817,091 | | | $ | 489,821 | |
Common shares outstanding ($0.01 par value, unlimited shares authorized) | | 34,601 | | | 20,787 | |
Net asset value per share | | $ | 23.61 | | | $ | 23.56 | |
Class D Shares: | | | | |
Net assets | | $ | 1,254 | | | $ | 146 | |
Common shares outstanding ($0.01 par value, unlimited shares authorized) | | 53 | | | 6 | |
Net asset value per share | | $ | 23.61 | | | $ | 23.56 | |
See notes to Consolidated Financial Statements.
Oaktree Strategic Credit Fund
Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, 2024 | | Three months ended March 31, 2023 | | Six months ended March 31, 2024 | | Six months ended March 31, 2023 |
Interest income: | | | | | | | |
Non-control/Non-affiliate investments | $ | 90,546 | | | $ | 20,951 | | | $ | 158,283 | | | $ | 35,046 | |
Interest on cash and cash equivalents | 3,215 | | | 203 | | | 6,050 | | | 376 | |
Total interest income | 93,761 | | | 21,154 | | | 164,333 | | | 35,422 | |
PIK interest income: | | | | | | | |
Non-control/Non-affiliate investments | 2,045 | | | 561 | | | 2,666 | | | 1,088 | |
Total PIK interest income | 2,045 | | | 561 | | | 2,666 | | | 1,088 | |
Fee income: | | | | | | | |
Non-control/Non-affiliate investments | 1,250 | | | 141 | | | 1,651 | | | 228 | |
Total fee income | 1,250 | | | 141 | | | 1,651 | | | 228 | |
Total investment income | 97,056 | | | 21,856 | | | 168,650 | | | 36,738 | |
Expenses: | | | | | | | |
Base management fee | 7,242 | | | 1,970 | | | 12,998 | | | 3,366 | |
Investment income incentive fee | 7,980 | | | 1,733 | | | 13,734 | | | 2,973 | |
Capital gains incentive fee | 319 | | | — | | | 2,460 | | | — | |
Professional fees | 613 | | | 790 | | | 1,448 | | | 1,188 | |
Class S and Class D distribution and shareholder servicing fees | 1,614 | | | 328 | | | 2,895 | | | 527 | |
Board of trustees fees | 116 | | | 66 | | | 207 | | | 132 | |
Organization expenses | 4 | | | — | | | 4 | | | 4 | |
Amortization of continuous offering costs | 211 | | | 944 | | | 433 | | | 1,792 | |
Interest expense | 24,180 | | | 3,574 | | | 41,920 | | | 6,380 | |
Administrator expense | 417 | | | 300 | | | 719 | | | 444 | |
General and administrative expenses | 431 | | | 347 | | | 1,055 | | | 525 | |
Total expenses | 43,127 | | | 10,052 | | | 77,873 | | | 17,331 | |
Management and incentive fees waived (Note 9) | — | | | — | | | — | | | (1,642) | |
Expense reimbursements (support) (Note 9) | — | | | — | | | 1,045 | | | (852) | |
Net expenses | 43,127 | | | 10,052 | | | 78,918 | | | 14,837 | |
Net investment income | 53,929 | | | 11,804 | | | 89,732 | | | 21,901 | |
Unrealized appreciation (depreciation): | | | | | | | |
Non-control/Non-affiliate investments | (3,220) | | | 8,088 | | | 18,557 | | | 5,727 | |
Foreign currency forward contracts | 2,565 | | | (34) | | | (2,293) | | | (515) | |
Net unrealized appreciation (depreciation) | (655) | | | 8,054 | | | 16,264 | | | 5,212 | |
Realized gains (losses): | | | | | | | |
Non-control/Non-affiliate investments | 3,789 | | | (1,256) | | | 2,711 | | | (1,893) | |
Foreign currency forward contracts | (442) | | | (485) | | | 1,089 | | | (508) | |
Net realized gains (losses) | 3,347 | | | (1,741) | | | 3,800 | | | (2,401) | |
Provision for income tax (expense) benefit | (144) | | | (54) | | | (385) | | | (105) | |
Net realized and unrealized gains (losses), net of taxes | 2,548 | | | 6,259 | | | 19,679 | | | 2,706 | |
Net increase (decrease) in net assets resulting from operations | $ | 56,477 | | | $ | 18,063 | | | $ | 109,411 | | | $ | 24,607 | |
See notes to Consolidated Financial Statements.
Oaktree Strategic Credit Fund
Consolidated Statements of Changes in Net Assets
(in thousands, except per share amounts)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, 2024 | | Three months ended March 31, 2023 | | Six months ended March 31, 2024 | | Six months ended March 31, 2023 |
Operations: | | | | | | | |
Net investment income | $ | 53,929 | | | $ | 11,804 | | | $ | 89,732 | | | $ | 21,901 | |
Net unrealized appreciation (depreciation) | (655) | | | 8,054 | | | 16,264 | | | 5,212 | |
Net realized gains (losses) | 3,347 | | | (1,741) | | | 3,800 | | | (2,401) | |
Provision for income tax (expense) benefit | (144) | | | (54) | | | (385) | | | (105) | |
Net increase (decrease) in net assets resulting from operations | 56,477 | | | 18,063 | | | 109,411 | | | 24,607 | |
Distributions to common shareholders: | | | | | | | |
Class I | (39,142) | | | (11,437) | | | (71,534) | | | (20,564) | |
Class S | (17,405) | | | (3,426) | | | (31,880) | | | (5,655) | |
Class D | (25) | | | — | | | (34) | | | — | |
Net decrease in net assets resulting from distributions | (56,572) | | | (14,863) | | | (103,448) | | | (26,219) | |
Share transactions: | | | | | | | |
Class I: | | | | | | | |
Issuance of Common shares in public offering | 301,199 | | | 132,246 | | | 610,377 | | | 216,728 | |
Share transfers between classes | 252 | | | — | | | 252 | | | — | |
Issuance of Common shares under dividend reinvestment plan | 8,013 | | | 1,422 | | | 13,152 | | | 2,467 | |
Repurchased shares, net of early repurchase deduction | (5,813) | | | — | | | (14,542) | | | — | |
Net increase from share transactions | 303,651 | | | 133,668 | | | 609,239 | | | 219,195 | |
Class S: | | | | | | | |
Issuance of Common shares in public offering | 155,916 | | | 93,136 | | | 315,146 | | | 138,362 | |
Share transfers between classes | (252) | | | — | | | (252) | | | — | |
Issuance of Common shares under dividend reinvestment plan | 8,035 | | | 1,401 | | | 14,541 | | | 2,188 | |
Repurchased shares, net of early repurchase deduction | (2,404) | | | — | | | (4,201) | | | — | |
Net increase from share transactions | 161,295 | | | 94,537 | | | 325,234 | | | 140,550 | |
Class D: | | | | | | | |
Issuance of Common shares in public offering | 715 | | | — | | | 1,094 | | | — | |
Issuance of Common shares under dividend reinvestment plan | 9 | | | — | | | 11 | | | — | |
Net increase from share transactions | 724 | | | — | | | 1,105 | | | — | |
Total increase (decrease) in net assets | 465,575 | | | 231,405 | | | 941,541 | | | 358,133 | |
Net assets at beginning of period | 2,005,171 | | | 493,455 | | | 1,529,205 | | | 366,727 | |
Net assets at end of period | $ | 2,470,746 | | | $ | 724,860 | | | $ | 2,470,746 | | | $ | 724,860 | |
Net asset value per common share | $ | 23.61 | | | $ | 23.42 | | | $ | 23.61 | | | $ | 23.42 | |
Common shares outstanding at end of period | 104,627 | | | 30,951 | | | 104,627 | | | 30,951 | |
See notes to Consolidated Financial Statements.
Oaktree Strategic Credit Fund
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
| | | | | | | | | | | | | | |
| | Six months ended March 31, 2024 | | Six months ended March 31, 2023 |
Operating activities: | | | | |
Net increase (decrease) in net assets resulting from operations | | $ | 109,411 | | | $ | 24,607 | |
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash used in operating activities: | | | | |
Net unrealized (appreciation) depreciation | | (16,264) | | | (5,212) | |
Net realized (gains) losses | | (3,800) | | | 2,401 | |
PIK interest income | | (2,666) | | | (1,088) | |
Accretion of original issue discount on investments | | (11,951) | | | (3,258) | |
Accretion of original issue discount on unsecured notes payable | | 133 | | | — | |
Amortization of deferred financing costs | | 2,263 | | | 464 | |
Amortization of deferred offering costs | | 433 | | | 1,792 | |
Deferred taxes | | — | | | (18) | |
Purchases of investments | | (1,961,240) | | | (569,089) | |
Proceeds from the sales and repayments of investments | | 406,530 | | | 106,087 | |
Changes in operating assets and liabilities: | | | | |
(Increase) decrease in due from affiliates | | 861 | | | (852) | |
(Increase) decrease in interest receivable | | (10,979) | | | (2,865) | |
(Increase) decrease in receivables from unsettled transactions | | (6,055) | | | (9,538) | |
(Increase) decrease in other assets | | (1,111) | | | 163 | |
Increase (decrease) in accounts payable, accrued expenses and other liabilities | | (181) | | | 280 | |
Increase (decrease) in base management fee and incentive fees payable | | 8,166 | | | 3,135 | |
Increase (decrease) in due to affiliates | | (5,660) | | | 2,084 | |
Increase (decrease) in interest payable | | 7,362 | | | 561 | |
Increase (decrease) in payables from unsettled transactions | | 100,627 | | | 59,212 | |
Net cash used in operating activities | | (1,384,121) | | | (391,134) | |
Financing activities: | | | | |
Distributions paid in cash | | (67,358) | | | (19,470) | |
Borrowings under credit facilities | | 400,000 | | | 215,000 | |
Repayments of borrowings under credit facilities | | — | | | (140,000) | |
Issuance of unsecured notes | | 348,236 | | | — | |
Proceeds from issuance of common shares | | 926,617 | | | 355,090 | |
Deferred financing costs paid | | (11,099) | | | (2,012) | |
Deferred offering costs paid | | (233) | | | (143) | |
Share repurchases paid | | (16,179) | | | — | |
Net cash provided by financing activities | | 1,579,984 | | | 408,465 | |
Effect of exchange rate changes on foreign currency | | (638) | | | (849) | |
Net increase (decrease) in cash and cash equivalents and restricted cash | | 195,225 | | | 16,482 | |
Cash and cash equivalents and restricted cash, beginning of period | | 151,136 | | | 58,443 | |
Cash and cash equivalents and restricted cash, end of period | | $ | 346,361 | | | $ | 74,925 | |
Supplemental information: | | | | |
Cash paid for interest | | $ | 32,161 | | | $ | 5,355 | |
Non-cash financing activities: | | | | |
Deferred financing costs incurred | | $ | 688 | | | $ | 257 | |
Deferred offering costs incurred | | 525 | | | 542 | |
Distribution payable | | 20,413 | | | 5,748 | |
Reinvestment of dividends during the period | | 27,704 | | | 4,655 | |
Shares repurchases accrued but not yet paid | | 7,901 | | | — | |
Reconciliation to the Statement of Assets and Liabilities | | March 31, 2024 | | September 30, 2023 |
Cash and cash equivalents | | $ | 329,908 | | | $ | 145,499 | |
Restricted cash | | 16,453 | | | 5,637 | |
Total cash and cash equivalents and restricted cash | | $ | 346,361 | | | $ | 151,136 | |
See notes to Consolidated Financial Statements.
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
March 31, 2024
(dollar amounts in thousands)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
Non-Control/Non-Affiliate Investments | | | | | | | | | | | | (7) |
37 Capital CLO 4 | Multi-Sector Holdings | CLO Notes | SOFR+ | 5.50% | 10.87% | | 1/15/2034 | | $ | 5,000 | | $ | 5,000 | | $ | 5,094 | | (5)(10) |
107-109 Beech OAK22 LLC | Real Estate Development | First Lien Revolver | | | 11.00% | | 2/27/2026 | | 11,883 | | 11,772 | | 11,666 | | (8)(9) |
107 Fair Street LLC | Real Estate Development | First Lien Term Loan | | | 12.50% | | 5/31/2024 | | 1,031 | | 1,025 | | 987 | | (8)(9)(11) |
112-126 Van Houten Real22 LLC | Real Estate Development | First Lien Term Loan | | | 12.00% | | 5/4/2024 | | 3,949 | | 3,945 | | 3,910 | | (8)(9)(11) |
AB BSL CLO 4 | Multi-Sector Holdings | CLO Notes | SOFR+ | 5.50% | 10.82% | | 4/20/2036 | | 3,800 | | 3,800 | | 3,852 | | (5)(10) |
Access CIG, LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 5.00% | 10.33% | | 8/18/2028 | | 39,325 | | 38,778 | | 39,417 | | (5) |
ACP Falcon Buyer Inc | Systems Software | First Lien Term Loan | SOFR+ | 6.50% | 11.83% | | 8/1/2029 | | 34,580 | | 33,658 | | 34,583 | | (5)(8) |
ACP Falcon Buyer Inc | Systems Software | First Lien Revolver | SOFR+ | 6.50% | | | 8/1/2029 | | — | | (142) | | — | | (5)(8)(9) |
Acquia Inc. | Application Software | First Lien Term Loan | SOFR+ | 7.00% | 12.48% | | 10/31/2025 | | 11,166 | | 10,972 | | 11,177 | | (5)(8) |
ADC Therapeutics SA | Biotechnology | First Lien Term Loan | SOFR+ | 7.50% | 12.96% | | 8/15/2029 | | 10,406 | | 9,996 | | 10,091 | | (5)(8)(10) |
ADC Therapeutics SA | Biotechnology | Warrants | | | | | | 45,727 | | | 275 | | 94 | | (8)(10) |
AIP RD Buyer Corp. | Distributors | Second Lien Term Loan | SOFR+ | 7.75% | 13.18% | | 12/21/2029 | | 4,093 | | 4,034 | | 4,064 | | (5)(8) |
AIP RD Buyer Corp. | Distributors | Common Stock | | | | | | 4,560 | | | 428 | | 636 | | (8) |
Alto Pharmacy Holdings, Inc. | Health Care Technology | First Lien Term Loan | SOFR+ | 11.50% | 4.92% | 11.99% | 10/14/2027 | | 14,112 | | 13,311 | | 12,948 | | (5)(8) |
Alto Pharmacy Holdings, Inc. | Health Care Technology | Warrants | | | | | | 878,545 | | | 943 | | 1,801 | | (8) |
American Airlines Group Inc. | Passenger Airlines | Fixed Rate Bond | | | 8.50% | | 5/15/2029 | | 6,534 | | 6,534 | | 6,907 | | (10) |
American Auto Auction Group, LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 5.00% | 10.46% | | 12/30/2027 | | 2,500 | | 2,482 | | 2,490 | | (5) |
American Auto Auction Group, LLC | Diversified Support Services | Second Lien Term Loan | SOFR+ | 8.75% | 14.21% | | 1/2/2029 | | 6,901 | | 6,806 | | 6,504 | | (5)(8) |
American Rock Salt Company LLC | Diversified Metals & Mining | First Lien Term Loan | SOFR+ | 4.00% | 9.44% | | 6/9/2028 | | 25,655 | | 24,423 | | 22,502 | | (5) |
American Tire Distributors, Inc. | Distributors | First Lien Term Loan | SOFR+ | 6.25% | 11.83% | | 10/20/2028 | | 12,665 | | 11,492 | | 11,050 | | (5) |
AmSpec Parent LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 5.75% | 11.05% | | 12/5/2030 | | 70,424 | | 68,745 | | 68,826 | | (5)(8) |
AmSpec Parent LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 5.75% | | | 12/5/2030 | | — | | (127) | | (116) | | (5)(8)(9) |
AmSpec Parent LLC | Diversified Support Services | First Lien Revolver | SOFR+ | 5.75% | | | 12/5/2029 | | — | | (225) | | (212) | | (5)(8)(9) |
Amynta Agency Borrower Inc. | Property & Casualty Insurance | First Lien Term Loan | SOFR+ | 4.25% | 9.55% | | 2/28/2028 | | 39,770 | | 39,489 | | 39,965 | | (5) |
Anastasia Parent, LLC | Personal Care Products | First Lien Term Loan | SOFR+ | 3.75% | 9.32% | | 8/11/2025 | | 6,804 | | 5,712 | | 4,985 | | (5) |
Anchorage Capital CLO 20 | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.61% | 12.93% | | 1/20/2035 | | 750 | | 715 | | 739 | | (5)(10) |
Arches Buyer Inc. | Interactive Media & Services | First Lien Term Loan | SOFR+ | 5.50% | 10.83% | | 12/6/2027 | | 94,203 | | 92,882 | | 92,988 | | (5)(8) |
Ardonagh Midco 3 PLC | Insurance Brokers | First Lien Term Loan | SOFR+ | 4.75% | 10.06% | | 2/17/2031 | | 89,235 | | 87,897 | | 87,897 | | (5)(8)(10) |
Ardonagh Midco 3 PLC | Insurance Brokers | First Lien Term Loan | SOFR+ | 4.75% | | | 2/17/2031 | | — | | (62) | | (66) | | (5)(8)(9)(10) |
ARES LXIV CLO | Multi-Sector Holdings | CLO Notes | SOFR+ | 3.75% | 9.06% | | 4/15/2035 | | 2,200 | | 2,055 | | 2,202 | | (5)(10) |
ARES LXVIII CLO | Multi-Sector Holdings | CLO Notes | SOFR+ | 5.75% | 11.07% | | 4/25/2035 | | 5,000 | | 5,000 | | 5,089 | | (5)(10) |
Ares XLIV CLO | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.13% | 12.45% | | 4/15/2034 | | 3,500 | | 3,396 | | 3,464 | | (5)(10) |
Artera Services, LLC | Construction & Engineering | First Lien Term Loan | SOFR+ | 4.50% | 9.81% | | 2/15/2031 | | 27,500 | | 27,294 | | 27,638 | | (5) |
Artera Services, LLC | Construction & Engineering | Fixed Rate Bond | | | 8.50% | | 2/15/2031 | | 12,660 | | 12,660 | | 12,989 | | |
ASP-R-PAC Acquisition Co LLC | Paper & Plastic Packaging Products & Materials | First Lien Term Loan | SOFR+ | 6.00% | 11.57% | | 12/29/2027 | | 4,837 | | 4,777 | | 4,559 | | (5)(8)(10) |
ASP-R-PAC Acquisition Co LLC | Paper & Plastic Packaging Products & Materials | First Lien Revolver | SOFR+ | 6.00% | 11.44% | | 12/29/2027 | | 100 | | 93 | | 66 | | (5)(8)(9)(10) |
Astra Acquisition Corp. | Application Software | First Lien Term Loan | SOFR+ | 5.25% | 10.82% | | 10/25/2028 | | 10,405 | | 8,525 | | 6,711 | | (5)(8) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
March 31, 2024
(dollar amounts in thousands)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
Asurion, LLC | Property & Casualty Insurance | First Lien Term Loan | SOFR+ | 4.00% | 9.43% | | 8/19/2028 | | $ | 14,682 | | $ | 14,272 | | $ | 14,178 | | (5) |
Asurion, LLC | Property & Casualty Insurance | First Lien Term Loan | SOFR+ | 4.25% | 9.68% | | 8/19/2028 | | 29,807 | | 28,985 | | 28,838 | | (5) |
athenahealth Group Inc. | Health Care Technology | First Lien Term Loan | SOFR+ | 3.25% | 8.58% | | 2/15/2029 | | 38,059 | | 36,839 | | 37,795 | | (5) |
athenahealth Group Inc. | Health Care Technology | Fixed Rate Bond | | | 6.50% | | 2/15/2030 | | 15,040 | | 13,158 | | 13,771 | | |
athenahealth Group Inc. | Health Care Technology | Preferred Equity | | | | | | 5,809 | | | 5,693 | | 5,824 | | (8) |
Avalara, Inc. | Application Software | First Lien Term Loan | SOFR+ | 7.25% | 12.56% | | 10/19/2028 | | 19,029 | | 18,668 | | 18,981 | | (5)(8) |
Avalara, Inc. | Application Software | First Lien Revolver | SOFR+ | 7.25% | | | 10/19/2028 | | — | | (36) | | (5) | | (5)(8)(9) |
Bain Capital Credit CLO, Limited | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.54% | 12.87% | | 4/20/2034 | | 1,750 | | 1,733 | | 1,733 | | (5)(10) |
Bain Capital Credit CLO 2022-3 | Multi-Sector Holdings | CLO Notes | SOFR+ | 3.70% | 9.02% | | 7/17/2035 | | 3,500 | | 3,372 | | 3,505 | | (5) |
Bain Capital Euro CLO 2021-2 | Multi-Sector Holdings | CLO Notes | E+ | 3.40% | 7.33% | | 7/17/2034 | | € | 1,210 | | 1,248 | | 1,246 | | (5)(10) |
Bamboo US Bidco LLC | Health Care Equipment | First Lien Term Loan | SOFR+ | 6.75% | 8.69% | 3.38% | 9/30/2030 | | $ | 25,175 | | 24,481 | | 24,546 | | (5)(8) |
Bamboo US Bidco LLC | Health Care Equipment | First Lien Term Loan | E+ | 6.75% | 7.29% | 3.38% | 9/30/2030 | | € | 15,664 | | 16,131 | | 16,494 | | (5)(8) |
Bamboo US Bidco LLC | Health Care Equipment | First Lien Term Loan | SOFR+ | 6.75% | 8.69% | 3.38% | 9/30/2030 | | $ | 417 | | 352 | | 319 | | (5)(8)(9) |
Bamboo US Bidco LLC | Health Care Equipment | First Lien Revolver | SOFR+ | 6.75% | | | 10/1/2029 | | — | | (143) | | (130) | | (5)(8)(9)(10) |
Bausch + Lomb Corporation | Health Care Supplies | First Lien Term Loan | SOFR+ | 3.35% | 8.68% | | 5/10/2027 | | 45,114 | | 44,438 | | 44,697 | | (5)(10) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 7.50% | | | 4/19/2027 | | — | | — | | — | | (5)(8)(9)(10) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 7.50% | 8.00% | 4.81% | 4/19/2027 | | 1,362 | | 1,361 | | 1,270 | | (5)(8)(10) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 7.50% | | | 4/19/2027 | | — | | — | | — | | (5)(8)(9)(10) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 7.50% | | | 4/19/2027 | | — | | — | | — | | (5)(8)(9)(10) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 7.50% | 8.00% | 4.81% | 4/19/2027 | | 3,283 | | 3,200 | | 3,062 | | (5)(8)(10) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | Warrants | | | | | | 15,566 | | | 74 | | 19 | | (8)(10) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | Warrants | | | | | | 4,471 | | | — | | 6 | | (8)(10) |
Birch Grove CLO 2 LTD | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.21% | 12.52% | | 10/19/2034 | | 5,375 | | 5,330 | | 5,385 | | (5)(10) |
Biscuit Parent, LLC | Application Software | First Lien Term Loan | SOFR+ | 4.75% | 10.05% | | 2/27/2031 | | 50,000 | | 49,250 | | 49,270 | | (5)(8) |
Biscuit Parent, LLC | Application Software | First Lien Revolver | SOFR+ | 4.75% | | | 2/27/2031 | | — | | (225) | | (219) | | (5)(8)(9) |
Blackhawk Network Holdings, Inc. | Data Processing & Outsourced Services | First Lien Term Loan | SOFR+ | 5.00% | 10.33% | | 3/12/2029 | | 57,043 | | 55,906 | | 57,207 | | (5) |
Carlyle Euro CLO 2021-2 | Multi-Sector Holdings | CLO Notes | E+ | 3.30% | 7.24% | | 10/15/2035 | | € | 1,400 | | 1,378 | | 1,485 | | (5)(10) |
CBAM 2017-2, LTD. | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.10% | 12.68% | | 7/17/2034 | | $ | 488 | | 457 | | 460 | | (5)(10) |
CCO Holdings LLC | Cable & Satellite | Fixed Rate Bond | | | 4.50% | | 5/1/2032 | | 12,441 | | 10,001 | | 10,006 | | (10) |
CD&R Firefly Bidco Limited | Other Specialty Retail | First Lien Term Loan | SONIA+ | 6.00% | 11.29% | | 6/21/2028 | | £ | 32,697 | | 39,673 | | 41,334 | | (5)(10) |
CD&R Firefly Bidco Limited | Other Specialty Retail | First Lien Term Loan | SONIA+ | 5.75% | 10.94% | | 3/1/2029 | | 18,365 | | 22,890 | | 23,092 | | (5)(10) |
Clear Channel Outdoor Holdings, Inc. | Advertising | First Lien Term Loan | SOFR+ | 4.00% | 9.44% | | 8/21/2028 | | $ | 14,283 | | 13,883 | | 14,301 | | (5)(10) |
Clear Channel Outdoor Holdings, Inc. | Advertising | Fixed Rate Bond | | | 9.00% | | 9/15/2028 | | 4,000 | | 4,000 | | 4,170 | | (10) |
Cloud Software Group, Inc. | Application Software | First Lien Term Loan | SOFR+ | 4.50% | 9.91% | | 3/30/2029 | | 38,559 | | 36,639 | | 38,428 | | (5) |
Cloud Software Group, Inc. | Application Software | First Lien Term Loan | SOFR+ | 4.50% | 9.83% | | 3/21/2031 | | 20,000 | | 19,850 | | 19,894 | | (5) |
Cloud Software Group, Inc. | Application Software | Fixed Rate Bond | | | 6.50% | | 3/31/2029 | | 8,874 | | 8,076 | | 8,428 | | |
Colony Holding Corporation | Distributors | First Lien Term Loan | SOFR+ | 6.60% | 11.91% | | 5/13/2026 | | 12,056 | | 11,821 | | 11,863 | | (5)(8) |
Colony Holding Corporation | Distributors | First Lien Term Loan | SOFR+ | 6.60% | 11.94% | | 5/13/2026 | | 3,920 | | 3,866 | | 3,857 | | (5)(8) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
March 31, 2024
(dollar amounts in thousands)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
Condor Merger Sub Inc. | Systems Software | Fixed Rate Bond | | | 7.38% | | 2/15/2030 | | $ | 9,277 | | $ | 8,689 | | $ | 8,518 | | |
Connect U.S. Finco LLC | Alternative Carriers | Fixed Rate Bond | | | 6.75% | | 10/1/2026 | | 9,800 | | 9,513 | | 9,613 | | (10) |
Coupa Holdings, LLC | Application Software | First Lien Term Loan | SOFR+ | 7.50% | 12.81% | | 2/27/2030 | | 13,464 | | 13,179 | | 13,262 | | (5)(8) |
Coupa Holdings, LLC | Application Software | First Lien Term Loan | SOFR+ | 7.50% | | | 2/27/2030 | | — | | (15) | | (11) | | (5)(8)(9) |
Coupa Holdings, LLC | Application Software | First Lien Revolver | SOFR+ | 7.50% | | | 2/27/2029 | | — | | (19) | | (14) | | (5)(8)(9) |
Covetrus, Inc. | Health Care Distributors | First Lien Term Loan | SOFR+ | 5.00% | 10.31% | | 10/13/2029 | | 30,801 | | 29,571 | | 30,876 | | (5) |
Crewline Buyer, Inc. | Systems Software | First Lien Term Loan | SOFR+ | 6.75% | 12.06% | | 11/8/2030 | | 43,911 | | 42,875 | | 42,936 | | (5)(8) |
Crewline Buyer, Inc. | Systems Software | First Lien Revolver | SOFR+ | 6.75% | | | 11/8/2030 | | — | | (108) | | (102) | | (5)(8)(9) |
Crown Subsea Communications Holding, Inc. | Alternative Carriers | First Lien Term Loan | SOFR+ | 4.75% | 10.07% | | 1/30/2031 | | 30,000 | | 29,700 | | 30,213 | | (5) |
Curium Bidco S.à.r.l. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 4.50% | 9.81% | | 7/31/2029 | | 8,403 | | 8,287 | | 8,456 | | (5)(10) |
CVAUSA Management, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.50% | 11.91% | | 5/22/2029 | | 21,761 | | 21,411 | | 21,434 | | (5)(8) |
CVAUSA Management, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.50% | | | 5/22/2029 | | — | | (130) | | (118) | | (5)(8)(9) |
CVAUSA Management, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.50% | | | 5/22/2029 | | — | | (100) | | (49) | | (5)(8)(9) |
CVAUSA Management, LLC | Health Care Services | First Lien Revolver | SOFR+ | 6.50% | | | 5/22/2029 | | — | | (66) | | (38) | | (5)(8)(9) |
Dealer Tire Financial, LLC | Distributors | Fixed Rate Bond | | | 8.00% | | 2/1/2028 | | 920 | | 886 | | 917 | | |
Delta Leasing SPV II LLC | Specialized Finance | Subordinated Debt Term Loan | | | 8.00% | 3.00% | 8/31/2029 | | 7,620 | | 7,620 | | 7,620 | | (8)(10) |
Delta Leasing SPV II LLC | Specialized Finance | Subordinated Debt Term Loan | | | 3.00% | 7.00% | 8/31/2029 | | 26,175 | | 26,175 | | 26,175 | | (8)(10) |
Delta Leasing SPV II LLC | Specialized Finance | Preferred Equity | | | | | | 330 | | | 330 | | 398 | | (8)(10) |
Delta Leasing SPV II LLC | Specialized Finance | Common Stock | | | | | | 2 | | | 2 | | 2 | | (8)(10) |
Delta Leasing SPV II LLC | Specialized Finance | Warrants | | | | | | 25 | | | — | | — | | (8)(10) |
DirecTV Financing, LLC | Cable & Satellite | First Lien Term Loan | SOFR+ | 5.25% | 10.69% | | 8/2/2029 | | 21,352 | | 20,928 | | 21,370 | | |
DTI Holdco, Inc. | Research & Consulting Services | First Lien Term Loan | SOFR+ | 4.75% | 10.06% | | 4/26/2029 | | 33,087 | | 31,933 | | 33,129 | | (5) |
Dukes Root Control Inc. | Environmental & Facilities Services | First Lien Term Loan | SOFR+ | 6.50% | 12.14% | | 12/8/2028 | | 11,745 | | 11,538 | | 11,598 | | (5)(8) |
Dukes Root Control Inc. | Environmental & Facilities Services | First Lien Term Loan | SOFR+ | 6.50% | 11.99% | | 12/8/2028 | | 1,055 | | 1,018 | | 1,019 | | (5)(8)(9) |
Dukes Root Control Inc. | Environmental & Facilities Services | First Lien Revolver | SOFR+ | 6.50% | 12.22% | | 12/8/2028 | | 1,143 | | 1,117 | | 1,125 | | (5)(8)(9) |
Eagle Parent Corp. | Diversified Support Services | First Lien Term Loan | SOFR+ | 4.25% | 9.55% | | 4/2/2029 | | 19,857 | | 19,729 | | 19,714 | | (5) |
Ecco Holdings Corp. | Construction Machinery & Heavy Transportation Equipment | First Lien Term Loan | SOFR+ | 5.75% | 11.06% | | 2/13/2031 | | 62,536 | | 61,309 | | 61,329 | | (5)(8) |
Ecco Holdings Corp. | Construction Machinery & Heavy Transportation Equipment | First Lien Term Loan | SOFR+ | 5.75% | | | 2/13/2031 | | — | | (133) | | (130) | | (5)(8)(9) |
Ecco Holdings Corp. | Construction Machinery & Heavy Transportation Equipment | First Lien Revolver | SOFR+ | 5.75% | 11.06% | | 2/13/2030 | | 225 | | 93 | | 95 | | (5)(8)(9) |
Entrata, Inc. | Application Software | First Lien Term Loan | SOFR+ | 6.00% | 11.33% | | 7/10/2030 | | 45,489 | | 44,470 | | 44,852 | | (5)(8) |
Entrata, Inc. | Application Software | First Lien Revolver | SOFR+ | 6.00% | | | 7/10/2028 | | — | | (111) | | (73) | | (5)(8)(9) |
Enverus Holdings, Inc. | Application Software | First Lien Term Loan | SOFR+ | 5.50% | 10.83% | | 12/24/2029 | | 54,170 | | 53,368 | | 53,401 | | (5)(8) |
Enverus Holdings, Inc. | Application Software | First Lien Term Loan | SOFR+ | 5.50% | | | 12/24/2029 | | — | | (39) | | (38) | | (5)(8)(9) |
Enverus Holdings, Inc. | Application Software | First Lien Revolver | SOFR+ | 5.50% | | | 12/24/2029 | | — | | (59) | | (59) | | (5)(8)(9) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
March 31, 2024
(dollar amounts in thousands)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
Establishment Labs Holdings Inc. | Health Care Technology | First Lien Term Loan | | | 3.00% | 6.00% | 4/21/2027 | | $ | 11,384 | | $ | 11,288 | | $ | 11,014 | | (8)(10) |
Establishment Labs Holdings Inc. | Health Care Technology | First Lien Term Loan | | | 3.00% | 6.00% | 4/21/2027 | | 1,823 | | 1,803 | | 1,764 | | (8)(10) |
Establishment Labs Holdings Inc. | Health Care Technology | First Lien Term Loan | | | 3.00% | 6.00% | 4/21/2027 | | — | | 1 | | — | | (8)(9)(10) |
Establishment Labs Holdings Inc. | Health Care Technology | First Lien Term Loan | | | 3.00% | 6.00% | 4/21/2027 | | — | | 1 | | — | | (8)(9)(10) |
Evergreen IX Borrower 2023, LLC | Application Software | First Lien Term Loan | SOFR+ | 6.00% | 11.31% | | 9/30/2030 | | 36,215 | | 35,375 | | 36,085 | | (5)(8) |
Evergreen IX Borrower 2023, LLC | Application Software | First Lien Revolver | SOFR+ | 6.00% | | | 10/1/2029 | | — | | (92) | | (14) | | (5)(8)(9) |
Fiesta Purchaser, Inc. | Packaged Foods & Meats | First Lien Term Loan | SOFR+ | 4.00% | 9.33% | | 2/12/2031 | | 10,000 | | 9,900 | | 10,028 | | (5) |
Fiesta Purchaser, Inc. | Packaged Foods & Meats | Fixed Rate Bond | | | 7.88% | | 3/1/2031 | | 7,940 | | 7,940 | | 8,206 | | |
Finastra USA, Inc. | Application Software | First Lien Term Loan | SOFR+ | 7.25% | 12.46% | | 9/13/2029 | | 43,732 | | 42,937 | | 42,857 | | (5)(8)(10) |
Finastra USA, Inc. | Application Software | First Lien Revolver | SOFR+ | 7.25% | 12.57% | | 9/13/2029 | | 841 | | 758 | | 750 | | (5)(8)(9)(10) |
Fortress Credit BSL XIV | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.65% | 12.97% | | 10/23/2034 | | 2,300 | | 2,077 | | 2,268 | | (5)(10) |
Frontier Communications Holdings, LLC | Integrated Telecommunication Services | First Lien Term Loan | SOFR+ | 3.75% | 9.19% | | 10/8/2027 | | 29,585 | | 29,034 | | 29,557 | | (5)(10) |
Frontier Communications Holdings, LLC | Integrated Telecommunication Services | Fixed Rate Bond | | | 6.00% | | 1/15/2030 | | 7,517 | | 6,382 | | 6,375 | | (10) |
Galileo Parent, Inc. | Aerospace & Defense | First Lien Term Loan | SOFR+ | 7.25% | 12.56% | | 5/3/2029 | | 20,176 | | 19,663 | | 19,873 | | (5)(8) |
Galileo Parent, Inc. | Aerospace & Defense | First Lien Revolver | SOFR+ | 7.25% | 12.56% | | 5/3/2029 | | 1,397 | | 1,317 | | 1,349 | | (5)(8)(9) |
Gallatin CLO X 2023-1 | Multi-Sector Holdings | CLO Notes | SOFR+ | 5.41% | 10.72% | | 10/14/2035 | | 5,000 | | 4,913 | | 4,973 | | (5)(10) |
GoldenTree Loan Management EUR CLO 2 DAC | Multi-Sector Holdings | CLO Notes | E+ | 2.85% | 6.82% | | 1/20/2032 | | € | 1,000 | | 883 | | 1,067 | | (5)(10) |
Greenway Health, LLC | Health Care Technology | First Lien Term Loan | SOFR+ | 6.75% | 11.93% | | 4/1/2029 | | $ | 25,000 | | 24,290 | | 24,600 | | (5)(8) |
Grove Hotel Parcel Owner, LLC | Hotels, Resorts & Cruise Lines | First Lien Term Loan | SOFR+ | 8.00% | 13.43% | | 6/21/2027 | | 17,419 | | 17,194 | | 17,070 | | (5)(8) |
Grove Hotel Parcel Owner, LLC | Hotels, Resorts & Cruise Lines | First Lien Term Loan | SOFR+ | 8.00% | | | 6/21/2027 | | — | | (46) | | (71) | | (5)(8)(9) |
Grove Hotel Parcel Owner, LLC | Hotels, Resorts & Cruise Lines | First Lien Revolver | SOFR+ | 8.00% | | | 6/21/2027 | | — | | (23) | | (35) | | (5)(8)(9) |
Harbor Purchaser Inc. | Education Services | First Lien Term Loan | SOFR+ | 5.25% | 10.68% | | 4/9/2029 | | 6,201 | | 5,980 | | 6,162 | | (5) |
Harrow, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 6.50% | 11.95% | | 1/19/2026 | | 9,319 | | 9,170 | | 9,226 | | (5)(8)(10) |
Harrow, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 6.50% | 11.95% | | 1/19/2026 | | 1,792 | | 1,759 | | 1,774 | | (5)(8)(10) |
Harrow, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 6.50% | | | 1/19/2026 | | — | | (80) | | (50) | | (5)(8)(9)(10) |
Hertz Vehicle Financing III | Specialized Finance | CLO Notes | | | 5.16% | | 6/26/2028 | | 7,500 | | 6,584 | | 6,846 | | (10) |
Hertz Vehicle Financing III | Specialized Finance | CLO Notes | | | 6.78% | | 9/25/2028 | | 8,377 | | 7,690 | | 8,059 | | (10) |
Horizon Aircraft Finance I Ltd. | Specialized Finance | CLO Notes | | | 4.46% | | 12/15/2038 | | 10,802 | | 9,149 | | 9,509 | | (10) |
Horizon Aircraft Finance II Ltd. | Specialized Finance | CLO Notes | | | 3.72% | | 7/15/2039 | | 2,085 | | 1,792 | | 1,856 | | (10) |
HPS Loan Management 10-2016 | Multi-Sector Holdings | CLO Notes | SOFR+ | 6.67% | 11.99% | | 4/20/2034 | | 2,250 | | 2,134 | | 2,134 | | (5)(10) |
HUB Pen Company, LLC | Other Specialty Retail | First Lien Term Loan | SOFR+ | 6.50% | 11.93% | | 12/31/2027 | | 27,198 | | 26,600 | | 26,790 | | (5)(8) |
HUB Pen Company, LLC | Other Specialty Retail | First Lien Revolver | | | 6.50% | | 12/31/2027 | | 108 | | 35 | | 58 | | (8)(9) |
Husky Injection Molding Systems Ltd. | Industrial Machinery & Supplies & Components | First Lien Term Loan | SOFR+ | 5.00% | 10.33% | | 2/1/2029 | | 34,030 | | 33,554 | | 34,161 | | (5)(10) |
Husky Injection Molding Systems Ltd. | Industrial Machinery & Supplies & Components | Fixed Rate Bond | | | 9.00% | | 2/15/2029 | | 15,445 | | 15,445 | | 15,991 | | (10) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
March 31, 2024
(dollar amounts in thousands)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
IAMGOLD Corporation | Gold | Second Lien Term Loan | SOFR+ | 8.25% | 13.56% | | 5/16/2028 | | $ | 28,394 | | $ | 27,692 | | $ | 27,897 | | (5)(8)(10) |
Icefall Parent, Inc. | Application Software | First Lien Term Loan | SOFR+ | 6.50% | 11.80% | | 1/25/2030 | | 27,948 | | 27,406 | | 27,423 | | (5)(8) |
Icefall Parent, Inc. | Application Software | First Lien Revolver | SOFR+ | 6.50% | | | 1/25/2030 | | — | | (52) | | (50) | | (5)(8)(9) |
iCIMs, Inc. | Application Software | First Lien Term Loan | SOFR+ | 7.25% | 12.58% | | 8/18/2028 | | 15,932 | | 15,748 | | 15,390 | | (5)(8) |
iCIMs, Inc. | Application Software | First Lien Term Loan | SOFR+ | 7.25% | 12.58% | | 8/18/2028 | | 2,325 | | 2,295 | | 2,288 | | (5)(8) |
iCIMs, Inc. | Application Software | First Lien Term Loan | SOFR+ | 7.25% | | | 8/18/2028 | | — | | — | | — | | (5)(8)(9) |
iCIMs, Inc. | Application Software | First Lien Revolver | SOFR+ | 6.75% | 12.05% | | 8/18/2028 | | 97 | | 78 | | 48 | | (5)(8)(9) |
Impel Pharmaceuticals Inc. | Health Care Technology | First Lien Term Loan | SOFR+ | 10.75% | | | 3/17/2027 | | 9,273 | | 8,854 | | 2,831 | | (5)(8)(12) |
Impel Pharmaceuticals Inc. | Health Care Technology | First Lien Term Loan | SOFR+ | 10.75% | | | 3/17/2027 | | 254 | | 238 | | 170 | | (5)(8)(12) |
Impel Pharmaceuticals Inc. | Health Care Technology | First Lien Term Loan | SOFR+ | 10.75% | | | 3/17/2027 | | 674 | | 656 | | 452 | | (5)(8)(12) |
Impel Pharmaceuticals Inc. | Health Care Technology | First Lien Term Loan | SOFR+ | 10.75% | | | 3/17/2027 | | 302 | | 298 | | 202 | | (5)(8)(12) |
Impel Pharmaceuticals Inc. | Health Care Technology | Warrants | | | | | | 127,376 | | | — | | — | | |
Innocoll Pharmaceuticals Limited | Health Care Technology | Warrants | | | | | | 36,087 | | | 85 | | — | | (8)(10) |
Inventus Power, Inc. | Electrical Components & Equipment | First Lien Term Loan | SOFR+ | 7.50% | 12.94% | | 6/30/2025 | | 43,545 | | 42,732 | | 42,561 | | (5)(8) |
Inventus Power, Inc. | Electrical Components & Equipment | First Lien Revolver | SOFR+ | 7.50% | | | 6/30/2025 | | — | | (93) | | (112) | | (5)(8)(9) |
IW Buyer LLC | Electrical Components & Equipment | First Lien Term Loan | SOFR+ | 6.75% | 12.18% | | 6/28/2029 | | 34,202 | | 33,306 | | 33,604 | | (5)(8) |
IW Buyer LLC | Electrical Components & Equipment | First Lien Revolver | SOFR+ | 6.75% | | | 6/28/2029 | | — | | (168) | | (113) | | (5)(8)(9) |
KDC/ONE Development Corp Inc | Personal Care Products | First Lien Term Loan | SOFR+ | 5.00% | 10.33% | | 8/15/2028 | | 23,750 | | 23,124 | | $ | 23,824 | | (5)(10) |
Kings Buyer, LLC | Environmental & Facilities Services | First Lien Term Loan | SOFR+ | 6.50% | 11.90% | | 10/29/2027 | | 4,778 | | 4,731 | | 4,714 | | (5)(8) |
Kings Buyer, LLC | Environmental & Facilities Services | First Lien Term Loan | SOFR+ | 6.50% | 11.93% | | 10/29/2027 | | 58,845 | | 58,073 | | 58,056 | | (5)(8) |
Kings Buyer, LLC | Environmental & Facilities Services | First Lien Revolver | PRIME+ | 5.50% | 14.00% | | 10/29/2027 | | 66 | | 60 | | 58 | | (5)(8)(9) |
Kings Buyer, LLC | Environmental & Facilities Services | First Lien Revolver | PRIME+ | 5.50% | 14.00% | | 10/29/2027 | | 488 | | 424 | | 423 | | (5)(8)(9) |
LABL, Inc. | Office Services & Supplies | First Lien Term Loan | SOFR+ | 5.00% | 10.43% | | 10/29/2028 | | 32,489 | | 31,783 | | 31,898 | | (5) |
Latam Airlines Group S.A. | Passenger Airlines | First Lien Term Loan | SOFR+ | 9.50% | 14.98% | | 10/12/2027 | | 11,972 | | 11,239 | | 12,441 | | (5)(10) |
Learfield Communications, LLC | Movies & Entertainment | First Lien Term Loan | SOFR+ | 5.50% | 10.83% | | 6/30/2028 | | 40,204 | | 40,036 | | 40,141 | | (5) |
LSL Holdco, LLC | Health Care Distributors | First Lien Term Loan | SOFR+ | 6.00% | 11.43% | | 1/31/2028 | | 8,951 | | 8,837 | | 8,296 | | (5)(8) |
LSL Holdco, LLC | Health Care Distributors | First Lien Term Loan | SOFR+ | 6.00% | 11.43% | | 1/31/2028 | | 1,042 | | 988 | | 966 | | (5)(8) |
LSL Holdco, LLC | Health Care Distributors | First Lien Revolver | SOFR+ | 6.00% | 11.43% | | 1/31/2028 | | 406 | | 393 | | 332 | | (5)(8)(9) |
Madison Park Euro Funding XIV | Multi-Sector Holdings | CLO Notes | E+ | 3.60% | 7.54% | | 7/15/2032 | | € | 6,450 | | 6,768 | | 6,760 | | (5)(10) |
Madison Park Funding LXIII | Multi-Sector Holdings | CLO Notes | SOFR+ | 5.50% | 10.91% | | 4/21/2035 | | $ | 5,000 | | 5,000 | | 5,107 | | (5)(10) |
Mauser Packaging Solutions Holding Company | Metal, Glass & Plastic Containers | First Lien Term Loan | SOFR+ | 4.00% | 9.33% | | 8/14/2026 | | 15,900 | | 15,814 | | 15,974 | | (5) |
Mauser Packaging Solutions Holding Company | Metal, Glass & Plastic Containers | Fixed Rate Bond | | | 7.88% | | 8/15/2026 | | 12,500 | | 12,362 | | 12,744 | | |
McAfee Corp. | Systems Software | First Lien Term Loan | SOFR+ | 3.75% | 9.18% | | 3/1/2029 | | 18,749 | | 18,042 | | 18,758 | | (5) |
Mesoblast, Inc. | Biotechnology | First Lien Term Loan | | | 9.75% | | 11/19/2026 | | 1,956 | | 1,860 | | 1,863 | | (8)(10) |
Mesoblast, Inc. | Biotechnology | Warrants | | | | | | 66,347 | | | 152 | | 116 | | (8)(10) |
Mesoblast, Inc. | Biotechnology | Warrants | | | | | | 17,058 | | | — | | 43 | | (8)(10) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
March 31, 2024
(dollar amounts in thousands)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
MHE Intermediate Holdings, LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 6.25% | 11.71% | | 7/21/2027 | | $ | 1,571 | | $ | 1,539 | | $ | 1,567 | | (5)(8) |
MHE Intermediate Holdings, LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 6.00% | 11.46% | | 7/21/2027 | | 5,259 | | 5,154 | | 5,207 | | (5)(8) |
Mitchell International, Inc. | Application Software | First Lien Term Loan | SOFR+ | 3.75% | 9.19% | | 10/15/2028 | | 22,253 | | 21,942 | | 22,287 | | (5) |
Mitchell International, Inc. | Application Software | Second Lien Term Loan | SOFR+ | 6.50% | 11.94% | | 10/15/2029 | | 170 | | 163 | | 170 | | (5) |
Monotype Imaging Holdings Inc. | Application Software | First Lien Term Loan | SOFR+ | 5.50% | 10.81% | | 2/28/2031 | | 72,289 | | 71,205 | | 71,234 | | (5)(8) |
Monotype Imaging Holdings Inc. | Application Software | First Lien Term Loan | SOFR+ | 5.50% | | | 2/28/2031 | | — | | (45) | | (45) | | (5)(8)(9) |
Monotype Imaging Holdings Inc. | Application Software | First Lien Revolver | SOFR+ | 5.50% | | | 2/28/2030 | | — | | (134) | | (132) | | (5)(8)(9) |
MRI Software LLC | Application Software | First Lien Term Loan | SOFR+ | 5.50% | 10.90% | | 2/10/2027 | | 4,573 | | 4,449 | | 4,523 | | (5)(8) |
MRI Software LLC | Application Software | First Lien Term Loan | SOFR+ | 5.50% | 10.90% | | 2/10/2027 | | 7,166 | | 7,160 | | 7,088 | | (5)(8) |
MRI Software LLC | Application Software | First Lien Term Loan | SOFR+ | 5.50% | | | 2/10/2027 | | — | | (136) | | — | | (5)(8)(9) |
MRI Software LLC | Application Software | First Lien Revolver | SOFR+ | 5.50% | | | 2/10/2027 | | — | | — | | (25) | | (5)(8)(9) |
Neptune Platform Buyer, LLC | Aerospace & Defense | First Lien Term Loan | SOFR+ | 5.25% | 10.56% | | 1/19/2031 | | 30,977 | | 30,513 | | 30,401 | | (5)(8) |
Neptune Platform Buyer, LLC | Aerospace & Defense | First Lien Term Loan | SOFR+ | 5.25% | | | 1/19/2031 | | — | | — | | (180) | | (5)(8)(9) |
Next Holdco, LLC | Health Care Technology | First Lien Term Loan | SOFR+ | 6.00% | 11.32% | | 11/12/2030 | | 46,624 | | 45,925 | | 46,004 | | (5)(8) |
Next Holdco, LLC | Health Care Technology | First Lien Term Loan | SOFR+ | 6.00% | | | 11/12/2030 | | — | | (90) | | (80) | | (5)(8)(9) |
Next Holdco, LLC | Health Care Technology | First Lien Revolver | SOFR+ | 6.00% | | | 11/9/2029 | | — | | (67) | | (58) | | (5)(8)(9) |
NFM & J, L.P. | Diversified Support Services | First Lien Term Loan | SOFR+ | 5.75% | 11.15% | | 11/10/2029 | | 22,258 | | 21,991 | | 21,849 | | (5)(8) |
NFM & J, L.P. | Diversified Support Services | First Lien Term Loan | SOFR+ | 5.75% | 11.18% | | 11/10/2029 | | 412 | | 288 | | 184 | | (5)(8)(9) |
NFM & J, L.P. | Diversified Support Services | First Lien Revolver | PRIME+ | 4.75% | 13.25% | | 11/10/2029 | | 207 | | 107 | | 115 | | (5)(8)(9) |
NFP Corp. | Diversified Financial Services | Fixed Rate Bond | | | 8.50% | | 10/1/2031 | | 5,000 | | 5,000 | | 5,507 | | |
NFP Corp. | Diversified Financial Services | Fixed Rate Bond | | | 7.50% | | 10/1/2030 | | 841 | | 823 | | 887 | | |
North Star Acquisitionco, LLC | Education Services | First Lien Term Loan | SOFR+ | 5.75% | 11.05% | | 5/3/2029 | | 36,441 | | 35,824 | | 36,168 | | (5)(8) |
North Star Acquisitionco, LLC | Education Services | First Lien Term Loan | SOFR+ | 6.00% | | | 5/3/2029 | | — | | (33) | | (31) | | (5)(8)(9) |
North Star Acquisitionco, LLC | Education Services | First Lien Revolver | SOFR+ | 6.00% | | | 5/3/2029 | | — | | (74) | | (33) | | (5)(8)(9) |
Northwoods Capital 25 Ltd | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.40% | 12.72% | | 7/20/2034 | | 700 | | 682 | | 692 | | (5)(10) |
Northwoods Capital XV | Multi-Sector Holdings | CLO Notes | SOFR+ | 4.01% | 9.34% | | 6/20/2034 | | 4,000 | | 3,919 | | 4,004 | | (5)(10) |
Ocean Trails CLO VIII | Multi-Sector Holdings | CLO Notes | SOFR+ | 4.01% | 9.33% | | 7/15/2034 | | 5,000 | | 4,664 | | 5,010 | | (5)(10) |
Ocean Trails CLO XIV | Multi-Sector Holdings | CLO Notes | SOFR+ | 5.82% | 11.14% | | 1/20/2035 | | 1,000 | | 1,000 | | 1,004 | | (5) |
Octagon 66 | Multi-Sector Holdings | CLO Notes | SOFR+ | 5.09% | 10.42% | | 11/16/2036 | | 3,000 | | 2,970 | | 3,044 | | (5)(10) |
OEConnection LLC | Application Software | Second Lien Term Loan | SOFR+ | 7.00% | 12.43% | | 9/25/2027 | | 5,355 | | 5,290 | | 5,282 | | (5)(8) |
OFSI Fund Ltd | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.48% | 12.80% | | 4/20/2034 | | 1,105 | | 1,047 | | 1,050 | | (5)(10) |
OneOncology, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.25% | 11.56% | | 6/9/2030 | | 22,771 | | 22,267 | | 22,543 | | (5)(8) |
OneOncology, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.25% | 13.75% | | 6/9/2030 | | 2,975 | | 2,831 | | 2,889 | | (5)(8)(9) |
OneOncology, LLC | Health Care Services | First Lien Revolver | SOFR+ | 6.25% | | | 6/9/2030 | | — | | (99) | | (46) | | (5)(8)(9) |
Oranje Holdco, Inc. | Systems Software | First Lien Term Loan | SOFR+ | 7.50% | 12.81% | | 2/1/2029 | | 15,746 | | 15,429 | | 15,510 | | (5)(8) |
Oranje Holdco, Inc. | Systems Software | First Lien Revolver | SOFR+ | 7.50% | | | 2/1/2029 | | — | | (40) | | (30) | | (5)(8)(9) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
March 31, 2024
(dollar amounts in thousands)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
OZLM XXIII Ltd | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.28% | 12.86% | | 4/15/2034 | | $ | 1,000 | | $ | 967 | | $ | 959 | | (5)(10) |
Peraton Corp. | Aerospace & Defense | First Lien Term Loan | SOFR+ | 3.75% | 9.18% | | 2/1/2028 | | 23,765 | | 23,655 | | 23,789 | | (5) |
PetSmart LLC | Other Specialty Retail | First Lien Term Loan | SOFR+ | 3.75% | 9.18% | | 2/11/2028 | | 15,833 | | 15,592 | | 15,817 | | (5) |
PetVet Care Centers, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.00% | 11.33% | | 11/15/2030 | | 73,463 | | 72,073 | | 72,148 | | (5)(8) |
PetVet Care Centers, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.00% | | | 11/15/2030 | | — | | (96) | | (85) | | (5)(8)(9) |
PetVet Care Centers, LLC | Health Care Services | First Lien Revolver | SOFR+ | 6.00% | | | 11/15/2029 | | — | | (180) | | (168) | | (5)(8)(9) |
PetVet Care Centers, LLC | Health Care Services | Preferred Equity | | | | | | 6,338 | | | 6,211 | | 6,592 | | (8) |
Pluralsight, LLC | Application Software | First Lien Term Loan | SOFR+ | 8.00% | 13.47% | | 4/6/2027 | | 26,144 | | 22,997 | | 23,556 | | (5)(8) |
Pluralsight, LLC | Application Software | First Lien Revolver | SOFR+ | 8.00% | 13.47% | | 4/6/2027 | | 1,639 | | 1,442 | | 1,477 | | (5)(8) |
PPW Aero Buyer, Inc. | Aerospace & Defense | First Lien Term Loan | SOFR+ | 7.00% | 12.33% | | 2/15/2029 | | 26,623 | | 25,758 | | 25,824 | | (5)(8) |
PPW Aero Buyer, Inc. | Aerospace & Defense | First Lien Revolver | SOFR+ | 7.00% | 12.33% | | 2/15/2029 | | 1,729 | | 1,612 | | 1,621 | | (5)(8)(9) |
Profrac Holdings II, LLC | Industrial Machinery & Supplies & Components | First Lien Floating Rate Bond | SOFR+ | 7.25% | 12.55% | | 1/23/2029 | | 68,574 | | 67,888 | | 67,957 | | (5)(8)(10) |
Project Accelerate Parent, LLC | Systems Software | First Lien Term Loan | SOFR+ | 5.25% | 10.55% | | 2/24/2031 | | 43,750 | | 43,313 | | 43,352 | | (5)(8) |
Project Accelerate Parent, LLC | Systems Software | First Lien Revolver | SOFR+ | 5.25% | | | 2/24/2031 | | — | | (63) | | (57) | | (5)(8)(9) |
Protein for Pets Opco, LLC | Packaged Foods & Meats | First Lien Term Loan | SOFR+ | 5.25% | 10.56% | | 9/20/2030 | | 63,733 | | 62,463 | | 62,458 | | (5)(8) |
Protein for Pets Opco, LLC | Packaged Foods & Meats | First Lien Revolver | SOFR+ | 5.25% | | | 9/20/2030 | | — | | (132) | | (133) | | (5)(8)(9) |
Quantum Bidco Limited | Food Distributors | First Lien Term Loan | SONIA+ | 5.50% | 10.97% | | 1/31/2028 | | £ | 9,861 | | 11,503 | | 11,934 | | (5)(8)(10) |
Radar Bidco Sarl | Air Freight & Logistics | First Lien Term Loan | SOFR+ | 4.25% | 9.58% | | 3/31/2031 | | $ | 22,500 | | 22,388 | | 22,528 | | (5)(10) |
Renaissance Holding Corp. | Education Services | First Lien Term Loan | SOFR+ | 4.25% | 9.58% | | 4/5/2030 | | 37,820 | | 37,307 | | 37,938 | | (5) |
Resistance Acquisition, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 7.75% | 13.05% | | 9/21/2028 | | 18,387 | | 17,976 | | 18,019 | | (5)(8) |
Rockford Tower CLO 2024-1 | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.48% | 12.81% | | 4/20/2037 | | 2,500 | | 2,475 | | 2,475 | | (5)(10) |
RR 24 | Multi-Sector Holdings | CLO Notes | SOFR+ | 8.30% | 13.65% | | 1/15/2036 | | 2,750 | | 2,750 | | 2,780 | | (5)(10) |
Salus Workers' Compensation, LLC | Diversified Financial Services | First Lien Term Loan | SOFR+ | 10.00% | 15.33% | | 10/7/2026 | | 15,510 | | 15,114 | | 15,045 | | (5)(8) |
Salus Workers' Compensation, LLC | Diversified Financial Services | First Lien Revolver | SOFR+ | 10.00% | | | 10/7/2026 | | — | | (48) | | (57) | | (5)(8)(9) |
Salus Workers' Compensation, LLC | Diversified Financial Services | Warrants | | | | | | 606,357 | | | 200 | | 291 | | (8) |
SCIH Salt Holdings Inc. | Diversified Chemicals | First Lien Term Loan | SOFR+ | 4.00% | 9.44% | | 3/16/2027 | | 26,736 | | 26,469 | | 26,815 | | (5) |
SCIH Salt Holdings Inc. | Diversified Chemicals | Fixed Rate Bond | | | 4.88% | | 5/1/2028 | | 14,450 | | 13,080 | | 13,477 | | |
SCP Eye Care Services, LLC | Health Care Services | Second Lien Term Loan | SOFR+ | 8.75% | 14.18% | | 10/7/2030 | | 5,881 | | 5,737 | | 5,881 | | (5)(8) |
SCP Eye Care Services, LLC | Health Care Services | Second Lien Term Loan | SOFR+ | 8.75% | 14.18% | | 10/7/2030 | | 727 | | 691 | | 727 | | (5)(8)(9) |
SCP Eye Care Services, LLC | Health Care Services | Common Stock | | | | | | 761 | | | 761 | | 761 | | (8) |
scPharmaceuticals Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 8.75% | 11.75% | | 10/13/2027 | | 7,654 | | 7,364 | | 7,444 | | (5)(8) |
scPharmaceuticals Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 8.75% | | | 10/13/2027 | | — | | — | | — | | (5)(8)(9) |
scPharmaceuticals Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 8.75% | | | 10/13/2027 | | — | | — | | — | | (5)(8)(9) |
scPharmaceuticals Inc. | Pharmaceuticals | Warrants | | | | | | 79,075 | | | 258 | | 225 | | (8) |
Secure Acquisition Inc. | Paper & Plastic Packaging Products & Materials | First Lien Term Loan | SOFR+ | 5.00% | 10.46% | | 12/16/2028 | | 1,749 | | 1,747 | | 1,757 | | (5) |
SEI Holding I Corporation | Trading Companies & Distributors | First Lien Term Loan | SOFR+ | 6.75% | 12.06% | | 3/27/2028 | | 17,332 | | 16,918 | | 17,245 | | (5)(8) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
March 31, 2024
(dollar amounts in thousands)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
SEI Holding I Corporation | Trading Companies & Distributors | First Lien Term Loan | SOFR+ | 6.75% | 12.09% | | 3/27/2028 | | $ | 2,494 | | $ | 2,442 | | $ | 2,481 | | (5)(8) |
SEI Holding I Corporation | Trading Companies & Distributors | First Lien Term Loan | SOFR+ | 6.25% | 11.58% | | 3/27/2028 | | 1,550 | | 1,484 | | 1,441 | | (5)(8)(9) |
SEI Holding I Corporation | Trading Companies & Distributors | First Lien Revolver | PRIME+ | 5.75% | 14.25% | | 3/27/2028 | | 500 | | 464 | | 493 | | (5)(8)(9) |
Seres Therapeutics, Inc. | Biotechnology | First Lien Term Loan | SOFR+ | 7.88% | 12.88% | | 4/27/2029 | | 11,547 | | 11,172 | | 11,027 | | (5)(8)(10) |
Seres Therapeutics, Inc. | Biotechnology | First Lien Term Loan | SOFR+ | 7.88% | 12.88% | | 4/27/2029 | | 4,330 | | 4,189 | | 4,135 | | (5)(8)(10) |
Seres Therapeutics, Inc. | Biotechnology | First Lien Term Loan | SOFR+ | 7.88% | | | 4/27/2029 | | — | | — | | — | | (5)(8)(9)(10) |
Seres Therapeutics, Inc. | Biotechnology | First Lien Term Loan | SOFR+ | 7.88% | | | 4/27/2029 | | — | | — | | — | | (5)(8)(9)(10) |
Seres Therapeutics, Inc. | Biotechnology | Warrants | | | | | | 93,470 | | | 293 | | 28 | | (8)(10) |
SM Wellness Holdings, Inc. | Health Care Services | First Lien Term Loan | SOFR+ | 4.50% | 10.07% | | 4/17/2028 | | 14,249 | | 13,450 | | 13,744 | | (5)(8) |
Southern Veterinary Partners, LLC | Health Care Facilities | First Lien Term Loan | SOFR+ | 4.00% | 9.44% | | 10/5/2027 | | 30,508 | | 30,271 | | 30,576 | | (5) |
SPX Flow, Inc. | Industrial Machinery & Supplies & Components | First Lien Term Loan | SOFR+ | 4.50% | 9.93% | | 4/5/2029 | | 29,496 | | 28,746 | | 29,654 | | (5) |
SPX Flow, Inc. | Industrial Machinery & Supplies & Components | Fixed Rate Bond | | | 8.75% | | 4/1/2030 | | 2,580 | | 2,486 | | 2,608 | | |
Staples, Inc. | Office Services & Supplies | First Lien Term Loan | SOFR+ | 5.00% | 10.44% | | 4/16/2026 | | 26,693 | | 26,424 | | 26,481 | | (5) |
Staples, Inc. | Office Services & Supplies | Fixed Rate Bond | | | 7.50% | | 4/15/2026 | | 4,730 | | 4,248 | | 4,621 | | |
Star Parent, Inc. | Life Sciences Tools & Services | First Lien Term Loan | SOFR+ | 4.00% | 9.31% | | 9/28/2030 | | 51,025 | | 50,089 | | 50,773 | | (5) |
Superior Industries International, Inc. | Auto Parts & Equipment | First Lien Term Loan | SOFR+ | 8.00% | 13.33% | | 12/16/2028 | | 33,143 | | 32,363 | | 32,819 | | (5)(8) |
SupplyOne Inc. | Paper & Plastic Packaging Products & Materials | First Lien Term Loan | SOFR+ | 4.25% | 9.58% | | 3/27/2031 | | 14,000 | | 13,860 | | 13,956 | | (5) |
Supreme Fitness Group NY Holdings, LLC | Leisure Facilities | First Lien Term Loan | SOFR+ | 7.00% | 12.59% | | 12/31/2026 | | 8,154 | | 8,065 | | 7,756 | | (5)(8) |
Supreme Fitness Group NY Holdings, LLC | Leisure Facilities | First Lien Term Loan | SOFR+ | 7.00% | 12.59% | | 12/31/2026 | | 698 | | 691 | | 664 | | (5)(8) |
Supreme Fitness Group NY Holdings, LLC | Leisure Facilities | First Lien Term Loan | SOFR+ | 7.00% | 12.59% | | 12/31/2026 | | 840 | | 809 | | 799 | | (5)(8) |
Supreme Fitness Group NY Holdings, LLC | Leisure Facilities | First Lien Revolver | SOFR+ | 7.00% | | | 12/31/2026 | | — | | (4) | | (19) | | (5)(8)(9) |
Tacala, LLC | Restaurants | First Lien Term Loan | SOFR+ | 4.00% | 9.33% | | 1/31/2031 | | 35,000 | | 34,913 | | 35,077 | | (5) |
Ten-X LLC | Interactive Media & Services | First Lien Term Loan | SOFR+ | 6.00% | 11.33% | | 5/26/2028 | | 24,736 | | 23,703 | | 23,907 | | (5)(8) |
THL Zinc Ventures Ltd | Diversified Metals & Mining | First Lien Term Loan | | | 13.00% | | 5/23/2026 | | 39,751 | | 39,382 | | 39,552 | | (8)(10) |
Touchstone Acquisition, Inc. | Health Care Supplies | First Lien Term Loan | SOFR+ | 6.00% | 11.41% | | 12/29/2028 | | 8,463 | | 8,348 | | 8,231 | | (5)(8) |
Transit Buyer LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 6.25% | 11.40% | | 1/31/2029 | | 8,384 | | 8,249 | | 8,275 | | (5)(8) |
Transit Buyer LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 6.25% | 11.40% | | 1/31/2029 | | 1,632 | | 1,570 | | 1,582 | | (5)(8)(9) |
Trident TPI Holdings, Inc. | Metal, Glass & Plastic Containers | First Lien Term Loan | SOFR+ | 4.00% | 9.57% | | 9/15/2028 | | 8,942 | | 8,932 | | 8,956 | | (5) |
Trident TPI Holdings, Inc. | Metal, Glass & Plastic Containers | First Lien Term Loan | SOFR+ | 5.25% | 10.56% | | 9/15/2028 | | 7,827 | | 7,680 | | 7,869 | | (5) |
Trinitas CLO VI Ltd. | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.08% | 12.40% | | 1/25/2034 | | 905 | | 850 | | 858 | | (5)(10) |
Trinitas CLO XII | Multi-Sector Holdings | CLO Notes | SOFR+ | 4.26% | 9.59% | | 4/25/2033 | | 4,500 | | 4,397 | | 4,511 | | (5)(10) |
Trinitas CLO XV DAC | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.71% | 13.03% | | 4/22/2034 | | 6,500 | | 5,816 | | 6,178 | | (5)(10) |
Uniti Group LP | Cable & Satellite | Fixed Rate Bond | | | 6.50% | | 2/15/2029 | | 990 | | 916 | | 768 | | (10) |
Uniti Group LP | Cable & Satellite | Fixed Rate Bond | | | 4.75% | | 4/15/2028 | | 1,328 | | 1,190 | | 1,161 | | (10) |
Venture 41 CLO | Multi-Sector Holdings | CLO Notes | SOFR+ | 4.13% | 9.45% | | 1/20/2034 | | 1,500 | | 1,478 | | 1,462 | | (5)(10) |
WAVE 2019-1 | Specialized Finance | CLO Notes | | | 3.60% | | 9/15/2044 | | 4,959 | | 4,108 | | 4,421 | | |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
March 31, 2024
(dollar amounts in thousands)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
Wellfleet CLO 2022-2, Ltd. | Multi-Sector Holdings | CLO Notes | SOFR+ | 8.56% | 13.86% | | 10/18/2035 | | $ | 1,500 | | $ | 1,445 | | $ | 1,515 | | (5)(10) |
WP CPP Holdings, LLC | Aerospace & Defense | First Lien Term Loan | SOFR+ | 7.50% | 8.72% | 4.13% | 11/28/2029 | | 53,584 | | 52,330 | | 52,390 | | (5)(8) |
WP CPP Holdings, LLC | Aerospace & Defense | First Lien Revolver | SOFR+ | 6.75% | | | 11/28/2029 | | — | | (138) | | (129) | | (5)(8)(9) |
Total Non-Control/Non-Affiliate Investments (142.5% of net assets) | | | | | | | | | | $ | 3,496,473 | | $ | 3,519,936 | | |
Cash and Cash Equivalents and Restricted Cash (14.0% of net assets) | | | | | | | | | | $ | 346,361 | | $ | 346,361 | | |
Total Portfolio Investments, Cash and Cash Equivalents and Restricted Cash (156.5% of net assets) | | | | | | | | | | $ | 3,842,834 | | $ | 3,866,297 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Derivative Instrument | | Notional Amount to be Purchased | | Notional Amount to be Sold | | Maturity Date | | Counterparty | | Cumulative Unrealized Appreciation /(Depreciation) |
Foreign currency forward contract | | $ | 70,422 | | | € | 65,253 | | | 5/9/2024 | | Bank of New York Mellon | | $ | (152) | |
Foreign currency forward contract | | $ | 49,168 | | | £ | 38,994 | | | 5/9/2024 | | Bank of New York Mellon | | (100) | |
| | | | | | | | | | $ | (252) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Derivative Instrument | | Company Receives | | Company Pays | | Counterparty | | Maturity Date | | Notional Amount | | Fair Value |
Interest rate swap | | Fixed 8.4% | | Floating 3-month SOFR +4.0405% | | BNP Paribas | | 11/14/2028 | | $350,000 | | $ | 2,944 | |
| | | | | | | | | | | | $ | 2,944 | |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
March 31, 2024
(dollar amounts in thousands)
(unaudited)
(1)All debt investments are income producing unless otherwise noted. All equity investments are non-income producing unless otherwise noted.
(2)See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition by geographic region.
(3)Each of the Company's investments is pledged as collateral under one or more of its credit facilities. A single investment may be divided into parts that are individually pledged as collateral to separate credit facilities.
(4)Interest rates may be adjusted from period to period on certain term loans and revolvers. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents.
(5)The interest rate on the principal balance outstanding for most floating rate loans is indexed to the secured overnight financing rate ("SOFR"), the euro interbank offered rate ("EURIBOR" or "E"), the sterling overnight index average ("SONIA") and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate or the alternate base rate based on each respective credit agreement and the cash interest rate as of period end. All LIBOR shown above is in U.S. dollars unless otherwise noted. As of March 31, 2024, the reference rates for the Company's variable rate loans were the 30-day SOFR at 5.33%, the 90-day SOFR at 5.31%, the 180-day SOFR at 5.23%, the PRIME at 8.50%, the SONIA at 5.19% and the 90-day EURIBOR at 3.88%. Most loans include an interest floor, which generally ranges from 0% to 2.75%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.
(6)Principal includes accumulated payment in kind ("PIK") interest and is net of repayments, if any. "€" signifies the investment is denominated in Euros. “£” signifies the investment is denominated in British Pounds. All other investments are denominated in U.S. dollars.
(7)Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments. Control Investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities and/or has the power to exercise control over the management or policies of the company. Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.
(8)As of March 31, 2024, these investments are categorized as Level 3 within the fair value hierarchy established by Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 820, Fair Value Measurements and Disclosures ("ASC 820") and were valued using significant unobservable inputs.
(9)Investment has undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.
(10)Investment is not a qualifying asset as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of March 31, 2024, qualifying assets represented 79.6% of the Company's total assets and non-qualifying assets represented 20.4% of the Company's total assets.
(11)This investment represents a participation interest in the underlying securities shown.
(12)This investment was on non-accrual status as of March 31, 2024.
See notes to Consolidated Financial Statements.
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
September 30, 2023
(dollar amounts in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
Non-Control/Non-Affiliate Investments | | | | | | | | | | | | (7) |
107-109 Beech OAK22 LLC | Real Estate Development | First Lien Revolver | | | 11.00% | | 2/27/2026 | | $ | 11,883 | | $ | 11,768 | | $ | 11,614 | | (8)(9) |
107 Fair Street LLC | Real Estate Development | First Lien Term Loan | | | 12.50% | | 5/31/2024 | | 1,031 | | 1,007 | | 987 | | (8)(9)(11) |
112-126 Van Houten Real22 LLC | Real Estate Development | First Lien Term Loan | | | 12.00% | | 5/4/2024 | | 3,287 | | 3,261 | | 3,248 | | (8)(9)(11) |
AB BSL CLO 4 | Multi-Sector Holdings | CLO Notes | SOFR+ | 5.50% | 10.46% | | 4/20/2036 | | 3,800 | | 3,800 | | 3,815 | | (5)(10) |
Access CIG, LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 5.00% | 10.32% | | 8/18/2028 | | 24,500 | | 23,956 | | 24,224 | | (5) |
ACP Falcon Buyer Inc | Systems Software | First Lien Term Loan | SOFR+ | 6.50% | 11.80% | | 8/1/2029 | | 34,667 | | 33,656 | | 33,696 | | (5)(8) |
ACP Falcon Buyer Inc | Systems Software | First Lien Revolver | SOFR+ | 6.50% | | | 8/1/2029 | | — | | (156) | | (149) | | (5)(8)(9) |
ADC Therapeutics SA | Biotechnology | First Lien Term Loan | SOFR+ | 7.50% | 13.04% | | 8/15/2029 | | 10,406 | | 9,957 | | 9,912 | | (5)(8)(10) |
ADC Therapeutics SA | Biotechnology | First Lien Term Loan | SOFR+ | 7.50% | | | 8/15/2029 | | — | | (60) | | (60) | | (5)(8)(9)(10) |
ADC Therapeutics SA | Biotechnology | Warrants | | | | | | 45,727 | | | 275 | | 9 | | (8)(10) |
AI Sirona (Luxembourg) Acquisition S.a.r.l. | Pharmaceuticals | First Lien Term Loan | E+ | 5.00% | 8.86% | | 9/30/2028 | | € | 21,000 | | 23,002 | | 22,242 | | (5)(10) |
AIP RD Buyer Corp. | Distributors | Second Lien Term Loan | SOFR+ | 7.75% | 13.17% | | 12/21/2029 | | $ | 4,563 | | 4,492 | | 4,516 | | (5)(8) |
AIP RD Buyer Corp. | Distributors | Common Stock | | | | | | 4,560 | | | 428 | | 721 | | (8) |
Altice France S.A. | Integrated Telecommunication Services | First Lien Term Loan | L+ | 4.00% | 9.63% | | 8/14/2026 | | 8,940 | | 8,728 | | 8,459 | | (5)(10) |
Altice France S.A. | Integrated Telecommunication Services | Fixed Rate Bond | | | 5.50% | | 10/15/2029 | | 7,200 | | 6,007 | | 5,188 | | (10) |
Alto Pharmacy Holdings, Inc. | Health Care Technology | First Lien Term Loan | SOFR+ | 11.50% | 5.00% | 11.99% | 10/14/2027 | | 13,299 | | 12,386 | | 12,236 | | (5)(8) |
Alto Pharmacy Holdings, Inc. | Health Care Technology | Warrants | | | | | | 878,545 | | | 943 | | 2,811 | | (8) |
American Auto Auction Group, LLC | Consumer Finance | Second Lien Term Loan | SOFR+ | 8.75% | 14.14% | | 1/2/2029 | | 6,901 | | 6,796 | | 6,107 | | (5)(8) |
American Rock Salt Company LLC | Diversified Metals & Mining | First Lien Term Loan | SOFR+ | 4.00% | 9.43% | | 6/9/2028 | | 20,324 | | 19,504 | | 18,918 | | (5) |
American Tire Distributors, Inc. | Distributors | First Lien Term Loan | SOFR+ | 6.25% | 11.81% | | 10/20/2028 | | 22,602 | | 20,490 | | 19,863 | | (5) |
Amynta Agency Borrower Inc. | Property & Casualty Insurance | First Lien Term Loan | SOFR+ | 5.00% | 10.42% | | 2/28/2028 | | 11,970 | | 11,651 | | 11,989 | | (5) |
Anastasia Parent, LLC | Personal Care Products | First Lien Term Loan | SOFR+ | 3.75% | 9.40% | | 8/11/2025 | | 6,840 | | 5,742 | | 4,934 | | (5) |
Ardonagh Midco 3 PLC | Insurance Brokers | First Lien Term Loan | E+ | 6.50% | 10.45% | | 7/14/2026 | | € | 9,600 | | 9,626 | | 10,266 | | (5)(8)(10) |
Ardonagh Midco 3 PLC | Insurance Brokers | First Lien Term Loan | SOFR+ | 6.75% | 12.57% | | 7/14/2026 | | $ | 3,520 | | 3,353 | | 3,591 | | (5)(8)(9)(10) |
ARES LXIV CLO | Multi-Sector Holdings | CLO Notes | SOFR+ | 3.75% | 9.06% | | 4/15/2035 | | 2,200 | | 2,051 | | 2,128 | | (5)(10) |
ARES LXVIII CLO | Multi-Sector Holdings | CLO Notes | SOFR+ | 5.75% | 10.83% | | 4/25/2035 | | 5,000 | | 5,000 | | 5,112 | | (5)(10) |
Arsenal AIC Parent LLC | Diversified Metals & Mining | First Lien Term Loan | SOFR+ | 4.50% | 9.88% | | 8/18/2030 | | 10,000 | | 9,900 | | 9,994 | | (5) |
ASP-R-PAC Acquisition Co LLC | Paper & Plastic Packaging Products & Materials | First Lien Term Loan | SOFR+ | 6.00% | 11.63% | | 12/29/2027 | | 4,862 | | 4,793 | | 4,577 | | (5)(8)(10) |
ASP-R-PAC Acquisition Co LLC | Paper & Plastic Packaging Products & Materials | First Lien Revolver | SOFR+ | 6.00% | | | 12/29/2027 | | — | | (8) | | (34) | | (5)(8)(9)(10) |
Astra Acquisition Corp. | Application Software | First Lien Term Loan | SOFR+ | 5.25% | 10.90% | | 10/25/2028 | | 4,848 | | 4,620 | | 3,663 | | (5) |
Asurion, LLC | Property & Casualty Insurance | First Lien Term Loan | SOFR+ | 4.00% | 9.42% | | 8/19/2028 | | 7,950 | | 7,673 | | 7,724 | | (5) |
Asurion, LLC | Property & Casualty Insurance | First Lien Term Loan | SOFR+ | 4.25% | 9.67% | | 8/19/2028 | | 15,945 | | 15,192 | | 15,518 | | (5) |
Asurion, LLC | Property & Casualty Insurance | Second Lien Term Loan | SOFR+ | 5.25% | 10.68% | | 1/20/2029 | | 7,500 | | 6,883 | | 6,680 | | (5) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
September 30, 2023
(dollar amounts in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
athenahealth Group Inc. | Health Care Technology | First Lien Term Loan | SOFR+ | 3.25% | 8.57% | | 2/15/2029 | | $ | 24,240 | | $ | 23,056 | | $ | 23,854 | | (5) |
athenahealth Group Inc. | Health Care Technology | Fixed Rate Bond | | | 6.50% | | 2/15/2030 | | 3,000 | | 2,597 | | 2,513 | | |
athenahealth Group Inc. | Health Care Technology | Preferred Equity | | | | | | 5,809 | | | 5,693 | | 5,418 | | (8) |
Avalara, Inc. | Application Software | First Lien Term Loan | SOFR+ | 7.25% | 12.64% | | 10/19/2028 | | 19,029 | | 18,629 | | 18,734 | | (5)(8) |
Avalara, Inc. | Application Software | First Lien Revolver | SOFR+ | 7.25% | | | 10/19/2028 | | — | | (40) | | (29) | | (5)(8)(9) |
Bamboo US Bidco LLC | Health Care Equipment | First Lien Term Loan | SOFR+ | 6.00% | 11.32% | | 9/30/2030 | | 24,960 | | 24,212 | | 24,211 | | (5)(8) |
Bamboo US Bidco LLC | Health Care Equipment | First Lien Term Loan | E+ | 6.00% | 9.97% | | 9/30/2030 | | € | 15,530 | | 15,949 | | 15,949 | | (5)(8) |
Bamboo US Bidco LLC | Health Care Equipment | First Lien Term Loan | SOFR+ | 6.00% | | | 9/30/2030 | | $ | — | | (59) | | (59) | | (5)(8)(9) |
Bamboo US Bidco LLC | Health Care Equipment | First Lien Revolver | SOFR+ | 6.00% | | | 10/1/2029 | | — | | (156) | | (156) | | (5)(8)(9) |
Bausch + Lomb Corp | Health Care Supplies | Fixed Rate Bond | | | 8.38% | | 10/1/2028 | | 6,000 | | 6,000 | | 6,025 | | (10) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | First Lien Term Loan | | | 8.00% | 2.25% | 4/19/2027 | | 3,220 | | 3,123 | | 2,967 | | (8)(10) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | First Lien Term Loan | | | | | 9/30/2032 | | 1,580 | | 1,580 | | 1,510 | | (8)(9)(10)(12) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | First Lien Term Loan | | | 8.00% | 2.25% | 4/19/2027 | | — | | — | | — | | (8)(9)(10) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | First Lien Term Loan | | | | | 9/30/2032 | | — | | — | | — | | (8)(9)(10)(12) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | First Lien Term Loan | | | 8.00% | 2.25% | 4/19/2027 | | — | | — | | — | | (8)(9)(10) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | First Lien Term Loan | | | | | 9/30/2032 | | — | | — | | — | | (8)(9)(10)(12) |
BioXcel Therapeutics, Inc. | Pharmaceuticals | Warrants | | | | | | 12,453 | | | 74 | | 1 | | (8)(10) |
CCO Holdings LLC | Cable & Satellite | Fixed Rate Bond | | | 4.50% | | 5/1/2032 | | 12,281 | | 10,034 | | 9,651 | | (10) |
CD&R Firefly Bidco Limited | Other Specialty Retail | First Lien Term Loan | SONIA+ | 6.00% | 11.29% | | 6/21/2028 | | £ | 21,086 | | 25,375 | | 25,215 | | (5)(10) |
Clear Channel Outdoor Holdings, Inc. | Advertising | First Lien Term Loan | SOFR+ | 3.50% | 9.13% | | 8/21/2026 | | $ | 6,915 | | 6,523 | | 6,732 | | (5)(10) |
Clear Channel Outdoor Holdings, Inc. | Advertising | Fixed Rate Bond | | | 5.13% | | 8/15/2027 | | 726 | | 644 | | 645 | | (10) |
Clear Channel Outdoor Holdings, Inc. | Advertising | Fixed Rate Bond | | | 9.00% | | 9/15/2028 | | 4,000 | | 4,000 | | 3,966 | | (10) |
Colony Holding Corporation | Distributors | First Lien Term Loan | SOFR+ | 6.50% | 11.97% | | 5/13/2026 | | 12,117 | | 11,825 | | 11,834 | | (5)(8) |
Colony Holding Corporation | Distributors | First Lien Term Loan | SOFR+ | 6.50% | 11.97% | | 5/13/2026 | | 3,940 | | 3,872 | | 3,848 | | (5)(8) |
Condor Merger Sub Inc. | Systems Software | Fixed Rate Bond | | | 7.38% | | 2/15/2030 | | 4,527 | | 4,505 | | 3,795 | | |
Coupa Holdings, LLC | Application Software | First Lien Term Loan | SOFR+ | 7.50% | 12.82% | | 2/27/2030 | | 13,464 | | 13,155 | | 13,158 | | (5)(8) |
Coupa Holdings, LLC | Application Software | First Lien Term Loan | SOFR+ | 7.50% | | | 2/27/2030 | | — | | (15) | | (13) | | (5)(8)(9) |
Coupa Holdings, LLC | Application Software | First Lien Revolver | SOFR+ | 7.50% | | | 2/27/2029 | | — | | (21) | | (21) | | (5)(8)(9) |
Covetrus, Inc. | Health Care Distributors | First Lien Term Loan | SOFR+ | 5.00% | 10.39% | | 10/13/2029 | | 23,976 | | 22,737 | | 23,758 | | (5) |
Cuppa Bidco BV | Soft Drinks & Non-alcoholic Beverages | First Lien Term Loan | E+ | 4.75% | 8.68% | | 7/30/2029 | | € | 5,666 | | 4,958 | | 5,542 | | (5)(10) |
Curium Bidco S.à.r.l. | Biotechnology | First Lien Term Loan | SOFR+ | 4.50% | 9.89% | | 7/31/2029 | | $ | 8,446 | | 8,316 | | 8,446 | | (5)(10) |
CVAUSA Management, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.50% | 11.93% | | 5/22/2029 | | 18,059 | | 17,673 | | 17,562 | | (5)(8) |
CVAUSA Management, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.50% | | | 5/22/2029 | | — | | (149) | | (152) | | (5)(8)(9) |
CVAUSA Management, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.50% | | | 5/22/2029 | | — | | (117) | | (63) | | (5)(8)(9) |
CVAUSA Management, LLC | Health Care Services | First Lien Revolver | SOFR+ | 6.50% | | | 5/22/2029 | | — | | (72) | | (70) | | (5)(8)(9) |
Dealer Tire Financial, LLC | Distributors | First Lien Term Loan | SOFR+ | 4.50% | 9.82% | | 12/14/2027 | | 11,123 | | 11,048 | | 11,157 | | (5) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
September 30, 2023
(dollar amounts in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
Delta Leasing SPV II LLC | Specialized Finance | Subordinated Debt Term Loan | | | 3.00% | 7.00% | 8/31/2029 | | $ | 13,792 | | $ | 13,792 | | $ | 13,792 | | (8)(9)(10) |
Delta Leasing SPV II LLC | Specialized Finance | Preferred Equity | | | | | | 330 | | | 330 | | 330 | | (8)(10) |
Delta Leasing SPV II LLC | Specialized Finance | Common Stock | | | | | | 2 | | | 2 | | 2 | | (8)(10) |
Delta Leasing SPV II LLC | Specialized Finance | Warrants | | | | | | 25 | | | — | | — | | (8)(10) |
DirecTV Financing, LLC | Cable & Satellite | First Lien Term Loan | SOFR+ | 5.00% | 10.43% | | 8/2/2027 | | 13,433 | | 13,051 | | 13,159 | | (5) |
DirecTV Financing, LLC | Cable & Satellite | Fixed Rate Bond | | | 5.88% | | 8/15/2027 | | 1,750 | | 1,593 | | 1,550 | | |
DTI Holdco, Inc. | Research & Consulting Services | First Lien Term Loan | SOFR+ | 4.75% | 10.12% | | 4/26/2029 | | 21,702 | | 20,717 | | 21,180 | | (5) |
Dukes Root Control Inc. | Environmental & Facilities Services | First Lien Term Loan | SOFR+ | 6.50% | 12.04% | | 12/8/2028 | | 11,804 | | 11,575 | | 11,705 | | (5)(8) |
Dukes Root Control Inc. | Environmental & Facilities Services | First Lien Term Loan | SOFR+ | 6.50% | 12.04% | | 12/8/2028 | | 666 | | 633 | | 641 | | (5)(8)(9) |
Dukes Root Control Inc. | Environmental & Facilities Services | First Lien Revolver | SOFR+ | 6.50% | 12.00% | | 12/8/2028 | | 580 | | 552 | | 568 | | (5)(8)(9) |
Entrata, Inc. | Application Software | First Lien Term Loan | SOFR+ | 6.00% | 11.33% | | 7/10/2030 | | 45,603 | | 44,500 | | 44,463 | | (5)(8) |
Entrata, Inc. | Application Software | First Lien Revolver | SOFR+ | 6.00% | | | 7/10/2028 | | — | | (124) | | (130) | | (5)(8)(9) |
Establishment Labs Holdings Inc. | Health Care Technology | First Lien Term Loan | | | 3.00% | 6.00% | 4/21/2027 | | 11,048 | | 10,937 | | 10,662 | | (8)(10) |
Establishment Labs Holdings Inc. | Health Care Technology | First Lien Term Loan | | | 3.00% | 6.00% | 4/21/2027 | | 1,769 | | 1,745 | | 1,707 | | (8)(10) |
Establishment Labs Holdings Inc. | Health Care Technology | First Lien Term Loan | | | 3.00% | 6.00% | 4/21/2027 | | — | | 1 | | — | | (8)(9)(10) |
Establishment Labs Holdings Inc. | Health Care Technology | First Lien Term Loan | | | 3.00% | 6.00% | 4/21/2027 | | — | | 1 | | — | | (8)(9)(10) |
Evergreen IX Borrower 2023, LLC | Application Software | First Lien Term Loan | SOFR+ | 6.00% | 11.32% | | 9/29/2030 | | 36,306 | | 35,399 | | 35,398 | | (5)(8) |
Evergreen IX Borrower 2023, LLC | Application Software | First Lien Revolver | SOFR+ | 6.00% | | | 9/29/2029 | | — | | (100) | | (100) | | (5)(8)(9) |
Finastra USA, Inc. | Application Software | First Lien Term Loan | SOFR+ | 7.25% | 12.55% | | 9/13/2029 | | 43,732 | | 42,864 | | 42,870 | | (5)(8)(10) |
Finastra USA, Inc. | Application Software | First Lien Revolver | SOFR+ | 7.25% | 12.55% | | 9/13/2029 | | 961 | | 871 | | 871 | | (5)(8)(9)(10) |
Frontier Communications Holdings, LLC | Integrated Telecommunication Services | First Lien Term Loan | SOFR+ | 3.75% | 9.18% | | 10/8/2027 | | 20,853 | | 20,306 | | 20,326 | | (5)(10) |
Frontier Communications Holdings, LLC | Integrated Telecommunication Services | Fixed Rate Bond | | | 6.00% | | 1/15/2030 | | 7,517 | | 6,311 | | 5,508 | | (10) |
Galileo Parent, Inc. | Aerospace & Defense | First Lien Term Loan | SOFR+ | 7.25% | 12.64% | | 5/3/2029 | | 20,277 | | 19,711 | | 19,711 | | (5)(8) |
Galileo Parent, Inc. | Aerospace & Defense | First Lien Revolver | SOFR+ | 7.25% | 12.64% | | 5/3/2029 | | 1,397 | | 1,309 | | 1,309 | | (5)(8)(9) |
Gallatin CLO X 2023-1 | Multi-Sector Holdings | CLO Notes | SOFR+ | 5.41% | 10.74% | | 10/14/2035 | | 5,000 | | 4,913 | | 4,932 | | (5)(10) |
Gibson Brands, Inc. | Leisure Products | First Lien Term Loan | SOFR+ | 5.00% | 10.57% | | 8/11/2028 | | 4,917 | | 4,772 | | 4,131 | | (5)(8) |
Global Aircraft Leasing Co Ltd | Trading Companies & Distributors | Fixed Rate Bond | | | 6.50% | | 9/15/2024 | | 7,645 | | 7,088 | | 7,294 | | (10) |
GoldenTree Loan Management EUR CLO 2 DAC | Multi-Sector Holdings | CLO Notes | E+ | 2.85% | 6.56% | | 1/20/2032 | | € | 1,000 | | 875 | | 963 | | (5)(10) |
Grove Hotel Parcel Owner, LLC | Hotels, Resorts & Cruise Lines | First Lien Term Loan | SOFR+ | 8.00% | 13.42% | | 6/21/2027 | | $ | 17,507 | | 17,246 | | 17,157 | | (5)(8) |
Grove Hotel Parcel Owner, LLC | Hotels, Resorts & Cruise Lines | First Lien Term Loan | SOFR+ | 8.00% | | | 6/21/2027 | | — | | (53) | | (71) | | (5)(8)(9) |
Grove Hotel Parcel Owner, LLC | Hotels, Resorts & Cruise Lines | First Lien Revolver | SOFR+ | 8.00% | | | 6/21/2027 | | — | | (26) | | (35) | | (5)(8)(9) |
Harbor Purchaser Inc. | Education Services | First Lien Term Loan | SOFR+ | 5.25% | 10.67% | | 4/9/2029 | | 10,445 | | 10,057 | | 9,914 | | (5) |
Harrow, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 6.50% | 11.89% | | 1/19/2026 | | 9,319 | | 9,129 | | 9,135 | | (5)(8)(10) |
Harrow, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 6.50% | 12.04% | | 1/19/2026 | | 1,792 | | 1,750 | | 1,757 | | (5)(8)(10) |
Harrow, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 6.50% | | | 1/19/2026 | | — | | (103) | | (99) | | (5)(8)(9)(10) |
Hertz Vehicle Financing III | Specialized Finance | CLO Notes | | | 5.16% | | 6/26/2028 | | 7,500 | | 6,496 | | 6,583 | | (10) |
Hertz Vehicle Financing III | Specialized Finance | CLO Notes | | | 6.78% | | 9/25/2028 | | 17,377 | | 15,825 | | 16,035 | | (10) |
Horizon Aircraft Finance I Ltd. | Specialized Finance | CLO Notes | | | 4.46% | | 12/15/2038 | | 6,770 | | 5,658 | | 5,841 | | (10) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
September 30, 2023
(dollar amounts in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
Horizon Aircraft Finance II Ltd. | Specialized Finance | CLO Notes | | | 3.72% | | 7/15/2039 | | $ | 2,300 | | $ | 1,969 | | $ | 1,981 | | (10) |
HUB Pen Company, LLC | Other Specialty Retail | First Lien Term Loan | SOFR+ | 6.50% | 11.93% | | 12/31/2027 | | 27,335 | | 26,653 | | 26,663 | | (5)(8) |
HUB Pen Company, LLC | Other Specialty Retail | First Lien Revolver | SOFR+ | 6.50% | 6.50% | | 12/31/2027 | | 108 | | 25 | | 26 | | (5)(8)(9) |
IAMGOLD Corporation | Gold | Second Lien Term Loan | SOFR+ | 8.25% | 13.62% | | 5/16/2028 | | 28,394 | | 27,607 | | 27,627 | | (5)(8)(10) |
iCIMs, Inc. | Application Software | First Lien Term Loan | SOFR+ | 7.25% | 12.63% | | 8/18/2028 | | 15,621 | | 15,411 | | 15,059 | | (5)(8) |
iCIMs, Inc. | Application Software | First Lien Term Loan | SOFR+ | 7.25% | 12.63% | | 8/18/2028 | | 2,325 | | 2,291 | | 2,286 | | (5)(8) |
iCIMs, Inc. | Application Software | First Lien Term Loan | SOFR+ | 7.25% | | | 8/18/2028 | | — | | — | | — | | (5)(8)(9) |
iCIMs, Inc. | Application Software | First Lien Revolver | SOFR+ | 6.75% | 12.14% | | 8/18/2028 | | 241 | | 221 | | 189 | | (5)(8)(9) |
Impel Pharmaceuticals Inc. | Health Care Technology | First Lien Term Loan | SOFR+ | 10.75% | | 16.06% | 3/17/2027 | | 9,679 | | 9,613 | | 8,904 | | (5)(8) |
Impel Pharmaceuticals Inc. | Health Care Technology | First Lien Term Loan | SOFR+ | 10.75% | | 16.05% | 3/17/2027 | | 286 | | 281 | | 286 | | (5)(8) |
Impel Pharmaceuticals Inc. | Health Care Technology | First Lien Term Loan | SOFR+ | 10.75% | | 16.06% | 3/17/2027 | | 250 | | 250 | | 250 | | (5)(8)(9) |
Impel Pharmaceuticals Inc. | Health Care Technology | Warrants | | | | | | 127,376 | | | — | | 53 | | |
Innocoll Pharmaceuticals Limited | Health Care Technology | First Lien Term Loan | SOFR+ | 5.75% | 11.14% | 2.75% | 1/26/2027 | | 3,665 | | 3,557 | | 3,354 | | (5)(8)(10) |
Innocoll Pharmaceuticals Limited | Health Care Technology | First Lien Term Loan | SOFR+ | 5.75% | | | 1/26/2027 | | — | | — | | — | | (5)(8)(9)(10) |
Innocoll Pharmaceuticals Limited | Health Care Technology | First Lien Term Loan | SOFR+ | 5.75% | | | 1/26/2027 | | — | | — | | — | | (5)(8)(9)(10) |
Innocoll Pharmaceuticals Limited | Health Care Technology | Warrants | | | | | | 36,087 | | | 85 | | 54 | | (8)(10) |
Inventus Power, Inc. | Electrical Components & Equipment | First Lien Term Loan | SOFR+ | 7.50% | 12.93% | | 6/30/2025 | | 43,765 | | 42,619 | | 42,776 | | (5)(8) |
Inventus Power, Inc. | Electrical Components & Equipment | First Lien Revolver | SOFR+ | 7.50% | | | 6/30/2025 | | — | | (130) | | (112) | | (5)(8)(9) |
IW Buyer LLC | Electrical Components & Equipment | First Lien Term Loan | SOFR+ | 6.75% | 12.17% | | 6/28/2029 | | 34,375 | | 33,388 | | 33,429 | | (5)(8) |
IW Buyer LLC | Electrical Components & Equipment | First Lien Revolver | SOFR+ | 6.75% | | | 6/28/2029 | | — | | (185) | | (177) | | (5)(8)(9) |
KDC/ONE Development Corp Inc | Personal Care Products | First Lien Term Loan | SOFR+ | 5.00% | 10.32% | | 8/15/2028 | | 30,000 | | 29,118 | | 28,995 | | (5)(10) |
Kindercare Learning Centers Kindercare Portfolio | Diversified Real Estate Activities | CLO Notes | SOFR+ | 2.41% | 7.75% | | 8/15/2038 | | 4,964 | | 4,619 | | 4,696 | | (5)(10) |
Kings Buyer, LLC | Environmental & Facilities Services | First Lien Term Loan | SOFR+ | 6.50% | 11.84% | | 10/29/2027 | | 4,811 | | 4,763 | | 4,739 | | (5)(8) |
Kings Buyer, LLC | Environmental & Facilities Services | First Lien Term Loan | SOFR+ | 6.50% | 11.80% | | 10/29/2027 | | 58,992 | | 58,110 | | 58,107 | | (5)(8) |
Kings Buyer, LLC | Environmental & Facilities Services | First Lien Revolver | SOFR+ | 6.50% | 11.84% | | 10/29/2027 | | 78 | | 72 | | 68 | | (5)(8)(9) |
Kings Buyer, LLC | Environmental & Facilities Services | First Lien Revolver | SOFR+ | 6.50% | | | 10/29/2027 | | — | | (73) | | (73) | | (5)(8)(9) |
LABL, Inc. | Office Services & Supplies | First Lien Term Loan | SOFR+ | 5.00% | 10.42% | | 10/29/2028 | | 21,627 | | 21,160 | | 21,588 | | (5) |
Latam Airlines Group S.A. | Passenger Airlines | First Lien Term Loan | SOFR+ | 9.50% | 14.95% | | 10/12/2027 | | 12,032 | | 11,191 | | 12,529 | | (5)(10) |
LSL Holdco, LLC | Health Care Distributors | First Lien Term Loan | SOFR+ | 6.00% | 11.42% | | 1/31/2028 | | 8,997 | | 8,867 | | 8,412 | | (5)(8) |
LSL Holdco, LLC | Health Care Distributors | First Lien Term Loan | SOFR+ | 6.00% | 11.42% | | 1/31/2028 | | 1,048 | | 986 | | 979 | | (5)(8) |
LSL Holdco, LLC | Health Care Distributors | First Lien Revolver | SOFR+ | 6.00% | | | 1/31/2028 | | — | | (15) | | (66) | | (5)(8)(9) |
Madison Park Funding LXIII | Multi-Sector Holdings | CLO Notes | SOFR+ | 5.50% | 10.58% | | 4/21/2035 | | 5,000 | | 5,000 | | 5,099 | | (5)(10) |
Mauser Packaging Solutions Holding Company | Metal, Glass & Plastic Containers | First Lien Term Loan | SOFR+ | 4.00% | 9.33% | | 8/14/2026 | | 15,980 | | 15,876 | | 15,992 | | (5) |
Mauser Packaging Solutions Holding Company | Metal, Glass & Plastic Containers | Fixed Rate Bond | | | 7.88% | | 8/15/2026 | | 5,000 | | 4,971 | | 4,829 | | |
McAfee Corp. | Systems Software | First Lien Term Loan | SOFR+ | 3.75% | 9.18% | | 3/1/2029 | | 17,857 | | 17,074 | | 17,472 | | (5) |
Medline Borrower, LP | Health Care Supplies | First Lien Term Loan | SOFR+ | 3.25% | 8.68% | | 10/23/2028 | | 22,886 | | 22,388 | | 22,851 | | (5) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
September 30, 2023
(dollar amounts in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
Mesoblast, Inc. | Biotechnology | First Lien Term Loan | | | 8.00% | 1.75% | 11/19/2026 | | $ | 2,325 | | $ | 2,189 | | $ | 2,046 | | (8)(10) |
Mesoblast, Inc. | Biotechnology | Warrants | | | | | | 66,347 | | | 152 | | 20 | | (8)(10) |
Mesoblast, Inc. | Biotechnology | Warrants | | | | | | 17,058 | | | — | | 9 | | (8)(10) |
MHE Intermediate Holdings, LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 6.25% | 11.77% | | 7/21/2027 | | 2,829 | | 2,763 | | 2,807 | | (5)(8) |
MHE Intermediate Holdings, LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 6.00% | 11.52% | | 7/21/2027 | | 5,286 | | 5,180 | | 5,207 | | (5)(8) |
Mitchell International, Inc. | Application Software | First Lien Term Loan | SOFR+ | 3.75% | 9.18% | | 10/15/2028 | | 23,392 | | 22,759 | | 23,048 | | (5) |
Mitchell International, Inc. | Application Software | Second Lien Term Loan | SOFR+ | 6.50% | 11.93% | | 10/15/2029 | | 4,000 | | 3,816 | | 3,696 | | (5) |
MND Holdings III Corp | Other Specialty Retail | First Lien Term Loan | SOFR+ | 7.50% | 12.89% | | 5/9/2028 | | 41,483 | | 40,802 | | 40,761 | | (5)(8) |
MND Holdings III Corp | Other Specialty Retail | First Lien Revolver | SOFR+ | 7.50% | 12.83% | | 5/9/2028 | | 1,500 | | 1,243 | | 1,311 | | (5)(8)(9) |
MRI Software LLC | Application Software | First Lien Term Loan | SOFR+ | 5.50% | 10.99% | | 2/10/2026 | | 4,597 | | 4,462 | | 4,502 | | (5)(8) |
MRI Software LLC | Application Software | First Lien Term Loan | SOFR+ | 5.50% | 10.99% | | 2/10/2026 | | 7,204 | | 7,197 | | 7,055 | | (5)(8) |
New Enterprise Stone & Lime Co Inc | Construction Materials | Fixed Rate Bond | | | 5.25% | | 7/15/2028 | | 2,250 | | 2,080 | | 2,022 | | |
NFP Corp. | Diversified Financial Services | Fixed Rate Bond | | | 4.88% | | 8/15/2028 | | 8,550 | | 7,672 | | 7,537 | | |
NFP Corp. | Diversified Financial Services | Fixed Rate Bond | | | 6.88% | | 8/15/2028 | | 3,784 | | 3,473 | | 3,246 | | |
NFP Corp. | Diversified Financial Services | Fixed Rate Bond | | | 8.50% | | 10/1/2031 | | 5,000 | | 5,000 | | 5,013 | | |
North Star Acquisitionco, LLC | Education Services | First Lien Term Loan | SOFR+ | 6.00% | 11.39% | | 5/3/2029 | | 36,625 | | 35,943 | | 35,951 | | (5)(8) |
North Star Acquisitionco, LLC | Education Services | First Lien Term Loan | SOFR+ | 6.00% | | | 5/3/2029 | | — | | (33) | | (31) | | (5)(8)(9) |
North Star Acquisitionco, LLC | Education Services | First Lien Revolver | SOFR+ | 6.00% | | | 5/3/2029 | | — | | (82) | | (81) | | (5)(8)(9) |
OEConnection LLC | Application Software | Second Lien Term Loan | SOFR+ | 7.00% | 12.49% | | 9/25/2027 | | 5,355 | | 5,281 | | 5,275 | | (5)(8) |
OneOncology, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.25% | 11.64% | | 6/9/2030 | | 22,885 | | 22,338 | | 22,354 | | (5)(8) |
OneOncology, LLC | Health Care Services | First Lien Term Loan | SOFR+ | 6.25% | | | 6/9/2030 | | — | | (107) | | (100) | | (5)(8)(9) |
OneOncology, LLC | Health Care Services | First Lien Revolver | SOFR+ | 6.25% | | | 6/9/2030 | | — | | (108) | | (106) | | (5)(8)(9) |
Oranje Holdco, Inc. | Systems Software | First Lien Term Loan | SOFR+ | 7.75% | 13.12% | | 2/1/2029 | | 15,746 | | 15,396 | | 15,450 | | (5)(8) |
Oranje Holdco, Inc. | Systems Software | First Lien Revolver | SOFR+ | 7.75% | | | 2/1/2029 | | — | | (44) | | (37) | | (5)(8)(9) |
Park Place Technologies, LLC | Internet Services & Infrastructure | First Lien Term Loan | SOFR+ | 5.00% | 10.42% | | 11/10/2027 | | 14,919 | | 14,556 | | 14,726 | | (5) |
Peraton Corp. | Aerospace & Defense | First Lien Term Loan | SOFR+ | 3.75% | 9.17% | | 2/1/2028 | | 19,890 | | 19,794 | | 19,874 | | (5) |
PetSmart LLC | Other Specialty Retail | First Lien Term Loan | SOFR+ | 3.75% | 9.17% | | 2/11/2028 | | 10,901 | | 10,689 | | 10,885 | | (5) |
Pluralsight, LLC | Application Software | First Lien Term Loan | SOFR+ | 8.00% | 13.45% | | 4/6/2027 | | 26,144 | | 22,474 | | 25,041 | | (5)(8) |
Pluralsight, LLC | Application Software | First Lien Revolver | SOFR+ | 8.00% | 13.45% | | 4/6/2027 | | 1,028 | | 798 | | 959 | | (5)(8)(9) |
PPW Aero Buyer, Inc. | Aerospace & Defense | First Lien Term Loan | SOFR+ | 7.00% | 12.32% | | 2/15/2029 | | 26,758 | | 25,799 | | 25,776 | | (5)(8) |
PPW Aero Buyer, Inc. | Aerospace & Defense | First Lien Revolver | SOFR+ | 7.00% | | | 2/15/2029 | | — | | (129) | | (132) | | (5)(8)(9) |
Profrac Holdings II, LLC | Industrial Machinery & Supplies & Components | First Lien Term Loan | SOFR+ | 7.25% | 12.78% | | 3/4/2025 | | 5,449 | | 5,372 | | 5,355 | | (5)(8) |
Profrac Holdings II, LLC | Industrial Machinery & Supplies & Components | First Lien Term Loan | SOFR+ | 7.25% | 12.78% | | 3/4/2025 | | 627 | | 620 | | 616 | | (5)(8) |
Quantum Bidco Limited | Food Distributors | First Lien Term Loan | SONIA+ | 5.75% | 11.21% | | 1/31/2028 | | £ | 5,470 | | $ | 6,111 | | $ | 6,109 | | (5)(8)(10) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
September 30, 2023
(dollar amounts in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
Renaissance Holding Corp. | Education Services | First Lien Term Loan | SOFR+ | 4.75% | 10.07% | | 4/7/2030 | | $ | 16,000 | | 15,552 | | 15,900 | | (5) |
Resistance Acquisition, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 7.75% | 13.06% | | 9/21/2028 | | 18,387 | | 17,930 | | 17,927 | | (5)(8) |
Resistance Acquisition, Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 7.75% | | | 9/21/2028 | | — | | — | | — | | (5)(8)(9) |
Salus Workers' Compensation, LLC | Diversified Financial Services | First Lien Term Loan | SOFR+ | 10.00% | 15.24% | | 10/7/2026 | | 15,595 | | 15,118 | | 15,127 | | (5)(8) |
Salus Workers' Compensation, LLC | Diversified Financial Services | First Lien Revolver | SOFR+ | 10.00% | | | 10/7/2026 | | — | | (58) | | (57) | | (5)(8)(9) |
Salus Workers' Compensation, LLC | Diversified Financial Services | Warrants | | | | | | 606,357 | | | 200 | | 994 | | (8) |
SCIH Salt Holdings Inc. | Diversified Metals & Mining | First Lien Term Loan | SOFR+ | 4.00% | 9.63% | | 3/16/2027 | | 22,904 | | 22,626 | | 22,801 | | (5) |
SCIH Salt Holdings Inc. | Diversified Metals & Mining | Fixed Rate Bond | | | 4.88% | | 5/1/2028 | | 5,000 | | 4,516 | | 4,418 | | |
SCP Eye Care Services, LLC | Health Care Services | Second Lien Term Loan | SOFR+ | 8.75% | 14.18% | | 10/7/2030 | | 5,881 | | 5,726 | | 5,710 | | (5)(8) |
SCP Eye Care Services, LLC | Health Care Services | Second Lien Term Loan | SOFR+ | 8.75% | | | 10/7/2030 | | — | | (26) | | (50) | | (5)(8)(9) |
SCP Eye Care Services, LLC | Health Care Services | Common Stock | | | | | | 761 | | | 761 | | 698 | | (8) |
scPharmaceuticals Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 8.75% | 11.75% | | 10/13/2027 | | 7,654 | | 7,323 | | 7,329 | | (5)(8) |
scPharmaceuticals Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 8.75% | | | 10/13/2027 | | — | | — | | — | | (5)(8)(9) |
scPharmaceuticals Inc. | Pharmaceuticals | First Lien Term Loan | SOFR+ | 8.75% | | | 10/13/2027 | | — | | — | | — | | (5)(8)(9) |
scPharmaceuticals Inc. | Pharmaceuticals | Warrants | | | | | | 79,075 | | | 258 | | 380 | | (8) |
SEI Holding I Corporation | Trading Companies & Distributors | First Lien Term Loan | SOFR+ | 6.75% | 12.14% | | 3/27/2028 | | 17,420 | | 16,951 | | 16,949 | | (5)(8) |
SEI Holding I Corporation | Trading Companies & Distributors | First Lien Term Loan | SOFR+ | 6.75% | 12.15% | | 3/27/2028 | | 1,368 | | 1,329 | | 1,334 | | (5)(8)(9) |
SEI Holding I Corporation | Trading Companies & Distributors | First Lien Revolver | SOFR+ | 6.75% | | | 3/27/2028 | | — | | (40) | | (41) | | (5)(8)(9) |
Seres Therapeutics, Inc. | Biotechnology | First Lien Term Loan | SOFR+ | 7.88% | 12.88% | | 4/27/2029 | | 11,547 | | 11,135 | | 11,139 | | (5)(8)(10) |
Seres Therapeutics, Inc. | Biotechnology | First Lien Term Loan | SOFR+ | 7.88% | 12.88% | | 4/27/2029 | | 4,330 | | 4,176 | | 4,177 | | (5)(8)(10) |
Seres Therapeutics, Inc. | Biotechnology | First Lien Term Loan | SOFR+ | 7.88% | | | 4/27/2029 | | — | | — | | — | | (5)(8)(9)(10) |
Seres Therapeutics, Inc. | Biotechnology | First Lien Term Loan | SOFR+ | 7.88% | | | 4/27/2029 | | — | | — | | — | | (5)(8)(9)(10) |
Seres Therapeutics, Inc. | Biotechnology | Warrants | | | | | | 93,470 | | | 293 | | 140 | | (8)(10) |
SM Wellness Holdings, Inc. | Health Care Services | First Lien Term Loan | SOFR+ | 4.75% | 10.38% | | 4/17/2028 | | 12,818 | | 11,979 | | 12,049 | | (5)(8) |
Southern Veterinary Partners, LLC | Health Care Facilities | First Lien Term Loan | SOFR+ | 4.00% | 9.43% | | 10/5/2027 | | 20,664 | | 20,456 | | 20,564 | | (5) |
SPX Flow, Inc. | Industrial Machinery & Supplies & Components | First Lien Term Loan | SOFR+ | 4.50% | 9.92% | | 4/5/2029 | | 24,496 | | 23,683 | | 24,477 | | (5) |
Star Parent, Inc. | Life Sciences Tools & Services | First Lien Term Loan | SOFR+ | 4.00% | 9.33% | | 9/28/2030 | | 28,000 | | 27,580 | | 27,419 | | (5) |
Sunshine Luxembourg VII Sarl | Personal Care Products | First Lien Term Loan | SOFR+ | 3.75% | 9.24% | | 10/1/2026 | | 10,360 | | 10,108 | | 10,355 | | (5)(10) |
Superior Industries International, Inc. | Auto Parts & Equipment | First Lien Term Loan | SOFR+ | 8.00% | 13.32% | | 12/16/2028 | | 33,311 | | 32,444 | | 33,061 | | (5)(8) |
Supreme Fitness Group NY Holdings, LLC | Leisure Facilities | First Lien Term Loan | SOFR+ | 7.00% | 12.51% | | 12/31/2026 | | 8,196 | | 8,090 | | 7,807 | | (5)(8) |
Supreme Fitness Group NY Holdings, LLC | Leisure Facilities | First Lien Term Loan | SOFR+ | 7.00% | 12.51% | | 12/31/2026 | | 702 | | 693 | | 668 | | (5)(8) |
Supreme Fitness Group NY Holdings, LLC | Leisure Facilities | First Lien Term Loan | SOFR+ | 7.00% | 12.51% | | 12/31/2026 | | 281 | | 271 | | 241 | | (5)(8)(9) |
Supreme Fitness Group NY Holdings, LLC | Leisure Facilities | First Lien Revolver | SOFR+ | 7.00% | 12.44% | | 12/31/2026 | | 396 | | 391 | | 377 | | (5)(8) |
Tacala, LLC | Restaurants | First Lien Term Loan | SOFR+ | 3.50% | 9.43% | | 2/5/2027 | | 11,945 | | 11,703 | | 11,919 | | (5) |
Tacala, LLC | Restaurants | Second Lien Term Loan | SOFR+ | 8.00% | 13.43% | | 2/4/2028 | | 7,310 | | 7,129 | | 7,094 | | (5) |
Ten-X LLC | Interactive Media & Services | First Lien Term Loan | SOFR+ | 6.00% | 11.32% | | 5/26/2028 | | 24,934 | | 23,766 | | 23,999 | | (5)(8) |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
September 30, 2023
(dollar amounts in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Portfolio Company | Industry | Type of Investment (1)(2)(3) | Index | Spread | Cash Interest Rate (4)(5) | PIK | Maturity Date | Shares | Principal (6) | Cost | Fair Value | Notes |
THL Zinc Ventures Ltd | Diversified Metals & Mining | First Lien Term Loan | | | 13.00% | | 5/23/2026 | | $ | 39,751 | | $ | 39,296 | | $ | 39,318 | | (8)(10) |
TIBCO Software Inc. | Application Software | First Lien Term Loan | SOFR+ | 4.50% | 9.99% | | 3/30/2029 | | 17,755 | | 16,613 | | 17,103 | | (5) |
Touchstone Acquisition, Inc. | Health Care Supplies | First Lien Term Loan | SOFR+ | 6.00% | 11.42% | | 12/29/2028 | | 8,485 | | 8,357 | | 8,261 | | (5)(8) |
Transit Buyer LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 6.25% | 11.70% | | 1/31/2029 | | 8,427 | | 8,277 | | 8,309 | | (5)(8) |
Transit Buyer LLC | Diversified Support Services | First Lien Term Loan | SOFR+ | 6.25% | | | 1/31/2029 | | — | | (69) | | (54) | | (5)(8)(9) |
Trident TPI Holdings, Inc. | Metal, Glass & Plastic Containers | First Lien Term Loan | SOFR+ | 4.00% | 9.65% | | 9/15/2028 | | 4,987 | | 4,987 | | 4,978 | | (5) |
Trinitas CLO XII | Multi-Sector Holdings | CLO Notes | SOFR+ | 4.26% | 9.61% | | 4/25/2033 | | 4,500 | | 4,394 | | 4,403 | | (5)(10) |
Trinitas CLO XV DAC | Multi-Sector Holdings | CLO Notes | SOFR+ | 7.71% | 13.06% | | 4/22/2034 | | 1,000 | | 816 | | 917 | | (5)(10) |
Uniti Group LP | Other Specialized REITs | Fixed Rate Bond | | | 6.50% | | 2/15/2029 | | 1,750 | | 1,630 | | 1,148 | | (10) |
Uniti Group LP | Other Specialized REITs | Fixed Rate Bond | | | 4.75% | | 4/15/2028 | | 2,200 | | 1,944 | | 1,799 | | (10) |
WAVE 2019-1 | Specialized Finance | CLO Notes | | | 3.60% | | 9/15/2044 | | 5,183 | | 4,282 | | 4,251 | | |
Wellfleet CLO 2022-2, Ltd. | Multi-Sector Holdings | CLO Notes | SOFR+ | 8.56% | 13.87% | | 10/18/2035 | | 1,500 | | 1,444 | | 1,494 | | (5)(10) |
WP CPP Holdings, LLC | Aerospace & Defense | First Lien Term Loan | SOFR+ | 3.75% | 9.27% | | 4/30/2025 | | 9,633 | | 9,108 | | 9,090 | | (5) |
WWEX Uni Topco Holdings, LLC | Air Freight & Logistics | First Lien Term Loan | SOFR+ | 4.00% | 9.65% | | 7/26/2028 | | 6,895 | | 6,590 | | 6,800 | | (5) |
Total Non-Control/Non-Affiliate Investments (126.0% of net assets) | | | | | | | | | | $ | 1,922,218 | | $ | 1,927,237 | | |
Cash and Cash Equivalents and Restricted Cash (9.9% of net assets) | | | | | | | | | | $ | 151,136 | | $ | 151,136 | | |
Total Portfolio Investments, Cash and Cash Equivalents and Restricted Cash (135.9% of net assets) | | | | | | | | | | $ | 2,073,354 | | $ | 2,078,373 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Derivative Instrument | | Notional Amount to be Purchased | | Notional Amount to be Sold | | Maturity Date | | Counterparty | | Cumulative Unrealized Appreciation /(Depreciation) |
Foreign currency forward contract | | $ | 47,642 | | | € | 43,834 | | | 11/9/2023 | | Bank of New York Mellon | | $ | 1,164 | |
Foreign currency forward contract | | $ | 20,888 | | | £ | 16,392 | | | 11/9/2023 | | Bank of New York Mellon | | 877 | |
| | | | | | | | | | $ | 2,041 | |
Oaktree Strategic Credit Fund
Consolidated Schedule of Investments
September 30, 2023
(dollar amounts in thousands)
(1)All debt investments are income producing unless otherwise noted. All equity investments are non-income producing unless otherwise noted.
(2)See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition by geographic region.
(3)Each of the Company's investments is pledged as collateral under one or more of its credit facilities. A single investment may be divided into parts that are individually pledged as collateral to separate credit facilities.
(4)Interest rates may be adjusted from period to period on certain term loans and revolvers. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents.
(5)The interest rate on the principal balance outstanding for most floating rate loans is indexed to SOFR, LIBOR or "L", SONIA and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate or the alternate base rate based on each respective credit agreement and the cash interest rate as of period end. All LIBOR shown above is in U.S. dollars unless otherwise noted. As of September 30, 2023, the reference rates for the Company's variable rate loans were the 30-day SOFR at 5.32%, the 90-day SOFR at 5.39%, the 180-day SOFR at 5.47%, the 90-day LIBOR at 5.65%, the SONIA at 5.19%, the 30-day EURIBOR at 3.42%, the 90-day EURIBOR at 3.82% and the 180-day EURIBOR at 3.95%. Most loans include an interest floor, which generally ranges from 0% to 2.75%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.
(6)Principal includes accumulated PIK interest and is net of repayments, if any. "€" signifies the investment is denominated in Euros. “£” signifies the investment is denominated in British Pounds. All other investments are denominated in U.S. dollars.
(7)Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments. Control Investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities and/or has the power to exercise control over the management or policies of the company. Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.
(8)As of September 30, 2023, these investments are categorized as Level 3 within the fair value hierarchy established by ASC 820 and were valued using significant unobservable inputs.
(9)Investment has undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.
(10)Investment is not a qualifying asset as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of September 30, 2023, qualifying assets represented 78.1% of the Company's total assets and non-qualifying assets represented 21.9% of the Company's total assets.
(11)This investment represents a participation interest in the underlying securities shown.
(12)This investment represents a revenue interest financing term loan in which the Company receives periodic interest payments based on a percentage of revenues earned at the respective portfolio company over the life of the loan.
See notes to Consolidated Financial Statements.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Note 1. Organization
Oaktree Strategic Credit Fund (the “Company”) is a Delaware statutory trust formed on November 24, 2021 and is structured as a non-diversified, closed-end management investment company. On February 3, 2022, the Company elected to be regulated as a business development company (a “BDC”) under the Investment Company Act of 1940, as amended (the “Investment Company Act”). The Company has elected to be treated, and intends to qualify annually to be treated, as a registered investment company (a “RIC”) under the Internal Revenue Code of 1986, as amended (the “Code”). Effective as of February 3, 2022, the Company is externally managed by Oaktree Fund Advisors, LLC (the "Adviser") pursuant to an investment advisory agreement (as amended and restated, the “Investment Advisory Agreement”), between the Company and the Adviser. The Adviser is an entity under common control with Oaktree Capital Group, LLC ("OCG"). In 2019, Brookfield Corporation (formerly known as Brookfield Asset Management, Inc., collectively with its affiliates, "Brookfield") acquired a majority economic interest in OCG. OCG operates as an independent business within Brookfield, with its own product offerings and investment, marketing and support teams.
The Company’s investment objective is to generate stable current income and long-term capital appreciation. The Company seeks to meet its investment objective by primarily investing in private debt opportunities.
In connection with its formation, the Company has the authority to issue an unlimited number of common shares of beneficial interest, par value $0.01 per share (“Common Shares”). The Company offers on a continuous basis up to $5.0 billion aggregate offering price of Common Shares (the “Maximum Offering Amount”) pursuant to an offering registered with the Securities and Exchange Commission. The Company offers to sell any combination of three classes of Common Shares, Class S shares, Class D shares and Class I shares, with a dollar value up to the Maximum Offering Amount. The share classes have different ongoing distribution and/or shareholder servicing fees.
The Company accepted purchase orders and held investors’ funds in an interest-bearing escrow account until the Company received purchase orders for Common Shares of at least $100.0 million, excluding subscriptions by Oaktree Fund GP I, L.P. in respect of the Class I shares purchased by Oaktree Fund GP I, L.P. prior to March 31, 2022.
As of June 1, 2022, the Company had satisfied the minimum offering requirement and the Board had authorized the release of proceeds from escrow. As of March 31, 2024, the Company has issued and sold 69,926,688 Class I shares for an aggregate purchase price of $1,656.1 million of which $100.0 million was purchased by an affiliate of the Adviser. As of March 31, 2024, the Company has issued and sold 33,792,645 Class S shares for an aggregate purchase price of $795.2 million. As of March 31, 2024, the Company has issued and sold 52,607 Class D shares for an aggregate purchase price of $1.2 million.
Note 2. Significant Accounting Policies
Basis of Presentation:
The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments of a normal recurring nature considered necessary for the fair presentation of the consolidated financial statements have been made. The Company is an investment company following the accounting and reporting guidance in FASB ASC Topic 946, Financial Services - Investment Companies ("ASC 946").
Use of Estimates:
The preparation of the consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions affecting amounts reported in the consolidated financial statements and accompanying notes. These estimates are based on the information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Changes in the economic and political environments, financial markets and any other parameters used in determining these estimates could cause actual results to differ and such differences could be material. Significant estimates include the valuation of investments and revenue recognition.
Consolidation:
The accompanying consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. The consolidated subsidiaries are wholly-owned and, as such, consolidated into the consolidated financial
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
statements. The assets of the consolidated subsidiaries are not directly available to satisfy the claims of the creditors of the Company. As an investment company, portfolio investments held by the Company are not consolidated into the consolidated financial statements but rather are included on the Consolidated Statement of Assets and Liabilities as investments at fair value.
Fair Value Measurements:
The Adviser, as the valuation designee of the Board pursuant to Rule 2a-5 under the Investment Company Act, determines the fair value of the Company's assets on at least a quarterly basis in accordance with ASC 820. ASC 820 defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments' complexity.
Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:
•Level 1 — Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date.
•Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities.
•Level 3 — Unobservable inputs that reflect the Adviser's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.
If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. The Adviser's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions.
Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, the Adviser obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of the Company's investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations.
The Adviser seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If the Adviser is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within the Adviser's set threshold, the Adviser seeks to obtain a quote directly from a broker making a market for the asset. The Adviser evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. The Adviser also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, the Adviser performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, the Adviser does not adjust any of the prices received from these sources.
If the quotations obtained from pricing vendors or brokers are determined not to be reliable or are not readily available, the Adviser values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value ("EV") of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that the Company is deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, the Adviser analyzes various factors, including the portfolio company’s historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company’s industry. the Adviser also utilizes some or all of the following
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company’s ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. The Adviser may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and the Adviser considers the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by the Company are substantially illiquid with no active transaction market, the Adviser depends on primary market data, including newly funded transactions and industry specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable.
The Adviser estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk free rate. Changes in the subjective input assumptions can materially affect the fair value estimates.
In December 2020, the SEC adopted Rule 2a-5 under the Investment Company Act. Rule 2a-5 permits boards of registered investment companies and Business Development Companies to either (i) choose to continue to determine fair value in good faith, or (ii) designate a valuation designee tasked with determining fair value in good faith, subject to the board’s oversight. The Company's Board of Trustees has designated the Adviser to serve as its valuation designee effective September 8, 2022.
The Adviser undertakes a multi-step valuation process each quarter in connection with determining the fair value of the Company's investments:
•The quarterly valuation process begins with each portfolio company or investment being initially valued by the Adviser's valuation team;
•Preliminary valuations are then reviewed and discussed with management of the Adviser;
•Separately, independent valuation firms prepare valuations of the Company's investments, on a selected basis, for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment, and submit the reports to the Company and provide such reports to the Adviser;
•The Adviser compares and contrasts its preliminary valuations to the valuations of the independent valuation firms and prepares a valuation report for the Audit Committee;
•The Audit Committee reviews the valuation report with the Adviser, and the Adviser responds and supplements the valuation report to reflect any discussions between the Adviser and the Audit Committee; and
•The Adviser, as valuation designee, determines the fair value of each investment in the Company's portfolio.
The fair value of the Company's investments as of March 31, 2024 and September 30, 2023 was determined by the Adviser, as the Company's valuation designee. The Company has and will continue to engage independent valuation firms each quarter to provide assistance regarding the determination of the fair value of a portion of its portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment.
Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material.
When the Company determines its net asset value as of the last day of a month that is not also the last day of a calendar quarter, the Company intends to update the value of securities with reliable market quotations to the most recent market quotation. For securities without reliable market quotations, pursuant to the Company's valuation policy, the Adviser’s valuation team will generally value such assets at the most recent quarterly valuation or, in the case of securities acquired after such date, cost, unless, in either case, the Adviser determines that since the most recent quarter end or the date of acquisition for securities acquired after quarter end, as the case may be, a significant observable change has occurred with respect to the
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
investment (which determination may be as a result of a material event at a portfolio company, material change in market spreads, secondary market transaction in the securities of an investment or otherwise). If the Adviser determines such a change has occurred with respect to one or more investments, the Adviser will determine whether to update the value for each relevant investment using a range of values from an independent valuation firm, where applicable, in accordance with the Company's valuation policy. Additionally, the Adviser may otherwise determine to update the most recent quarter end valuation of an investment without reliable market quotations that the Adviser considers to be material to the Company using a range of values from an independent valuation firm.
With the exception of the line items entitled "deferred financing costs," "deferred offering costs," "other assets," "unsecured notes payable," and "credit facilities payable," which are reported at amortized cost, all assets and liabilities on the Consolidated Statements of Assets and Liabilities approximate fair value. The carrying value of the line items titled "due from affiliates," "interest receivable," "receivables from unsettled transactions," "accounts payable, accrued expenses and other liabilities," "dividends payable," "base management fee and incentive fee payable," "payable for share repurchases," "interest payable," "payables from unsettled transactions" and "due to affiliates" approximate fair value due to their short maturities.
Foreign Currency Translation:
The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company’s investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company.
Derivative Instruments:
Foreign Currency Forward Contracts
The Company uses foreign currency forward contracts to reduce the Company's exposure to fluctuations in the value of foreign currencies. In a foreign currency forward contract, the Company agrees to receive or deliver a fixed quantity of one currency for another at a pre-determined price at a future date. Foreign currency forward contracts are marked-to-market at the applicable forward rate. Unrealized appreciation (depreciation) on foreign currency forward contracts is recorded within derivative assets or derivative liabilities on the Consolidated Statement of Assets and Liabilities by counterparty on a net basis, not taking into account collateral posted which is recorded separately, if applicable. Purchases and settlements of foreign currency forward contracts having the same settlement date and counterparty are generally settled net and any realized gains or losses are recognized on the settlement date. The Company does not utilize hedge accounting with respect to foreign currency forward contracts and as such, the Company recognizes its foreign currency forward contracts at fair value with changes included in the net unrealized appreciation (depreciation) on the Consolidated Statement of Operations.
Interest Rate Swaps:
The Company uses interest rate swaps to hedge some of the Company's fixed rate debt. The Company designated the interest rate swaps as the hedging instruments in an effective hedge accounting relationship, and therefore the periodic payments are recognized as components of interest expense in the Consolidated Statements of Operations. Depending on the nature of the balance at period end, the fair value of each interest rate swap is either included as a derivative asset or derivative liability on the Company's Consolidated Statements of Assets and Liabilities. The change in fair value of the interest rate swaps is offset by a change in the carrying value of the fixed rate debt. Any amounts paid to the counterparty to cover collateral obligations under the terms of the interest rate swap agreements are included in due from broker on the Company's Consolidated Statements of Assets and Liabilities.
Secured Borrowings:
Securities sold and simultaneously repurchased at a premium are reported as financing transactions in accordance with FASB ASC Topic 860, Transfers and Servicing ("ASC 860"). Amounts payable to the counterparty are due on the repurchase settlement date and, excluding accrued interest, such amounts are presented in the accompanying Consolidated Statement of Assets and Liabilities as secured borrowings. Premiums payable are separately reported as accrued interest.
Investment Income:
Interest Income
Interest income, adjusted for accretion of original issue discount ("OID"), is recorded on an accrual basis to the extent that such amounts are expected to be collected. The Company stops accruing interest on investments when it is determined that
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management’s judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash, and the portfolio company, in management’s judgment, is likely to continue timely payment of its remaining obligations. As of March 31, 2024, there was one investment on non-accrual status that represented 0.3% and 0.1% of total debt investments at cost and fair value, respectively. As of September 30, 2023, there were no investments on non-accrual status.
In connection with its investment in a portfolio company, the Company sometimes receives nominal cost equity that is valued as part of the negotiation process with the portfolio company. When the Company receives nominal cost equity, the Company allocates its cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan.
PIK Interest Income
The Company's investments in debt securities may contain PIK interest provisions. PIK interest, which generally represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. The Company generally ceases accruing PIK interest if there is insufficient value to support the accrual or if the Company does not expect the portfolio company to be able to pay all principal and interest due. The Company's decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; the Company's assessment of the portfolio company's business development success; information obtained by the Company in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. The Company's determination to cease accruing PIK interest is generally made well before the Company's full write-down of a loan or debt security. In addition, if it is subsequently determined that the Company will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on the Company’s debt investments increases the recorded cost bases of these investments in the consolidated financial statements including for purposes of computing the capital gains incentive fee payable by the Company to the Adviser. To maintain its status as a RIC, certain income from PIK interest may be required to be distributed to the Company’s shareholders, even though the Company has not yet collected the cash and may never do so.
Fee Income
The Adviser or its affiliates may provide financial advisory services to portfolio companies in connection with structuring a transaction and in return the Company may receive fees for capital structuring services. These fees are generally non-recurring and are recognized by the Company upon the investment closing date. The Company may also receive additional fees in the ordinary course of business, including servicing, amendment, exit and prepayment fees, which are classified as fee income and recognized as they are earned or the services are rendered.
Dividend Income
The Company generally recognizes dividend income on the ex-dividend date for public securities and the record date for private equity investments. Distributions received from private equity investments are evaluated to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company will not record distributions from private equity investments as dividend income unless there are sufficient earnings at the portfolio company prior to the distribution. Distributions that are classified as a return of capital are recorded as a reduction in the cost basis of the investment.
Cash and Cash Equivalents and Restricted Cash:
Cash and cash equivalents consist of demand deposits and highly liquid investments with maturities of three months or less, when acquired. The Company places its cash and cash equivalents with financial institutions and, at times, cash held in bank accounts may exceed the Federal Deposit Insurance Corporation ("FDIC") insurance limit. Cash and cash equivalents are included on the Company's Consolidated Schedule of Investments and cash equivalents are classified as Level 1 assets.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
As of March 31, 2024, included in restricted cash was $12.3 million that was held at Citibank, N.A. in connection with the Company’s JPM Agreements (defined below). Pursuant to the terms of the JPM Agreements, the Company was restricted in terms of access to the $12.3 million until the occurrence of the periodic distribution dates and, in connection therewith, the Company’s submission of its required periodic reporting schedules and verifications of the Company’s compliance with the terms of the JPM Agreements. As of March 31, 2024, included in restricted cash was $1.7 million that was held at Citibank, N.A. in connection with the Company’s SMBC Loan and Security Agreement (defined below). Pursuant to the terms of the SMBC Loan and Security Agreement, the Company was restricted in terms of access to the $1.7 million until the occurrence of the periodic distribution dates and, in connection therewith, the Company’s submission of its required periodic reporting schedules and verifications of the Company’s compliance with the terms of the SMBC Loan and Security Agreement. As of March 31, 2024, included in restricted cash was $2.4 million that was held at Wells Fargo, N.A. in connection with the Company’s CIBC Loan and Servicing Agreement (defined below). Pursuant to the terms of the Loan and Servicing Agreement, the Company was restricted in terms of access to the $2.4 million until the occurrence of the periodic distribution dates and, in connection therewith, the Company’s submission of its required periodic reporting schedules and verifications of the Company’s compliance with the terms of the CIBC Loan and Servicing Agreement.
Receivables/Payables from Unsettled Transactions:
Receivables/payables from unsettled transactions consist of amounts receivable to or payable by the Company for transactions that have not settled at the reporting date.
Deferred Financing Costs:
Deferred financing costs consist of fees and expenses paid in connection with the closing or amending of credit facilities. Deferred financing costs incurred in connection with credit facilities are capitalized as an asset when incurred. Deferred financing costs incurred in connection with all other debt arrangements are a direct deduction from the related debt liability when incurred. Deferred financing costs are amortized using the effective interest method over the term of the respective debt arrangement. This amortization expense is included in interest expense in the Company's Consolidated Statement of Operations. Upon early termination or modification of a credit facility, all or a portion of unamortized fees related to such facility may be accelerated into interest expense.
Organization and Offering Costs:
Costs associated with the organization of the Company will be expensed as incurred. Costs associated with the offering of Common Shares of the Company are capitalized as "deferred offering costs" on the Consolidated Statements of Assets and Liabilities and amortized over a twelve-month period from incurrence.
For the three and six months ended March 31, 2024, the Company expensed organization costs of $4. For the three and six months ended March 31, 2023, the Company expensed organization costs of zero and $4, respectively. As of March 31, 2024 and September 30, 2023, $594 and $270, respectively, of offering costs were capitalized on the Consolidated Statements of Assets and Liabilities. For the three and six months ended March 31, 2024, the Company amortized offering costs of $211 and $433, respectively. For the three and six months ended March 31, 2023, the Company amortized offering costs of $944 and $1,792, respectively.
Allocation of Income, Expenses, Gains and Losses:
Income, expenses (other than those attributable to a specific class), gains and losses are allocated to each class of shares based upon the relative proportion of net assets represented by such class. Operating expenses directly attributable to a specific class are charged against the operations of that class.
Distributions:
To the extent that the Company has taxable income available, the Company intends to make monthly distributions to its shareholders. Distributions to shareholders are recorded on the record date. All distributions will be paid at the discretion of the Board and will depend on the Company’s earnings, financial condition, maintenance of the Company's tax treatment as a RIC, compliance with applicable BDC regulations and such other factors as the Board may deem relevant from time to time. Although the gross distribution per share is generally equivalent for each share class, the net distribution for each share class is reduced for any class specific expenses, including distribution and shareholder servicing fees, if any.
Income Taxes:
On February 3, 2022, the Company elected to be regulated as a BDC under the Investment Company Act. The Company has elected to be treated as a RIC under the Code. So long as the Company maintains its status as a RIC, it generally will not pay corporate-level U.S. federal income taxes on any ordinary income or capital gains that it distributes at least annually to its shareholders as dividends. Rather, any tax liability related to income earned and distributed by the Company would represent obligations of the Company’s investors and would not be reflected in the consolidated financial statements of the Company.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
The Company evaluates tax positions taken or expected to be taken in the course of preparing its consolidated financial statements to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority. Tax positions not deemed to meet the “more-likely-than-not” threshold are reserved and recorded as a tax benefit or expense in the current year. All penalties and interest associated with income taxes are included in income tax expense. Conclusions regarding tax positions are subject to review and may be adjusted at a later date based on factors including, but not limited to, on-going analyses of tax laws, regulations and interpretations thereof. Management has analyzed the Company's tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax year 2022.
To qualify for and maintain qualification as a RIC, the Company must, among other things, meet certain source-of-income and asset diversification requirements. In addition, to qualify for RIC tax treatment, the Company must distribute to its shareholders, for each taxable year, at least 90% of its “investment company taxable income” for that year, which is generally its ordinary income plus the excess, if any, of its realized net short-term capital gains over its realized net long-term capital losses.
In addition, based on the excise tax distribution requirements, the Company is subject to a 4% nondeductible federal excise tax on undistributed income unless the Company distributes in a timely manner in each taxable year an amount at least equal to the sum of (1) 98% of its ordinary income for the calendar year, (2) 98.2% of capital gain net income (both long-term and short-term) for the one-year period ending October 31 in that calendar year and (3) any income realized, but not distributed, in prior years. For this purpose, however, any ordinary income or capital gain net income retained by the Company that is subject to corporate income tax is considered to have been distributed. The Company did not incur a U.S. federal excise tax for calendar years 2023 and 2022.
The Company holds certain portfolio investments through a taxable subsidiary. The purpose of the Company's taxable subsidiary is to permit the Company to hold equity investments in portfolio companies which are "pass through" entities for U.S. federal income tax purposes in order to comply with the RIC tax requirements. The taxable subsidiary is consolidated for financial reporting purposes, and portfolio investments held by it are included in the Company’s consolidated financial statements as portfolio investments and recorded at fair value. The taxable subsidiary is not consolidated with the Company for U.S. federal income tax purposes and may generate income tax expense, or benefit, and the related tax assets and liabilities, as a result of their ownership of certain portfolio investments. This income tax expense, if any, would be reflected in the Company's Consolidated Statement of Operations. The Company uses the liability method to account for its taxable subsidiary's income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net operating loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences.
Recently Adopted Accounting Pronouncements
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023 and interim period within fiscal years beginning after December 15, 2024. The Company does not expect this guidance to materially impact its consolidated financial statements.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Note 3. Portfolio Investments
Portfolio Composition
As of March 31, 2024, the fair value of the Company's investment portfolio was $3,519.9 million and was composed of investments in 162 portfolio companies. As of September 30, 2023, the fair value of the Company's investment portfolio was $1,927.2 million and was composed of investments in 123 portfolio companies.
As of March 31, 2024 and September 30, 2023, the Company's investment portfolio consisted of the following:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
Cost: | | | | % of Total Investments | | | | % of Total Investments |
Senior Secured Debt | | $ | 3,268,410 | | | 93.48 | % | | $ | 1,814,372 | | | 94.39 | % |
Subordinated Debt | | 212,358 | | | 6.07 | % | | 98,352 | | | 5.12 | % |
Preferred Equity | | 12,234 | | | 0.35 | % | | 6,023 | | | 0.31 | % |
Common Equity and Warrants | | 3,471 | | | 0.10 | % | | 3,471 | | | 0.18 | % |
Total | | $ | 3,496,473 | | | 100.00 | % | | $ | 1,922,218 | | | 100.00 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
Fair Value: | | | | % of Total Investments | | % of Net Assets | | | | % of Total Investments | | % of Net Assets |
Senior Secured Debt | | $ | 3,285,724 | | | 93.35 | % | | 132.99 | % | | $ | 1,817,981 | | | 94.32 | % | | 118.88 | % |
Subordinated Debt | | 217,376 | | | 6.18 | % | | 8.80 | % | | 97,616 | | | 5.07 | % | | 6.38 | % |
Preferred Equity | | 12,814 | | | 0.36 | % | | 0.52 | % | | 5,748 | | | 0.30 | % | | 0.38 | % |
Common Equity and Warrants | | 4,022 | | | 0.11 | % | | 0.16 | % | | 5,892 | | | 0.31 | % | | 0.39 | % |
Total | | $ | 3,519,936 | | | 100.00 | % | | 142.47 | % | | $ | 1,927,237 | | | 100.00 | % | | 126.03 | % |
The composition of the Company's debt investments as of March 31, 2024 and September 30, 2023 by floating rates and fixed rates was as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
| | Fair Value | | % of Debt Investments | | Fair Value | | % of Debt Investments |
Floating rate | | $ | 3,220,136 | | | 91.92 | % | | $ | 1,716,908 | | | 89.63 | % |
Fixed rate | | 282,964 | | | 8.08 | % | | 198,689 | | | 10.37 | % |
Total | | $ | 3,503,100 | | | 100.00 | % | | $ | 1,915,597 | | | 100.00 | % |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
The geographic composition of the Company's portfolio is determined by the location of the corporate headquarters of the portfolio company, which may not be indicative of the primary source of the portfolio company's business. The following tables show the portfolio composition by geographic region at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
Cost: | | | | % of Total Investments | | | | % of Total Investments |
United States | | $ | 3,122,417 | | | 89.31 | % | | $ | 1,673,820 | | | 87.08 | % |
United Kingdom | | 171,414 | | | 4.90 | % | | 44,465 | | | 2.31 | % |
Canada | | 99,815 | | | 2.85 | % | | 56,725 | | | 2.95 | % |
India | | 39,382 | | | 1.13 | % | | 39,296 | | | 2.04 | % |
Costa Rica | | 13,093 | | | 0.37 | % | | 12,684 | | | 0.66 | % |
Chile | | 11,239 | | | 0.32 | % | | 11,191 | | | 0.58 | % |
Switzerland | | 10,271 | | | 0.29 | % | | 10,172 | | | 0.53 | % |
France | | 9,394 | | | 0.27 | % | | 14,735 | | | 0.77 | % |
Cayman Islands | | 9,149 | | | 0.26 | % | | 12,746 | | | 0.66 | % |
Luxembourg | | 8,287 | | | 0.24 | % | | 41,426 | | | 2.16 | % |
Australia | | 2,012 | | | 0.06 | % | | — | | | — | % |
Netherlands | | — | | | — | % | | 4,958 | | | 0.26 | % |
Total | | $ | 3,496,473 | | | 100.00 | % | | $ | 1,922,218 | | | 100.00 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
Fair Value: | | | | % of Total Investments | | % of Net Assets | | | | % of Total Investments | | % of Net Assets |
United States | | $ | 3,139,825 | | | 89.21 | % | | 127.11 | % | | $ | 1,677,990 | | | 87.07 | % | | 109.75 | % |
United Kingdom | | 173,804 | | | 4.94 | % | | 7.03 | % | | 45,181 | | | 2.34 | % | | 2.95 | % |
Canada | | 101,873 | | | 2.89 | % | | 4.12 | % | | 56,622 | | | 2.94 | % | | 3.70 | % |
India | | 39,552 | | | 1.12 | % | | 1.60 | % | | 39,318 | | | 2.04 | % | | 2.57 | % |
Costa Rica | | 12,778 | | | 0.36 | % | | 0.52 | % | | 12,369 | | | 0.64 | % | | 0.81 | % |
Chile | | 12,441 | | | 0.35 | % | | 0.50 | % | | 12,529 | | | 0.65 | % | | 0.82 | % |
Switzerland | | 10,185 | | | 0.29 | % | | 0.41 | % | | 9,861 | | | 0.51 | % | | 0.64 | % |
Cayman Islands | | 9,509 | | | 0.27 | % | | 0.38 | % | | 13,135 | | | 0.68 | % | | 0.86 | % |
France | | 9,491 | | | 0.27 | % | | 0.38 | % | | 13,647 | | | 0.71 | % | | 0.89 | % |
Luxembourg | | 8,456 | | | 0.24 | % | | 0.34 | % | | 41,043 | | | 2.13 | % | | 2.68 | % |
Australia | | 2,022 | | | 0.06 | % | | 0.08 | % | | — | | | — | % | | — | % |
Netherlands | | — | | | — | % | | — | % | | 5,542 | | | 0.29 | % | | 0.36 | % |
Total | | $ | 3,519,936 | | | 100.00 | % | | 142.47 | % | | $ | 1,927,237 | | | 100.00 | % | | 126.03 | % |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
The composition of the Company's portfolio by industry at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets as of March 31, 2024 and September 30, 2023 was as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| March 31, 2024 | | September 30, 2023 |
Cost: | | | % of Total Investments | | | | % of Total Investments |
Application Software | $ | 521,279 | | | 14.92 | % | | $ | 261,061 | | | 13.60 | % |
Diversified Support Services | 175,086 | | | 5.01 | % | | 40,107 | | | 2.09 | % |
Health Care Technology | 163,226 | | | 4.67 | % | | 71,145 | | | 3.70 | % |
Systems Software | 161,653 | | | 4.62 | % | | 70,431 | | | 3.66 | % |
Aerospace & Defense | 154,710 | | | 4.42 | % | | 75,592 | | | 3.93 | % |
Industrial Machinery & Supplies & Components | 148,119 | | | 4.24 | % | | 29,675 | | | 1.54 | % |
Health Care Services | 144,761 | | | 4.14 | % | | 57,898 | | | 3.01 | % |
Interactive Media & Services | 116,585 | | | 3.33 | % | | 23,766 | | | 1.24 | % |
Other Specialty Retail | 104,790 | | | 3.00 | % | | 104,787 | | | 5.45 | % |
Multi-Sector Holdings | 89,719 | | | 2.57 | % | | 28,293 | | | 1.47 | % |
Insurance Brokers | 87,835 | | | 2.51 | % | | 12,979 | | | 0.68 | % |
Property & Casualty Insurance | 82,746 | | | 2.37 | % | | 41,399 | | | 2.15 | % |
Packaged Foods & Meats | 80,171 | | | 2.29 | % | | — | | | — | % |
Education Services | 79,004 | | | 2.26 | % | | 61,437 | | | 3.20 | % |
Environmental & Facilities Services | 76,961 | | | 2.20 | % | | 75,632 | | | 3.93 | % |
Electrical Components & Equipment | 75,777 | | | 2.17 | % | | 75,692 | | | 3.94 | % |
Diversified Metals & Mining | 63,805 | | | 1.82 | % | | 95,842 | | | 4.99 | % |
Specialized Finance | 63,450 | | | 1.81 | % | | 48,354 | | | 2.52 | % |
Office Services & Supplies | 62,455 | | | 1.79 | % | | 21,160 | | | 1.10 | % |
Construction Machinery & Heavy Transportation Equipment | 61,269 | | | 1.75 | % | | — | | | — | % |
Data Processing & Outsourced Services | 55,906 | | | 1.60 | % | | — | | | — | % |
Health Care Supplies | 52,786 | | | 1.51 | % | | 36,745 | | | 1.91 | % |
Life Sciences Tools & Services | 50,089 | | | 1.43 | % | | 27,580 | | | 1.43 | % |
Pharmaceuticals | 49,369 | | | 1.41 | % | | 64,066 | | | 3.33 | % |
Metal, Glass & Plastic Containers | 44,788 | | | 1.28 | % | | 25,834 | | | 1.34 | % |
Health Care Equipment | 40,821 | | | 1.17 | % | | 39,946 | | | 2.08 | % |
Movies & Entertainment | 40,036 | | | 1.15 | % | | — | | | — | % |
Construction & Engineering | 39,954 | | | 1.14 | % | | — | | | — | % |
Health Care Distributors | 39,789 | | | 1.14 | % | | 32,575 | | | 1.69 | % |
Diversified Chemicals | 39,549 | | | 1.13 | % | | — | | | — | % |
Alternative Carriers | 39,213 | | | 1.12 | % | | — | | | — | % |
Integrated Telecommunication Services | 35,416 | | | 1.01 | % | | 41,352 | | | 2.15 | % |
Restaurants | 34,913 | | | 1.00 | % | | 18,832 | | | 0.98 | % |
Cable & Satellite | 33,035 | | | 0.94 | % | | 24,678 | | | 1.28 | % |
Distributors | 32,527 | | | 0.93 | % | | 52,155 | | | 2.71 | % |
Auto Parts & Equipment | 32,363 | | | 0.93 | % | | 32,444 | | | 1.69 | % |
Research & Consulting Services | 31,933 | | | 0.91 | % | | 20,717 | | | 1.08 | % |
Health Care Facilities | 30,271 | | | 0.87 | % | | 20,456 | | | 1.06 | % |
Personal Care Products | 28,836 | | | 0.82 | % | | 44,968 | | | 2.34 | % |
Biotechnology | 27,937 | | | 0.80 | % | | 36,433 | | | 1.90 | % |
Gold | 27,692 | | | 0.79 | % | | 27,607 | | | 1.44 | % |
Air Freight & Logistics | 22,388 | | | 0.64 | % | | 6,590 | | | 0.34 | % |
Trading Companies & Distributors | 21,308 | | | 0.61 | % | | 25,328 | | | 1.32 | % |
Diversified Financial Services | 21,089 | | | 0.60 | % | | 31,405 | | | 1.63 | % |
Paper & Plastic Packaging Products & Materials | 20,477 | | | 0.59 | % | | 4,785 | | | 0.25 | % |
Advertising | 17,883 | | | 0.51 | % | | 11,167 | | | 0.58 | % |
Passenger Airlines | 17,773 | | | 0.51 | % | | 11,191 | | | 0.58 | % |
Hotels, Resorts & Cruise Lines | 17,125 | | | 0.49 | % | | 17,167 | | | 0.89 | % |
Real Estate Development | 16,742 | | | 0.48 | % | | 16,036 | | | 0.83 | % |
Food Distributors | 11,503 | | | 0.33 | % | | 6,111 | | | 0.32 | % |
Leisure Facilities | 9,561 | | | 0.27 | % | | 9,445 | | | 0.49 | % |
Internet Services & Infrastructure | — | | | — | % | | 14,556 | | | 0.76 | % |
Consumer Finance | — | | | — | % | | 6,796 | | | 0.35 | % |
Soft Drinks & Non-alcoholic Beverages | — | | | — | % | | 4,958 | | | 0.26 | % |
Leisure Products | — | | | — | % | | 4,772 | | | 0.25 | % |
Diversified Real Estate Activities | — | | | — | % | | 4,619 | | | 0.24 | % |
Other Specialized REITs | — | | | — | % | | 3,574 | | | 0.19 | % |
Construction Materials | — | | | — | % | | 2,080 | | | 0.11 | % |
Total | $ | 3,496,473 | | | 100.00 | % | | $ | 1,922,218 | | | 100.00 | % |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| March 31, 2024 | | September 30, 2023 |
Fair Value: | | | % of Total Investments | | % of Net Assets | | | | % of Total Investments | | % of Net Assets |
Application Software | $ | 524,177 | | | 14.91 | % | | 21.22 | % | | $ | 263,077 | | | 13.67 | % | | 17.23 | % |
Diversified Support Services | 175,402 | | 4.98 | % | | 7.10 | % | | 40,493 | | | 2.10 | % | | 2.65 | % |
Systems Software | 163,468 | | 4.64 | % | | 6.62 | % | | 70,227 | | | 3.64 | % | | 4.59 | % |
Health Care Technology | 159,038 | | 4.52 | % | | 6.44 | % | | 72,102 | | | 3.74 | % | | 4.71 | % |
Aerospace & Defense | 154,938 | | 4.40 | % | | 6.27 | % | | 75,628 | | | 3.92 | % | | 4.95 | % |
Industrial Machinery & Supplies & Components | 150,371 | | 4.27 | % | | 6.09 | % | | 30,448 | | | 1.58 | % | | 1.99 | % |
Health Care Services | 146,215 | | 4.15 | % | | 5.92 | % | | 57,832 | | | 3.00 | % | | 3.78 | % |
Interactive Media & Services | 116,895 | | 3.32 | % | | 4.73 | % | | 23,999 | | | 1.25 | % | | 1.57 | % |
Other Specialty Retail | 107,091 | | 3.04 | % | | 4.33 | % | | 104,861 | | | 5.44 | % | | 6.86 | % |
Multi-Sector Holdings | 92,105 | | 2.62 | % | | 3.73 | % | | 28,863 | | | 1.50 | % | | 1.89 | % |
Insurance Brokers | 87,831 | | 2.50 | % | | 3.55 | % | | 13,857 | | | 0.72 | % | | 0.91 | % |
Property & Casualty Insurance | 82,981 | | 2.36 | % | | 3.36 | % | | 41,911 | | | 2.17 | % | | 2.74 | % |
Packaged Foods & Meats | 80,559 | | 2.29 | % | | 3.26 | % | | — | | | — | % | | — | % |
Education Services | 80,204 | | 2.28 | % | | 3.25 | % | | 61,653 | | | 3.20 | % | | 4.03 | % |
Environmental & Facilities Services | 76,993 | | 2.19 | % | | 3.12 | % | | 75,755 | | | 3.93 | % | | 4.95 | % |
Electrical Components & Equipment | 75,940 | | 2.16 | % | | 3.07 | % | | 75,916 | | | 3.94 | % | | 4.96 | % |
Specialized Finance | 64,886 | | 1.84 | % | | 2.63 | % | | 48,815 | | | 2.53 | % | | 3.19 | % |
Office Services & Supplies | 63,000 | | 1.79 | % | | 2.55 | % | | 21,588 | | | 1.12 | % | | 1.41 | % |
Diversified Metals & Mining | 62,054 | | 1.76 | % | | 2.51 | % | | 95,449 | | | 4.95 | % | | 6.24 | % |
Construction Machinery & Heavy Transportation Equipment | 61,294 | | 1.74 | % | | 2.48 | % | | — | | | — | % | | — | % |
Data Processing & Outsourced Services | 57,207 | | 1.63 | % | | 2.32 | % | | — | | | — | % | | — | % |
Health Care Supplies | 52,928 | | 1.50 | % | | 2.14 | % | | 37,137 | | | 1.93 | % | | 2.43 | % |
Life Sciences Tools & Services | 50,773 | | 1.44 | % | | 2.05 | % | | 27,419 | | | 1.42 | % | | 1.79 | % |
Pharmaceuticals | 49,451 | | 1.40 | % | | 2.00 | % | | 63,149 | | | 3.28 | % | | 4.13 | % |
Metal, Glass & Plastic Containers | 45,543 | | 1.29 | % | | 1.84 | % | | 25,799 | | | 1.34 | % | | 1.69 | % |
Health Care Equipment | 41,229 | | 1.17 | % | | 1.67 | % | | 39,945 | | | 2.07 | % | | 2.61 | % |
Construction & Engineering | 40,627 | | 1.15 | % | | 1.64 | % | | — | | | — | % | | — | % |
Health Care Distributors | 40,470 | | 1.15 | % | | 1.64 | % | | 33,083 | | | 1.72 | % | | 2.16 | % |
Diversified Chemicals | 40,292 | | 1.14 | % | | 1.63 | % | | — | | | — | % | | — | % |
Movies & Entertainment | 40,141 | | 1.14 | % | | 1.62 | % | | — | | | — | % | | — | % |
Alternative Carriers | 39,826 | | 1.13 | % | | 1.61 | % | | — | | | — | % | | — | % |
Integrated Telecommunication Services | 35,932 | | 1.02 | % | | 1.45 | % | | 39,481 | | | 2.05 | % | | 2.58 | % |
Restaurants | 35,077 | | 1.00 | % | | 1.42 | % | | 19,013 | | | 0.99 | % | | 1.24 | % |
Cable & Satellite | 33,305 | | 0.95 | % | | 1.35 | % | | 24,360 | | | 1.26 | % | | 1.59 | % |
Research & Consulting Services | 33,129 | | 0.94 | % | | 1.34 | % | | 21,180 | | | 1.10 | % | | 1.39 | % |
Auto Parts & Equipment | 32,819 | | 0.93 | % | | 1.33 | % | | 33,061 | | | 1.72 | % | | 2.16 | % |
Distributors | 32,387 | | 0.92 | % | | 1.31 | % | | 51,939 | | | 2.69 | % | | 3.40 | % |
Health Care Facilities | 30,576 | | 0.87 | % | | 1.24 | % | | 20,564 | | | 1.07 | % | | 1.34 | % |
Personal Care Products | 28,809 | | 0.82 | % | | 1.17 | % | | 44,284 | | | 2.30 | % | | 2.90 | % |
Gold | 27,897 | | 0.79 | % | | 1.13 | % | | 27,627 | | | 1.43 | % | | 1.81 | % |
Biotechnology | 27,397 | | 0.78 | % | | 1.11 | % | | 35,838 | | | 1.86 | % | | 2.34 | % |
Air Freight & Logistics | 22,528 | | 0.64 | % | | 0.91 | % | | 6,800 | | | 0.35 | % | | 0.44 | % |
Diversified Financial Services | 21,673 | | 0.62 | % | | 0.88 | % | | 31,860 | | | 1.65 | % | | 2.08 | % |
Trading Companies & Distributors | 21,660 | | 0.62 | % | | 0.88 | % | | 25,536 | | | 1.33 | % | | 1.67 | % |
Paper & Plastic Packaging Products & Materials | 20,338 | | 0.58 | % | | 0.82 | % | | 4,543 | | | 0.24 | % | | 0.30 | % |
Passenger Airlines | 19,348 | | 0.55 | % | | 0.78 | % | | 12,529 | | | 0.65 | % | | 0.82 | % |
Advertising | 18,471 | | 0.52 | % | | 0.75 | % | | 11,343 | | | 0.59 | % | | 0.74 | % |
Hotels, Resorts & Cruise Lines | 16,964 | | 0.48 | % | | 0.69 | % | | 17,051 | | | 0.88 | % | | 1.12 | % |
Real Estate Development | 16,563 | | 0.47 | % | | 0.67 | % | | 15,849 | | | 0.82 | % | | 1.04 | % |
Food Distributors | 11,934 | | 0.34 | % | | 0.48 | % | | 6,109 | | | 0.32 | % | | 0.40 | % |
Leisure Facilities | 9,200 | | 0.26 | % | | 0.37 | % | | 9,093 | | | 0.47 | % | | 0.59 | % |
Internet Services & Infrastructure | — | | | — | % | | — | % | | 14,726 | | | 0.76 | % | | 0.96 | % |
Consumer Finance | — | | | — | % | | — | % | | 6,107 | | | 0.32 | % | | 0.40 | % |
Soft Drinks & Non-alcoholic Beverages | — | | | — | % | | — | % | | 5,542 | | | 0.29 | % | | 0.36 | % |
Diversified Real Estate Activities | — | | | — | % | | — | % | | 4,696 | | | 0.24 | % | | 0.31 | % |
Leisure Products | — | | | — | % | | — | % | | 4,131 | | | 0.21 | % | | 0.27 | % |
Other Specialized REITs | — | | | — | % | | — | % | | 2,947 | | | 0.15 | % | | 0.19 | % |
Construction Materials | — | | | — | % | | — | % | | 2,022 | | | 0.10 | % | | 0.13 | % |
Total | $ | 3,519,936 | | | 100.00 | % | | 142.47 | % | | $ | 1,927,237 | | | 100.00 | % | | 126.03 | % |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Fair Value Measurements
The following table presents the financial instruments carried at fair value as of March 31, 2024 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Level 1 | | Level 2 | | Level 3 | | Total |
Senior secured debt | | $ | — | | | $ | 1,275,835 | | | $ | 2,009,889 | | | $ | 3,285,724 | |
Subordinated debt (including CLO Notes) | | — | | | 183,581 | | | 33,795 | | | 217,376 | |
Common equity and warrants | | — | | | — | | | 4,022 | | | 4,022 | |
Preferred equity | | — | | | — | | | 12,814 | | | 12,814 | |
Total investments at fair value | | — | | | 1,459,416 | | | 2,060,520 | | | 3,519,936 | |
Derivative asset | | — | | | 2,944 | | | — | | | 2,944 | |
Total assets at fair value | | $ | — | | | $ | 1,462,360 | | | $ | 2,060,520 | | | $ | 3,522,880 | |
Derivative liabilities | | $ | — | | | $ | 252 | | | $ | — | | | $ | 252 | |
Total liabilities at fair value | | $ | — | | | $ | 252 | | | $ | — | | | $ | 252 | |
The following table presents the financial instruments carried at fair value as of September 30, 2023 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Level 1 | | Level 2 | | Level 3 | | Total |
Senior secured debt | | $ | — | | | $ | 754,220 | | | $ | 1,063,761 | | | $ | 1,817,981 | |
Subordinated debt (including CLO Notes) | | — | | | 83,824 | | | 13,792 | | | 97,616 | |
Common equity and warrants | | — | | | 53 | | | 5,839 | | | 5,892 | |
Preferred equity | | — | | | — | | | 5,748 | | | 5,748 | |
Total investments at fair value | | — | | | 838,097 | | | 1,089,140 | | | 1,927,237 | |
Derivative asset | | — | | | 2,041 | | | — | | | 2,041 | |
Total assets at fair value | | $ | — | | | $ | 840,138 | | | $ | 1,089,140 | | | $ | 1,929,278 | |
When a determination is made to classify a financial instrument within Level 3 of the valuation hierarchy, the determination is based upon the fact that the unobservable factors are significant to the overall fair value measurement. However, Level 3 financial instruments typically have both unobservable or Level 3 components and observable components (i.e. components that are actively quoted and can be validated by external sources). Accordingly, the appreciation (depreciation) in the tables below includes changes in fair value due in part to observable factors that are part of the valuation methodology.
The principal value of any borrowings outstanding under the ING Credit Agreement (as defined below), the JPM Loan and Security Agreement (as defined below), the SMBC Loan and Security Agreement (as defined below), the CIBC Loan and Servicing Agreement (as defined below), the DBNY Loan Financing and Servicing Agreement (as defined below) and the MS Loan and Servicing Agreement (as defined below) approximates fair value due to its variable rate and is included in Level 3 of the hierarchy.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
The following table provides a roll-forward of the changes in fair value from December 31, 2023 to March 31, 2024, for all investments for which the Company determined fair value using unobservable (Level 3) factors:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Senior Secured Debt | | Subordinated Debt | | Preferred Equity | | Common Equity and Warrants | | Total |
Fair value as of December 31, 2023 | | $ | 1,621,228 | | | $ | 25,352 | | | $ | 12,091 | | | $ | 5,072 | | | $ | 1,663,743 | |
Purchases | | 470,302 | | | 7,612 | | | — | | | — | | | 477,914 | |
Sales and repayments | | (92,492) | | | — | | | — | | | — | | | (92,492) | |
Transfers in (a) | | 6,785 | | | — | | | — | | | — | | | 6,785 | |
Capitalized PIK interest income | | 1,587 | | | 831 | | | — | | | — | | | 2,418 | |
Accretion of OID | | 3,911 | | | — | | | — | | | — | | | 3,911 | |
Net unrealized appreciation (depreciation) | | (1,853) | | | — | | | 723 | | | (1,050) | | | (2,180) | |
Net realized gains (losses) | | 421 | | | — | | | — | | | — | | | 421 | |
Fair value as of March 31, 2024 | | $ | 2,009,889 | | | $ | 33,795 | | | $ | 12,814 | | | $ | 4,022 | | | $ | 2,060,520 | |
Net unrealized appreciation (depreciation) relating to Level 3 assets still held at March 31, 2024 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended March 31, 2024 | | $ | 535 | | | $ | — | | | $ | 723 | | | $ | (1,050) | | | $ | 208 | |
__________(a) There were transfers into Level 3 from Level 2 for certain investments during the three months ended March 31, 2024 as a result of a change in the number of market quotes available and/or a change in market liquidity.
The following table provides a roll-forward of the changes in fair value from December 31, 2022 to March 31, 2023, for all investments for which the Company determined fair value using unobservable (Level 3) factors:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Senior Secured Debt | | Subordinated Debt | | Preferred Equity | | Common Equity and Warrants | | Total |
Fair value as of December 31, 2022 | | $ | 285,703 | | | $ | 6,606 | | | $ | 5,195 | | | $ | 3,557 | | | $ | 301,061 | |
Purchases | | 108,414 | | | — | | | — | | | — | | | 108,414 | |
Sales and repayments | | (3,093) | | | — | | | — | | | — | | | (3,093) | |
Transfers in (a) | | — | | | 1,547 | | | — | | | — | | | 1,547 | |
Capitalized PIK interest income | | 443 | | | 118 | | | — | | | — | | | 561 | |
Accretion of OID | | 561 | | | 1 | | | — | | | — | | | 562 | |
Net unrealized appreciation (depreciation) | | 819 | | | 77 | | | (114) | | | 498 | | | 1,280 | |
Fair value as of March 31, 2023 | | $ | 392,847 | | | $ | 8,349 | | | $ | 5,081 | | | $ | 4,055 | | | $ | 410,332 | |
Net unrealized appreciation (depreciation) relating to Level 3 assets still held at March 31, 2023 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended March 31, 2023 | | $ | 819 | | | $ | 77 | | | $ | (114) | | | $ | 498 | | | $ | 1,280 | |
__________(a) There were transfers into Level 3 from Level 2 for certain investments during the three months ended March 31, 2023 as a result of a change in the number of market quotes available and/or a change in market liquidity.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
The following table provides a roll-forward of the changes in fair value from September 30, 2023 to March 31, 2024, for all investments for which the Company determined fair value using unobservable (Level 3) factors:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Senior Secured Debt | | Subordinated Debt | | Preferred Equity | | Common Equity and Warrants | | Total |
Fair value as of September 30, 2023 | | $ | 1,063,761 | | | $ | 13,792 | | | $ | 5,748 | | | $ | 5,839 | | | $ | 1,089,140 | |
Purchases | | 1,040,445 | | | 19,173 | | | 6,211 | | | — | | | 1,065,829 | |
Sales and repayments | | (111,892) | | | — | | | — | | | — | | | (111,892) | |
Transfers in (a) | | 10,757 | | | — | | | — | | | — | | | 10,757 | |
Capitalized PIK interest income | | 2,208 | | | 830 | | | — | | | — | | | 3,038 | |
Accretion of OID | | 6,295 | | | — | | | — | | | — | | | 6,295 | |
Net unrealized appreciation (depreciation) | | (1,869) | | | — | | | 855 | | | (1,817) | | | (2,831) | |
Net realized gains (losses) | | 184 | | | — | | | — | | | — | | | 184 | |
Fair value as of March 31, 2024 | | $ | 2,009,889 | | | $ | 33,795 | | | $ | 12,814 | | | $ | 4,022 | | | $ | 2,060,520 | |
Net unrealized appreciation (depreciation) relating to Level 3 assets still held at March 31, 2024 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the six months ended March 31, 2024 | | $ | (1,934) | | | $ | — | | | $ | 855 | | | $ | (1,817) | | | $ | (2,896) | |
__________(a) There were transfers into Level 3 from Level 2 for certain investments during the six months ended March 31, 2024 as a result of a change in the number of market quotes available and/or a change in market liquidity.
The following table provides a roll-forward of the changes in fair value from September 30, 2022 to March 31, 2023, for all investments for which the Company determined fair value using unobservable (Level 3) factors:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Senior Secured Debt | | Subordinated Debt | | Preferred Equity | | Common Equity and Warrants | | Total |
Fair value as of September 30, 2022 | | $ | 153,069 | | | $ | 3,303 | | | $ | 5,497 | | | $ | 1,023 | | | $ | 162,892 | |
Purchases | | 241,049 | | | 4,806 | | | — | | | 2,162 | | | 248,017 | |
Sales and repayments | | (3,538) | | | — | | | — | | | — | | | (3,538) | |
Transfers in (a) | | 3,815 | | | — | | | — | | | — | | | 3,815 | |
Capitalized PIK interest income | | 970 | | | 118 | | | — | | | — | | | 1,088 | |
Accretion of OID | | 951 | | | 1 | | | — | | | — | | | 952 | |
Net unrealized appreciation (depreciation) | | (3,469) | | | 121 | | | (416) | | | 870 | | | (2,894) | |
Fair value as of March 31, 2023 | | $ | 392,847 | | | $ | 8,349 | | | $ | 5,081 | | | $ | 4,055 | | | $ | 410,332 | |
Net unrealized appreciation (depreciation) relating to Level 3 assets still held at March 31, 2023 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the six months ended March 31, 2023 | | $ | (3,471) | | | $ | 121 | | | $ | (416) | | | $ | 870 | | | $ | (2,896) | |
__________(a) There were transfers into Level 3 from Level 2 for certain investments during the six months ended March 31, 2023 as a result of a change in the number of market quotes available and/or a change in market liquidity.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Significant Unobservable Inputs for Level 3 Investments
The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which were carried at fair value as of March 31, 2024:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Asset | | Fair Value | | Valuation Technique | | Unobservable Input | | Range | | Weighted Average (a) |
Senior secured debt | | $ | 1,884,764 | | | Market Yield | | Market Yield | | (b) | 9.0% | - | 21.0% | | 11.9% |
| | 6,711 | | Enterprise Value | | EBITDA Multiple | | (e) | 8.0x | - | 10.0x | | 9.0x |
| | 62,325 | | Transaction Precedent | | Transaction Price | | (c) | N/A | - | N/A | | N/A |
| | 56,089 | | Broker Quotations | | Broker Quoted Price | | (d) | N/A | - | N/A | | N/A |
Subordinated debt | | 33,795 | | Market Yield | | Market Yield | | (b) | 9.0% | - | 12.0% | | 10.2% |
Common equity and warrants & preferred equity | | 2,332 | | Enterprise Value | | Revenue Multiple | | (e) | 0.7x | - | 3.2x | | 0.8x |
| | 7,512 | | Enterprise Value | | EBITDA Multiple | | (e) | 6.0x | - | 15.1x | | 13.7x |
| | 6,992 | | Transaction Precedent | | Transaction Price | | (c) | N/A | - | N/A | | N/A |
Total | | $ | 2,060,520 | | | | | | | | | | | | |
_____________________
(a) Weighted averages are calculated based on fair value of investments.
(b) Used when a market participant would take into account market yield when pricing the investment.
(c) Used when there is an observable transaction or pending event for the investment.
(d) The Adviser generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. The Adviser evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated.
(e) Used when a market participant would use such multiple when pricing the investment.
The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which were carried at fair value as of September 30, 2023:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Asset | | Fair Value | | Valuation Technique | | Unobservable Input | | Range | | Weighted Average (a) |
Senior secured debt | | $ | 906,639 | | | Market Yield | | Market Yield | | (b) | 10.0% | - | 32.0% | | 13.3% |
| | 93,170 | | Transaction Precedent | | Transaction Price | | (c) | N/A | - | N/A | | N/A |
| | 63,952 | | Broker Quotations | | Broker Quoted Price | | (d) | N/A | - | N/A | | N/A |
Subordinated debt | | 13,792 | | Market Yield | | Market Yield | | (b) | 9.0% | - | 11.0% | | 10.0% |
Common equity and warrants & preferred equity | | 3,424 | | Enterprise Value | | Revenue Multiple | | (e) | 0.7x | - | 3.2x | | 0.7x |
| | 7,831 | | Enterprise Value | | EBITDA Multiple | | (e) | 6.0x | - | 15.1x | | 12.9x |
| | 332 | | Transaction Precedent | | Transaction Price | | (c) | N/A | - | N/A | | N/A |
Total | | $ | 1,089,140 | | | | | | | | | | | | |
_____________________
(a) Weighted averages are calculated based on fair value of investments.
(b) Used when a market participant would take into account market yield when pricing the investment.
(c) Used when there is an observable transaction or pending event for the investment.
(d) The Adviser generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. The Adviser evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated.
(e) Used when a market participant would use such multiple when pricing the investment.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Under the market yield technique, the significant unobservable input used in the fair value measurement of the Company's investments in debt securities is the market yield. Increases or decreases in the market yield may result in a lower or higher fair value measurement, respectively.
Under the EV technique, the significant unobservable input used in the fair value measurement of the Company's investments in debt or equity securities is the earnings before interest, taxes, depreciation and amortization ("EBITDA"), revenue or asset multiple, as applicable. Increases or decreases in the valuation multiples in isolation may result in a higher or lower fair value measurement, respectively.
Note 4. Fee Income
For the three and six months ended March 31, 2024, the Company recorded total fee income of $1,250 and $1,651, respectively, of which $26 and $58, respectively, was recurring in nature. For the three and six months ended March 31, 2023, the Company recorded total fee income of $141 and $228, respectively, of which $99 and $161, respectively, was recurring in nature. Recurring fee income consisted of servicing fees.
Note 5. Share Data and Distributions
Changes in Net Assets
The following table presents the changes in net assets for the three and six months ended March 31, 2024:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Common Shares | | | | | | |
(Share amounts in thousands) | | Shares | | Par Value | | Additional Paid-in-Capital | | Accumulated Distributable Earnings (Loss) | | Total Net Assets |
Balance at September 30, 2023 | | 64,896 | | | $ | 649 | | | $ | 1,536,305 | | | $ | (7,749) | | | $ | 1,529,205 | |
Issuance of Common Shares in public offering | | 19,952 | | | 199 | | | 468,588 | | | — | | | 468,787 | |
Issuance of Common Shares under dividend reinvestment plan | | 496 | | | 5 | | | 11,642 | | | — | | | 11,647 | |
Shares repurchased, net of early repurchase deduction | | (446) | | | (4) | | | (10,522) | | | — | | | (10,526) | |
Net investment income | | — | | | — | | | — | | | 35,803 | | | 35,803 | |
Net unrealized appreciation (depreciation) | | — | | | — | | | — | | | 16,919 | | | 16,919 | |
Net realized gains (losses) | | — | | | — | | | — | | | 453 | | | 453 | |
Provision for income tax (expense) benefit | | — | | | — | | | — | | | (241) | | | (241) | |
Distributions to shareholders | | — | | | — | | | — | | | (46,876) | | | (46,876) | |
Balance at December 31, 2023 | | 84,898 | | | $ | 849 | | | $ | 2,006,013 | | | $ | (1,691) | | | $ | 2,005,171 | |
Issuance of Common Shares in public offering | | 19,399 | | | 194 | | | 457,636 | | | — | | | 457,830 | |
Issuance of Common Shares under dividend reinvestment plan | | 679 | | | 7 | | | 16,050 | | | — | | | 16,057 | |
Shares repurchased, net of early repurchase deduction | | (349) | | | (4) | | | (8,213) | | | — | | | (8,217) | |
Net investment income | | — | | | — | | | — | | | 53,929 | | | 53,929 | |
Net unrealized appreciation (depreciation) | | — | | | — | | | — | | | (655) | | | (655) | |
Net realized gains (losses) | | — | | | — | | | — | | | 3,347 | | | 3,347 | |
Provision for income tax (expense) benefit | | — | | | — | | | — | | | (144) | | | (144) | |
Distributions to shareholders | | — | | | — | | | — | | | (56,572) | | | (56,572) | |
Balance at March 31, 2024 | | 104,627 | | | $ | 1,046 | | | $ | 2,471,486 | | | $ | (1,786) | | | $ | 2,470,746 | |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
The following table presents the changes in net assets for the three and six months ended March 31, 2023:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Common Shares | | | | | | |
(Share amounts in thousands) | | Shares | | Par Value | | Additional Paid-in-Capital | | Accumulated Distributable Earnings (Loss) | | Total Net Assets |
Balance at September 30, 2022 | | 15,628 | | | $ | 156 | | | $ | 380,646 | | | $ | (14,075) | | | $ | 366,727 | |
Issuance of Common Shares | | 5,536 | | | 55 | | | 129,653 | | | — | | | 129,708 | |
Issuance of Common Shares under dividend reinvestment plan | | 78 | | | 1 | | | 1,831 | | | — | | | 1,832 | |
Net investment income | | — | | | — | | | — | | | 10,097 | | | 10,097 | |
Net unrealized appreciation (depreciation) | | — | | | — | | | — | | | (2,842) | | | (2,842) | |
Net realized gains (losses) | | — | | | — | | | — | | | (660) | | | (660) | |
Provision for income tax (expense) benefit | | — | | | — | | | — | | | (51) | | | (51) | |
Distributions to shareholders | | — | | | — | | | — | | | (11,356) | | | (11,356) | |
Balance at December 31, 2022 | | 21,242 | | | 212 | | | 512,130 | | | (18,887) | | | 493,455 | |
Issuance of Common Shares | | 9,589 | | | 97 | | | 225,285 | | | — | | | 225,382 | |
Issuance of Common Shares under dividend reinvestment plan | | 120 | | | 1 | | | 2,822 | | | — | | | 2,823 | |
Net investment income | | — | | | — | | | — | | | 11,804 | | | 11,804 | |
Net unrealized appreciation (depreciation) | | — | | | — | | | — | | | 8,054 | | | 8,054 | |
Net realized gains (losses) | | — | | | — | | | — | | | (1,741) | | | (1,741) | |
Provision for income tax (expense) benefit | | — | | | — | | | — | | | (54) | | | (54) | |
Distributions to shareholders | | — | | | — | | | — | | | (14,863) | | | (14,863) | |
Balance at March 31, 2023 | | 30,951 | | | $ | 310 | | | $ | 740,237 | | | $ | (15,687) | | | $ | 724,860 | |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Capital Activity
In connection with its formation, the Company has the authority to issue an unlimited number of Class I, Class S and Class D common shares of beneficial interest at $0.01 per share par value. As of March 31, 2024, the Company has issued and sold 69,926,688 Class I shares for an aggregate purchase price of $1,656.1 million. As of March 31, 2024, the Company has issued and sold 33,792,645 Class S shares for an aggregate purchase price of $795.2 million. As of March 31, 2024, the Company has issued and sold 52,607 Class D shares for an aggregate purchase price of $1.2 million. As of March 31, 2024, the Company has issued 888,513 Class I shares, 988,557 Class S shares and 499 Class D shares pursuant to its distribution reinvestment plan.
The following table summarizes transactions in common shares of beneficial interest for the six months ended March 31, 2024:
| | | | | | | | | | | |
| Shares | | Amount |
Class I | | | |
Issuance of Common Shares in public offering | 25,921,513 | | | $ | 610,377 | |
Share transfers between classes | 10,652 | | | 252 | |
Issuance of Common Shares under dividend reinvestment plan | 554,879 | | | 13,152 | |
Share repurchases, net of early repurchase deduction | (616,810) | | | (14,542) | |
Net increase (decrease) | 25,870,234 | | | $ | 609,239 | |
Class S | | | |
Issuance of Common Shares in public offering | 13,384,213 | | | $ | 315,146 | |
Share transfers between classes | (10,652) | | | (252) | |
Issuance of Common Shares under dividend reinvestment plan | 617,672 | | | 14,541 | |
Share repurchases, net of early repurchase deduction | (178,223) | | | (4,201) | |
Net increase (decrease) | 13,813,010 | | | $ | 325,234 | |
Class D | | | |
Issuance of Common Shares in public offering | 46,430 | | | $ | 1,094 | |
Issuance of Common Shares under dividend reinvestment plan | 482 | | | 11 | |
Share repurchases, net of early repurchase deduction | — | | | — | |
Net increase (decrease) | 46,912 | | | $ | 1,105 | |
Total net increase (decrease) | 39,730,156 | | | $ | 935,578 | |
The following table summarizes transactions in common shares of beneficial interest for the six months ended March 31, 2023:
| | | | | | | | | | | |
| Shares | | Amount |
Class I | | | |
Issuance of Common Shares | 9,233,040 | | | $ | 216,728 | |
Issuance of Common Shares under dividend reinvestment plan | 105,206 | | | 2,467 | |
Share repurchases, net of early repurchase deduction | — | | | — | |
Net increase (decrease) | 9,338,246 | | | $ | 219,195 | |
Class S | | | |
Issuance of Common Shares | 5,890,761 | | | $ | 138,362 | |
Issuance of Common Shares under dividend reinvestment plan | 93,306 | | | 2,188 | |
Share repurchases, net of early repurchase deduction | — | | | — | |
Net increase (decrease) | 5,984,067 | | | $ | 140,550 | |
Total net increase (decrease) | 15,322,313 | | | $ | 359,745 | |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Net Asset Value per Share and Offering Price
The Company determines NAV per share for each class of shares as of the last calendar day of each month. Share issuances pursuant to accepted monthly subscriptions are effective the first calendar day of each month. Shares are issued and sold at a purchase price equivalent to the most recent NAV per share available for each share class, which will be the prior calendar day NAV per share (i.e. the prior month-end NAV). The following table summarizes each month-end NAV per share for Class I, Class S and Class D shares during the six months ended March 31, 2024 and 2023:
| | | | | | | | | | | | | | | | | |
| Class I Shares | | Class S Shares | | Class D Shares |
October 31, 2023 | $ | 23.39 | | | $ | 23.39 | | | $ | 23.39 | |
November 30, 2023 | $ | 23.51 | | | $ | 23.51 | | | $ | 23.51 | |
December 31, 2023 | $ | 23.62 | | | $ | 23.62 | | | $ | 23.62 | |
January 31, 2024 | $ | 23.60 | | | $ | 23.60 | | | $ | 23.60 | |
February 29, 2024 | $ | 23.58 | | | $ | 23.58 | | | $ | 23.58 | |
March 31, 2024 | $ | 23.61 | | | $ | 23.61 | | | $ | 23.61 | |
| | | | | | | | | | | | | | | | | |
| Class I Shares | | Class S Shares | | Class D Shares |
October 31, 2022 | $ | 23.33 | | | $ | 23.33 | | | — | |
November 30, 2022 | $ | 23.46 | | | $ | 23.46 | | | — | |
December 31, 2022 | $ | 23.23 | | | $ | 23.23 | | | — | |
January 31, 2023 | $ | 23.64 | | | $ | 23.64 | | | — | |
February 28, 2023 | $ | 23.56 | | | $ | 23.56 | | | — | |
March 31, 2023 | $ | 23.42 | | | $ | 23.42 | | | — | |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Distributions
The Board authorizes and declares monthly distribution amounts per share of outstanding Common Shares. The following table presents distributions that were declared during the six months ended March 31, 2024:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Class I |
Distribution | | Date Declared | | Record Date | | Payment Date | | Distribution Per Share | | Distribution Amount |
Monthly | | October 25, 2023 | | October 31, 2023 | | November 28, 2023 | | $ | 0.1900 | | | $ | 9,259 | |
Monthly | | November 27, 2023 | | November 30, 2023 | | December 27, 2023 | | 0.1900 | | | 9,916 | |
Special | | December 14, 2023 | | December 15, 2023 | | December 27, 2023 | | 0.0400 | | | 2,296 | |
Monthly | | December 20, 2023 | | December 31, 2023 | | February 1, 2024 | | 0.1900 | | | 10,921 | |
Monthly | | January 24, 2024 | | January 31, 2024 | | February 27, 2024 | | 0.1900 | | | 11,872 | |
Monthly | | February 27, 2024 | | February 29, 2024 | | March 27, 2024 | | 0.2000 | | | 13,229 | |
Monthly | | March 26, 2024 | | March 27, 2024 | | April 29, 2024 | | 0.2000 | | | 14,041 | |
| | | | | | | | $ | 1.2000 | | | $ | 71,534 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Class S |
Distribution | | Date Declared | | Record Date | | Payment Date | | Distribution Per Share | | Distribution Amount |
Monthly | | October 25, 2023 | | October 31, 2023 | | November 28, 2023 | | $ | 0.1733 | | | $ | 4,105 | |
Monthly | | November 27, 2023 | | November 30, 2023 | | December 27, 2023 | | 0.1734 | | | 4,436 | |
Special | | December 14, 2023 | | December 15, 2023 | | December 27, 2023 | | 0.0400 | | | 1,109 | |
Monthly | | December 20, 2023 | | December 31, 2023 | | February 1, 2024 | | 0.1733 | | | 4,825 | |
Monthly | | January 24, 2024 | | January 31, 2024 | | February 27, 2024 | | 0.1733 | | | 5,191 | |
Monthly | | February 27, 2024 | | February 29, 2024 | | March 27, 2024 | | 0.1833 | | | 5,853 | |
Monthly | | March 26, 2024 | | March 27, 2024 | | April 29, 2024 | | 0.1833 | | | 6,361 | |
| | | | | | | | $ | 1.0999 | | | $ | 31,880 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Class D |
Distribution | | Date Declared | | Record Date | | Payment Date | | Distribution Per Share | | Distribution Amount |
Monthly | | October 25, 2023 | | October 31, 2023 | | November 28, 2023 | | $ | 0.1851 | | | $ | 1 | |
Monthly | | November 27, 2023 | | November 30, 2023 | | December 27, 2023 | | 0.1851 | | | $ | 3 | |
Special | | December 14, 2023 | | December 15, 2023 | | December 27, 2023 | | 0.0400 | | | $ | 1 | |
Monthly | | December 20, 2023 | | December 31, 2023 | | February 1, 2024 | | 0.1851 | | | $ | 4 | |
Monthly | | January 24, 2024 | | January 31, 2024 | | February 27, 2024 | | 0.1851 | | | $ | 5 | |
Monthly | | February 27, 2024 | | February 29, 2024 | | March 27, 2024 | | 0.1951 | | | $ | 10 | |
Monthly | | March 26, 2024 | | March 27, 2024 | | April 29, 2024 | | 0.1951 | | | $ | 10 | |
| | | | | | | | $ | 1.1706 | | | $ | 34 | |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
The following table presents distributions that were declared during the six months ended March 31, 2023:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Class I |
Distribution | | Date Declared | | Record Date | | Payment Date | | Distribution Per Share | | Distribution Amount |
Monthly | | October 26, 2022 | | October 31, 2022 | | November 28, 2022 | | $ | 0.1800 | | | $ | 2,470 | |
Monthly | | November 21, 2022 | | November 30, 2022 | | December 28, 2022 | | 0.1900 | | | 2,818 | |
Monthly | | December 21, 2022 | | December 31, 2022 | | January 30, 2023 | | 0.1900 | | | 3,171 | |
Special | | December 21, 2022 | | December 31, 2022 | | January 30, 2023 | | 0.0400 | | | 668 | |
Monthly | | January 24, 2023 | | January 31, 2023 | | February 24, 2023 | | 0.1900 | | | 3,351 | |
Monthly | | February 22, 2023 | | February 28, 2023 | | March 29, 2023 | | 0.1900 | | | 3,834 | |
Monthly | | March 22, 2023 | | March 31, 2023 | | April 27, 2023 | | 0.1900 | | | 4,252 | |
| | | | | | | | $ | 1.1700 | | | $ | 20,564 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Class S |
Distribution | | Date Declared | | Record Date | | Payment Date | | Distribution Per Share | | Distribution Amount |
Monthly | | October 26, 2022 | | October 31, 2022 | | November 28, 2022 | | $ | 0.1634 | | | $ | 574 | |
Monthly | | November 21, 2022 | | November 30, 2022 | | December 28, 2022 | | 0.1735 | | | 684 | |
Monthly | | December 21, 2022 | | December 31, 2022 | | January 30, 2023 | | 0.1734 | | | 789 | |
Special | | December 21, 2022 | | December 31, 2022 | | January 30, 2023 | | 0.0400 | | | 182 | |
Monthly | | January 24, 2023 | | January 31, 2023 | | February 24, 2023 | | 0.1735 | | | 916 | |
Monthly | | February 22, 2023 | | February 28, 2023 | | March 29, 2023 | | 0.1733 | | | 1,024 | |
Monthly | | March 22, 2023 | | March 31, 2023 | | April 27, 2023 | | 0.1733 | | | 1,486 | |
| | | | | | | | $ | 1.0704 | | | $ | 5,655 | |
Distribution Reinvestment Plan
The Company has adopted a distribution reinvestment plan, pursuant to which the Company will reinvest all cash dividends declared by the Board on behalf of its shareholders who do not elect to receive their dividends in cash as provided below. As a result, if the Board authorizes, and the Company declares, a cash dividend or other distribution, then shareholders who have not opted out of the Company's distribution reinvestment plan will have their cash distributions automatically reinvested in additional shares, rather than receiving the cash dividend or other distribution. Distributions on fractional shares will be credited to each participating shareholder’s account to three decimal places.
Character of Distributions
The Company may fund its cash distributions to shareholders from any source of funds available to the Company, including but not limited to offering proceeds, net investment income from operations, capital gains proceeds from the sale of assets, dividends or other distributions paid to it on account of preferred and common equity investments in portfolio companies and expense support from the Adviser, which is subject to recoupment.
Through March 31, 2024, a portion of the Company’s distributions resulted from expense support from the Adviser, and future distributions may result from expense support from the Adviser, each of which is subject to repayment by the Company within three years from the date of payment. The purpose of this arrangement is to avoid distributions being characterized as a return of capital for U.S. federal income tax purposes. Shareholders should understand that any such distribution is not based solely on the Company’s investment performance, and can only be sustained if the Company achieves positive investment performance in future periods and/or the Adviser continues to provide expense support. Shareholders should also understand that the Company’s future repayments of expense support will reduce the distributions that they would otherwise receive. There can be no assurance that the Company will achieve the performance necessary to sustain these distributions, or be able to pay distributions at all.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Sources of distributions, other than net investment income and realized gains on a U.S. GAAP basis, include required adjustments to U.S. GAAP net investment income in the current period to determine taxable income available for distributions. The following tables reflect the sources of cash distributions on a U.S. GAAP basis that the Company has declared on its Common Shares for the six months ended March 31, 2024:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Class I | | Class S | | Class D |
Source of Distribution | | Per Share | | Amount | | Per Share | | Amount | | Per Share | | Amount |
Net investment income | | $ | 1.0384 | | | $ | 62,260 | | | $ | 0.9391 | | | $ | 27,441 | | | $ | 1.0126 | | | $ | 30 | |
Distributions in excess of net investment income | | 0.1616 | | | 9,274 | | | 0.1608 | | | 4,439 | | | 0.1580 | | | 4 | |
Total | | $ | 1.2000 | | | $ | 71,534 | | | $ | 1.0999 | | | $ | 31,880 | | | $ | 1.1706 | | | $ | 34 | |
The following tables reflect the sources of cash distributions on a U.S. GAAP basis that the Company has declared on its Common Shares for the six months ended March 31, 2023:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Class I | | Class S |
Source of Distribution | | Per Share | | Amount | | Per Share | | Amount |
Net investment income | | $ | 1.1162 | | | $ | 19,399 | | | $ | 0.9024 | | | $ | 4,614 | |
Distributions in excess of net investment income | | 0.0538 | | | 1,165 | | | 0.1680 | | | 1,041 | |
Total | | $ | 1.1700 | | | $ | 20,564 | | | $ | 1.0704 | | | $ | 5,655 | |
Share Repurchase Program
At the discretion of the Board of Trustees, during the quarter ended September 30, 2022 the Company commenced a share repurchase program pursuant to which the Company intends to offer to repurchase, in each quarter, up to 5% of Common Shares outstanding (either by number of shares or aggregate NAV) as of the close of the previous calendar quarter. The Board may amend or suspend the share repurchase program at any time if it deems such action to be in the best interest of shareholders. As a result, share repurchases may not be available each quarter. The Company intends to conduct such repurchase offers pursuant to tender offers in accordance with the requirements of Rule 13e-4 promulgated under the Securities Exchange Act of 1934, as amended, and the Investment Company Act. All shares purchased pursuant to the terms of each tender offer will be retired and thereafter will be authorized and unissued shares.
Under the share repurchase program, to the extent the Company offers to repurchase shares in any particular quarter, it is expected to repurchase shares at the expiration of the tender offer at a purchase price equal to the NAV per share as of the last calendar day of the applicable quarter (the “Valuation Date”), except that shares that have a prospective repurchase date that is within the one-year period following the original issue date of the shares will be subject to an early repurchase deduction of 2% of such NAV (an “Early Repurchase Deduction”). The one-year holding period will be deemed satisfied if the shares to be repurchased would have been outstanding for one year or longer as of the subscription closing date immediately following the applicable Valuation Date, which subscription closing date the Company deems the prospective repurchase date for the applicable offer. The Early Repurchase Deduction will be retained by the Company for the benefit of remaining shareholders.
During the six months ended March 31, 2024, the Company repurchased pursuant to such tender offers an aggregate of 616,810 Class I and 178,223 Class S shares. The following table presents the share repurchases completed during the six months ended March 31, 2024:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Repurchase Pricing Date | | Total Number of Shares Repurchased (all classes) | | Percentage of Outstanding Shares Repurchased (1) | | Price Paid Per Share | | Amount Repurchased (all classes)(2) |
December 31, 2023 | | 446,089 | | | 0.69 | % | | $ | 23.62 | | | $ | 10,526 | |
March 31, 2024 | | 348,944 | | | 0.41 | % | | 23.61 | | | 8,217 | |
_____________________
(1) Percentage is based on total shares as of the close of the previous calendar quarter.
(2) Amounts shown net of Early Repurchase Deduction, where applicable.
There were no share repurchases during the six months ended March 31, 2023.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Note 6. Borrowings
ING Credit Agreement
On March 25, 2022 (the “ING Closing Date”), the Company entered into a senior secured revolving credit agreement (the “ING Credit Agreement”) among the Company, as borrower, the lenders party thereto, and ING Capital LLC (“ING”), as administrative agent.
Effective on and as of May 25, 2022, the Company entered into an incremental commitment and assumption agreement (the “Incremental Commitment and Assumption Agreement”) among the Company, as borrower, the subsidiary guarantor party thereto (the “Subsidiary Guarantor”), ING, as administrative agent and issuing bank, Sumitomo Mitsui Banking Corporation and MUFG Bank, LTD, (together with Sumitomo Mitsui Banking Corporation, the “Assuming Lenders”). Pursuant to the Incremental Commitment and Assumption Agreement, among other things, each Assuming Lender (i) became a Lender (as defined in the ING Credit Agreement) under the ING Credit Agreement and (ii) agreed to make a Commitment (as defined in the ING Credit Agreement) to the Company in the amount of $150 million. The Incremental Commitment and Assumption Agreement increased the aggregate amount of Commitments under the ING Credit Agreement from $150 million to $450 million (the "Maximum Commitment"), subject to the lesser of (i) a borrowing base and (ii) the Maximum Commitment, and provided that, with respect to any lender, its individual commitment is not exceeded. The revolving credit facility has a four year availability period (the “Availability Period”) during which loans may be made and the ING Credit Agreement has a stated maturity dated that is five years from the ING Closing Date (the “Maturity Date”). Following the Availability Period the Company will be required in certain circumstances to prepay loans prior to the Maturity Date. The ING Credit Agreement provides for the issuance of letters of credit during the Availability Period in an aggregate amount of $25 million. Borrowings under the ING Credit Agreement may be used for general corporate purposes, including making investments and permitted distributions.
Effective on and as of October 6, 2022, the Company entered into a subsequent incremental commitment and assumption agreement (the “Subsequent Incremental Commitment and Assumption Agreement”) among the Company, as borrower, the Subsidiary Guarantor, ING, as administrative agent and issuing bank, and Apple Bank For Savings, as an Assuming Lender. Pursuant to the Subsequent Incremental Commitment and Assumption Agreement, Apple Bank For Savings (i) became a Lender under the ING Credit Agreement and (ii) agreed to make a Commitment to the Company in the amount of $40 million. The Subsequent Incremental Commitment and Assumption Agreement increased the aggregate amount of Commitments under the ING Credit Agreement from $450 million to $490 million.
Effective on and as of June 28, 2023 (the “New Effective Date”), the Company entered into Amendment No. 1 (the “ING Credit Agreement Amendment”) to the ING Credit Agreement. As a result of the ING Credit Agreement Amendment, the ING Credit Agreement provides for a senior secured revolving credit facility of up to $1,110 million (the “Increased Maximum Commitment”), increased from $490 million, subject to the lesser of (i) a borrowing base and (ii) the Increased Maximum Commitment, and provided that, with respect to any lender, its individual commitment is not exceeded. The revolving credit facility has a four year availability period (the “New Availability Period”) commencing from the New Effective Date during which loans may be made and a stated maturity date that is five years from the New Effective Date (the “New Maturity Date”). Following the New Availability Period, the Company will be required in certain circumstances to prepay loans prior to the New Maturity Date. The ING Credit Agreement provides for the issuance of letters of credit during the New Availability Period in an aggregate amount of $25 million. Borrowings under the ING Credit Agreement may be used for general corporate purposes, including making investments and permitted distributions.
Effective on and as of August 15, 2023, the Company entered into a subsequent incremental commitment and assumption agreement (the “Second Subsequent Incremental Commitment and Assumption Agreement”) among the Company, as borrower, the Subsidiary Guarantor, ING, as administrative agent and issuing bank, and Deutsche Bank AG, New York Branch and US Bank National Association, as Assuming Lenders. Pursuant to the Subsequent Incremental Commitment and Assumption Agreement, the Assuming Lenders (i) became Lenders under the ING Credit Agreement and (ii) agreed to make a Commitment to the Company in the aggregate amount of $75 million. The Second Subsequent Incremental Commitment and Assumption Agreement increased the aggregate amount of Commitments under the ING Credit Agreement from $1,110 million to $1,185 million.
All obligations under the ING Credit Agreement are secured by a first-priority security interest (subject to certain exceptions) in substantially all of the present and future property and assets of the Company and of the sole current and certain future subsidiaries of the Company and guaranteed by such subsidiaries.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Borrowings under the ING Credit Agreement shall be denominated in U.S. Dollars and bore, prior to the New Effective Date, interest at a rate per annum equal to either (1) SOFR, as adjusted, plus 1.875% per annum or (2) the alternative base rate (which is the greatest of the (a) prime rate, (b) the federal funds effective rate plus ½ of 1%, (c) the overnight bank funding rate plus ½ of 1%, (d) certain rates based on SOFR and (e) 0) (“ABR”) plus 0.875% per annum. On and after the New Effective Date, borrowings under the ING Credit Agreement bear interest at a rate per annum equal to either (1) the SOFR, as adjusted, plus 2.15% per annum, or, following the first year after the New Effective Date, plus 2.05% per annum if the Company has and maintains an investment grade credit rating or (2) the alternative base rate (which is the greatest of the (a) prime rate, (b) the federal funds effective rate plus ½ of 1%, (c) the overnight bank funding rate plus ½ of 1%, (d) certain rates based on SOFR and (e) 0) (“ABR”) plus 1.15% per annum or, following the first year after the New Effective Date, plus 1.05% per annum if the Company has and maintains investment grade credit rating. The Company may elect either an ABR or SOFR borrowing at each drawdown request, and loans may be converted from one rate to another at any time at the Company’s option, subject to certain conditions. Prior to the New Effective Date, the Company paid a commitment fee at a rate of 0.375% per annum on the daily unused portion of the aggregate commitments under the ING Credit Agreement. On and after the New Effective Date, the Company will pay a commitment fee at a rate of 0.375% per annum on the daily unused portion of the aggregate commitments under the ING Credit Agreement, subject to increase to 1.00% per annum on the daily unused amount if the daily unused amount is greater than or equal to 65% of the aggregate commitments under the ING Credit Agreement.
At any time during the New Availability Period, the Company may propose an increase in the Increased Maximum Commitment to an amount not to exceed the greater of (a) $1,250.0 million and (b) 150% of shareholders’ equity as of the date on which such increased amount is to be effective, subject to certain conditions, including the consent of the lenders to increase their commitments and of ING.
The Company has made customary representations and warranties and is required to comply with various affirmative and negative covenants, reporting requirements and other customary requirements for similar credit facilities. Borrowings under the ING Credit Agreement are subject to the leverage restrictions contained in the Investment Company Act.
The ING Credit Agreement contains customary events of default for similar financing transactions. Upon the occurrence and during the continuation of an event of default, ING may terminate the commitments and declare the outstanding loans and all other obligations under the ING Credit Agreement immediately due and payable.
As of March 31, 2024 and September 30, 2023, the Company had $450.0 million and $320.0 million outstanding under the ING Credit Agreement. For the six months ended March 31, 2024 and March 31, 2023, the Company’s borrowings under the ING Credit Agreement bore interest at a weighted average rate of 7.69% and 6.21%, respectively. The Company recorded $9,393 and $18,710 of interest expense (inclusive of fees) related to the ING Credit Agreement for the three and six months ended March 31, 2024, respectively. The Company recorded $3,212 and $6,018 of interest expense (inclusive of fees) related to the ING Facility for the three and six months ended March 31, 2023, respectively.
JPM SPV Facility
On February 24, 2023 (the “JPM Closing Date”), the Company entered into a loan and security agreement (as amended, the “JPM Loan and Security Agreement”) among OSCF Lending SPV, LLC (“OSCF Lending SPV”), a wholly owned subsidiary of the Company, as borrower, the Company, as parent and servicer, Citibank, N.A., as collateral agent and securities intermediary, Virtus Group, LP, as collateral administrator, the lenders party thereto, and JPMorgan Chase Bank, National Association (“JPM”), as administrative agent, pursuant to which JPM agreed to extend credit to OSCF Lending SPV in an aggregate principal amount up to $150 million at any one time outstanding. Effective on and as of July 5, 2023, the Company entered into Amendment No. 1 (the “JPM Loan and Security Agreement Amendment”) to the JPM Loan and Security Agreement, pursuant to which JPM has increased its commitment to extend credit to OSCF Lending SPV to an aggregate principal amount up to $300 million (the “JPM Maximum Commitment”).
The JPM Loan and Security Agreement provides for a senior secured revolving credit facility that has a three-year reinvestment period (the “JPM Availability Period”) and a stated maturity date that is five years after the JPM Closing Date. Subject to certain conditions, including consent of the lenders and JPM, as administrative agent, at any time during the JPM Availability Period, OSCF Lending SPV may propose one or more increases in the JPM Maximum Commitment up to an amount not to exceed $500 million. Borrowings under the JPM Loan and Security Agreement shall be denominated in U.S. Dollars and bear interest at a rate per annum equal to the forward-looking term rate with a three-month tenor, based on the secured overnight financing rate as administered by the Federal Reserve Bank of New York (or a successor administrator), and as published by CME Group Benchmark Administration Limited (or a successor administrator), plus 2.95%.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
The obligations of OSCF Lending SPV under the JPM Loan and Security Agreement are secured by all of the assets held by OSCF Lending SPV, including certain loans sold or to be sold or transferred or to be transferred by the Company to OSCF Lending SPV (such loans, the “Loans”) pursuant to the terms of the Sale and Participation Agreement, dated as of the JPM Closing Date (the “JPM Sale Agreement” and, together with the JPM Loan and Security Agreement, the “JPM Agreements”), between OSCF Lending SPV, as buyer, and the Company, as seller, pursuant to which the Company will sell Loans to OSCF Lending SPV from time to time. Under the Agreements, the Company and OSCF Lending SPV, as applicable, have made representations and warranties regarding the Loans, as well as their businesses, and are required to comply with various covenants, servicing procedures, limitations on the disposition of Loans, reporting requirements and other customary requirements for similar revolving funding facilities.
Borrowings under the JPM Loan and Security Agreement are subject to various covenants under the JPM Agreements as well as the asset coverage requirement contained in the Investment Company Act.
As of March 31, 2024, OSCF Lending SPV had $220.0 million outstanding under the JPM Loan and Security Agreement. For the six months ended March 31, 2024 and March 31, 2023, OSCF Lending SPV’s borrowings under the JPM Loan and Security Agreement bore interest at a weighted average rate of 8.55% and 7.80%, respectively. The Company recorded $4,237 and $7,829 of interest expense (inclusive of fees) related to the JPM Loan and Security Agreement for the three and six months ended March 31, 2024, respectively. The Company recorded $361 of interest expense (inclusive of fees) related to the JPM Loan and Security Agreement for the three and six months ended March 31, 2023.
SMBC SPV Facility
Effective on and as of September 29, 2023 (the “SMBC Closing Date”), the Company entered into a loan and security agreement (as amended, the “SMBC Loan and Security Agreement”) among OSCF Lending III SPV, LLC (“OSCF Lending III SPV”), a wholly owned subsidiary of the Company, as borrower, the Company, as transferor and servicer, Citibank, N.A., as the account bank, Virtus Group, LP, as collateral custodian, the lenders party thereto, and Sumitomo Mitsui Banking Corporation (“SMBC”), as administrative agent and collateral agent, pursuant to which SMBC agreed to extend credit to OSCF Lending III SPV in an aggregate principal amount up to $150 million at any one time outstanding.
Effective on and as of December 22, 2023, the Company entered into the First Amendment to Loan and Servicing Agreement among OSCF Lending III SPV, the Company, Citibank, N.A., Virtus Group, LP and SMBC, which amended the SMBC Loan and Security Agreement to adjust the concentration limits set forth therein for certain large middle market loan assets that do not contain a maintenance covenant.
The SMBC Loan and Security Agreement provides for a senior secured revolving credit facility that has a three-year reinvestment period (the “SMBC Availability Period”) and a stated maturity date that is five years after the SMBC Closing Date. Borrowings under the SMBC Loan and Servicing Agreement shall be denominated in U.S. Dollars and bear interest at a rate per annum equal to, at the request of OSCF Lending III SPV, either (1) SOFR plus 2.45% up to and including 3.00% depending on the collateral securing the facility or (2) the base rate (which is the greatest of the (a) prime rate, (b) federal funds effective rate plus 1/2 of 1%, (c) zero (0%) and (d) one month SOFR plus 1%) plus 1.45% up to and including 2.00% depending on the collateral securing the facility. The Company is required to pay a non-usage fee of 0.50% on undrawn borrowings during the first three months of the facility and thereafter 0.50% or 0.75% during the remainder of the SMBC Availability Period depending on amounts borrowed by the Company under the facility.
The obligations of OSCF Lending III SPV under the SMBC Loan and Security Agreement are secured by all of the assets held by OSCF Lending III SPV, including certain loans sold or to be sold or transferred or to be transferred by the Company to OSCF Lending SPV (such loans, the “SMBC Transferred Loans”) pursuant to the terms of the Sale and Participation Agreement, dated as of the SMBC Closing Date (the “SMBC Sale Agreement” and, together with the SMBC Loan and Security Agreement, the “SMBC Agreements”), between OSCF Lending III SPV, as buyer, and the Company, as seller, pursuant to which the Company will sell SMBC Transferred Loans to OSCF Lending III SPV from time to time. Under the SMBC Agreements, the Company and OSCF Lending SPV, as applicable, have made representations and warranties regarding the SMBC Transferred Loans, as well as their businesses, and are required to comply with various covenants, servicing procedures, limitations on the disposition of SMBC Transferred Loans, reporting requirements and other customary requirements for similar revolving funding facilities.
Borrowings under the SMBC Loan and Security Agreement are subject to various covenants under the SMBC Agreements as well as the asset coverage requirement contained in the Investment Company Act.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
As of March 31, 2024, the Company had $50.0 million outstanding under the SMBC Loan and Security Agreement. For the six months ended March 31, 2024, the Company’s borrowings under the SMBC Loan and Security Agreement bore interest at a weighted average rate of 8.26%. The Company recorded $655 and $942 of interest expense (inclusive of fees) related to the SMBC Loan and Security Agreement for the three and six months ended March 31, 2024, respectively.
CIBC SPV Facility
Effective on and as of November 21, 2023 (the “CIBC Closing Date”), the Company entered into a loan and servicing agreement (as amended, the “CIBC Loan and Servicing Agreement”) among OSCF Lending V SPV, LLC (“OSCF Lending V SPV”), a wholly owned subsidiary of the Company, as borrower, the Company, as transferor and servicer, Computershare Trust Company, N.A., as securities intermediary, collateral custodian, collateral agent and collateral administrator, the lenders party thereto, and Canadian Imperial Bank of Commerce (“CIBC”), as administrative agent, pursuant to which CIBC agreed to extend credit to OSCF Lending V SPV in an aggregate principal amount up to $150 million (the “ CIBC Maximum Commitment”) at any one time outstanding.
The CIBC Loan and Servicing Agreement provides for a senior secured revolving credit facility that has a two-year reinvestment period (the “CIBC Availability Period”) and a stated maturity date that is two years after the CIBC Closing Date. Subject to certain conditions, including consent of the lenders and CIBC as administrative agent, during the CIBC Availability Period, OSCF Lending V SPV may propose up to four increases in the CIBC Maximum Commitment up to an amount not to exceed $500 million in the aggregate.
Borrowings under the CIBC Loan and Servicing Agreement shall be denominated in U.S. Dollars and bear interest at a rate per annum equal to, at the request of OSCF Lending V SPV, as borrower, either (1) the SOFR, plus 1.95% or (2) the base rate (which is the greatest of the (a) prime rate, (b) federal funds effective rate plus 1/2 of 1%, (c) zero (0%) and (d) one month SOFR plus 1%) plus 0.95%. The applicable spread otherwise in effect shall be increased by 2% per annum after the stated maturity date or when an event of default has occurred and is continuing. The Company is required to pay a non-usage fee of 0.50% on undrawn borrowings beginning six months after the CIBC Closing Date.
The obligations of OSCF Lending V SPV under the CIBC Loan and Security Agreement are secured by all of the assets held by OSCF Lending V SPV, including loans it has made or acquired (the “OSCF Lending V SPV Loans”). Under the Loan and Servicing Agreement, OSCF Lending V SPV, as borrower, and the Company, as servicer, have made representations and warranties regarding the OSCF Lending V SPV Loans, as well as the borrower’s and servicer’s businesses, and are required to comply with various covenants, servicing procedures, limitations on the disposition of the OSCF Lending V SPV Loans, reporting requirements and other customary requirements for similar revolving funding facilities.
The CIBC Loan and Servicing Agreement contains customary events of default for similar financing transactions. Upon the occurrence and during the continuation of an event of default, CIBC, as administrative agent, may terminate the commitments and declare the outstanding borrowings and all other obligations under the CIBC Loan and Servicing Agreement immediately due and payable.
Borrowings under the CIBC Loan and Servicing Agreement are subject to various covenants as well as the asset coverage requirement contained in the Investment Company Act.
As of March 31, 2024, the Company had $125.0 million outstanding under the CIBC Loan and Servicing Agreement. For the six months ended March 31, 2024, the Company’s borrowings under the CIBC Loan and Servicing Agreement bore interest at a weighted average rate of 7.38%. The Company recorded $774 and $849 of interest expense (inclusive of fees), related to the CIBC Loan and Servicing Agreement for the three and six months ended March 31, 2024, respectively.
DBNY SPV Facility
On February 15, 2024 (the “DBNY Closing Date”), the Company entered into a loan financing and servicing agreement (the “DBNY Loan Financing and Servicing Agreement”), among OSCF Lending IV SPV, LLC (“OSCF Lending IV SPV”), a wholly owned subsidiary of the Company, as borrower, the Company, as servicer and equityholder, the lenders party thereto, Deutsche Bank AG, New York Branch (“DBNY”), as facility agent, the other agents parties thereto and Deutsche Bank National Trust Company, as collateral agent and collateral custodian, pursuant to which DBNY has agreed to extend credit to
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
OSCF Lending IV SPV in an aggregate principal amount up to $300 million (the “DBNY Facility Amount”) at any one time outstanding.
The DBNY Loan Financing and Servicing Agreement provides for a senior secured revolving credit facility that has a three-year reinvestment period (the “DBNY Availability Period”). Borrowings under the DBNY Loan Financing and Servicing Agreement shall be denominated in EUR, AUD, CAD, GBP or USD and bear interest at a rate per annum equal to the sum of, for any accrual period and any lender, (i) the applicable margin and (ii) the cost of funds rate for such accrual period and such lender. The applicable margin will be 2.40% per annum prior to the end of the DBNY Availability Period and 3.05% per annum thereafter; provided that, on and after the occurrence of any Event of Default (as defined in the DBNY Loan Financing and Servicing Agreement), the applicable margin shall be increased by 2.00% per annum. The cost of funds rate will be, (a) for each conduit lender, the lower of (x) such conduit lender’s Commercial Paper Rate (as defined in the DBNY Loan Financing and Servicing Agreement) and (y) the SOFR for a three-month tenor as quoted by CME Group Benchmark Administration Limited (which shall in no event be lower than 0.25%), and (b) for each committed lender, the base rate determined by reference to the applicable benchmark index depending on the currency denomination of the advances.
The obligations of OSCF Lending IV SPV under the DBNY Loan Financing and Servicing Agreement are secured by all of the assets held by OSCF Lending IV SPV, including loans it has made or acquired (the “OSCF Lending IV SPV Loans”), except for certain Retained Interests (as defined in the DBNY Loan Financing and Servicing Agreement). Under the Loan Financing and Servicing Agreement, OSCF Lending IV SPV, as borrower, and the Company, as servicer, have made representations and warranties regarding the OSCF Lending IV SPV Loans, as well as our businesses, and are required to comply with various covenants, servicing procedures, limitations on the disposition of the OSCF Lending IV SPV Loans, reporting requirements and other customary requirements for similar revolving funding facilities. Borrowings under the DBNY Loan Financing and Servicing Agreement are subject to various covenants under the DBNY Loan Financing and Servicing Agreement.
The DBNY Loan Financing and Servicing Agreement contains customary events of default for similar financing transactions. Upon the occurrence and during the continuation of an event of default, DBNY, as facility agent, may terminate the commitments and declare the outstanding borrowings and all other obligations under the DBNY Loan Financing and Servicing Agreement immediately due and payable.
Subject to certain conditions, including consent of DBNY, as facility agent, OSCF Lending IV SPV may (i) propose increases in the DBNY Facility Amount up to an amount not to exceed $1 billion in the aggregate, (ii) add additional lender groups and/or (iii) increase the commitment of any lender group with the consent of such lender group. The DBNY Facility Amount may, subject to certain conditions, including consent of DBNY, as facility agent, be so increased to $400 million on the earlier of (x) the three-month anniversary of the DBNY Closing Date and (y) the date selected by OSCF Lending IV SPV (via written notice to DBNY, as facility agent) to so increase the DBNY Facility Amount.
As of March 31, 2024, no amounts were outstanding under the DBNY Loan Financing and Serving Agreement. The Company recorded $431 of interest expense (inclusive of fees) related to the DBNY Loan Financing and Serving Agreement for the six months ended March 31, 2024.
MS SPV Facility
On February 23, 2024 (the “MS Closing Date”), the Company entered into a loan and servicing agreement (the “MS Loan and Servicing Agreement”), among OSCF Lending II SPV, LLC (“OSCF Lending II SPV”), a wholly owned subsidiary of us, as borrower, the Company, as transferor and servicer, Citibank, N.A., as the collateral agent, account bank and collateral custodian, Virtus Group, LP, as collateral administrator, each of the lenders from time to time party thereto, and Morgan Stanley Asset Funding, Inc. (“MS”), as the administrative agent, pursuant to which MS has agreed to extend credit to OSCF Lending II SPV in an aggregate principal amount up to $200 million (the “MS Maximum Commitment”) at any one time outstanding.
The MS Loan and Servicing Agreement provides for a senior secured revolving credit facility that has a three-year reinvestment period (the “MS Availability Period”) and a stated maturity date that is five years after the MS Closing Date. Advances under the MS Loan and Servicing Agreement shall be denominated in U.S. Dollars and bear interest at a rate per annum equal to SOFR plus 2.35% during the MS Availability Period and 2.85% thereafter; provided that the applicable margin shall be increased by 2.00% per annum (i) during the existence of a Specified Event of Default (as defined in the MS Loan and Servicing Agreement), (ii) upon written notice from MS, as administrative agent (at the direction of required lenders) to OSCF
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Lending II SPV and us during the existence of any other Event of Default (as defined in the MS Loan and Servicing Agreement) or (iii) after a Facility Maturity Date (as defined in the MS Loan and Servicing Agreement).
The obligations of OSCF Lending II SPV under the MS Loan and Servicing Agreement are secured by all of the assets held by OSCF Lending II SPV, including certain loans it has made or acquired (such loans, the “OSCF Lending II SPV Loans”), except for certain Retained Interests (as defined in the MS Loan and Servicing Agreement). Under the MS Loan and Servicing Agreement, OSCF Lending II SPV, as borrower, and the Company, as servicer, have made representations and warranties regarding the OSCF Lending II SPV Loans, as well as the Company's businesses, and are required to comply with various covenants, servicing procedures, limitations on the disposition of Loans, reporting requirements and other customary requirements for similar revolving funding facilities.
The MS Loan and Servicing Agreement contains customary events of default for similar financing transactions. Upon the occurrence and during the continuation of an event of default, MS, as administrative agent may terminate the commitments and declare the outstanding loans and all other obligations under the MS Loan and Servicing Agreement immediately due and payable.
Borrowings under the MS Loan and Servicing Agreement are subject to various covenants under the MS Loan and Servicing Agreement as well as the asset coverage requirement contained in the Investment Company Act.
As of March 31, 2024, no amounts were outstanding under the MS Loan and Serving Agreement. The Company recorded $85 of interest expense (inclusive of fees) related to the MS Loan and Serving Agreement for the six months ended March 31, 2024.
2028 Unsecured Notes
On November 14, 2023, the Company issued $350 million aggregate principal amount of its 8.400% Notes due 2028 (the “2028 Unsecured Notes”) in a transaction exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act pursuant to an indenture, dated as of November 14, 2023 (the “Base Indenture”), between the Company and Deutsche Bank Trust Company Americas, as trustee (the “Notes Trustee”), and (2) a first supplemental indenture (the “First Supplemental Indenture” and together with the Base Indenture, the “Indenture”) to the Base Indenture.
The 2028 Unsecured Notes mature on November 14, 2028, unless previously redeemed or repurchased in accordance with their terms. The 2028 Unsecured Notes bear interest at a rate of 8.400% per year payable semi-annually in arrears on May 14 and November 14 of each year, commencing on May 14, 2024. The 2028 Unsecured Notes are the Company’s direct, unsecured obligations and rank senior in right of payment to its future indebtedness that is expressly subordinated in right of payment to the 2028 Unsecured Notes; equal in right of payment to its existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of its secured indebtedness (including existing unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by its subsidiaries, financing vehicles or similar facilities.
The Indenture contains certain covenants, including a covenant requiring the Company to comply with Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act, or any successor provisions, but giving effect to any exemptive relief granted to the Company by the SEC and to provide financial information to the holders of the 2028 Unsecured Notes and the Notes Trustee if the Company should no longer be subject to the reporting requirements under the Exchange Act. These covenants are subject to important limitations and exceptions that are set forth in the Indenture.
In connection with the 2028 Unsecured Notes, the Company entered into an interest rate swap to more closely align the interest rate payable on the 2028 Unsecured Notes with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 8.400% and pays a floating interest rate of the three-month SOFR plus 4.0405% on a notional amount of $350 million.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
The below table presents the components of the carrying value of the 2028 Notes as of March 31, 2024:
| | | | | | | | |
($ in millions) | | |
Principal | | $ | 350.0 | |
Unamortized financing costs | | (4.0) | |
Unaccreted discount | | (1.6) | |
Interest rate swap fair value adjustment | | 2.9 | |
Net carrying value | | $ | 347.3 | |
Fair Value | | $ | 372.1 | |
Market quotes are utilized as of the valuation date to estimate the fair value of the 2028 Notes, which are included in Level 2 of the hierarchy.
The below table presents the components of interest and other debt expenses related to the 2028 Notes for the three and six months ended March 31, 2024:
| | | | | | | | | | | | | | |
($ in millions) | | Three months ended March 31, 2024 | | Six months ended March 31, 2024 |
Coupon interest | | $ | 7.4 | | | $ | 11.1 | |
Amortization of financing costs and discount | | 0.3 | | | 0.5 | |
Effect of interest rate swap | | 0.9 | | | 1.5 | |
Total interest expense | | $ | 8.6 | | | $ | 13.1 | |
Coupon interest rate (net of effect of interest rate swaps) | | 9.490 | % | | 9.490 | % |
Note 7. Taxable/Distributable Income
Taxable income differs from net increase (decrease) in net assets resulting from operations primarily due to: (1) unrealized appreciation (depreciation) on investments and foreign currency, as gains and losses are not included in taxable income until they are realized, (2) organizational and deferred offering costs and (3) the capital gains incentive fee accrual.
Presented below is a reconciliation of net increase (decrease) in net assets resulting from operations to taxable income for the three and six months ended March 31, 2024 and 2023:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, 2024 | | Three months ended March 31, 2023 | | Six months ended March 31, 2024 | | Six months ended March 31, 2023 |
Net increase (decrease) in net assets resulting from operations | $ | 56,477 | | | $ | 18,063 | | | $ | 109,411 | | | $ | 24,607 | |
Net unrealized (appreciation) depreciation | 655 | | | (8,054) | | | (16,264) | | | (5,212) | |
Book/tax difference due to capital gains incentive fees | 319 | | | — | | | 2,460 | | | — | |
Other book/tax differences | (724) | | | 1,018 | | | (5,259) | | | 596 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Taxable income (1) | $ | 56,727 | | | $ | 11,027 | | | $ | 90,348 | | | $ | 19,991 | |
__________________
(1)The Company's taxable income for the three and six months ended March 31, 2024 is an estimate and will not be finally determined until the Company files its tax return for the fiscal year ending September 30, 2024. The final taxable income may be different than the estimate.
For the three months ended March 31, 2024, the Company recognized a total provision for income tax expense of $144, which was comprised of a current tax expense of $144.
For the six months ended March 31, 2024, the Company recognized a total provision for income tax expense of $385, which was comprised of a current tax expense of $385.
As of September 30, 2023, the Company's last tax year end, the components of accumulated overdistributed earnings on a tax basis were as follows:
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
| | | | | |
Undistributed ordinary income, net | $ | (7,672) | |
Net realized capital losses | (2,585) | |
Unrealized gains, net | 2,508 | |
Accumulated overdistributed earnings | $ | (7,749) | |
The aggregate cost of investments for U.S. federal income tax purposes was $1,926.3 million as of September 30, 2023. As of September 30, 2023, the aggregate gross unrealized appreciation for all investments in which there was an excess of value over cost for U.S. federal income tax purposes was $23.8 million. As of September 30, 2023, the aggregate gross unrealized depreciation for all investments in which there was an excess of cost for U.S. federal income tax purposes over value was $21.3 million. Net unrealized appreciation based on the aggregate cost of investments for U.S. federal income tax purposes was $2.5 million.
Note 8. Concentration of Credit Risks
The Company deposits its cash with financial institutions and at times such balances may be in excess of the FDIC insurance limit. The Company limits its exposure to credit loss by depositing its cash with high credit quality financial institutions and monitoring their financial stability.
Note 9. Related Party Transactions
Investment Advisory Agreement
Effective as of February 3, 2022, the Company has entered into the Investment Advisory Agreement with the Adviser. The Company will pay the Adviser a fee for its services consisting of two components: a management fee and an incentive fee.
Management Fee
Under the Investment Advisory Agreement, the management fee is payable monthly in arrears at an annual rate of 1.25% of the value of the Company's net assets as of the beginning of the first calendar day of the applicable month. For purposes of calculating the management fee, net assets means the Company's total net assets determined on a consolidated basis in accordance with GAAP. For the first calendar month in which the Company had operations, net assets were measured as of June 1, 2022, the date on which the Company broke escrow. In addition, the Adviser waived its management fee through November 2022, the first six months following June 1, 2022, the date on which the Company broke escrow for its continuous offering. For the three and six months ended March 31, 2024, base management fees were $7,242 and $12,998, respectively, none of which was waived. For the three months ended March 31, 2023, base management fees were $1,970, none of which was waived. For the six months ended March 31, 2023, base management fees were $3,366, of which $877 was waived.
Incentive Fee
The Incentive Fee consists of two parts: the Investment Income Incentive Fee and the Capital Gains Incentive Fee (each defined below) (collectively referred to as the "Incentive Fee").
Investment Income Incentive Fee
The Investment Income Incentive Fee is calculated based on the Company’s Pre-Incentive Fee Net Investment Income, which means consolidated interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies) accrued during the calendar quarter, minus the Company's operating expenses accrued for the quarter (including the management fee, expenses payable under the Administration Agreement entered into between the Company and the Administrator, and any interest expense or fees on any credit facilities or outstanding debt and dividends paid on any issued and outstanding preferred shares, but excluding the Incentive Fee and any distribution and/or shareholder servicing fees).
Pre-Incentive Fee Net Investment Income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with payment-in-kind interest and zero-coupon securities), accrued income that has not
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
yet been received in cash. For the avoidance of doubt, Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. The impact of any expense support payments and recoupments are also excluded from Pre-Incentive Fee Net Investment Income.
Pre-Incentive Fee Net Investment Income, expressed as a rate of return on the value of the Company's net assets at the end of the immediately preceding quarter, is compared to a hurdle of 1.25% per quarter (5.0% annualized) (the “Hurdle Rate”). The Company will pay the Adviser an incentive fee quarterly in arrears with respect to the Company's Pre-Incentive Fee Net Investment Income in each calendar quarter as follows:
•Hurdle Rate Return: No incentive fee based on Pre-Incentive Fee Net Investment Income in any calendar quarter in which the Company's Pre-Incentive Fee Net Investment Income does not exceed the Hurdle Rate;
•Catch-Up: 100% of the Pre-Incentive Fee Net Investment Income, if any, that exceeds the Hurdle Rate but is less than a 1.4286% (5.714% annualized) rate of return in any such calendar quarter (the “Catch-Up”), which is intended to provide the Adviser with approximately 12.5% of the Pre-Incentive Fee Net Investment Income as if the Hurdle Rate did not apply, if the Pre-Incentive Fee Net Investment Income exceeds the Hurdle Rate in any calendar quarter; and
•87.5/12.5 Split: 12.5% of the Pre-Incentive Fee Net Investment Income, if any, that exceeds a 1.4286% (5.714% annualized) rate of return in such calendar quarter so that once the Hurdle Rate is reached and the Catch-Up is achieved, 12.5% of the Pre-Incentive Fee Net Investment Income thereafter is allocated to
the Adviser.
The Adviser waived the Investment Income Incentive Fee through November 2022, the first six months following June 1, 2022, the date on which the Company broke escrow for its continuous offering.
For the three and six months ended March 31, 2024, the Investment Income Incentive Fee was $7,980 and $13,734, none of which was waived. For the three months ended March 31, 2023, the Investment Income Incentive Fee was $1,733, none of which was waived. For the six months ended March 31, 2023, the Investment Income Incentive Fee was $2,973, of which $765 was waived.
Capital Gains Incentive Fee
In addition to the Investment Income Incentive Fee described above, commencing on September 30, 2022, the Adviser is entitled to receive a Capital Gains Incentive Fee (as defined below) under the Investment Advisory Agreement. The Capital Gains Incentive Fee is determined and payable in arrears as of the end of each fiscal year. The Capital Gains Incentive Fee is equal to 12.5% of the realized capital gains, if any, on a cumulative basis from inception through the end of each fiscal year, computed net of all realized capital losses on a cumulative basis and unrealized capital depreciation, less the aggregate amount of any previously paid Capital Gains Incentive Fee, provided, that the Capital Gains Incentive Fee determined as of September 30, 2022 is calculated for a period of shorter than 12 calendar months to take into account any realized capital gains computed net of all realized capital losses and unrealized capital depreciation from the date of inception through the end of the fiscal year 2022 (the “Capital Gains Incentive Fee”). The payment obligation with respect to the Capital Gains Incentive Fee is allocated in the same manner across the Class S shares, Class D shares and Class I shares. As of March 31, 2024, the Company did not incur any Capital Gains Incentive Fees under the Investment Advisory Agreement.
Although the Capital Gains Incentive Fee due to the Adviser is not payable until it is contractually due based on the Investment Advisory Agreement, the Company accrues this component at the end of each reporting period based on the Company’s realized capital gains, if any, on a cumulative basis from inception through the end of each reporting period, computed net of all realized capital losses on a cumulative basis and unrealized capital depreciation, less the aggregate amount of any previously paid Capital Gains Incentive Fee, as contractually included in the calculation of the Capital Gains Incentive Fee, plus the cumulative amount of unrealized capital appreciation. If such amount is positive at the end of a period, then the Company will accrue an incentive fee equal to 12.5% of such amount. If such amount is negative, then there will be no accrual for such period or an appropriate reduction in any amount previously accrued. U.S. GAAP requires that the Capital Gains Incentive Fee accrual consider cumulative unrealized capital appreciation in the calculation, as a Capital Gains Incentive Fee would be payable if such unrealized capital appreciation were realized. There can be no assurance that such unrealized capital appreciation will be realized in the future. For the three and six months ended March 31, 2024, there were $319 and $2,460 of accrued Capital Gains Incentive Fees. For the three and six months ended March 31, 2023, there were no accrued Capital Gains Incentive Fees. As of March 31, 2024, there were $2,737 of accrued Capital Gains Incentive Fees accrued since inception.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Administration Agreement
Effective as of February 3, 2022, the Company has entered into an Administration Agreement (as amended and restated, the “Administration Agreement”) with Oaktree Fund Administration, LLC (the “Administrator”), an affiliate of the Adviser. Pursuant to the Administration Agreement, the Administrator furnishes the Company with office facilities (certain of which are located in buildings owned by a Brookfield affiliate), equipment and clerical, bookkeeping and record keeping services at such facilities. Under the Administration Agreement, the Administrator performs, or oversees the performance of, the Company’s required administrative services, which include, among other things, providing assistance in accounting, legal, compliance, operations, technology and investor relations, and being responsible for the financial records that the Company is required to maintain and preparing reports to shareholders and reports filed with the SEC. In addition, the Administrator assists the Company in determining and publishing the NAV, overseeing the preparation and filing of tax returns and the printing and dissemination of reports to the Company’s shareholders, and generally overseeing the payment of expenses and the performance of administrative and professional services rendered to the Company by others.
Payments under the Administration Agreement are equal to an amount that reimburses the Administrator for its costs and expenses incurred in performing its obligations under the Administration Agreement and providing personnel and facilities. The Company bears all of the costs and expenses of any sub-administration agreements that the Administrator enters into.
For the avoidance of doubt, the Company bears its allocable portion of the costs of the compensation, benefits, and related administrative expenses (including travel expenses) of the Company’s officers who provide operational and administrative services under the Administration Agreement, their respective staffs and other professionals who provide services to the Company (including, in each case, employees of the Administrator or an affiliate) who assist with the preparation, coordination, and administration of the foregoing or provide other “back office” or “middle office” financial or operational services to the Company. The Company reimburses the Administrator (or its affiliates) for an allocable portion of the compensation paid by the Administrator (or its affiliates) to such individuals (based on a percentage of time such individuals devote, on an estimated basis, to the Company’s business and affairs and to acting on the Company’s behalf). The Company's Board reviews the fees payable under the Administration Agreement to determine that these fees are reasonable and comparable to administrative services charged by unaffiliated third parties.
For the three months ended March 31, 2024, the Company incurred $543 of expenses under the Administration Agreement, of which $417 was included in administrator expense, $101 was included in general and administrative expenses and $25 was included in organization expenses and amortization of continuous offering costs on the Consolidated Statements of Operations. For the six months ended March 31, 2024, the Company incurred $912 of expenses under the Administration Agreement, of which $719 was included in administrator expense, $162 was included in general and administrative expenses and $31 was included in organization expenses and amortization of continuous offering costs on the Consolidated Statements of Operations. For the three months ended March 31, 2023, the Company incurred $364 of expenses under the Administration Agreement, of which $300 was included in administrator expense and $64 was included in general and administrative expenses on the Consolidated Statements of Operations. For the six months ended March 31, 2023, the Company incurred $540 of expenses under the Administration Agreement, of which $444 was included in administrator expense, $88 was included in general and administrative expenses and $8 was included in organization expenses and amortization of offering costs on the Consolidated Statements of Operations.
Certain Terms of the Investment Advisory Agreement and Administration Agreement
Each of the Investment Advisory Agreement and the Administration Agreement is effective as of February 3, 2022. Unless earlier terminated as described below, each of the Investment Advisory Agreement and the Administration Agreement will remain in effect for a period of two years from the date it first becomes effective and will remain in effect from year-to-year thereafter if approved annually by a majority of the Board or by the holders of a majority of the Company’s outstanding voting securities and, in each case, a majority of the independent Trustees. The Company may terminate the Investment Advisory Agreement or the Administration Agreement, without payment of any penalty, upon 60 days’ written notice. In addition, without payment of any penalty, the Adviser may terminate the Investment Advisory Agreement upon 120 days’ written notice and the Administrator may terminate the Administration Agreement upon 60 days’ written notice. The Investment Advisory Agreement will automatically terminate in the event of its assignment within the meaning of the Investment Company Act and related SEC guidance and interpretations.
Distribution Manager Agreement
Effective as of February 3, 2022, the Company has entered into a Distribution Manager Agreement (as amended and restated, the “Distribution Manager Agreement”) with Brookfield Oaktree Wealth Solutions LLC (the “Distribution Manager”), an affiliate of the Adviser. Under the terms of the Distribution Manager Agreement, the Distribution Manager serves as the distribution manager for the Company’s initial offering of Common Shares. The Distribution Manager is entitled to receive
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
distribution and/or shareholder servicing fees monthly in arrears at an annual rate of 0.85% of the value of the Company’s net assets attributable to Class S shares as of the beginning of the first calendar day of the month. The Distribution Manager is entitled to receive distribution and/or shareholder servicing fees monthly in arrears at an annual rate of 0.25% of the value of the Company’s net assets attributable to Class D shares as of the beginning of the first calendar day of the month. No distribution and/or shareholding servicing fees are paid with respect to Class I shares. The distribution and/or shareholder servicing fees are payable to the Distribution Manager, but the Distribution Manager anticipates that all or a portion of the shareholder servicing fees will be retained by, or reallowed (paid) to, participating broker-dealers.
The Company will cease paying the shareholder servicing and/or distribution fee on the Class S shares and Class D shares on the earlier to occur of the following: (i) a listing of Class I shares, (ii) a merger or consolidation with or into another entity, or the sale or other disposition of all or substantially all of the Company's assets or (iii) the date following the completion of the primary portion of the initial offering on which, in the aggregate, underwriting compensation from all sources in connection with the initial offering, including the shareholder servicing and/or distribution fee and other underwriting compensation, is equal to 10% of the gross proceeds from the initial offering. In addition, consistent with the exemptive relief allowing the Company to offer multiple classes of shares, at the end of the month in which the Distribution Manager in conjunction with the transfer agent determines that total transaction or other fees, including upfront placement fees or brokerage commissions, and shareholder servicing and/or distribution fees paid with respect to the shares held in a shareholder’s account would exceed, in the aggregate, 10% of the gross proceeds from the sale of such shares (or a lower limit as determined by the Distribution Manager or the applicable selling agent), the Company will cease paying the shareholder servicing and/or distribution fee on the Class S shares and Class D shares in such shareholder’s account. Compensation paid with respect to the shares in a shareholder’s account will be allocated among each share such that the compensation paid with respect to each individual share will not exceed 10% of the offering price of such share. The Company may modify this requirement in a manner that is consistent with applicable exemptive relief. At the end of such month, the applicable Class S shares or Class D shares in such shareholder’s account will convert into a number of Class I shares (including any fractional shares), with an equivalent aggregate NAV as such Class S or Class D shares.
The Distribution Manager is a broker-dealer registered with the SEC and is a member of the Financial Industry Regulatory Authority (“FINRA”).
Either party may terminate the Distribution Manager Agreement upon 60 days’ written notice to the other party or immediately upon notice to the other party in the event such other party failed to comply with a material provision of the Distribution Manager Agreement. The Company's obligations under the Distribution Manager Agreement to pay the shareholder servicing and/or distribution fees with respect to the Class S and Class D shares will survive termination of the agreement until such shares are no longer outstanding (including such shares that have been converted into Class I shares, as described above).
Distribution and Servicing Plan
Effective as of February 3, 2022, the Company established a distribution and servicing plan (the “Distribution and Servicing Plan”). The following table shows the shareholder servicing and/or distribution fees the Company pays the Distribution Manager with respect to the Class S, Class D and Class I on an annualized basis as a percentage of the Company’s NAV for such class.
| | | | | |
Shareholder Servicing and/or Distribution Fee as a % of NAV |
Class I shares | — | % |
Class S shares | 0.85 | % |
Class D shares | 0.25 | % |
The shareholder servicing and/or distribution fees is paid monthly in arrears, calculated using the NAV of the applicable class as of the beginning of the first calendar day of the month and subject to FINRA and other limitations on underwriting compensation. Class I shares are not subject to a shareholder servicing and/or distribution fee.
The Distribution Manager reallows (pay) all or a portion of the shareholder servicing and/or distribution fees to participating brokers and servicing brokers for ongoing shareholder services performed by such brokers, and will waive shareholder servicing and/or distribution fees to the extent a broker is not eligible to receive it for failure to provide such services. Because the shareholder servicing and/or distribution fees with respect to Class S shares and Class D shares are calculated based on the aggregate NAV for all of the outstanding shares of each such class, it reduces the NAV with respect to all shares of each such class, including shares issued under the Company’s distribution reinvestment plan.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Broker eligibility to receive the shareholder servicing and/or distribution fee is conditioned on a broker providing the following ongoing services with respect to the Class S or Class D shares: assistance with recordkeeping, answering investor inquiries regarding the Company, including regarding distribution payments and reinvestments, helping investors understand their investments upon their request, and assistance with share repurchase requests. The shareholder servicing and/or distribution fees are ongoing fees that are not paid at the time of purchase.
For the three and six months ended March 31, 2024, the Company recorded distribution and shareholder servicing fees of $1,614 and $2,895, respectively, primarily all of which were attributable to Class S shares. For the three and six months ended March 31, 2023, the Company recorded distribution and shareholder servicing fees of $328 and $527, respectively, all of which were attributable to Class S shares.
Expense Support and Conditional Reimbursement Agreement
Effective as of February 3, 2022, the Company has entered into an Expense Support and Conditional Reimbursement Agreement (the “Expense Support Agreement”) with the Adviser. The Adviser may elect to pay certain expenses (each, an “Expense Payment”), provided that no portion of the payment will be used to pay any interest or distribution and/or shareholder servicing fees of the Company. Any Expense Payment that the Adviser has committed to pay must be paid by the Adviser to the Company in any combination of cash or other immediately available funds no later than forty-five days after such commitment was made in writing, and/or offset against amounts due from the Company to the Adviser or its affiliates.
Following any calendar month in which Available Operating Funds (as defined below) exceed the cumulative distributions accrued to the Company’s shareholders based on distributions declared with respect to record dates occurring in such calendar month (the amount of such excess being hereinafter referred to as “Excess Operating Funds”), the Company shall pay such Excess Operating Funds, or a portion thereof, to the Adviser until such time as all Expense Payments made by the Adviser to the Company within three years prior to the last business day of such calendar month have been reimbursed. Any payments required to be made by the Company shall be referred to herein as a “Reimbursement Payment.” “Available Operating Funds” means the sum of (i) net investment company taxable income (including net short-term capital gains reduced by net long-term capital losses), (ii) net capital gains (including the excess of net long-term capital gains over net short-term capital losses) and (iii) dividends and other distributions paid to the Company on account of investments in portfolio companies (to the extent such amounts listed in clause (iii) are not included under clauses (i) and (ii) above).
The Company’s obligation to make a Reimbursement Payment shall automatically become a liability of the Company on the last business day of the applicable calendar month, except to the extent the Adviser has waived its right to receive such payment for the applicable month.
For the six months ended March 31, 2024, the Adviser did not make any Expense Payments. For the six months ended March 31, 2024, the Company made reimbursement payments of $1,045 to the Adviser. For the six months ended March 31, 2023, the Adviser made Expense Payments in the amount of $852. For the six months ended March 31, 2023, the Adviser waived its right to receive a Reimbursement Payment from the Company and as of March 31, 2023, no Reimbursement Payments were made to the Adviser. As of March 31, 2024, there were no amounts due to the Adviser from the Company under the Expense Support Agreement.
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Note 10. Financial Highlights
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(Share amounts in thousands) | Three months ended March 31, 2024 | | Three months ended March 31, 2023 | | Six months ended March 31, 2024 | | Six months ended March 31, 2023 |
| Class I | | Class S | | Class D | | Class I | | Class S | | Class I | | Class S | | Class D | | Class I | | Class S |
Net asset value at beginning of period | $ | 23.62 | | | $ | 23.62 | | | $ | 23.62 | | | $ | 23.23 | | | $ | 23.23 | | | $ | 23.56 | | | $ | 23.56 | | | $ | 23.56 | | | $ | 23.47 | | | $ | 23.47 | |
Net investment income (1) | 0.57 | | | 0.52 | | | 0.56 | | | 0.45 | | | 0.40 | | | 1.04 | | | 0.94 | | | 1.01 | | | 0.99 | | | 0.89 | |
Net unrealized appreciation (depreciation) (1)(2) | (0.02) | | | (0.02) | | | (0.02) | | | 0.37 | | | 0.37 | | | 0.17 | | | 0.17 | | | 0.17 | | | 0.22 | | | 0.22 | |
Net realized gains (losses) (1) | 0.03 | | | 0.03 | | | 0.03 | | | (0.06) | | | (0.06) | | | 0.04 | | | 0.04 | | | 0.04 | | | (0.09) | | | (0.09) | |
Net increase (decrease) in net assets resulting from operations | 0.58 | | | 0.53 | | | 0.57 | | | 0.76 | | | 0.71 | | | 1.25 | | | 1.15 | | | 1.22 | | | 1.12 | | | 1.02 | |
Distributions of net investment income to shareholders | (0.57) | | | (0.52) | | | (0.56) | | | (0.52) | | | (0.35) | | | (1.04) | | | (0.94) | | | (1.01) | | | (1.12) | | | (0.90) | |
Distributions in excess of net investment income | (0.02) | | | (0.02) | | | (0.02) | | | (0.05) | | | (0.17) | | | (0.16) | | | (0.16) | | | (0.16) | | | (0.05) | | | (0.17) | |
Net asset value at end of period | $ | 23.61 | | | $ | 23.61 | | | $ | 23.61 | | | $ | 23.42 | | | $ | 23.42 | | | $ | 23.61 | | | $ | 23.61 | | | $ | 23.61 | | | $ | 23.42 | | | $ | 23.42 | |
Total return (3) | 2.48 | % | | 2.26 | % | | 2.41 | % | | 3.28 | % | | 3.06 | % | | 5.43 | % | | 4.98 | % | | 5.30 | % | | 4.88 | % | | 4.43 | % |
Common shares outstanding at beginning of the period | 57,111 | | | 27,765 | | | 22 | | | 16,690 | | | 4,552 | | | 44,103 | | | 20,787 | | | 6 | | | 13,040 | | | 2,588 | |
Common shares outstanding at end of period | 69,973 | | | 34,601 | | | 53 | | | 22,379 | | | 8,572 | | | 69,973 | | | 34,601 | | | 53 | | | 22,379 | | | 8,572 | |
Net assets at the beginning of the period | $ | 1,348,877 | | | $ | 655,764 | | | $ | 530 | | | $ | 387,720 | | | $ | 105,735 | | | $ | 1,039,238 | | | $ | 489,821 | | | $ | 146 | | | $ | 305,989 | | | $ | 60,738 | |
Net assets at end of period | $ | 1,652,401 | | | $ | 817,091 | | | $ | 1,254 | | | $ | 524,123 | | | $ | 200,737 | | | $ | 1,652,401 | | | $ | 817,091 | | | $ | 1,254 | | | $ | 524,123 | | | $ | 200,737 | |
Average net assets (4) | $ | 1,563,298 | | | $ | 762,803 | | | $ | 1,045 | | | $ | 478,071 | | | $ | 155,948 | | | $ | 1,402,988 | | | $ | 683,680 | | | $ | 695 | | | $ | 415,419 | | | $ | 124,584 | |
Ratio of net investment income to average net assets (5) | 2.40 | % | | 2.19 | % | | 2.34 | % | | 1.91 | % | | 1.70 | % | | 4.41 | % | | 3.99 | % | | 4.28 | % | | 4.16 | % | | 3.70 | % |
Ratio of total expenses to average net assets (5)(7) | 1.78 | % | | 1.99 | % | | 1.84 | % | | 1.54 | % | | 1.74 | % | | 3.57 | % | | 3.99 | % | | 3.70 | % | | 3.11 | % | | 3.53 | % |
Ratio of net expenses to average net assets (5) | 1.78 | % | | 1.99 | % | | 1.84 | % | | 1.54 | % | | 1.74 | % | | 3.62 | % | | 4.05 | % | | 3.76 | % | | 2.64 | % | | 3.11 | % |
Ratio of portfolio turnover to average investments at fair value (5) | 10.03 | % | | 10.03 | % | | 10.03 | % | | 8.81 | % | | 8.81 | % | | 14.87 | % | | 14.87 | % | | 14.87 | % | | 16.28 | % | | 16.28 | % |
Weighted average outstanding debt | $ | 1,006,868 | | | $ | 1,006,868 | | | $ | 1,006,868 | | | $ | 177,444 | | | $ | 177,444 | | | $ | 870,164 | | | $ | 870,164 | | | $ | 870,164 | | | $ | 166,154 | | | $ | 166,154 | |
Average debt per share (1) | $ | 10.25 | | | $ | 10.25 | | | $ | 10.25 | | | $ | 6.61 | | | $ | 6.61 | | | $ | 9.86 | | | $ | 9.86 | | | $ | 9.86 | | | $ | 7.25 | | | $ | 7.25 | |
Asset coverage ratio (6) | 306.49 | % | | 306.49 | % | | 306.49 | % | | 581.63 | % | | 581.63 | % | | 306.49 | % | | 306.49 | % | | 306.49 | % | | 581.63 | % | | 581.63 | % |
| | | | | |
(1) | Calculated based upon weighted average shares outstanding for the period. |
(2) | The amount shown may not correspond with the net unrealized appreciation on investments for the three and six months ended March 31, 2024 and 2023 as it includes the effect of the timing of equity issuances. |
(3) | Total return is calculated as the change in NAV per share during the period, plus distributions per share or capital activity, if any, divided by the beginning NAV per share, assuming a dividend reinvestment price equal to the NAV per share at the beginning of the period. |
(4) | Calculated based upon the weighted average net assets for the period. |
(5) | Financial results for the three and six months ended March 31, 2024 and 2023 have not been annualized for purposes of this ratio. |
(6) | Based on outstanding senior securities of $1,195.3 million and $150.5 million as of March 31, 2024 and 2023. |
(7) | Total expenses to average net assets is prior to management fee waivers and expense support/reimbursements provided by the Adviser. |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Note 11. Derivative Instruments
The Company enters into foreign currency forward contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company’s investments denominated in foreign currencies. In order to better define its contractual rights and to secure rights that will help the Company mitigate its counterparty risk, the Company entered into an International Swaps and Derivatives Association, Inc. Master Agreement (the "ISDA Master Agreement") with its derivative counterparty, Bank of New York Mellon. The ISDA Master Agreement permits a single net payment in the event of a default or similar event. As of March 31, 2024, no cash collateral has been pledged to cover obligations and no cash collateral has been received from the counterparty with respect to the Company's forward currency contracts.
Certain information related to the Company’s foreign currency forward contracts is presented below as of March 31, 2024.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Description | | Notional Amount to be Purchased | | Notional Amount to be Sold | | Maturity Date | | Gross Amount of Recognized Assets | | Gross Amount of Recognized Liabilities | | Balance Sheet Location of Net Amounts |
Foreign currency forward contract | | $ | 70,422 | | | € | 65,253 | | | 5/9/2024 | | $ | — | | | $ | 152 | | | Derivative liability |
Foreign currency forward contract | | $ | 49,168 | | | £ | 38,994 | | | 5/9/2024 | | — | | | 100 | | | Derivative liability |
| | | | | | | | $ | — | | | $ | 252 | | | |
Certain information related to the Company’s foreign currency forward contracts is presented below as of September 30, 2023.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Description | | Notional Amount to be Purchased | | Notional Amount to be Sold | | Maturity Date | | Gross Amount of Recognized Assets | | Gross Amount of Recognized Liabilities | | Balance Sheet Location of Net Amounts |
Foreign currency forward contract | | $ | 47,642 | | | € | 43,834 | | | 11/9/2023 | | $ | 1,164 | | | $ | — | | | Derivative asset |
Foreign currency forward contract | | $ | 20,888 | | | £ | 16,392 | | | 11/9/2023 | | 877 | | | — | | | Derivative asset |
| | | | | | | | $ | 2,041 | | | $ | — | | | |
In connection with the issuance of the 2028 Notes, the Company entered into interest rate swap agreements with the BNP Paribas pursuant to ISDA Master Agreements. Certain information related to the Company’s interest rate swaps is presented below as of March 31, 2024.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Description | | Notional Amount | | Maturity Date | | Gross Amount of Recognized Assets | | Gross Amount of Recognized Liabilities | | Balance Sheet Location of Net Amounts |
Interest rate swap | | $ | 350,000 | | | 11/14/2028 | | $ | 2,944 | | | $ | — | | | Derivative asset |
| | | | | | $ | 2,944 | | | $ | — | | | |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Note 12. Commitments and Contingencies
Off-Balance Sheet Arrangements
The Company is a party to financial instruments with off-balance sheet risk in the normal course of business to meet the financial needs of its portfolio companies. As indicated in the table below, as of March 31, 2024, off-balance sheet arrangements consisted of $356,706 of unfunded commitments to provide debt financing to certain of the Company's portfolio companies. As of September 30, 2023, off-balance sheet arrangements consisted of $224,611 of unfunded commitments to provide debt financing to certain of the Company's portfolio companies. Such commitments are subject to the portfolio company's satisfaction of certain financial and nonfinancial covenants and may involve, to varying degrees, elements of credit risk in excess of the amount recognized in the Consolidated Statements of Assets and Liabilities.
A list of unfunded commitments by investment as of March 31, 2024 and September 30, 2023 is shown in the table below: | | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
MRI Software LLC | | $ | 25,000 | | | $ | — | |
AmSpec Parent LLC | | 19,666 | | | — | |
PetVet Care Centers, LLC | | 19,210 | | | — | |
107-109 Beech OAK22 LLC | | 16,983 | | | 16,983 | |
NFM & J, L.P. | | 16,740 | | | — | |
Next Holdco, LLC | | 16,443 | | | — | |
Monotype Imaging Holdings Inc. | | 15,061 | | | — | |
Biscuit Parent, LLC | | 15,000 | | | — | |
CVAUSA Management, LLC | | 13,657 | | | 17,469 | |
Ecco Holdings Corp. | | 13,296 | | | — | |
Seres Therapeutics, Inc. | | 12,990 | | | 12,990 | |
OneOncology, LLC | | 10,184 | | | 13,159 | |
Neptune Platform Buyer, LLC | | 9,023 | | | — | |
Bamboo US Bidco LLC | | 8,684 | | | 9,100 | |
Ardonagh Midco 3 PLC | | 8,219 | | | 3,520 | |
North Star Acquisitionco, LLC | | 7,732 | | | 7,732 | |
scPharmaceuticals Inc. | | 7,654 | | | 7,654 | |
Enverus Holdings, Inc. | | 6,830 | | | — | |
Protein for Pets Opco, LLC | | 6,639 | | | — | |
IW Buyer LLC | | 6,432 | | | 6,432 | |
Project Accelerate Parent, LLC | | 6,250 | | | — | |
WP CPP Holdings, LLC | | 5,831 | | | — | |
ACP Falcon Buyer Inc | | 5,333 | | | 5,333 | |
Grove Hotel Parcel Owner, LLC | | 5,305 | | | 5,305 | |
Entrata, Inc. | | 5,211 | | | 5,211 | |
Harrow, Inc. | | 5,018 | | | 5,018 | |
Kings Buyer, LLC | | 4,994 | | | 5,471 | |
Inventus Power, Inc. | | 4,967 | | | 4,967 | |
SEI Holding I Corporation | | 4,896 | | | 2,633 | |
Crewline Buyer, Inc. | | 4,573 | | | — | |
BioXcel Therapeutics, Inc. | | 4,471 | | | 6,932 | |
iCIMs, Inc. | | 4,416 | | | 4,774 | |
Evergreen IX Borrower 2023, LLC | | 4,006 | | | 4,006 | |
Finastra USA, Inc. | | 3,697 | | | 3,577 | |
107 Fair Street LLC | | 3,434 | | | 3,434 | |
Establishment Labs Holdings Inc. | | 3,378 | | | 3,378 | |
HUB Pen Company, LLC | | 3,213 | | | 3,213 | |
Icefall Parent, Inc. | | 2,662 | | | — | |
Transit Buyer LLC | | 2,214 | | | 3,850 | |
Dukes Root Control Inc. | | 2,146 | | | 3,104 | |
OAKTREE STRATEGIC CREDIT FUND
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
| | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
Coupa Holdings, LLC | | $ | 2,122 | | | $ | 2,122 | |
Oranje Holdco, Inc. | | 1,968 | | | 1,968 | |
Avalara, Inc. | | 1,903 | | | 1,903 | |
Salus Workers' Compensation, LLC | | 1,898 | | | 1,898 | |
PPW Aero Buyer, Inc. | | 1,874 | | | 3,603 | |
Galileo Parent, Inc. | | 1,757 | | | 1,757 | |
112-126 Van Houten Real22 LLC | | 1,230 | | | 1,892 | |
SCP Eye Care Services, LLC | | 1,003 | | | 1,730 | |
LSL Holdco, LLC | | 609 | | | 1,015 | |
ASP-R-PAC Acquisition Co LLC | | 488 | | | 588 | |
Supreme Fitness Group NY Holdings, LLC | | 396 | | | 561 | |
Delta Leasing SPV II LLC | | — | | | 11,560 | |
Resistance Acquisition, Inc. | | — | | | 10,507 | |
MND Holdings III Corp | | — | | | 9,331 | |
ADC Therapeutics SA | | — | | | 4,770 | |
Innocoll Pharmaceuticals Limited | | — | | | 2,656 | |
Impel Pharmaceuticals Inc. | | — | | | 894 | |
Pluralsight, LLC | | — | | | 611 | |
| | $ | 356,706 | | | $ | 224,611 | |
Note 13. Subsequent Events
The Company's management evaluated subsequent events through the date of issuance of the consolidated financial statements. There have been no subsequent events that occurred during such period that would require disclosure in, or would be required to be recognized in, the consolidated financial statements as of and for the three months ended March 31, 2024, except as discussed below.
Share Issuance
On April 1, 2024, the Company issued and sold pursuant to its continuous public offering 4,653,090 Class I shares for proceeds of $109.9 million, 1,979,996 Class S shares for proceeds of $46.7 million and 424 Class D shares for proceeds equivalent to the then-current NAV of such Class D shares.
Distributions
On April 18, 2024, the Board of Trustees of the Company declared a regular distribution on its outstanding common shares of beneficial interest in the amount per share set forth below:
| | | | | | | | | | | | | | | | | | | | |
| | Gross Distribution | | Shareholder Servicing and/or Distribution Fee | | Net Distribution |
Class I shares | | $ | 0.2000 | | | $ | — | | | $ | 0.2000 | |
Class S shares | | $ | 0.2000 | | | $ | 0.0167 | | | $ | 0.1833 | |
Class D shares | | $ | 0.2000 | | | $ | 0.0049 | | | $ | 0.1951 | |
The distribution is payable to shareholders of record as of April 29, 2024 and will be paid on or about May 30, 2024. The distribution will be paid in cash or reinvested in Common Shares for shareholders participating in the Company’s distribution reinvestment plan.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and the notes thereto included elsewhere in this quarterly report on Form 10-Q. All amounts are shown in thousands, except share and per share amounts, percentages and as otherwise indicated.
Some of the statements in this quarterly report on Form 10-Q constitute forward-looking statements because they relate to future events or the future performance or financial condition of Oaktree Strategic Credit Fund ( the "Company", which may also be referred to as "we," "us" or "our"). The forward-looking statements contained in this quarterly report on Form 10-Q may include statements as to:
•our future operating results and distribution projections;
•the ability of Oaktree Fund Advisors, LLC (our "Adviser" and, collectively with its affiliates, "Oaktree") to implement its future plans with respect to our business and to achieve our investment objective;
•the ability of Oaktree and its affiliates to attract and retain highly talented professionals;
•our business prospects and the prospects of our portfolio companies;
•the impact of the investments that we expect to make;
•the ability of our portfolio companies to achieve their objectives;
•our expected financings and investments and additional leverage we may seek to incur in the future;
•the adequacy of our cash resources and working capital;
•the timing of cash flows, if any, from the operations of our portfolio companies; and
•the impact of current global economic conditions, including those caused by inflation, a rising interest rate environment and geopolitical events on all of the foregoing.
In addition, words such as “anticipate,” “believe,” “expect,” “seek,” “plan,” “should,” “estimate,” “project” and “intend” indicate forward-looking statements, although not all forward-looking statements include these words. The forward-looking statements contained in this quarterly report on Form 10-Q involve risks and uncertainties. Our actual results could differ materially from those implied or expressed in the forward-looking statements for any reason, including the factors set forth in “Item 1A. Risk Factors” in our annual report on Form 10-K for the year ended September 30, 2023 and elsewhere in this quarterly report on Form 10-Q.
Other factors that could cause actual results to differ materially include:
•changes or potential disruptions in our operations, the economy, financial markets or political environment, including
those caused by inflation and a rising interest rate environment;
•risks associated with possible disruption in our operations, the operations of our portfolio companies or the economy generally due to terrorism, war or other geopolitical conflict, natural disasters or pandemics;
•future changes in laws or regulations (including the interpretation of these laws and regulations by regulatory authorities) and conditions in our operating areas, particularly with respect to business development companies ("BDCs") or regulated investment companies ("RICs"); and
•other considerations that may be disclosed from time to time in our publicly disseminated documents and filings.
We have based the forward-looking statements included in this quarterly report on Form 10-Q on information available to us on the date of this quarterly report, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we in the future may file with the Securities and Exchange Commission (the “SEC”), including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.
Business Overview
We are a Delaware statutory trust formed on November 24, 2021 and are structured as a non-diversified, closed-end management investment company. On February 3, 2022, we elected to be regulated as a BDC under the Investment Company Act of 1940, as amended (the “Investment Company Act”). We have elected to be treated, and intend to qualify annually to be treated as a RIC under the Internal Revenue Code of 1986, as amended (the “Code”). Effective as of February 3, 2022, we are externally managed by the Adviser pursuant to an investment advisory agreement (as amended and restated, the “Investment Advisory Agreement”), between us and the Adviser. The Adviser is a subsidiary of Oaktree Capital Group, LLC ("OCG"). In 2019, Brookfield Asset Management Inc. ("Brookfield") acquired a majority economic interest in OCG. OCG operates as an independent business within Brookfield, with its own product offerings and investment, marketing and support teams.
Our investment objective is to generate stable current income and long-term capital appreciation. We seek to meet our investment objective by primarily investing in private debt opportunities.
We have the authority to issue an unlimited number of common shares of beneficial interest, par value $0.01 per share (“Common Shares”). We are offering on a best efforts, continuous basis up to $5.0 billion aggregate offering price of Common Shares (the “Maximum Offering Amount”) pursuant to an offering registered with the SEC. We offer to sell any combination of three classes of Common Shares, Class S shares, Class D shares and Class I shares, and, commencing May 13, 2024, Class T shares, with a dollar value up to the Maximum Offering Amount. The share classes have different ongoing distribution and/or shareholder servicing fees.
We accepted purchase orders and held investors’ funds in an interest-bearing escrow account until we received purchase orders for Common Shares of at least $100.0 million, excluding subscriptions by Oaktree Fund GP I, L.P. in respect of the Class I shares purchased by Oaktree Fund GP I, L.P. prior to March 31, 2022.
As of June 1, 2022, we had satisfied the minimum offering requirement and our board of trustees (the "Board of Trustees" or the "Board") had authorized the release of proceeds from escrow. As of March 31, 2024, we have issued and sold 69,926,688 Class I shares for an aggregate purchase price of $1,656.1 million of which $100.0 million was purchased by an affiliate of the Adviser. As of March 31, 2024, we have issued and sold 33,792,645 Class S shares for an aggregate purchase price of $795.2 million. As of March 31, 2024, we have issued and sold 52,607 Class D shares for an aggregate purchase price of $1.2 million. As of March 31, 2024, the Company has not issued or sold any Class T shares.
Business Environment and Developments
Global financial markets have experienced an increase in volatility as concerns about the impact of higher inflation, elevated interest rates, a potential slowdown in economic activity and the current conflicts in the Middle East have weighed on market participants. These factors have created disruptions in supply chains and economic activity and have had a particularly adverse impact on certain companies in the energy, raw materials and transportation sectors, among others. These uncertainties can ultimately impact the overall supply and demand of the market through changing spreads, deal terms and structures and equity purchase price multiples.
We are unable to predict the full effects of these macroeconomic events or how they might evolve. We continue to closely monitor the impact these events have on our business, industry and portfolio companies and will provide constructive solutions where necessary.
Against this backdrop, we believe attractive risk-adjusted returns can be achieved by making loans to middle market companies that typically possess resilient business models with strong underlying fundamentals. Given the breadth of the investment platform and decades of credit investing experience of Oaktree and its affiliates, we believe that we have the resources and experience to source, diligence and structure investments in these companies.
Critical Accounting Estimates
Fair Value Measurements
Our Adviser, as the valuation designee of our Board pursuant to Rule 2a-5 under the Investment Company Act, determines the fair value of our assets on at least a quarterly basis in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"), Topic 820, Fair Value Measurements and Disclosures ("ASC 820"). ASC 820 defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments' complexity.
Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:
•Level 1 — Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date.
•Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities.
•Level 3 — Unobservable inputs that reflect the Adviser's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.
If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. The Adviser's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions.
Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, the Adviser obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of our investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations.
The Adviser seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If the Adviser is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within the Adviser's set threshold, the Adviser seeks to obtain a quote directly from a broker making a market for the asset. The Adviser evaluates the quotations provided by pricing vendors and brokers based on available market information, including
trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. The Adviser also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, the Adviser performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, the Adviser does not adjust any of the prices received from these sources.
If the quotations obtained from pricing vendors or brokers are determined not to be reliable or are not readily available, the Adviser values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value ("EV") of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that we are deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, the Adviser analyzes various factors, including the portfolio company’s historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company’s industry. the Adviser also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company’s ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. The Adviser may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and the Adviser considers the current contractual interest rate, the capital structure and other terms of the investment relative to our risk and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by us are substantially illiquid with no active transaction market, the Adviser depends on primary market data, including newly funded transactions and industry specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable.
The Adviser estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk free rate. Changes in the subjective input assumptions can materially affect the fair value estimates.
The fair value of our investments as of March 31, 2024 and September 30, 2023 was determined by the Adviser, as our valuation designee. We have and will continue to engage independent valuation firms each quarter to provide assistance regarding the determination of the fair value of a portion of our portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment.
Certain factors that may be considered in determining the fair value of our investments include the nature and realizable value of any collateral, the portfolio company’s earnings and its ability to make payments on its indebtedness, the markets in which the portfolio company does business, comparison to comparable publicly-traded companies, discounted cash flow and other relevant factors. Because such valuations, and particularly valuations of private securities and private companies, are inherently uncertain, may fluctuate over short periods of time and may be based on estimates, Oaktree's determinations of fair value may differ materially from the values that would have been used if a ready market for these securities existed. Due to these uncertainties, Oaktree's fair value determinations may cause our net asset value on a given date to materially understate or overstate the value that we may ultimately realize upon the sale of one or more of our investments.
When we determine our net asset value as of the last day of a month that is not also the last day of a calendar quarter, we intend to update the value of securities with reliable market quotations to the most recent market quotation. For securities without reliable market quotations, pursuant to our valuation policy, the Adviser’s valuation team will generally value such assets at the most recent quarterly valuation or, in the case of securities acquired after such date, cost, unless, in either case, the Adviser determines that since the most recent quarter end or the date of acquisition for securities acquired after quarter end, as the case may be, a significant observable change has occurred with respect to the investment (which determination may be as a result of a material event at a portfolio company, material change in market spreads, secondary market transaction in the securities of an investment or otherwise). If the Adviser determines such a change has occurred with respect to one or more investments, the Adviser will determine whether to update the value for each relevant investment using a range of values from an independent valuation firm, where applicable, in accordance with our valuation policy. Additionally, the Adviser may
otherwise determine to update the most recent quarter end valuation of an investment without reliable market quotations that the Adviser considers to be material to us using a range of values from an independent valuation firm.
As of March 31, 2024, we held $3,519.9 million of investments at fair value, up from $1,927.2 million held at September 30, 2023, primarily driven by new originations funded primarily by cash proceeds from our continuous public offering.
Revenue Recognition
We generate revenues in the form of interest income on debt investments and, to a lesser extent, capital gains and distributions, if any, on equity securities that we may acquire in portfolio companies. Some of our investments provide for deferred interest payments or payment-in-kind ("PIK") interest income. The principal amount of the debt investments and any accrued but unpaid interest generally becomes due at the maturity date.
Interest Income
Interest income, adjusted for accretion of original issue discount ("OID"), is recorded on an accrual basis to the extent that such amounts are expected to be collected. We stop accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management’s judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash, and the portfolio company, in management’s judgment, is likely to continue timely payment of its remaining obligations. As of March 31, 2024, there was one investment on non-accrual status that in the aggregate represented 0.3% and 0.1% of total debt investments at cost and fair value, respectively. As of September 30, 2023, there were no investments on non-accrual status.
In connection with our investment in a portfolio company, we sometimes receive nominal cost equity that is valued as part of the negotiation process with the portfolio company. When we receive nominal cost equity, we allocate our cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan.
PIK Interest Income
Our investments in debt securities may contain PIK interest provisions. PIK interest, which generally represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. We generally cease accruing PIK interest if there is insufficient value to support the accrual or if we do not expect the portfolio company to be able to pay all principal and interest due. Our decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; our assessment of the portfolio company's business development success; information obtained by us in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. Our determination to cease accruing PIK interest is generally made well before our full write-down of a loan or debt security. In addition, if it is subsequently determined that we will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on our debt investments increases the recorded cost bases of these investments in our consolidated financial statements including for purposes of computing the capital gains incentive fee payable by us to the Adviser. To
maintain our status as a RIC, certain income from PIK interest may be required to be distributed to our shareholders even though we have not yet collected the cash and may never do so.
Portfolio Composition
As of March 31, 2024, the fair value of our investment portfolio was $3,519.9 million and was composed of investments in 162 portfolio companies. As of September 30, 2023, the fair value of our investment portfolio was $1,927.2 million and was composed of investments in 123 portfolio companies.
As of March 31, 2024 and September 30, 2023, our investment portfolio consisted of the following:
| | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
Cost: | | | | |
Senior Secured Debt | | 93.48 | % | | 94.39 | % |
Subordinated Debt | | 6.07 | % | | 5.12 | % |
Preferred Equity | | 0.35 | % | | 0.31 | % |
Common Equity and Warrants | | 0.10 | % | | 0.18 | % |
Total | | 100.00 | % | | 100.00 | % |
| | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
Fair Value: | | | | |
Senior Secured Debt | | 93.35 | % | | 94.32 | % |
Subordinated Debt | | 6.18 | % | | 5.07 | % |
Preferred Equity | | 0.36 | % | | 0.30 | % |
Common Equity and Warrants | | 0.11 | % | | 0.31 | % |
Total | | 100.00 | % | | 100.00 | % |
The table below describes investments by industry composition based on fair value as a percentage of total investments:
| | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
Fair Value: | | | | |
Application Software | | 14.91 | % | | 13.67 | % |
Diversified Support Services | | 4.98 | % | | 2.10 | % |
Systems Software | | 4.64 | % | | 3.64 | % |
Health Care Technology | | 4.52 | % | | 3.74 | % |
Aerospace & Defense | | 4.40 | % | | 3.92 | % |
Industrial Machinery & Supplies & Components | | 4.27 | % | | 1.58 | % |
Health Care Services | | 4.15 | % | | 3.00 | % |
Interactive Media & Services | | 3.32 | % | | 1.25 | % |
Other Specialty Retail | | 3.04 | % | | 5.44 | % |
Multi-Sector Holdings | | 2.62 | % | | 1.50 | % |
Insurance Brokers | | 2.50 | % | | 0.72 | % |
Property & Casualty Insurance | | 2.36 | % | | 2.17 | % |
Packaged Foods & Meats | | 2.29 | % | | — | % |
Education Services | | 2.28 | % | | 3.20 | % |
Environmental & Facilities Services | | 2.19 | % | | 3.93 | % |
Electrical Components & Equipment | | 2.16 | % | | 3.94 | % |
Specialized Finance | | 1.84 | % | | 2.53 | % |
Office Services & Supplies | | 1.79 | % | | 1.12 | % |
Diversified Metals & Mining | | 1.76 | % | | 4.95 | % |
Construction Machinery & Heavy Transportation Equipment | | 1.74 | % | | — | % |
Data Processing & Outsourced Services | | 1.63 | % | | — | % |
Health Care Supplies | | 1.50 | % | | 1.93 | % |
Life Sciences Tools & Services | | 1.44 | % | | 1.42 | % |
Pharmaceuticals | | 1.40 | % | | 3.28 | % |
Metal, Glass & Plastic Containers | | 1.29 | % | | 1.34 | % |
Health Care Equipment | | 1.17 | % | | 2.07 | % |
Construction & Engineering | | 1.15 | % | | — | % |
Health Care Distributors | | 1.15 | % | | 1.72 | % |
Diversified Chemicals | | 1.14 | % | | — | % |
Movies & Entertainment | | 1.14 | % | | — | % |
Alternative Carriers | | 1.13 | % | | — | % |
Integrated Telecommunication Services | | 1.02 | % | | 2.05 | % |
Restaurants | | 1.00 | % | | 0.99 | % |
Cable & Satellite | | 0.95 | % | | 1.26 | % |
Research & Consulting Services | | 0.94 | % | | 1.10 | % |
Auto Parts & Equipment | | 0.93 | % | | 1.72 | % |
Distributors | | 0.92 | % | | 2.69 | % |
Health Care Facilities | | 0.87 | % | | 1.07 | % |
Personal Care Products | | 0.82 | % | | 2.30 | % |
Gold | | 0.79 | % | | 1.43 | % |
Biotechnology | | 0.78 | % | | 1.86 | % |
Air Freight & Logistics | | 0.64 | % | | 0.35 | % |
Diversified Financial Services | | 0.62 | % | | 1.65 | % |
Trading Companies & Distributors | | 0.62 | % | | 1.33 | % |
Paper & Plastic Packaging Products & Materials | | 0.58 | % | | 0.24 | % |
Passenger Airlines | | 0.55 | % | | 0.65 | % |
Advertising | | 0.52 | % | | 0.59 | % |
Hotels, Resorts & Cruise Lines | | 0.48 | % | | 0.88 | % |
Real Estate Development | | 0.47 | % | | 0.82 | % |
Food Distributors | | 0.34 | % | | 0.32 | % |
Leisure Facilities | | 0.26 | % | | 0.47 | % |
Internet Services & Infrastructure | | — | % | | 0.76 | % |
Consumer Finance | | — | % | | 0.32 | % |
Soft Drinks & Non-alcoholic Beverages | | — | % | | 0.29 | % |
Diversified Real Estate Activities | | — | % | | 0.24 | % |
Leisure Products | | — | % | | 0.21 | % |
Other Specialized REITs | | — | % | | 0.15 | % |
Construction Materials | | — | % | | 0.10 | % |
Total | | 100.00 | % | | 100.00 | % |
The geographic composition of our portfolio is determined by the location of the corporate headquarters of the portfolio company, which may not be indicative of the primary source of the portfolio company's business. The table below describes investments by geographic composition at fair value as a percentage of total investments:
| | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
United States | | 89.21 | % | | 87.07 | % |
United Kingdom | | 4.94 | % | | 2.34 | % |
Canada | | 2.89 | % | | 2.94 | % |
India | | 1.12 | % | | 2.04 | % |
Costa Rica | | 0.36 | % | | 0.64 | % |
Chile | | 0.35 | % | | 0.65 | % |
Switzerland | | 0.29 | % | | 0.51 | % |
Cayman Islands | | 0.27 | % | | 0.68 | % |
France | | 0.27 | % | | 0.71 | % |
Luxembourg | | 0.24 | % | | 2.13 | % |
Australia | | 0.06 | % | | — | % |
Netherlands | | — | % | | 0.29 | % |
Total | | 100.00 | % | | 100.00 | % |
See the Schedule of Investments as of March 31, 2024 and September 30, 2023, in our consolidated financial statements in Part I, Item 1, of this quarterly report on Form 10-Q, for more information on these investments, including a list of companies and the type, cost and fair value of investments.
Discussion and Analysis of Results and Operations
Results of Operations
The principal measure of our financial performance is the net increase (decrease) in net assets resulting from operations, which includes net investment income, net realized gains (losses) and net unrealized appreciation (depreciation). Net investment income is the difference between our income from interest income and fee income and net expenses. Net realized gains (losses) on investments is the difference between the proceeds received from dispositions of portfolio investments and their stated costs. Net unrealized appreciation (depreciation) is the net change in the fair value of our investment portfolio during the reporting period, including the reversal of previously recorded unrealized appreciation (depreciation) when gains or losses are realized. The net increase or decrease in net assets from operations may vary substantially from period to period as a result of various factors, including the recognition of realized gains and losses and net change in unrealized appreciation and depreciation.
Comparison of three and six months ended March 31, 2024 and March 31, 2023
Investment Income
Total investment income for the three months ended March 31, 2024 was $97,056 and consisted of $95,806 of interest income primarily from portfolio investments (including $2,045 of PIK interest income) and $1,250 of fee income. Total investment income for the three months ended March 31, 2023 was $21,856 and consisted of $21,715 of interest income primarily from portfolio investments (including $561 of PIK interest income) and $141 of fee income. The increase in total investment income was primarily driven by the increase in the size of the investment portfolio.
Total investment income for the six months ended March 31, 2024 was $168,650 and consisted of $166,999 of interest income primarily from portfolio investments (including $2,666 of PIK interest income) and $1,651 of fee income. Total investment income for the six months ended March 31, 2023 was $36,738 and consisted of $36,510 of interest income primarily from portfolio investments (including $1,088 of PIK interest income) and $228 of fee income. The increase in total investment income was primarily driven by the increase in the size of the investment portfolio. Based on fair value as of March 31, 2024, the weighted average yield on our debt investments was 11.4%, consistent with 11.4% as of March 31, 2023.
Expenses
Net expenses for the three months ended March 31, 2024 were $43,127, up significantly from $10,052 for the three months ended March 31, 2023. The increase was mainly driven by a larger investment portfolio attributable to new capital raised pursuant to our continuous public offering. Net expenses for the six months ended March 31, 2024 were $78,918, up significantly from $14,837 for the six months ended March 31, 2023. The increase was mainly driven by a larger investment portfolio attributable to new capital raised pursuant to our continuous public offering. Net expenses consisted of the following:
| | | | | | | | | | | | | | | | | | | | | | | |
| For the three months ended March 31, 2024 | | For the three months ended March 31, 2023 | | For the six months ended March 31, 2024 | | For the six months ended March 31, 2023 |
Expenses: | | | | | | | |
Base management fee | $ | 7,242 | | | $ | 1,970 | | | $ | 12,998 | | | $ | 3,366 | |
Investment income incentive fee | 7,980 | | | 1,733 | | | 13,734 | | | 2,973 | |
Capital gains incentive fee | 319 | | | — | | | 2,460 | | | — | |
Professional fees | 613 | | | 790 | | | 1,448 | | | 1,188 | |
Class S and Class D distribution and shareholder servicing fees | 1,614 | | | 328 | | | 2,895 | | | 527 | |
Board of trustees fees | 116 | | | 66 | | | 207 | | | 132 | |
Organization expenses | 4 | | | — | | | 4 | | | 4 | |
Amortization of continuous offering costs | 211 | | | 944 | | | 433 | | | 1,792 | |
Interest expense | 24,180 | | | 3,574 | | | 41,920 | | | 6,380 | |
Administrator expense | 417 | | | 300 | | | 719 | | | 444 | |
General and administrative expenses | 431 | | | 347 | | | 1,055 | | | 525 | |
Total expenses | $ | 43,127 | | | $ | 10,052 | | | $ | 77,873 | | | $ | 17,331 | |
Management and incentive fees waived | — | | | — | | | — | | | (1,642) | |
Expense reimbursements (support) | — | | | — | | | 1,045 | | | (852) | |
Net expenses | $ | 43,127 | | | $ | 10,052 | | | $ | 78,918 | | | $ | 14,837 | |
For the six months ended March 31, 2024, the Adviser did not make any Expense Payments. For the six months ended March 31, 2024, the Company made reimbursement payments of $1,045 to the Adviser. For the six months ended March 31, 2023, the Adviser made Expense Payments in accordance with the Expense Support Agreement in the amount of $852. For the six months ended March 31, 2023, the Adviser waived its right to receive a Reimbursement Payment from us as of March 31, 2023 and no Reimbursement Payments were made to the Adviser. As of March 31, 2024, there were no amounts due to the Adviser from us under the Expense Support Agreement.
The Adviser waived management and incentive fees through November 2022, the first six months following June 1, 2022, the date on which we broke escrow for our continuous offering. For the three and six months ended March 31, 2024, base management fees were $7,242 and $12,998, respectively, none of which was waived. For the three and six months ended March 31, 2024, investment income incentive fees were $7,980 and $13,734, respectively, none of which was waived. For the three months ended March 31, 2023, base management fees were $1,970, none of which was waived. For the six months ended March 31, 2023, base management fees were $3,366, of which $877 was waived. For the three months ended March 31, 2023, the Investment Income Incentive Fee was $1,733, none of which was waived. For the six months ended March 31, 2023, the Investment Income Incentive Fee was $2,973, of which $765 was waived. See Note 9, Related Party Transactions, to our Consolidated Financial Statements, included in Part I, Item 1 of this Form 10-Q.
Net Unrealized Appreciation (Depreciation)
Net unrealized depreciation was $655 for the three months ended March 31, 2024 which was primarily driven by unrealized depreciation across the investment portfolio, partially offset by unrealized appreciation related to foreign currency forward contracts. This consisted of $9.2 million of net unrealized depreciation related to exited investments (a portion of which resulted in a reclassification to realized gains) and $0.3 million of net unrealized depreciation on equity investments, partially offset by $6.3 million of net unrealized appreciation on debt investments and $2.6 million of net unrealized appreciation of foreign currency forward contracts.
Net unrealized appreciation was $16,264 for the six months ended March 31, 2024 which was primarily driven by unrealized appreciation across the investment portfolio, partially offset by unrealized depreciation related to foreign currency forward contracts. This consisted of $20.4 million of net unrealized appreciation on debt investments, partially offset by $2.3 million of net unrealized depreciation of foreign currency forward contracts, $1.0 million of net unrealized depreciation on equity investments and $0.8 million of net unrealized depreciation related to exited investments (a portion of which resulted in a reclassification to realized gains).
Net unrealized appreciation was $8,054 and $5,212 for the three and six months ended March 31, 2023, respectively. which was primarily driven by unrealized appreciation across the debt portfolio. For the three months ended March 31, 2023, this consisted of $5.7 million of net unrealized appreciation on debt investments, $2.0 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and $0.4 million of net unrealized appreciation on equity investments. For the six months ended March 31, 2023, this consisted of $2.7 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses), $2.6 million of net unrealized appreciation on debt investments and $0.5 million of net unrealized appreciation on equity investments, partially offset by $0.5 million of net unrealized depreciation of foreign currency forward contracts.
Net Realized Gains (Losses)
Net realized gains were $3,347 for the three months ended March 31, 2024 which was primarily driven by realized gains related to the exits of certain investments, partially offset by realized losses related to foreign currency forward contracts. Net realized gains were $3,800 for the six months ended March 31, 2024 which was primarily related to the exits of certain investments and foreign currency forward contracts. Net realized losses were $1,741 and $2,401 for the three and six months ended March 31, 2023 and primarily related to the exits of certain investments and foreign currency forward contracts.
Financial Condition, Liquidity and Capital Resources
We expect to generate cash from (1) the cash proceeds from our continuous public offering, (2) cash flows from operations, including earnings on investments, as well as interest earned from the temporary investment of cash in cash-equivalents, U.S. high-quality debt investments that mature in one year or less, (3) borrowings from banks, including secured borrowings, unsecured debt offerings, and any other financing arrangements we may enter into in the future and (4) any future offerings of equity or debt securities.
Our primary use of cash is for (1) investments in portfolio companies and other investments, (2) the cost of operations (including our expenses, the Management Fee and the Incentive Fee), (3) debt service, repayment and other financing costs of our borrowings, (4) funding repurchases under our share repurchase program, and (5) cash distributions to the shareholders.
For the six months ended March 31, 2024, we experienced a net increase in cash and cash equivalents of $195.2 million. During that period, $1,384.1 million of cash was used in operating activities, primarily consisting of cash used to fund new investments, partially offset by proceeds from the sales and repayments of investments. During the same period, cash provided by financing activities was $1,580.0 million, due primarily from $926.6 million of proceeds from the issuance of common shares, $348.2 million of proceeds from the issuance of unsecured notes and $400.0 million of borrowings under the credit facilities, partially offset by $67.4 million of distributions paid to shareholders, $16.2 million of shares repurchases paid and $11.3 million of deferred financing and offering costs paid.
For the six months ended March 31, 2023, we experienced a net increase in cash and cash equivalents of $16.5 million. During that period, $391.1 million of cash was used in operating activities, primarily consisting of cash used to fund new investments, partially offset by proceeds from the sales and repayments of investments. During the same period, cash provided by financing activities was $408.5 million, due primarily from $355.1 million of proceeds from the issuance of common shares and $75.0 million of net borrowings under the credit facilities, partially offset by $19.5 million of distributions paid to shareholders.
As of March 31, 2024, we had $346.4 million of cash and cash equivalents (including restricted cash of $16.5 million), portfolio investments (at fair value) of $3,519.9 million, $23.2 million of interest receivable, $1,440.0 million of undrawn capacity on our credit facilities (subject to borrowing base and other limitations), $188.9 million of net payables from unsettled transactions, $845.0 million of borrowings outstanding under our credit facilities and $347.3 million of unsecured notes payable (net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment).
As of September 30, 2023, we had $151.1 million of cash and cash equivalents (including restricted cash of $5.6 million), portfolio investments (at fair value) of $1,927.2 million, $12.6 million of interest receivable, $0.9 million of due from affiliates, $1,190.0 million of undrawn capacity on our credit facilities (subject to borrowing base and other limitations), $94.3 million of net payables from unsettled transactions and $445.0 million of borrowings outstanding under our credit facilities.
We are a party to financial instruments with off-balance sheet risk in the normal course of business to meet the financial needs of our portfolio companies. As of March 31, 2024 and September 30, 2023, off-balance sheet arrangements consisted of $356,706 and $224,611, respectively, of unfunded commitments to provide debt financing to certain of our portfolio companies. Such commitments are subject to the portfolio company's satisfaction of certain financial and nonfinancial covenants and may involve, to varying degrees, elements of credit risk in excess of the amount recognized in our Consolidated Statements of Assets and Liabilities.
Contractual Obligations | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Debt Outstanding as of September 30, 2023 | | Debt Outstanding as of March 31, 2024 | | Weighted average debt outstanding for the six months ended March 31, 2024 | | Maximum debt outstanding for the six months ended March 31, 2024 |
ING Credit Agreement | | $ | 320,000 | | | $ | 450,000 | | | $ | 416,557 | | | $ | 450,000 | |
JPM SPV Facility | | 125,000 | | | 220,000 | | | 161,667 | | | 220,000 | |
SMBC SPV Facility | | — | | | 50,000 | | | 9,563 | | | 50,000 | |
CIBC SPV Facility | | — | | | 125,000 | | | 16,530 | | | 125,000 | |
2028 Notes | | — | | | 350,000 | | | 265,847 | | | 350,000 | |
Total debt | | $ | 445,000 | | | $ | 1,195,000 | | | $ | 870,164 | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Payments due by period as of March 31, 2024 |
| | Total | | < 1 year | | 1-3 years | | 3-5 years |
ING Credit Agreement | | $ | 450,000 | | | $ | — | | | $ | — | | | $ | 450,000 | |
Interest due on ING Credit Agreement | | 144,756 | | | 34,088 | | | 68,176 | | | 42,492 | |
JPM Loan and Security Agreement | | 220,000 | | | — | | | — | | | 220,000 | |
Interest due on JPM Loan and Security Agreement | | 71,090 | | | 18,209 | | | 36,418 | | | 16,463 | |
SMBC Loan and Security Agreement | | 50,000 | | | — | | | — | | | 50,000 | |
Interest due on SMBC Loan and Security Agreement | | 18,556 | | | 4,122 | | | 8,244 | | | 6,190 | |
CIBC Loan and Servicing Agreement | | 125,000 | | | — | | | 125,000 | | | — | |
Interest due on CIBC Loan and Servicing Agreement | | 14,944 | | | 9,091 | | | 5,853 | | | — | |
2028 Notes | | 350,000 | | | — | | | — | | | 350,000 | |
Interest due on 2028 Notes | | 151,383 | | | 32,715 | | | 65,430 | | | 53,238 | |
Total | | $ | 1,595,729 | | | $ | 98,225 | | | $ | 309,121 | | | $ | 1,188,383 | |
Equity Activity
As of March 31, 2024, we have issued and sold 69,926,688 Class I shares for an aggregate purchase price of $1,656.1 million. As of March 31, 2024, we have issued and sold 33,792,645 Class S shares for an aggregate purchase price of $795.2 million. As of March 31, 2024, we have issued and sold 52,607 Class D shares for an aggregate purchase price of $1.2 million. As of March 31, 2024, we have issued 888,513 Class I shares, 988,557 Class S and 499 Class D shares pursuant to our distribution reinvestment plan.
The following table summarizes transactions in common shares of beneficial interest for the six months ended March 31, 2024:
| | | | | | | | | | | |
| Shares | | Amount |
Class I | | | |
Issuance of Common Shares in public offering | 25,921,513 | | | $ | 610,377 | |
Share transfers between classes | 10,652 | | | 252 | |
Issuance of Common Shares under dividend reinvestment plan | 554,879 | | | 13,152 | |
Share repurchases, net of early repurchase deduction | (616,810) | | | (14,542) | |
Net increase (decrease) | 25,870,234 | | | $ | 609,239 | |
Class S | | | |
Issuance of Common Shares in public offering | 13,384,213 | | | $ | 315,146 | |
Share transfers between classes | (10,652) | | | (252) | |
Issuance of Common Shares under dividend reinvestment plan | 617,672 | | | 14,541 | |
Share repurchases, net of early repurchase deduction | (178,223) | | | (4,201) | |
Net increase (decrease) | 13,813,010 | | | $ | 325,234 | |
Class D | | | |
Issuance of Common Shares in public offering | 46,430 | | | $ | 1,094 | |
Issuance of Common Shares under dividend reinvestment plan | 482 | | | 11 | |
Share repurchases, net of early repurchase deduction | — | | | — | |
Net increase (decrease) | 46,912 | | | $ | 1,105 | |
Total net increase (decrease) | 39,730,156 | | | $ | 935,578 | |
Net Asset Value per Share and Offering Price
We determine NAV per share for each class of shares as of the last calendar day of each month. Share issuances pursuant to accepted monthly subscriptions are effective the first calendar day of each month. Shares are issued and sold at a purchase price equivalent to the most recent NAV per share available for each share class, which will be the prior calendar day NAV per share (i.e. the prior month-end NAV). The following table summarizes each month-end NAV per share for Class I, Class S and Class D shares during the six months ended March 31, 2024 and 2023:
| | | | | | | | | | | | | | | | | |
| Class I Shares | | Class S Shares | | Class D Shares |
October 31, 2023 | $ | 23.39 | | | $ | 23.39 | | | $ | 23.39 | |
November 30, 2023 | $ | 23.51 | | | $ | 23.51 | | | $ | 23.51 | |
December 31, 2023 | $ | 23.62 | | | $ | 23.62 | | | $ | 23.62 | |
January 31, 2024 | $ | 23.60 | | | $ | 23.60 | | | $ | 23.60 | |
February 29, 2024 | $ | 23.58 | | | $ | 23.58 | | | $ | 23.58 | |
March 31, 2024 | $ | 23.61 | | | $ | 23.61 | | | $ | 23.61 | |
| | | | | | | | | | | | | | | | | |
| Class I Shares | | Class S Shares | | Class D Shares |
October 31, 2022 | $ | 23.33 | | | $ | 23.33 | | | — | |
November 30, 2022 | $ | 23.46 | | | $ | 23.46 | | | — | |
December 31, 2022 | $ | 23.23 | | | $ | 23.23 | | | — | |
January 31, 2023 | $ | 23.64 | | | $ | 23.64 | | | — | |
February 28, 2023 | $ | 23.56 | | | $ | 23.56 | | | — | |
March 31, 2023 | $ | 23.42 | | | $ | 23.42 | | | — | |
Distributions
The Board authorizes and declares monthly distribution amounts per share of outstanding common shares of beneficial interest. The following table presents distributions that were declared during the six months ended March 31, 2024:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Class I |
Distribution | | Date Declared | | Record Date | | Payment Date | | Net Distribution Per Share | | Distribution Amount |
Monthly | | October 25, 2023 | | October 31, 2023 | | November 28, 2023 | | $ | 0.1900 | | | $ | 9,259 | |
Monthly | | November 27, 2023 | | November 30, 2023 | | December 27, 2023 | | 0.1900 | | | 9,916 | |
Special | | December 14, 2023 | | December 15, 2023 | | December 27, 2023 | | 0.0400 | | | 2,296 | |
Monthly | | December 20, 2023 | | December 31, 2023 | | February 1, 2024 | | 0.1900 | | | 10,921 | |
Monthly | | January 24, 2024 | | January 31, 2024 | | February 27, 2024 | | 0.1900 | | | 11,872 | |
Monthly | | February 27, 2024 | | February 29, 2024 | | March 27, 2024 | | 0.2000 | | | 13,229 | |
Monthly | | March 26, 2024 | | March 27, 2024 | | April 29, 2024 | | 0.2000 | | | 14,041 | |
| | | | | | | | $ | 1.2000 | | | $ | 71,534 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Class S |
Distribution | | Date Declared | | Record Date | | Payment Date | | Net Distribution Per Share | | Distribution Amount |
Monthly | | October 25, 2023 | | October 31, 2023 | | November 28, 2023 | | $ | 0.1733 | | | $ | 4,105 | |
Monthly | | November 27, 2023 | | November 30, 2023 | | December 27, 2023 | | 0.1734 | | | 4,436 | |
Special | | December 14, 2023 | | December 15, 2023 | | December 27, 2023 | | 0.0400 | | | 1,109 | |
Monthly | | December 20, 2023 | | December 31, 2023 | | February 1, 2024 | | 0.1733 | | | 4,825 | |
Monthly | | January 24, 2024 | | January 31, 2024 | | February 27, 2024 | | 0.1733 | | | 5,191 | |
Monthly | | February 27, 2024 | | February 29, 2024 | | March 27, 2024 | | 0.1833 | | | 5,853 | |
Monthly | | March 26, 2024 | | March 27, 2024 | | April 29, 2024 | | 0.1833 | | | 6,361 | |
| | | | | | | | $ | 1.0999 | | | $ | 31,880 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Class D |
Distribution | | Date Declared | | Record Date | | Payment Date | | Distribution Per Share | | Distribution Amount |
Monthly | | October 25, 2023 | | October 31, 2023 | | November 28, 2023 | | $ | 0.1851 | | | $ | 1 | |
Monthly | | November 27, 2023 | | November 30, 2023 | | December 27, 2023 | | 0.1851 | | | 3 | |
Special | | December 14, 2023 | | December 15, 2023 | | December 27, 2023 | | 0.0400 | | | 1 | |
Monthly | | December 20, 2023 | | December 31, 2023 | | February 1, 2024 | | 0.1851 | | | 4 | |
Monthly | | January 24, 2024 | | January 31, 2024 | | February 27, 2024 | | 0.1851 | | | 5 | |
Monthly | | February 27, 2024 | | February 29, 2024 | | March 27, 2024 | | 0.1951 | | | 10 | |
Monthly | | March 26, 2024 | | March 27, 2024 | | April 29, 2024 | | 0.1951 | | | 10 | |
| | | | | | | | $ | 1.1706 | | | $ | 34 | |
The following table presents distributions that were declared during the three months ended March 31, 2023:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Class I |
Distribution | | Date Declared | | Record Date | | Payment Date | | Distribution Per Share | | Distribution Amount |
Monthly | | October 26, 2022 | | October 31, 2022 | | November 28, 2022 | | $ | 0.1800 | | | $ | 2,470 | |
Monthly | | November 21, 2022 | | November 30, 2022 | | December 28, 2022 | | 0.1900 | | | 2,818 | |
Monthly | | December 21, 2022 | | December 31, 2022 | | January 30, 2023 | | 0.1900 | | | 3,171 | |
Special | | December 21, 2022 | | December 31, 2022 | | January 30, 2023 | | 0.0400 | | | 668 | |
Monthly | | January 24, 2023 | | January 31, 2023 | | February 24, 2023 | | 0.1900 | | | 3,351 | |
Monthly | | February 22, 2023 | | February 28, 2023 | | March 29, 2023 | | 0.1900 | | | 3,834 | |
Monthly | | March 22, 2023 | | March 31, 2023 | | April 27, 2023 | | 0.1900 | | | 4,252 | |
| | | | | | | | $ | 1.1700 | | | $ | 20,564 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Class S |
Distribution | | Date Declared | | Record Date | | Payment Date | | Distribution Per Share | | Distribution Amount |
Monthly | | October 26, 2022 | | October 31, 2022 | | November 28, 2022 | | $ | 0.1634 | | | $ | 574 | |
Monthly | | November 21, 2022 | | November 30, 2022 | | December 28, 2022 | | 0.1735 | | | 684 | |
Monthly | | December 21, 2022 | | December 31, 2022 | | January 30, 2023 | | 0.1734 | | | 789 | |
Special | | December 21, 2022 | | December 31, 2022 | | January 30, 2023 | | 0.0400 | | | 182 | |
Monthly | | January 24, 2023 | | January 31, 2023 | | February 24, 2023 | | 0.1735 | | | 916 | |
Monthly | | February 22, 2023 | | February 28, 2023 | | March 29, 2023 | | 0.1733 | | | 1,024 | |
Monthly | | March 22, 2023 | | March 31, 2023 | | April 27, 2023 | | 0.1733 | | | 1,486 | |
| | | | | | | | $ | 1.0704 | | | $ | 5,655 | |
Distribution Reinvestment Plan
We have adopted a distribution reinvestment plan, pursuant to which we will reinvest all cash dividends declared by the Board on behalf of our shareholders who do not elect to receive their dividends in cash as provided below. As a result, if the Board authorizes, and we declare, a cash dividend or other distribution, then shareholders who have not opted out of our distribution reinvestment plan will have their cash distributions automatically reinvested in additional shares, rather than receiving the cash dividend or other distribution. Distributions on fractional shares will be credited to each participating shareholder’s account to three decimal places.
Share Repurchase Program
At the discretion of our Board of Trustees, during the quarter ended September 30, 2022 we commenced a share repurchase program pursuant to which we intend to offer to repurchase up to 5% of our Common Shares outstanding (by number of shares or aggregate NAV) as of the close of the previous calendar quarter. Our Board of Trustees may amend or suspend the share repurchase program at any time if it deems such action to be in our best interest and the best interest of our shareholders. As a result, share repurchases may not be available each quarter. Following any such suspension, the Board of Trustees will consider on at least a quarterly basis whether the continued suspension of the share repurchase program is in the best interest of us and shareholders, and will reinstate the share repurchase program when and if appropriate and subject to its fiduciary duty to us and shareholders.
We intend to conduct repurchase offers under the share repurchase program pursuant to tender offers in accordance with the requirements of Rule 13e-4 promulgated under the Exchange Act and the Investment Company Act. All shares purchased by us pursuant to the terms of each tender offer will be retired.
Under our share repurchase program, to the extent we offer to repurchase shares in any particular quarter, we expect to repurchase shares at the expiration of the tender offer at a purchase price equal to the NAV per share as of the last calendar day of the applicable quarter (the “Valuation Date”), except that shares that have a prospective repurchase date that is within the one-year period following the original issue date of the shares will be subject to an early repurchase deduction of 2% of such NAV (an “Early Repurchase Deduction”). The one-year holding period will be deemed satisfied if the shares to be repurchased would have been outstanding for one year or longer as of the subscription closing date immediately following the applicable Valuation Date, which subscription closing date the Company deems the prospective repurchase date for the applicable offer. The Early Repurchase Deduction will be retained by us for the benefit of remaining shareholders.
During the six months ended March 31, 2024, we repurchased pursuant to such tender offers an aggregate of 616,810 Class I and 178,223 Class S shares. The following table presents the share repurchases completed during the six months ended March 31, 2024:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Repurchase Pricing Date | | Total Number of Shares Repurchased (all classes) | | Percentage of Outstanding Shares Repurchased (1) | | Price Paid Per Share | | Amount Repurchased (all classes)(2) |
December 31, 2023 | | 446,089 | | | 0.69 | % | | $ | 23.62 | | | $ | 10,526 | |
March 31, 2024 | | 348,944 | | | 0.41 | % | | $ | 23.61 | | | $ | 8,217 | |
_____________________
(1) Percentage is based on total shares as of the close of the previous calendar quarter.
(2) Amounts shown net of Early Repurchase Deduction, where applicable.
Leverage
To seek to enhance our returns, we use and expect to continue to use leverage as market conditions permit and at the discretion of the Adviser. However, as a BDC, subject to certain limited exceptions, we are currently only allowed to borrow amounts in accordance with the asset coverage requirements in the Investment Company Act of 1940, as amended (the “Investment Company Act”). On March 23, 2018, the Small Business Credit Availability Act (the “SBCAA”) was enacted into law. The SBCAA, among other things, amended Section 61(a) of the Investment Company Act to add a new Section 61(a)(2) that reduces the asset coverage requirements applicable to BDCs from 200% to 150% so long as the BDC meets certain disclosure requirements, which we have made, and obtains certain approvals, which we have obtained. Accordingly, we are subject to an asset coverage requirement of 150%. We intend to use leverage in the form of borrowings, including loans from certain financial institutions, and the issuance of debt securities. We may also use leverage in the form of the issuance of preferred shares, but do not currently intend to do so. In determining whether to borrow money, we will analyze the maturity, covenant package and rate structure of the proposed borrowings as well as the risks of such borrowings compared to our investment outlook. Any such leverage is expected to be applied on a position-by-position basis, meaning little-to-no leverage may be applied to certain investments, while others may have more leverage applied. Any such leverage would also be expected to increase the total capital available for investment by the Company. We may also create leverage by securitizing our assets (including in CLOs) and retaining the equity portion of the securitized vehicle.
ING Credit Agreement
On March 25, 2022 (the “ING Closing Date”), we entered into a senior secured revolving credit agreement (the “ING Credit Agreement”) among us, as borrower, the lenders party thereto, and ING Capital LLC (“ING”), as administrative agent.
Effective on and as of May 25, 2022, we entered into an incremental commitment and assumption agreement (the “Incremental Commitment and Assumption Agreement”) among us, as borrower, the subsidiary guarantor party thereto (the “Subsidiary Guarantor”), ING, as administrative agent and issuing bank, Sumitomo Mitsui Banking Corporation and MUFG Bank, LTD, (together with Sumitomo Mitsui Banking Corporation, the “Assuming Lenders”). Pursuant to the Incremental Commitment and Assumption Agreement, among other things, each Assuming Lender (i) became a Lender (as defined in the ING Credit Agreement) under the ING Credit Agreement and (ii) agreed to make a Commitment (as defined in the ING Credit Agreement) to us in the amount of $150 million. The Incremental Commitment and Assumption Agreement increased the aggregate amount of Commitments under the ING Credit Agreement from $150 million to $450 million (the "Maximum Commitment"), subject to the lesser of (i) a borrowing base and (ii) the Maximum Commitment, and provided that, with respect to any lender, its individual commitment is not exceeded. The revolving credit facility has a four year availability period (the “Availability Period”) during which loans may be made and the ING Credit Agreement has a stated maturity dated that is five years from the ING Closing Date (the “Maturity Date”). Following the Availability Period we will be required in certain circumstances to prepay loans prior to the Maturity Date. The ING Credit Agreement provides for the issuance of letters of credit during the Availability Period in an aggregate amount of $25 million. Borrowings under the ING Credit Agreement may be used for general corporate purposes, including making investments and permitted distributions.
Effective on and as of October 6, 2022, we entered into a subsequent incremental commitment and assumption agreement (the “Subsequent Incremental Commitment and Assumption Agreement”) among us, as borrower, the Subsidiary Guarantor, ING, as administrative agent and issuing bank, and Apple Bank For Savings, as an Assuming Lender. Pursuant to the Subsequent Incremental Commitment and Assumption Agreement, Apple Bank For Savings (i) became a Lender under the ING Credit Agreement and (ii) agreed to make a Commitment to us in the amount of $40 million. The Subsequent Incremental
Commitment and Assumption Agreement increased the aggregate amount of Commitments under the ING Credit Agreement from $450 million to $490 million.
Effective on and as of June 28, 2023 (the “New Effective Date”), we entered into Amendment No. 1 (the “ING Credit Agreement Amendment”) to the ING Credit Agreement. As a result of the ING Credit Agreement Amendment, the ING Credit Agreement provides for a senior secured revolving credit facility of up to $1,110 million (the “Increased Maximum Commitment”), increased from $490 million, subject to the lesser of (i) a borrowing base and (ii) the Increased Maximum Commitment, and provided that, with respect to any lender, its individual commitment is not exceeded. The revolving credit facility has a four year availability period (the “New Availability Period”) commencing from the New Effective Date during which loans may be made and a stated maturity date that is five years from the New Effective Date (the “New Maturity Date”). Following the New Availability Period, we will be required in certain circumstances to prepay loans prior to the New Maturity Date. The ING Credit Agreement provides for the issuance of letters of credit during the New Availability Period in an aggregate amount of $25 million. Borrowings under the ING Credit Agreement may be used for general corporate purposes, including making investments and permitted distributions.
Effective on and as of August 15, 2023, we entered into a subsequent incremental commitment and assumption agreement (the “Second Subsequent Incremental Commitment and Assumption Agreement”) among us, as borrower, the Subsidiary Guarantor, ING, as administrative agent and issuing bank, and Deutsche Bank AG, New York Branch and US Bank National Association, as Assuming Lenders. Pursuant to the Subsequent Incremental Commitment and Assumption Agreement, the Assuming Lenders (i) became Lenders under the ING Credit Agreement and (ii) agreed to make a Commitment to us in the aggregate amount of $75 million. The Second Subsequent Incremental Commitment and Assumption Agreement increased the aggregate amount of Commitments under the ING Credit Agreement from $1,110 million to $1,185 million.
All obligations under the ING Credit Agreement are secured by a first-priority security interest (subject to certain exceptions) in substantially all of the present and future property and assets of us and of the sole current and certain future subsidiaries of us and guaranteed by such subsidiaries.
Borrowings under the ING Credit Agreement shall be denominated in U.S. Dollars and bear interest at a rate per annum equal to either (1) SOFR, as adjusted, plus 1.875% per annum or (2) the alternative base rate (which is the greatest of the (a) prime rate, (b) the federal funds effective rate plus ½ of 1%, (c) the overnight bank funding rate plus ½ of 1%, (d) certain rates based on SOFR and (e) 0) (“ABR”) plus 0.875% per annum. On and after the New Effective Date, borrowings under the ING Credit Agreement bear interest at a rate per annum equal to either (1) the SOFR, as adjusted, plus 2.15% per annum, or, following the first year after the New Effective Date, plus 2.05% per annum if the Company has and maintains an investment grade credit rating or (2) the alternative base rate (which is the greatest of the (a) prime rate, (b) the federal funds effective rate plus ½ of 1%, (c) the overnight bank funding rate plus ½ of 1%, (d) certain rates based on SOFR and (e) 0) (“ABR”) plus 1.15% per annum or, following the first year after the New Effective Date, plus 1.05% per annum if the Company has and maintains investment grade credit rating. We may elect either an ABR or SOFR borrowing at each drawdown request, and loans may be converted from one rate to another at any time at our option, subject to certain conditions. Prior to the New Effective Date, we paid a commitment fee at a rate of 0.375% per annum on the daily unused portion of the aggregate commitments under the ING Credit Agreement. On and after the New Effective Date, we will pay a commitment fee at a rate of 0.375% per annum on the daily unused portion of the aggregate commitments under the ING Credit Agreement, subject to increase to 1.00% per annum on the daily unused amount if the daily unused amount is greater than or equal to 65% of the aggregate commitments under the ING Credit Agreement.
At any time during the New Availability Period, the Borrower may propose an increase in the Increased Maximum Commitment to an amount not to exceed the greater of (a) $1,250.0 million and (b) 150% of shareholders’ equity as of the date on which such increased amount is to be effective, subject to certain conditions, including the consent of the lenders to increase their commitments and of ING.
We have made customary representations and warranties and are required to comply with various affirmative and negative covenants, reporting requirements and other customary requirements for similar credit facilities. As of March 31, 2024, we were in compliance with all financial covenants under the ING Credit Agreement based on the financial information contained in this Quarterly Report on Form 10-Q. Borrowings under the ING Credit Agreement are subject to the leverage restrictions contained in the Investment Company Act.
The ING Credit Agreement contains customary events of default for similar financing transactions. Upon the occurrence and during the continuation of an event of default, ING may terminate the commitments and declare the outstanding loans and all other obligations under the ING Credit Agreement immediately due and payable.
As of March 31, 2024 and September 30, 2023, we had $450.0 million and $320.0 million outstanding under the ING Credit Agreement. For the six months ended March 31, 2024 and March 31, 2023, our borrowings under the ING Credit Agreement bore interest at a weighted average rate of 7.69% and 6.21%, respectively. We recorded $9,393 and $18,710 of interest expense (inclusive of fees) related to the ING Credit Agreement for the three and six months ended March 31, 2024, respectively. We recorded $3,212 and $6,018 of interest expense (inclusive of fees) related to the ING Facility for the three and six months ended March 31, 2023, respectively.
JPM SPV Facility
On February 24, 2023 (the “JPM Closing Date”), we entered into a loan and security agreement (as amended, the “JPM
Loan and Security Agreement”) among OSCF Lending SPV, LLC (“OSCF Lending SPV”), a wholly owned subsidiary of us, as borrower, us, as parent and servicer, Citibank, N.A., as collateral agent and securities intermediary, Virtus Group, LP, as collateral administrator, the lenders party thereto, and JPMorgan Chase Bank, National Association (“JPM”), as administrative agent, pursuant to which JPM agreed to extend credit to OSCF Lending SPV in an aggregate principal amount up to $150 million at any one time outstanding. Effective on and as of July 5, 2023, the Company entered into Amendment No. 1 (the “JPM Loan and Security Agreement Amendment”) to the JPM Loan and Security Agreement, pursuant to which JPM has increased its commitment to extend credit to OSCF Lending SPV to an aggregate principal amount up to $300 million (the “JPM Maximum Commitment”).
The JPM Loan and Security Agreement provides for a senior secured revolving credit facility that has a three-year reinvestment period (the “JPM Availability Period”) and a stated maturity date that is five years after the JPM Closing Date. Subject to certain conditions, including consent of the lenders and JPM, as administrative agent, at any time during the JPM Availability Period, OSCF Lending SPV may propose one or more increases in the JPM Maximum Commitment up to an amount not to exceed $500 million. Borrowings under the JPM Loan and Security Agreement shall be denominated in U.S. Dollars and bear interest at a rate per annum equal to the forward-looking term rate with a three-month tenor, based on the SOFR as administered by the Federal Reserve Bank of New York (or a successor administrator), and as published by CME Group Benchmark Administration Limited (or a successor administrator), plus 2.95%.
The obligations of OSCF Lending SPV under the JPM Loan and Security Agreement are secured by all of the assets held by OSCF Lending SPV, including certain loans sold or to be sold or transferred or to be transferred by us to OSCF Lending SPV (such loans, the “JPM Transferred Loans”) pursuant to the terms of the Sale and Participation Agreement, dated as of the JPM Closing Date (the “JPM Sale Agreement” and, together with the JPM Loan and Security Agreement, the “JPM Agreements”), between OSCF Lending SPV, as buyer, and we, as seller, pursuant to which we will sell JPM Transferred Loans to OSCF Lending SPV from time to time. Under the JPM Agreements, we and OSCF Lending SPV, as applicable, have made representations and warranties regarding the JPM Transferred Loans, as well as their businesses, and are required to comply with various covenants, servicing procedures, limitations on the disposition of JPM Transferred Loans, reporting requirements and other customary requirements for similar revolving funding facilities.
Borrowings under the JPM Loan and Security Agreement are subject to various covenants under the JPM Agreements as well as the asset coverage requirement contained in the Investment Company Act.
As of March 31, 2024, OSCF Lending SPV had $220.0 million outstanding under the JPM Loan and Security Agreement. For the six months ended March 31, 2024 and March 31, 2023, OSCF Lending SPV’s borrowings under the JPM Loan and Security Agreement bore interest at a weighted average rate of 8.55% and 7.80%, respectively. We recorded $4,237 and $7,829 of interest expense (inclusive of fees) related to the JPM Loan and Security Agreement for the three and six months ended March 31, 2024, respectively. We recorded $361 of interest expense (inclusive of fees) related to the JPM Loan and Security Agreement for the three and six months ended March 31, 2023.
SMBC SPV Facility
Effective on and as of September 29, 2023 (the “SMBC Closing Date”), we entered into a loan and security agreement (as amended, the “SMBC Loan and Security Agreement”) among OSCF Lending III SPV, LLC (“OSCF Lending III SPV”), a wholly owned subsidiary of us, as borrower, us, as transferor and servicer, Citibank, N.A., as the account bank, Virtus Group, LP, as collateral custodian, the lenders party thereto, and Sumitomo Mitsui Banking Corporation (“SMBC”), as administrative agent and collateral agent, pursuant to which SMBC agreed to extend credit to OSCF Lending III SPV in an aggregate principal amount up to $150 million at any one time outstanding.
Effective on and as of December 22, 2023, the Company entered into the First Amendment to Loan and Servicing Agreement among OSCF Lending III SPV, the Company, Citibank, N.A., Virtus Group, LP and SMBC, which amended the SMBC Loan and Security Agreement to adjust the concentration limits set forth therein for certain large middle market loan
assets that do not contain a maintenance covenant. The SMBC Loan and Security Agreement provides for a senior secured revolving credit facility that has a three-year reinvestment period (the “SMBC Availability Period”) and a stated maturity date that is five years after the SMBC Closing Date. Borrowings under the SMBC Loan and Servicing Agreement shall be denominated in U.S. Dollars and bear interest at a rate per annum equal to, at the request of OSCF Lending III SPV, either (1) SOFR plus 2.45% up to and including 3.00% depending on the collateral securing the facility or (2) the base rate (which is the greatest of the (a) prime rate, (b) federal funds effective rate plus 1/2 of 1%, (c) zero (0%) and (d) one month SOFR plus 1%) plus 1.45% up to and including 2.00% depending on the collateral securing the facility. We are required to pay a non-usage fee of 0.50% on undrawn borrowings during the first three months of the facility and thereafter 0.50% or 0.75% during the remainder of the SMBC Availability Period depending on amounts borrowed by us under the facility.
The obligations of OSCF Lending III SPV under the SMBC Loan and Security Agreement are secured by all of the assets held by OSCF Lending III SPV, including certain loans sold or to be sold or transferred or to be transferred by us to OSCF Lending SPV (such loans, the “SMBC Transferred Loans”) pursuant to the terms of the Sale and Participation Agreement, dated as of the SMBC Closing Date (the “SMBC Sale Agreement” and, together with the SMBC Loan and Security Agreement, the “SMBC Agreements”), between OSCF Lending III SPV, as buyer, and we, as seller, pursuant to which we will sell SMBC Transferred Loans to OSCF Lending III SPV from time to time. Under the SMBC Agreements, we and OSCF Lending SPV, as applicable, have made representations and warranties regarding the SMBC Transferred Loans, as well as their businesses, and are required to comply with various covenants, servicing procedures, limitations on the disposition of SMBC Transferred Loans, reporting requirements and other customary requirements for similar revolving funding facilities.
Borrowings under the SMBC Loan and Security Agreement are subject to various covenants under the SMBC Agreements as well as the asset coverage requirement contained in the Investment Company Act.
As of March 31, 2024, we had $50.0 million outstanding under the SMBC Loan and Security Agreement. For the six months ended March 31, 2024, our borrowings under the SMBC Loan and Security Agreement bore interest at a weighted average rate of 8.26%. We recorded $655 and $942 of interest expense (inclusive of fees) related to the SMBC Loan and Security Agreement for the three and six months ended March 31, 2024, respectively.
CIBC SPV Facility
Effective on and as of November 21, 2023 (the “CIBC Closing Date”), we entered into a loan and servicing agreement (as amended, the “CIBC Loan and Servicing Agreement”) among OSCF Lending V SPV, LLC (“OSCF Lending V SPV”), a wholly owned subsidiary of us, as borrower, we, as transferor and servicer, Computershare Trust Company, N.A., as securities intermediary, collateral custodian, collateral agent and collateral administrator, the lenders party thereto, and Canadian Imperial Bank of Commerce (“CIBC”), as administrative agent, pursuant to which CIBC agreed to extend credit to OSCF Lending V SPV in an aggregate principal amount up to $150 million (the “ CIBC Maximum Commitment”) at any one time outstanding.
The CIBC Loan and Servicing Agreement provides for a senior secured revolving credit facility that has a two-year reinvestment period (the “CIBC Availability Period”) and a stated maturity date that is two years after the CIBC Closing Date. Subject to certain conditions, including consent of the lenders and CIBC as administrative agent, during the CIBC Availability Period, OSCF Lending V SPV may propose up to four increases in the CIBC Maximum Commitment up to an amount not to exceed $500 million in the aggregate.
Borrowings under the CIBC Loan and Servicing Agreement shall be denominated in U.S. Dollars and bear interest at a rate per annum equal to, at the request of OSCF Lending V SPV, as borrower, either (1) the SOFR, plus 1.95% or (2) the base rate (which is the greatest of the (a) prime rate, (b) federal funds effective rate plus 1/2 of 1%, (c) zero (0%) and (d) one month SOFR plus 1%) plus 0.95%. The applicable spread otherwise in effect shall be increased by 2% per annum after the stated maturity date or when an event of default has occurred and is continuing. We are required to pay a non-usage fee of 0.50% on undrawn borrowings beginning six months after the CIBC Closing Date.
The obligations of OSCF Lending V SPV under the CIBC Loan and Security Agreement are secured by all of the assets held by OSCF Lending V SPV, including loans it has made or acquired (the “OSCF Lending V SPV Loans”). Under the Loan and Servicing Agreement, OSCF Lending V SPV, as borrower, and us, as servicer, have made representations and warranties regarding the OSCF Lending V SPV Loans, as well as the borrower’s and servicer’s businesses, and are required to comply with various covenants, servicing procedures, limitations on the disposition of the OSCF Lending V SPV Loans, reporting requirements and other customary requirements for similar revolving funding facilities.
The CIBC Loan and Servicing Agreement contains customary events of default for similar financing transactions. Upon the occurrence and during the continuation of an event of default, CIBC, as administrative agent, may terminate the
commitments and declare the outstanding borrowings and all other obligations under the CIBC Loan and Servicing Agreement immediately due and payable.
Borrowings under the CIBC Loan and Servicing Agreement are subject to various covenants as well as the asset coverage requirement contained in the Investment Company Act.
As of March 31, 2024, we had $125.0 million outstanding under the CIBC Loan and Servicing Agreement. For the six months ended March 31, 2024, our borrowings under the CIBC Loan and Servicing Agreement bore interest at a weighted average rate of 7.38%. We recorded $774 and $849 of interest expense (inclusive of fees) related to the CIBC Loan and Servicing Agreement for the three and six months ended March 31, 2024, respectively.
DBNY SPV Facility
On February 15, 2024 (the “DBNY Closing Date”), we entered into a loan financing and servicing agreement (the “DBNY Loan Financing and Servicing Agreement”), among OSCF Lending IV SPV, LLC (“OSCF Lending IV SPV”), a wholly owned subsidiary of us, as borrower, we, as servicer and equityholder, the lenders party thereto, Deutsche Bank AG, New York Branch (“DBNY”), as facility agent, the other agents parties thereto and Deutsche Bank National Trust Company, as collateral agent and collateral custodian, pursuant to which DBNY has agreed to extend credit to OSCF Lending IV SPV in an aggregate principal amount up to $300 million (the “DBNY Facility Amount”) at any one time outstanding.
The DBNY Loan Financing and Servicing Agreement provides for a senior secured revolving credit facility that has a three-year reinvestment period (the “DBNY Availability Period”). Borrowings under the DBNY Loan Financing and Servicing Agreement shall be denominated in EUR, AUD, CAD, GBP or USD and bear interest at a rate per annum equal to the sum of, for any accrual period and any lender, (i) the applicable margin and (ii) the cost of funds rate for such accrual period and such lender. The applicable margin will be 2.40% per annum prior to the end of the DBNY Availability Period and 3.05% per annum thereafter; provided that, on and after the occurrence of any Event of Default (as defined in the DBNY Loan Financing and Servicing Agreement), the applicable margin shall be increased by 2.00% per annum. The cost of funds rate will be, (a) for each conduit lender, the lower of (x) such conduit lender’s Commercial Paper Rate (as defined in the DBNY Loan Financing and Servicing Agreement) and (y) the SOFR for a three-month tenor as quoted by CME Group Benchmark Administration Limited (which shall in no event be lower than 0.25%), and (b) for each committed lender, the base rate determined by reference to the applicable benchmark index depending on the currency denomination of the advances.
The obligations of OSCF Lending IV SPV under the DBNY Loan Financing and Servicing Agreement are secured by all of the assets held by OSCF Lending IV SPV, including loans it has made or acquired (the “OSCF Lending IV SPV Loans”), except for certain Retained Interests (as defined in the DBNY Loan Financing and Servicing Agreement). Under the Loan Financing and Servicing Agreement, OSCF Lending IV SPV, as borrower, and we, as servicer, have made representations and warranties regarding the OSCF Lending IV SPV Loans, as well as our businesses, and are required to comply with various covenants, servicing procedures, limitations on the disposition of the OSCF Lending IV SPV Loans, reporting requirements and other customary requirements for similar revolving funding facilities. Borrowings under the DBNY Loan Financing and Servicing Agreement are subject to various covenants under the DBNY Loan Financing and Servicing Agreement.
The DBNY Loan Financing and Servicing Agreement contains customary events of default for similar financing transactions. Upon the occurrence and during the continuation of an event of default, DBNY, as facility agent, may terminate the commitments and declare the outstanding borrowings and all other obligations under the DBNY Loan Financing and Servicing Agreement immediately due and payable.
Subject to certain conditions, including consent of DBNY, as facility agent, OSCF Lending IV SPV may (i) propose increases in the DBNY Facility Amount up to an amount not to exceed $1 billion in the aggregate, (ii) add additional lender groups and/or (iii) increase the commitment of any lender group with the consent of such lender group. The DBNY Facility Amount may, subject to certain conditions, including consent of DBNY, as facility agent, be so increased to $400 million on the earlier of (x) the three-month anniversary of the DBNY Closing Date and (y) the date selected by OSCF Lending IV SPV (via written notice to DBNY, as facility agent) to so increase the DBNY Facility Amount.
As of March 31, 2024, no amounts were outstanding under the DBNY Loan Financing and Serving Agreement. We recorded $431 of interest expense (inclusive of fees) related to the DBNY Loan Financing and Serving Agreement for the six months ended March 31, 2024.
MS SPV Facility
On February 23, 2024 (the “MS Closing Date”), we entered into a loan and servicing agreement (the “MS Loan and Servicing Agreement”), among OSCF Lending II SPV, LLC (“OSCF Lending II SPV”), a wholly owned subsidiary of us, as borrower, we, as transferor and servicer, Citibank, N.A., as the collateral agent, account bank and collateral custodian, Virtus Group, LP, as collateral administrator, each of the lenders from time to time party thereto, and Morgan Stanley Asset Funding, Inc. (“MS”), as the administrative agent, pursuant to which MS has agreed to extend credit to OSCF Lending II SPV in an aggregate principal amount up to $200 million (the “MS Maximum Commitment”) at any one time outstanding.
The MS Loan and Servicing Agreement provides for a senior secured revolving credit facility that has a three-year reinvestment period (the “MS Availability Period”) and a stated maturity date that is five years after the MS Closing Date. Advances under the MS Loan and Servicing Agreement shall be denominated in U.S. Dollars and bear interest at a rate per annum equal to SOFR plus 2.35% during the MS Availability Period and 2.85% thereafter; provided that the applicable margin shall be increased by 2.00% per annum (i) during the existence of a Specified Event of Default (as defined in the MS Loan and Servicing Agreement), (ii) upon written notice from MS, as administrative agent (at the direction of required lenders) to OSCF Lending II SPV and us during the existence of any other Event of Default (as defined in the MS Loan and Servicing Agreement) or (iii) after a Facility Maturity Date (as defined in the MS Loan and Servicing Agreement).
The obligations of OSCF Lending II SPV under the MS Loan and Servicing Agreement are secured by all of the assets held by OSCF Lending II SPV, including certain loans it has made or acquired (such loans, the “OSCF Lending II SPV Loans”), except for certain Retained Interests (as defined in the MS Loan and Servicing Agreement). Under the MS Loan and Servicing Agreement, OSCF Lending II SPV, as borrower, and we, as servicer, have made representations and warranties regarding the OSCF Lending II SPV Loans, as well as our businesses, and are required to comply with various covenants, servicing procedures, limitations on the disposition of Loans, reporting requirements and other customary requirements for similar revolving funding facilities.
The MS Loan and Servicing Agreement contains customary events of default for similar financing transactions. Upon the occurrence and during the continuation of an event of default, MS, as administrative agent may terminate the commitments and declare the outstanding loans and all other obligations under the MS Loan and Servicing Agreement immediately due and payable.
Borrowings under the MS Loan and Servicing Agreement are subject to various covenants under the MS Loan and Servicing Agreement as well as the asset coverage requirement contained in the Investment Company Act.
As of March 31, 2024, no amounts were outstanding under the MS Loan and Serving Agreement. We recorded $85 of interest expense (inclusive of fees) related to the MS Loan and Serving Agreement for the six months ended March 31, 2024.
2028 Unsecured Notes
On November 14, 2023, we issued $350 million aggregate principal amount of its 8.400% Notes due 2028 (the “2028 Unsecured Notes”) in a transaction exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act pursuant to an indenture, dated as of November 14, 2023 (the “Base Indenture”), between us and Deutsche Bank Trust Company Americas, as trustee (the “Notes Trustee”), and (2) a first supplemental indenture (the “First Supplemental Indenture” and together with the Base Indenture, the “Indenture”) to the Base Indenture.
The 2028 Unsecured Notes mature on November 14, 2028, unless previously redeemed or repurchased in accordance with their terms. The 2028 Unsecured Notes bear interest at a rate of 8.400% per year payable semi-annually in arrears on May 14 and November 14 of each year, commencing on May 14, 2024. The 2028 Unsecured Notes are our direct, unsecured obligations and rank senior in right of payment to its future indebtedness that is expressly subordinated in right of payment to the 2028 Unsecured Notes; equal in right of payment to its existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of its secured indebtedness (including existing unsecured indebtedness that we later secures) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by its subsidiaries, financing vehicles or similar facilities.
The Indenture contains certain covenants, including a covenant requiring us to comply with Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act, or any successor provisions, but giving effect to any exemptive relief granted to us by the SEC and to provide financial information to the holders of the 2028 Unsecured Notes and
the Notes Trustee if we should no longer be subject to the reporting requirements under the Exchange Act. These covenants are subject to important limitations and exceptions that are set forth in the Indenture.
In connection with the 2028 Unsecured Notes, we entered into an interest rate swap to more closely align the interest rate payable on the 2028 Unsecured Notes with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, we receive a fixed interest rate of 8.400% and pays a floating interest rate of the three-month SOFR plus 4.0405% on a notional amount of $350 million.
The below table presents the components of the carrying value of the 2028 Notes as of March 31, 2024:
| | | | | | | | |
($ in millions) | | |
Principal | | $ | 350.0 | |
Unamortized financing costs | | (4.0) | |
Unaccreted discount | | (1.6) | |
Interest rate swap fair value adjustment | | 2.9 | |
Net carrying value | | $ | 347.3 | |
Fair Value | | $ | 372.1 | |
The below table presents the components of interest and other debt expenses related to the 2028 Notes for the three and six months ended March 31, 2024:
| | | | | | | | | | | | | | |
($ in millions) | | Three months ended March 31, 2024 | | Six months ended March 31, 2024 |
Coupon interest | | $ | 7.4 | | | $ | 11.1 | |
Amortization of financing costs and discount | | 0.3 | | | 0.5 | |
Effect of interest rate swap | | 0.9 | | | 1.5 | |
Total interest expense | | $ | 8.6 | | | $ | 13.1 | |
Coupon interest rate (net of effect of interest rate swaps) | | 9.490 | % | | 9.490 | % |
Regulated Investment Company Status and Distributions
We anticipate that we will make quarterly distributions of at least 90% of our realized net ordinary income and net short-term capital gains in excess of our net long-term capital losses, if any, then available for distribution, each as determined by our Board in accordance with applicable law. Any distributions will be declared out of assets legally available for distribution. We expect quarterly distributions to be paid from income primarily generated by interest earned on our investments, although distributions to shareholders may also include a return of capital.
We have elected to be treated, and intend to qualify annually to be treated, as a RIC under Subchapter M of the Code. To maintain RIC qualification, we must distribute to our shareholders, for each tax year, at least 90% of our “investment company taxable income” for that year. In order to avoid certain excise taxes imposed on RICs, we intend to distribute during each calendar year an amount at least equal to the sum of: (1) 98% of our ordinary income for the calendar year; (2) 98.2% of our capital gain net income (both long-term and short-term) for the one-year period ending on October 31 of the calendar year; and, (3) any undistributed ordinary income and capital gain net income for preceding years on which we paid no U.S. federal income tax less certain over-distributions in prior years. In addition, although we currently intend to distribute realized net capital gains (i.e., net long term capital gains in excess of short term capital losses), if any, at least annually, we may in the future decide to retain such capital gains for investment, pay U.S. federal income tax on such amounts at regular corporate tax rates, and elect to treat such gains as deemed distributions to shareholders. We can offer no assurance that we will achieve results that will permit the payment of any cash distributions and, to the extent that we issue senior securities, we will be prohibited from making distributions if doing so causes us to fail to maintain the asset coverage ratios stipulated by the Investment Company Act or if distributions are limited by the terms of any of our borrowings.
Depending on the level of taxable income and net capital gain earned in a year, we may choose to carry forward taxable income or net capital gain for distribution in the following year and pay the applicable U.S. federal excise tax. Distributions will be appropriately adjusted for any taxes payable by us or any direct or indirect subsidiary through which it invests (including any corporate, state, local, non-U.S. and withholding taxes). Any Incentive Fee to be paid to our Adviser will not be reduced to take into account any such taxes.
We may generate qualified net interest income or qualified net short-term capital gains that may be exempt from U.S. withholding tax when distributed to foreign shareholders. A RIC is permitted to designate distributions of qualified net interest income and qualified short-term capital gains as exempt from U.S. withholding tax when paid to non-U.S. shareholders with proper documentation.
Recent Developments
Share Issuance
On April 1, 2024, we issued and sold pursuant to our continuous public offering 4,653,090 Class I shares for proceeds of $109.9 million, 1,979,996 Class S shares for proceeds of $46.7 million and 424 Class D shares for proceeds equivalent to the then-current NAV of such Class D shares.
Distributions
On April 18, 2024, our Board of Trustees declared a regular distribution on its outstanding common shares of beneficial interest in the amount per share set forth below: | | | | | | | | | | | | | | | | | | | | |
| | Gross Distribution | | Shareholder Servicing and/or Distribution Fee | | Net Distribution |
Class I shares | | $ | 0.2000 | | | $ | — | | | $ | 0.2000 | |
Class S shares | | $ | 0.2000 | | | $ | 0.0167 | | | $ | 0.1833 | |
Class D shares | | $ | 0.2000 | | | $ | 0.0049 | | | $ | 0.1951 | |
The distribution was payable to shareholders of record as of April 29, 2024 and was paid on May 30, 2024. The distribution was paid in cash or reinvested in Common Shares for shareholders participating in our distribution reinvestment plan.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
We are subject to financial market risks, including changes in the valuations of our investment portfolio and interest rates.
Valuation Risk
Our investments often do not have a readily available market price, and we value these investments at fair value as determined in good faith by our Adviser, as the valuation designee appointed by our Board of Trustees pursuant to Rule 2a-5 under the Investment Company Act. There is no single standard for determining fair value in good faith and valuation methodologies involve a significant degree of judgment. In addition, our valuation methodology utilizes discount rates in part in valuing our investments, and changes in those discount rates may have an impact on the valuation of our investments. Accordingly, valuations by us do not necessarily represent the amounts which may eventually be realized from sales or other dispositions of investments. Estimated fair values may differ from the values that would have been used had a ready market for the investment existed, and the differences could be material to our consolidated financial statements.
Interest Rate Risk
We are subject to financial market risks, including changes in interest rates. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle funds investments. Our risk management procedures are designed to identify and analyze our risk, to set appropriate policies and to continually monitor these risks. Our investment income will be affected by changes in various interest rates, including SOFR, EURIBOR, SONIA and prime rates, to the extent our debt investments include floating interest rates.
As of March 31, 2024, 91.9% of our debt investment portfolio at fair value bore interest at floating rates. As of September 30, 2023, 89.6% of our debt investment portfolio at fair value bore interest at floating rates. The composition of our floating rate debt investments by interest rate floor as of March 31, 2024 and September 30, 2023 was as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
($ in thousands) | | Fair Value | | % of Floating Rate Portfolio | | Fair Value | | % of Floating Rate Portfolio |
0% | | $ | 778,467 | | | 24.17 | % | | $ | 248,903 | | | 14.50 | % |
>0% and <1% | | 1,365,021 | | | 42.39 | | | 603,477 | | | 35.15 | |
1% | | 934,147 | | | 29.01 | | | 681,256 | | | 39.68 | |
>1% | | 142,501 | | | 4.43 | | | 183,272 | | | 10.67 | |
Total | | $ | 3,220,136 | | | 100.00 | % | | $ | 1,716,908 | | | 100.00 | % |
| | | | | | | | |
Based on our Consolidated Statement of Assets and Liabilities as of March 31, 2024, the following table shows the approximate annualized net increase (decrease) in net assets resulting from operations (excluding the impact of any potential incentive fees) of hypothetical base rate changes in interest rates, assuming no changes in our investment and capital structure. However, there can be no assurances our portfolio companies will be able to meet their contractual obligations at any or all levels of increases in interest rates.
| | | | | | | | | | | | | | | | | | | | |
Basis point increase ($ in thousands) | | Increase in Interest Income | | (Increase) in Interest Expense | | Net increase in net assets resulting from operations |
250 | | $ | 81,309 | | | $ | (29,875) | | | $ | 51,434 | |
200 | | 65,048 | | | (23,900) | | | 41,148 | |
150 | | 48,786 | | | (17,925) | | | 30,861 | |
100 | | 32,524 | | | (11,950) | | | 20,574 | |
50 | | 16,262 | | | (5,975) | | | 10,287 | |
| | | | | | | | | | | | | | | | | | | | |
Basis point decrease ($ in thousands) | | (Decrease) in Interest Income | | Decrease in Interest Expense | | Net (decrease) in net assets resulting from operations |
50 | | $ | (16,262) | | | $ | 5,975 | | | $ | (10,287) | |
100 | | (32,524) | | | 11,950 | | | (20,574) | |
150 | | (48,786) | | | 17,925 | | | (30,861) | |
200 | | (65,048) | | | 23,900 | | | (41,148) | |
250 | | (81,309) | | | 29,875 | | | (51,434) | |
We regularly measure exposure to interest rate risk. We assess interest rate risk and manage our interest rate exposure on an ongoing basis by comparing our interest rate sensitive assets to our interest rate sensitive liabilities. Based on this review, we determine whether or not any hedging transactions are necessary to mitigate exposure to changes in interest rates. The interest rate on the principal balance outstanding for primarily all floating rate loans is indexed to the SOFR and/or an alternate base rate, which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. The following table shows a comparison of the interest rate base for our outstanding debt investments, at principal, and our outstanding borrowings as of March 31, 2024 and September 30, 2023:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | March 31, 2024 | | September 30, 2023 |
($ in thousands) | | Debt Investments | | Borrowings | | Debt Investments | | Borrowings |
Prime rate | | $ | 2,990 | | | $ | — | | | $ | — | | | $ | — | |
LIBOR | | | | | | | | |
90 day | | — | | | — | | | 8,940 | | | — | |
EURIBOR | | | | | | | | |
30 day | | € | — | | | — | | | € | 21,000 | | | — | |
90 day | | 25,724 | | | — | | | 16,530 | | | — | |
180 day | | — | | | — | | | 15,266 | | | — | |
SOFR | | | | | | | | |
30 day | | $ | 1,321,601 | | | 625,000 | | | $ | 761,709 | | | 320,000 | |
90 day (a) | | 1,821,488 | | | 570,000 | | | 877,157 | | | 125,000 | |
180 day | | 30,145 | | | — | | | 30,006 | | | — | |
SONIA | | | | | | | | |
90 day | | £ | 51,062 | | | — | | | £ | 21,086 | | | — | |
180 day | | 9,861 | | | — | | | 5,470 | | | — | |
Fixed rate | | $ | 292,270 | | | — | | | $ | 216,996 | | | — | |
_____________________
(a) Borrowings include the 2028 Notes, which effectively pay interest at a floating rate under the terms of the interest rate swap.
Item 4. Controls and Procedures
As of the end of the period covered by this report, management, with the participation of the Company’s Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Based on the evaluation of our disclosure controls and procedures as of March 31, 2024, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in timely identifying, recording, processing, summarizing and reporting any material information relating to us that is required to be disclosed in the reports we file or submit under the Exchange Act.
There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II
Item 1. Legal Proceedings
From time to time, we may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights under loans to or other contracts with our portfolio companies. We are not currently subject to any material legal proceedings, and, to our knowledge, no material legal proceeding is threatened against us.
Item 1A. Risk Factors
Except as set forth below, there have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended September 30, 2023.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
There were no unregistered sales of our equity securities during the three months ended March 31, 2024.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
During the fiscal quarter ended March 31, 2024, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement”.
Item 6. Exhibits
The following exhibits are filed as part of this report or hereby incorporated by reference to exhibits previously filed with the SEC:
| | | | | | | | |
Exhibit | | Description |
| | Loan Financing and Servicing Agreement, dated as of February 15, 2024, among OSCF Lending IV SPV, LLC, as borrower, Oaktree Strategic Credit Fund, as servicer and equityholder, the lenders party thereto, Deutsche Bank AG, New York Branch, as facility agent, the other agents parties thereto and Deutsche Bank National Trust Company, as collateral agent and collateral custodian. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed February 22, 2024) |
| | Loan and Servicing Agreement, dated as of February 23, 2024, among OSCF Lending II SPV, LLC, as borrower, Oaktree Strategic Credit Fund, as transferor and servicer, Citibank, N.A., as the collateral agent, account bank and collateral custodian, Virtus Group, LP, as collateral administrator, each of the lenders from time to time party thereto, and Morgan Stanley Asset Funding, Inc., as the administrative agent. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed February 28, 2024) |
| | Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.* |
| | Certification of Chief Financial Officer (Principal Financial Officer) Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.* |
| | Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
| | Certification of Chief Financial Officer (Principal Financial Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
101.INS* | | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
101.SCH* | | Inline XBRL Taxonomy Extension Schema Document. |
101.DEF* | | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
101.LAB* | | Inline XBRL Taxonomy Extension Label Linkbase Document. |
101.PRE* | | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
104* | | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | | | |
| | |
OAKTREE STRATEGIC CREDIT FUND |
| |
By: | | /s/ Armen Panossian |
| | Armen Panossian |
| | Chairman, Chief Executive Officer and Chief Investment Officer |
| |
By: | | /s/ Christopher McKown |
| | Christopher McKown |
| | Chief Financial Officer and Treasurer |
Date: May 13, 2024